<?xml version="1.0" encoding="UTF-8" ?>
<!DOCTYPE PubmedArticleSet>
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34362880</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction.</ArticleTitle>
        <Pagination>
          <StartPage>775</StartPage>
          <MedlinePgn>775</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">775</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-021-04066-z</ELocationID>
        <Abstract>
          <AbstractText>The cysteine protease, caspase-8, undergoes dimerization, processing, and activation following stimulation of cells with death ligands such as TRAIL, and mediates TRAIL induction of the extrinsic apoptosis pathway. In addition, caspase-8 mediates TRAIL-induced activation of NF-ÎºB and upregulation of immunosuppressive chemokines/cytokines, via a mechanism independent of caspase-8 catalytic activity. The gene encoding procaspase-8 is mutated in 10% of human head and neck squamous cell carcinomas (HNSCCs). Despite a paucity of experimental evidence, HNSCC-associated caspase-8 mutations are commonly assumed to be loss of function. To investigate their functional properties and phenotypic effects, 18 HNSCC-associated caspase-8 mutants were expressed in doxycycline-inducible fashion in cell line models wherein the endogenous wild-type caspase-8 was deleted. We observed that 5/8 mutants in the amino-terminal prodomain, but 0/10 mutants in the carboxyl-terminal catalytic region, retained an ability to mediate TRAIL-induced apoptosis. Caspase-8 proteins with mutations in the prodomain were defective in dimerization, whereas all ten of the catalytic region mutants efficiently dimerized, revealing an inverse relationship between dimerization and apoptosis induction for the mutant proteins. Roughly half (3/8) of the prodomain mutants and 9/10 of the catalytic region mutants retained the ability to mediate TRAIL induction of immunosuppressive CXCL1, IL-6, or IL-8. Doxycycline-induced expression of wild-type caspase-8 or a representative mutant led to an increased percentage of T and NKT cells in syngeneic HNSCC xenograft tumors. These findings demonstrate that HNSCC-associated caspase-8 mutants retain properties that may influence TRAIL-mediated apoptosis and cytokine induction, as well as the composition of the tumor microenvironment.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Zhibin</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dabas</LastName>
            <ForeName>Hadas</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leonard</LastName>
            <ForeName>Brandon C</ForeName>
            <Initials>BC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shiah</LastName>
            <ForeName>Jamie V</ForeName>
            <Initials>JV</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grandis</LastName>
            <ForeName>Jennifer R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Daniel E</ForeName>
            <Initials>DE</Initials>
            <Identifier Source="ORCID">0000-0003-2505-530X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA, USA. daniel.johnson@ucsf.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 DE024728</GrantID>
            <Acronym>DE</Acronym>
            <Agency>NIDCR NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 CA231998</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053181">Caspase 8</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053181" MajorTopicYN="N">Caspase 8</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053221" MajorTopicYN="N">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34362880</ArticleId>
        <ArticleId IdType="pmc">PMC8346537</ArticleId>
        <ArticleId IdType="doi">10.1038/s41419-021-04066-z</ArticleId>
        <ArticleId IdType="pii">10.1038/s41419-021-04066-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Orning P, Lien E. Multiple roles of caspase-8 in cell death, inflammation, and innate immunity. J Leukoc Biol. 2021;109:121&#x2013;41. doi: 10.1002/JLB.3MR0420-305R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/JLB.3MR0420-305R</ArticleId>
            <ArticleId IdType="pubmed">32531842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwarzer R, Laurien L, Pasparakis M. New insights into the regulation of apoptosis, necroptosis, and pyroptosis by receptor interacting protein kinase 1 and caspase-8. Curr Opin Cell Biol. 2020;63:186&#x2013;93. doi: 10.1016/j.ceb.2020.02.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ceb.2020.02.004</ArticleId>
            <ArticleId IdType="pubmed">32163825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leonard BC, Johnson DE. Signaling by cell surface death receptors: alterations in head and neck cancer. Adv Biol Regul. 2018;67:170&#x2013;8. doi: 10.1016/j.jbior.2017.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbior.2017.10.006</ArticleId>
            <ArticleId IdType="pmc">PMC5854325</ArticleId>
            <ArticleId IdType="pubmed">29066276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henry CM, Martin SJ. Caspase-8 acts in a non-enzymatic role as a scaffold for assembly of a pro-inflammatory &#x201c;FADDosome&#x201d; complex upon TRAIL stimulation. Mol Cell. 2017;65:715&#x2013;29. doi: 10.1016/j.molcel.2017.01.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2017.01.022</ArticleId>
            <ArticleId IdType="pubmed">28212752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartwig T, Montinaro A, von Karstedt S, Sevko A, Surinova S, Chakravarthy A, et al. The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Mol Cell. 2017;65:730&#x2013;42. doi: 10.1016/j.molcel.2017.01.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2017.01.021</ArticleId>
            <ArticleId IdType="pmc">PMC5316415</ArticleId>
            <ArticleId IdType="pubmed">28212753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419:395&#x2013;9. doi: 10.1038/nature01063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature01063</ArticleId>
            <ArticleId IdType="pubmed">12353035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niemela J, Kuehn HS, Kelly C, Zhang M, Davies J, Melendez J, et al. Caspase-8 deficiency presenting as late-onset multi-organ lymphocytic infiltration with granulomas in two adult siblings. J Clin Immunol. 2015;35:348&#x2013;55. doi: 10.1007/s10875-015-0150-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-015-0150-8</ArticleId>
            <ArticleId IdType="pmc">PMC4439260</ArticleId>
            <ArticleId IdType="pubmed">25814141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanderova V, Grombirikova H, Zentsova I, Reblova K, Klocperk A, Fejtkova M, et al. Lymphoproliferation, immunodeficiency and early-onset inflammatory bowel disease associated with a novel mutation in Caspase 8. Haematologica. 2019;104:e32&#x2013;e4. doi: 10.3324/haematol.2018.201673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2018.201673</ArticleId>
            <ArticleId IdType="pmc">PMC6312013</ArticleId>
            <ArticleId IdType="pubmed">30337362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15:362&#x2013;74. doi: 10.1038/nri3834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3834</ArticleId>
            <ArticleId IdType="pubmed">26008591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riley JS, Malik A, Holohan C, Longley DB. DED or alive: assembly and regulation of the death effector domain complexes. Cell Death Dis. 2015;6:e1866. doi: 10.1038/cddis.2015.213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2015.213</ArticleId>
            <ArticleId IdType="pmc">PMC4558505</ArticleId>
            <ArticleId IdType="pubmed">26313917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickens LS, Boyd RS, Jukes-Jones R, Hughes MA, Robinson GL, Fairall L, et al. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell. 2012;47:291&#x2013;305. doi: 10.1016/j.molcel.2012.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2012.05.004</ArticleId>
            <ArticleId IdType="pmc">PMC3477315</ArticleId>
            <ArticleId IdType="pubmed">22683266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park HH. Molecular basis of dimerization of initiator caspase was revealed by crystal structure of caspase-8 pro-domain. Cell Death Differ. 2019;26:1213&#x2013;20. doi: 10.1038/s41418-018-0200-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-018-0200-x</ArticleId>
            <ArticleId IdType="pmc">PMC6748139</ArticleId>
            <ArticleId IdType="pubmed">30206319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen C, Pei J, Guo X, Zhou L, Li Q, Quan J. Structural basis for dimerization of the death effector domain of the F122A mutant of Caspase-8. Sci Rep. 2018;8:16723. doi: 10.1038/s41598-018-35153-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-35153-5</ArticleId>
            <ArticleId IdType="pmc">PMC6233201</ArticleId>
            <ArticleId IdType="pubmed">30425291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schleich K, Warnken U, Fricker N, Ozturk S, Richter P, Kammerer K, et al. Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol Cell. 2012;47:306&#x2013;19. doi: 10.1016/j.molcel.2012.05.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2012.05.006</ArticleId>
            <ArticleId IdType="pubmed">22683265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreuz S, Siegmund D, Rumpf JJ, Samel D, Leverkus M, Janssen O, et al. NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol. 2004;166:369&#x2013;80. doi: 10.1083/jcb.200401036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.200401036</ArticleId>
            <ArticleId IdType="pmc">PMC2172264</ArticleId>
            <ArticleId IdType="pubmed">15289496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401&#x2013;4. doi: 10.1158/2159-8290.CD-12-0095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-12-0095</ArticleId>
            <ArticleId IdType="pmc">PMC3956037</ArticleId>
            <ArticleId IdType="pubmed">22588877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. doi: 10.1126/scisignal.2004088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2004088</ArticleId>
            <ArticleId IdType="pmc">PMC4160307</ArticleId>
            <ArticleId IdType="pubmed">23550210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173:291&#x2013;304. doi: 10.1016/j.cell.2018.03.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.03.022</ArticleId>
            <ArticleId IdType="pmc">PMC5957518</ArticleId>
            <ArticleId IdType="pubmed">29625048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576&#x2013;82. doi: 10.1038/nature14129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14129</ArticleId>
            <ArticleId IdType="pmc">PMC4311405</ArticleId>
            <ArticleId IdType="pubmed">25631445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157&#x2013;60. doi: 10.1126/science.1208130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1208130</ArticleId>
            <ArticleId IdType="pmc">PMC3415217</ArticleId>
            <ArticleId IdType="pubmed">21798893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154&#x2013;7. doi: 10.1126/science.1206923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1206923</ArticleId>
            <ArticleId IdType="pmc">PMC3162986</ArticleId>
            <ArticleId IdType="pubmed">21798897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013;3:770&#x2013;81. doi: 10.1158/2159-8290.CD-12-0537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-12-0537</ArticleId>
            <ArticleId IdType="pmc">PMC3858325</ArticleId>
            <ArticleId IdType="pubmed">23619168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Prim. 2020;6:92. doi: 10.1038/s41572-020-00224-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-020-00224-3</ArticleId>
            <ArticleId IdType="pmc">PMC7944998</ArticleId>
            <ArticleId IdType="pubmed">33243986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uzunparmak B, Gao M, Lindemann A, Erikson K, Wang L, Lin E, et al. Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis. JCI Insight. 2020;5:e139837. PMID: 33108350. PMCID:PMC7714407. 10.1172/jci.insight.139837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7714407</ArticleId>
            <ArticleId IdType="pubmed">33108350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett. 2009;281:128&#x2013;33. doi: 10.1016/j.canlet.2008.11.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2008.11.023</ArticleId>
            <ArticleId IdType="pubmed">19111387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene. 2003;22:8543&#x2013;67. doi: 10.1038/sj.onc.1207107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1207107</ArticleId>
            <ArticleId IdType="pubmed">14634618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C, Egloff AM, Sen M, Grandis JR, Johnson DE. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol Oncol. 2014;8:1220&#x2013;30. doi: 10.1016/j.molonc.2014.03.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2014.03.018</ArticleId>
            <ArticleId IdType="pmc">PMC4198498</ArticleId>
            <ArticleId IdType="pubmed">24816188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Hassan A, Bose K. Molecular basis of death effector domain chain assembly and its role in caspase-8 activation. FASEB J. 2016;30:186&#x2013;200. doi: 10.1096/fj.15-272997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.15-272997</ArticleId>
            <ArticleId IdType="pubmed">26370846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang DW, Xing Z, Capacio VL, Peter ME, Yang X. Interdimer processing mechanism of procaspase-8 activation. EMBO J. 2003;22:4132&#x2013;42. doi: 10.1093/emboj/cdg414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/cdg414</ArticleId>
            <ArticleId IdType="pmc">PMC175803</ArticleId>
            <ArticleId IdType="pubmed">12912912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schleich K, Buchbinder JH, Pietkiewicz S, Kahne T, Warnken U, Ozturk S, et al. Molecular architecture of the DED chains at the DISC: regulation of procaspase-8 activation by short DED proteins c-FLIP and procaspase-8 prodomain. Cell Death Differ. 2016;23:681&#x2013;94. doi: 10.1038/cdd.2015.137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.137</ArticleId>
            <ArticleId IdType="pmc">PMC4986640</ArticleId>
            <ArticleId IdType="pubmed">26494467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Judd NP, Allen CT, Winkler AE, Uppaluri R. Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. Otolaryngol Head Neck Surg. 2012;147:493&#x2013;500. doi: 10.1177/0194599812442037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0194599812442037</ArticleId>
            <ArticleId IdType="pmc">PMC6346425</ArticleId>
            <ArticleId IdType="pubmed">22434099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS, Jr, et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012;72:365&#x2013;74. doi: 10.1158/0008-5472.CAN-11-1831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-1831</ArticleId>
            <ArticleId IdType="pmc">PMC3286642</ArticleId>
            <ArticleId IdType="pubmed">22086849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onken MD, Winkler AE, Kanchi KL, Chalivendra V, Law JH, Rickert CG, et al. A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res. 2014;20:2873&#x2013;84. doi: 10.1158/1078-0432.CCR-14-0205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0205</ArticleId>
            <ArticleId IdType="pmc">PMC4096804</ArticleId>
            <ArticleId IdType="pubmed">24668645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP, Hakem R, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011;471:368&#x2013;72. doi: 10.1038/nature09857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09857</ArticleId>
            <ArticleId IdType="pmc">PMC3060292</ArticleId>
            <ArticleId IdType="pubmed">21368762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grootjans S, Vanden Berghe T, Vandenabeele P. Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ. 2017;24:1184&#x2013;95. doi: 10.1038/cdd.2017.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2017.65</ArticleId>
            <ArticleId IdType="pmc">PMC5520172</ArticleId>
            <ArticleId IdType="pubmed">28498367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, et al. ATR inhibition sensitizes HPV(-) and HPV(+) head and neck squamous cell carcinoma to cisplatin. Oral Oncol. 2019;95:35&#x2013;42. doi: 10.1016/j.oraloncology.2019.05.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.oraloncology.2019.05.028</ArticleId>
            <ArticleId IdType="pmc">PMC6827881</ArticleId>
            <ArticleId IdType="pubmed">31345392</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34285232</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>02</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-1723</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature communications</Title>
          <ISOAbbreviation>Nat Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour.</ArticleTitle>
        <Pagination>
          <StartPage>4405</StartPage>
          <MedlinePgn>4405</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">4405</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-24603-w</ELocationID>
        <Abstract>
          <AbstractText>Stimulator of interferon genes (STING) promotes anti-tumour immunity by linking innate and adaptive immunity, but it remains unclear how intratumoural treatment with STING agonists yields anti-tumour effects. Here we demonstrate that intratumoural injection of the STING agonist cGAMP induces strong, rapid, and selective apoptosis of tumour endothelial cells (ECs) in implanted LLC tumour, melanoma and breast tumour, but not in spontaneous breast cancer and melanoma. In both implanted and spontaneous tumours, cGAMP greatly increases TNFÎ± from tumour-associated myeloid cells. However, compared to spontaneous tumour ECs, implanted tumour ECs are more vulnerable to TNFÎ±-TNFR1 signalling-mediated apoptosis, which promotes effective anti-tumour activity. The spontaneous tumour's refractoriness to cGAMP is abolished by co-treatment with AKT 1/2 inhibitor (AKTi). Combined treatment with cGAMP and AKTi induces extensive tumour EC apoptosis, leading to extensive tumour apoptosis and marked growth suppression of the spontaneous tumour. These findings propose an advanced avenue for treating primary tumours that are refractory to single STING agonist therapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jeong</LastName>
            <ForeName>Seung-Hwan</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Myung Jin</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Vascular Research, Institute for Basic Science, Daejeon, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Seunghyeok</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Vascular Research, Institute for Basic Science, Daejeon, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>JungMo</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Vascular Research, Institute for Basic Science, Daejeon, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koh</LastName>
            <ForeName>Gou Young</ForeName>
            <Initials>GY</Initials>
            <Identifier Source="ORCID">0000-0002-1231-1485</Identifier>
            <AffiliationInfo>
              <Affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea. gykoh@kaist.ac.kr.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Vascular Research, Institute for Basic Science, Daejeon, Republic of Korea. gykoh@kaist.ac.kr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Commun</MedlineTA>
        <NlmUniqueID>101528555</NlmUniqueID>
        <ISSNLinking>2041-1723</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009712">Nucleotides, Cyclic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047888">Receptors, Tumor Necrosis Factor, Type I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C532857">STING1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C530855">Sting1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000630923">Tnf protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C506236">Tnfrsf1a protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C584311">cyclic guanosine monophosphate-adenosine monophosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
          <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061307" MajorTopicYN="N">Human Umbilical Vein Endothelial Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015552" MajorTopicYN="N">Injections, Intralesional</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009712" MajorTopicYN="N">Nucleotides, Cyclic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047888" MajorTopicYN="N">Receptors, Tumor Necrosis Factor, Type I</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>5</Hour>
          <Minute>56</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34285232</ArticleId>
        <ArticleId IdType="pmc">PMC8292391</ArticleId>
        <ArticleId IdType="doi">10.1038/s41467-021-24603-w</ArticleId>
        <ArticleId IdType="pii">10.1038/s41467-021-24603-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Vanpouille-Box C, Demaria S, Formenti SC, Galluzzi L. Cytosolic DNA sensing in organismal tumor control. Cancer Cell. 2018;34:361&#x2013;378. doi: 10.1016/j.ccell.2018.05.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.05.013</ArticleId>
            <ArticleId IdType="pubmed">30216189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barber GNSTING. Infection, inflammation and cancer. Nat. Rev. Immunol. 2015;15:760&#x2013;770. doi: 10.1038/nri3921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3921</ArticleId>
            <ArticleId IdType="pmc">PMC5004891</ArticleId>
            <ArticleId IdType="pubmed">26603901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakhoum SF, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553:467&#x2013;472. doi: 10.1038/nature25432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature25432</ArticleId>
            <ArticleId IdType="pmc">PMC5785464</ArticleId>
            <ArticleId IdType="pubmed">29342134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ablasser A, et al. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature. 2013;503:530&#x2013;534. doi: 10.1038/nature12640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12640</ArticleId>
            <ArticleId IdType="pmc">PMC4142317</ArticleId>
            <ArticleId IdType="pubmed">24077100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun L, Wu J, Du F, Chen X. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339:786&#x2013;791. doi: 10.1126/science.1232458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1232458</ArticleId>
            <ArticleId IdType="pmc">PMC3863629</ArticleId>
            <ArticleId IdType="pubmed">23258413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng L, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843&#x2013;852. doi: 10.1016/j.immuni.2014.10.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.10.019</ArticleId>
            <ArticleId IdType="pmc">PMC5155593</ArticleId>
            <ArticleId IdType="pubmed">25517616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaidt MM, et al. The DNA inflammasome in human myeloid cells is initiated by a STING-cell death program upstream of NLRP3. Cell. 2017;171:1110&#x2013;1124. doi: 10.1016/j.cell.2017.09.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.09.039</ArticleId>
            <ArticleId IdType="pmc">PMC5901709</ArticleId>
            <ArticleId IdType="pubmed">29033128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo SR, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41:830&#x2013;842. doi: 10.1016/j.immuni.2014.10.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.10.017</ArticleId>
            <ArticleId IdType="pmc">PMC4384884</ArticleId>
            <ArticleId IdType="pubmed">25517615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corrales L, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11:1018&#x2013;1030. doi: 10.1016/j.celrep.2015.04.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2015.04.031</ArticleId>
            <ArticleId IdType="pmc">PMC4440852</ArticleId>
            <ArticleId IdType="pubmed">25959818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 2016;17:1142&#x2013;1149. doi: 10.1038/ni.3558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3558</ArticleId>
            <ArticleId IdType="pubmed">27648547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schadt L, et al. Cancer-cell-intrinsic cGAS expression mediates tumor immunogenicity. Cell Rep. 2019;29:1236&#x2013;1248. doi: 10.1016/j.celrep.2019.09.065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2019.09.065</ArticleId>
            <ArticleId IdType="pubmed">31665636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu, J. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 7, 283ra52 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4504692</ArticleId>
            <ArticleId IdType="pubmed">25877890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcus A, et al. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. 2018;49:754&#x2013;763. doi: 10.1016/j.immuni.2018.09.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2018.09.016</ArticleId>
            <ArticleId IdType="pmc">PMC6488306</ArticleId>
            <ArticleId IdType="pubmed">30332631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J. Clin. Invest. 2019;129:4350&#x2013;4364. doi: 10.1172/JCI125413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI125413</ArticleId>
            <ArticleId IdType="pmc">PMC6763266</ArticleId>
            <ArticleId IdType="pubmed">31343989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reisl&#xe4;nder T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: a STING in the tale. Mol. Cell. 2020;80:21&#x2013;28. doi: 10.1016/j.molcel.2020.07.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2020.07.026</ArticleId>
            <ArticleId IdType="pubmed">32810436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Won JK, Bakhoum SF. The cytosolic DNA-sensing cGAS&#x2013;sting pathway in cancer. Cancer Discov. 2020;10:26&#x2013;39. doi: 10.1158/2159-8290.CD-19-0761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0761</ArticleId>
            <ArticleId IdType="pmc">PMC7151642</ArticleId>
            <ArticleId IdType="pubmed">31852718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts ZJ, et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J. Exp. Med. 2007;204:1559&#x2013;1569. doi: 10.1084/jem.20061845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20061845</ArticleId>
            <ArticleId IdType="pmc">PMC2118649</ArticleId>
            <ArticleId IdType="pubmed">17562815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1&#x2013;10. doi: 10.1016/j.immuni.2013.07.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2013.07.012</ArticleId>
            <ArticleId IdType="pubmed">23890059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell. Mol. Immunol. 2020;17:807&#x2013;821. doi: 10.1038/s41423-020-0488-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41423-020-0488-6</ArticleId>
            <ArticleId IdType="pmc">PMC7395159</ArticleId>
            <ArticleId IdType="pubmed">32612154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demaria O, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl Acad. Sci. U. S. A. 2015;112:15408&#x2013;15413. doi: 10.1073/pnas.1512832112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1512832112</ArticleId>
            <ArticleId IdType="pmc">PMC4687570</ArticleId>
            <ArticleId IdType="pubmed">26607445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francica BJ, et al. TNFa and radioresistant stromal cells are essential for therapeutic efficacy of cyclic dinucleotide STING agonists in nonimmunogenic tumors. Cancer Immunol. Res. 2018;6:422&#x2013;433. doi: 10.1158/2326-6066.CIR-17-0263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-17-0263</ArticleId>
            <ArticleId IdType="pmc">PMC6215542</ArticleId>
            <ArticleId IdType="pubmed">29472271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daei Farshchi Adli A, Jahanban-Esfahlan R, Seidi K, Samandari-Rad S, Zarghami N. An overview on Vadimezan (DMXAA): the vascular disrupting agent. Chem. Biol. Drug Des. 2018;91:996&#x2013;1006. doi: 10.1111/cbdd.13166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cbdd.13166</ArticleId>
            <ArticleId IdType="pubmed">29288534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin EN, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 2020;369:993&#x2013;999. doi: 10.1126/science.abb4255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abb4255</ArticleId>
            <ArticleId IdType="pubmed">32820126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivick KE, et al. Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity. Cell Rep. 2018;25:3074&#x2013;3085. doi: 10.1016/j.celrep.2018.11.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.11.047</ArticleId>
            <ArticleId IdType="pubmed">30540940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu J, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 2015;7:283ra52&#x2013;283ra52. doi: 10.1126/scitranslmed.aaa4306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaa4306</ArticleId>
            <ArticleId IdType="pmc">PMC4504692</ArticleId>
            <ArticleId IdType="pubmed">25877890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257&#x2013;262. doi: 10.1016/S1535-6108(03)00248-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00248-4</ArticleId>
            <ArticleId IdType="pubmed">14585353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M&#xe9;ndez-Pertuz M, et al. Modulation of telomere protection by the PI3K/AKT pathway. Nat. Commun. 2017;8:1&#x2013;16. doi: 10.1038/s41467-017-01329-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-01329-2</ArticleId>
            <ArticleId IdType="pmc">PMC5668434</ArticleId>
            <ArticleId IdType="pubmed">29097657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Toker A. Review AKT/PKB signaling: navigating the network. Cell. 2017;169:381&#x2013;405. doi: 10.1016/j.cell.2017.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.04.001</ArticleId>
            <ArticleId IdType="pmc">PMC5546324</ArticleId>
            <ArticleId IdType="pubmed">28431241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Augustin HG, Young Koh G, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin&#x2014;Tie system. Nat. Rev. Mol. Cell Biol. 2009;10:165&#x2013;177. doi: 10.1038/nrm2639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2639</ArticleId>
            <ArticleId IdType="pubmed">19234476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol. 2016;17:611&#x2013;625. doi: 10.1038/nrm.2016.87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm.2016.87</ArticleId>
            <ArticleId IdType="pubmed">27461391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hideshima T, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053&#x2013;4062. doi: 10.1182/blood-2005-08-3434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2005-08-3434</ArticleId>
            <ArticleId IdType="pmc">PMC1895278</ArticleId>
            <ArticleId IdType="pubmed">16418332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann. Med. 2014;46:372&#x2013;383. doi: 10.3109/07853890.2014.912836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/07853890.2014.912836</ArticleId>
            <ArticleId IdType="pubmed">24897931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song S, et al. Decreased expression of STING predicts poor prognosis in patients with gastric cancer. Sci. Rep. 2017;7:39858. doi: 10.1038/srep39858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep39858</ArticleId>
            <ArticleId IdType="pmc">PMC5296877</ArticleId>
            <ArticleId IdType="pubmed">28176788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gulen, M. F. et al. Signalling strength determines proapoptotic functions of STING. Nat. Commun. 8, 427 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5585373</ArticleId>
            <ArticleId IdType="pubmed">28874664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016;533:493&#x2013;498. doi: 10.1038/nature18268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature18268</ArticleId>
            <ArticleId IdType="pmc">PMC5021195</ArticleId>
            <ArticleId IdType="pubmed">27225120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okabe K, et al. Neurons limit angiogenesis by titrating VEGF in retina. Cell. 2014;159:584&#x2013;596. doi: 10.1016/j.cell.2014.09.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.09.025</ArticleId>
            <ArticleId IdType="pubmed">25417109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>R&#xfc;egg C, et al. Evidence for the involvement of endothelial cell integrin &#x3b1;V&#x3b2;3 in the disruption of the tumor vasculature induced by TNF and IFN-&#x3b3;. Nat. Med. 1998;4:408&#x2013;414. doi: 10.1038/nm0498-408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0498-408</ArticleId>
            <ArticleId IdType="pubmed">9546785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deroose, J. P., Gr&#xfc;nhagen, D. J., De Wilt, J. H. W., Eggermont, A. M. M. &amp; Verhoef, C. Treatment modifications in tumour necrosis factor-&#x3b1; (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas. Eur. J. Cancer51, 367&#x2013;373 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25529370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huyghe L, et al. Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies. EMBO Mol. Med. 2020;12:e11223. doi: 10.15252/emmm.201911223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201911223</ArticleId>
            <ArticleId IdType="pmc">PMC7709889</ArticleId>
            <ArticleId IdType="pubmed">31912630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss, J. M. et al. The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. Oncoimmunology6, e1346765 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5665074</ArticleId>
            <ArticleId IdType="pubmed">29123960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R. &amp; F&#xf6;rster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res.8, 265&#x2013;77 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10621974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivashkiv LB. IFN&#x3b3;: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 2018;18:545&#x2013;558. doi: 10.1038/s41577-018-0029-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-018-0029-z</ArticleId>
            <ArticleId IdType="pmc">PMC6340644</ArticleId>
            <ArticleId IdType="pubmed">29921905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bieler G, et al. Distinctive role of integrin-mediated adhesion in TNF-induced PKB/Akt and NF-&#x3ba;B activation and endothelial cell survival. Oncogene. 2007;26:5722&#x2013;5732. doi: 10.1038/sj.onc.1210354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1210354</ArticleId>
            <ArticleId IdType="pubmed">17369858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalucka J, et al. Single-cell transcriptome atlas of murine endothelial cells. Cell. 2020;180:764&#x2013;779. doi: 10.1016/j.cell.2020.01.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.01.015</ArticleId>
            <ArticleId IdType="pubmed">32059779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nat. Rev. Cancer. 2017;17:751&#x2013;765. doi: 10.1038/nrc.2017.92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2017.92</ArticleId>
            <ArticleId IdType="pubmed">29077691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kersten K, Visser KE, Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol. Med. 2017;9:137&#x2013;153. doi: 10.15252/emmm.201606857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201606857</ArticleId>
            <ArticleId IdType="pmc">PMC5286388</ArticleId>
            <ArticleId IdType="pubmed">28028012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E. &amp; Kroemer, G. Trial watch: STING agonists in cancer therapy. Oncoimmunology9, 1777624 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7466854</ArticleId>
            <ArticleId IdType="pubmed">32934881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dharaneeswaran H, et al. FOXO1-mediated activation of akt plays a critical role in vascular homeostasis. Circ. Res. 2014;115:238&#x2013;251. doi: 10.1161/CIRCRESAHA.115.303227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.115.303227</ArticleId>
            <ArticleId IdType="pmc">PMC4961050</ArticleId>
            <ArticleId IdType="pubmed">24874427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim, Y. H. et al. A MST1-FOXO1 cascade establishes endothelial tip cell polarity and facilitates sprouting angiogenesis. Nat. Commun.10, 838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6381131</ArticleId>
            <ArticleId IdType="pubmed">30783090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, et al. Massively evoking immunogenic cell death by focused mitochondrial oxidative stress using an AIE luminogen with a twisted molecular structure. Adv. Mater. 2019;31:1&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31696981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dankort D, et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 2009;41:544&#x2013;552. doi: 10.1038/ng.356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.356</ArticleId>
            <ArticleId IdType="pmc">PMC2705918</ArticleId>
            <ArticleId IdType="pubmed">19282848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivera LB, Bergers G. Tumor angiogenesis, from foe to friend. Science. 2015;349:694&#x2013;695. doi: 10.1126/science.aad0862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad0862</ArticleId>
            <ArticleId IdType="pubmed">26273044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat. Rev. Cancer. 2005;5:423&#x2013;435. doi: 10.1038/nrc1628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1628</ArticleId>
            <ArticleId IdType="pubmed">15928673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conlon J, et al. Mouse, but not Human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J. Immunol. 2013;190:5216&#x2013;5225. doi: 10.4049/jimmunol.1300097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1300097</ArticleId>
            <ArticleId IdType="pmc">PMC3647383</ArticleId>
            <ArticleId IdType="pubmed">23585680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Downey CM, Aghaei M, Schwendener RA, Jirik FR. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2&#x2032;3&#x2032;-cGAMP, induces M2 macrophage repolarization. PLoS ONE. 2014;9:10&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4062468</ArticleId>
            <ArticleId IdType="pubmed">24940883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L, et al. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nat. Commun. 2019;10:1&#x2013;15. doi: 10.1038/s41467-018-07882-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-07882-8</ArticleId>
            <ArticleId IdType="pmc">PMC6814770</ArticleId>
            <ArticleId IdType="pubmed">31653838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu, S. et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat. Cell Biol21, 1027&#x2013;1040 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31332347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crompton JG, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015;75:296&#x2013;305. doi: 10.1158/0008-5472.CAN-14-2277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-2277</ArticleId>
            <ArticleId IdType="pmc">PMC4384335</ArticleId>
            <ArticleId IdType="pubmed">25432172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klebanoff, C. A. et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight2, e95103 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5752304</ArticleId>
            <ArticleId IdType="pubmed">29212954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, et al. YAP/TAZ regulates sprouting angiogenesis and vascular barrier maturation. J. Clin. Invest. 2017;127:3441&#x2013;3461. doi: 10.1172/JCI93825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI93825</ArticleId>
            <ArticleId IdType="pmc">PMC5669570</ArticleId>
            <ArticleId IdType="pubmed">28805663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong HW, et al. Transcriptional regulation of endothelial cell behavior during sprouting angiogenesis. Nat. Commun. 2017;8:1&#x2013;14. doi: 10.1038/s41467-016-0009-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-016-0009-6</ArticleId>
            <ArticleId IdType="pmc">PMC5620061</ArticleId>
            <ArticleId IdType="pubmed">28959057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge SX, Son EW, Yao R. iDEP: An integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinform. 2018;19:1&#x2013;24. doi: 10.1186/s12859-018-2486-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12859-018-2486-6</ArticleId>
            <ArticleId IdType="pmc">PMC6299935</ArticleId>
            <ArticleId IdType="pubmed">30567491</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34037385</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-4804</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>64</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medicinal chemistry</Title>
          <ISOAbbreviation>J Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo.</ArticleTitle>
        <Pagination>
          <StartPage>7646</StartPage>
          <EndPage>7666</EndPage>
          <MedlinePgn>7646-7666</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.1c00370</ELocationID>
        <Abstract>
          <AbstractText>Two series of novel o-(biphenyl-3-ylmethoxy)nitrophenyl compounds (A1-31 and B1-17) were designed as programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors. All compounds showed significant inhibitory activity with IC50 values ranging from 2.7 to 87.4 nM except compound A17, and compound B2 displayed the best activity. Further experiments showed that B2 bound to the PD-L1 protein without obvious toxicity in Lewis lung carcinoma (LLC) cells. Furthermore, B2 significantly promoted interferon-gamma secretion in a dose-dependent manner in vitro and in vivo. Especially, B2 exhibited potent in vivo anticancer efficacy in an LLC-bearing allograft mouse model at a low dose of 5 mg/kg, which was more active than BMS-1018 (tumor growth inhibition rate: 48.5% vs 17.8%). A panel of immunohistochemistry and flow cytometry assays demonstrated that B2 effectively counteracted PD-1-induced immunosuppression in the tumor microenvironment, thereby triggering antitumor immunity. These results indicate that B2 is a promising PD-1/PD-L1 inhibitor worthy of further development.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>OuYang</LastName>
            <ForeName>Yiqiang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Junfeng</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Haiqing</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Shuanglong</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yue</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yuezhen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Organic Chemistry, School of Science, China Pharmaceutical University, Nanjing 211198, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Wenjie</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Qiang</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lai</LastName>
            <ForeName>Yisheng</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-8026-7949</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Med Chem</MedlineTA>
        <NlmUniqueID>9716531</NlmUniqueID>
        <ISSNLinking>0022-2623</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009578">Nitrobenzenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009578" MajorTopicYN="N">Nitrobenzenes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34037385</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.jmedchem.1c00370</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33762321</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2051-1426</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal for immunotherapy of cancer</Title>
          <ISOAbbreviation>J Immunother Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e002355</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/jitc-2021-002355</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">The most common clinical outcome observed after treatment with immune checkpoint inhibitor antibodies is disease stabilization. Using vaccines to generate high levels of tumor antigen-specific T-helper 1 (Th1), we show that tumors not eradicated by vaccination demonstrate prolonged disease stabilization. We evaluated the mechanism by which type I T cells inhibit disease progression and potentially influence the subsequent clinical response to standard therapy in treatment refractory cancers.</AbstractText>
          <AbstractText Label="METHODS">We employed a meta-analysis of studies with tumor growth from four different vaccines in two different mammary cancer models. The T-cell subtype and cytokine essential for vaccine-induced tumor inhibition was determined by in vivo neutralization studies and immunohistochemistry. The role of interferon gamma (IFN-&#x3b3;) in receptor tyrosine kinase and downstream signaling was determined by immunoblotting. The role of suppressor of cytokine signaling 1 (SOCS1) on IFN-&#x3b3; signaling was evaluated on SOCS1-silenced cells with immunoblotting and immunoprecipitation. The effect of vaccination on growth factor receptor signaling pathways, performed in both luminal (TgMMTVneu) and basal (C3(1)-Tag) mammary cancer models treated with paclitaxel or an anti-HER2-neu monoclonal antibody were assessed via immunoblotting.</AbstractText>
          <AbstractText Label="RESULTS">Immunization with an epitope-based vaccine targeting a representative tumor antigen resulted in elevated tumor trafficking Tbet+CD4 T cells, decreased tumor proliferation and increased apoptosis compared with control vaccinated mice. The resulting disease stabilization was dependent on IFN-&#x3b3;-secreting CD4[+] T cells. In the presence of excess IFN-&#x3b3;, SOCS1 became upregulated in tumor cells, bound insulin receptor, insulin like growth factor receptor 1 and epidermal growth factor receptor resulting in profound oncogenic signaling inhibition. Silencing SOCS1 restored growth factor receptor signaling and proliferation and prevented cell death. Similar signaling perturbations were detected in vaccinated mice developing antigen-specific Th1 cells. Vaccination synergized with standard therapies and restored disease sensitivity to treatment with both a neu-specific antibody and paclitaxel in TgMMTVneu and to paclitaxel in C3(1)-Tag. Combination of vaccination and chemotherapy or biological therapy was more effective than monotherapy alone in either model and resulted in complete resolution of disease in some individuals.</AbstractText>
          <AbstractText Label="CONCLUSIONS">These data suggest the clinical activity of type I T cells extends beyond direct tumor killing and immune therapies designed to increase type I T cells and could be integrated into standard chemotherapy regimens to enhance therapeutic efficacy.</AbstractText>
          <CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cecil</LastName>
            <ForeName>Denise</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-9923-3618</Identifier>
            <AffiliationInfo>
              <Affiliation>UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, WA, USA dcecil@uw.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Kyong Hwa</ForeName>
            <Initials>KH</Initials>
            <AffiliationInfo>
              <Affiliation>Korea University, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Curtis</LastName>
            <ForeName>Benjamin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, WA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corulli</LastName>
            <ForeName>Lauren</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, WA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Disis</LastName>
            <ForeName>Mary Nora</ForeName>
            <Initials>MN</Initials>
            <AffiliationInfo>
              <Affiliation>UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, WA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA101190</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 CA141539</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>N01CN53300</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Immunother Cancer</MedlineTA>
        <NlmUniqueID>101620585</NlmUniqueID>
        <ISSNLinking>2051-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015513">Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019496" MajorTopicYN="N">Cancer Vaccines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015513" MajorTopicYN="N">Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CD4-positive T-lymphocytes</Keyword>
        <Keyword MajorTopicYN="N">immunization</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: DC and MD are inventors on patents held by the University of Washington, and MD holds stock in Epithany. Epitope sequences presented have been included in the US patent 61/972,176.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>5</Hour>
          <Minute>51</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33762321</ArticleId>
        <ArticleId IdType="pmc">PMC7993179</ArticleId>
        <ArticleId IdType="doi">10.1136/jitc-2021-002355</ArticleId>
        <ArticleId IdType="pii">jitc-2021-002355</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Iglesia MD, Parker JS, Hoadley KA, et al. . Genomic analysis of immune cell infiltrates across 11 tumor types. J Natl Cancer Inst 2016;108. 10.1093/jnci/djw144. [Epub ahead of print: 22 06 2016].</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djw144</ArticleId>
            <ArticleId IdType="pmc">PMC5241901</ArticleId>
            <ArticleId IdType="pubmed">27335052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HJ, Lee J-J, Song IH, et al. . Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Breast Cancer Res Treat 2015;151:619&#x2013;27. 10.1007/s10549-015-3438-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-015-3438-8</ArticleId>
            <ArticleId IdType="pubmed">26006068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prat A, Navarro A, Par&#xe9; L, et al. . Immune-Related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res 2017;77:3540&#x2013;50. 10.1158/0008-5472.CAN-16-3556</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-3556</ArticleId>
            <ArticleId IdType="pubmed">28487385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brockwell NK, Parker BS. Tumor inherent interferons: impact on immune reactivity and immunotherapy. Cytokine 2019;118:42-47. 10.1016/j.cyto.2018.04.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2018.04.006</ArticleId>
            <ArticleId IdType="pubmed">29681426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cecil DL, Slota M, O'Meara MM, et al. . Immunization against HIF-1&#x3b1; Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo. Clin Cancer Res 2017;23:3396&#x2013;404. 10.1158/1078-0432.CCR-16-1678</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-1678</ArticleId>
            <ArticleId IdType="pmc">PMC5493515</ArticleId>
            <ArticleId IdType="pubmed">28039264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Disis ML, Gad E, Herendeen DR, et al. . A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res 2013;6:1273&#x2013;82. 10.1158/1940-6207.CAPR-13-0182</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1940-6207.CAPR-13-0182</ArticleId>
            <ArticleId IdType="pmc">PMC3864759</ArticleId>
            <ArticleId IdType="pubmed">24154719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wargo JA, Cooper ZA, Flaherty KT. Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov 2014;4:1377&#x2013;86. 10.1158/2159-8290.CD-14-0477</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-14-0477</ArticleId>
            <ArticleId IdType="pmc">PMC4258160</ArticleId>
            <ArticleId IdType="pubmed">25395294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nanda R, Chow LQM, Dees EC, et al. . Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016;34:2460&#x2013;7. 10.1200/JCO.2015.64.8931</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.64.8931</ArticleId>
            <ArticleId IdType="pmc">PMC6816000</ArticleId>
            <ArticleId IdType="pubmed">27138582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamanishi J, Mandai M, Ikeda T, et al. . Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015;33:4015&#x2013;22. 10.1200/JCO.2015.62.3397</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.62.3397</ArticleId>
            <ArticleId IdType="pubmed">26351349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garon EB, Rizvi NA, Hui R, et al. . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018&#x2013;28. 10.1056/NEJMoa1501824</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1501824</ArticleId>
            <ArticleId IdType="pubmed">25891174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Percie du Sert N, Hurst V, Ahluwalia A, et al. . The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Exp Physiol 2020;105:1459&#x2013;66. 10.1113/EP088870</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/EP088870</ArticleId>
            <ArticleId IdType="pubmed">32666546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plymate SR, Haugk K, Coleman I, et al. . An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007;13:6429&#x2013;39. 10.1158/1078-0432.CCR-07-0648</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-07-0648</ArticleId>
            <ArticleId IdType="pubmed">17975155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalkhali-Ellis Z, Abbott DE, Bailey CM, et al. . Ifn-Gamma regulation of vacuolar pH, cathepsin D processing and autophagy in mammary epithelial cells. J Cell Biochem 2008;105:208&#x2013;18. 10.1002/jcb.21814</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.21814</ArticleId>
            <ArticleId IdType="pmc">PMC2575810</ArticleId>
            <ArticleId IdType="pubmed">18494001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garc&#xed;a-Tu&#xf1;&#xf3;n I, Ricote M, Ruiz A A, et al. . Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer 2007;7:158. 10.1186/1471-2407-7-158</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-7-158</ArticleId>
            <ArticleId IdType="pmc">PMC1976422</ArticleId>
            <ArticleId IdType="pubmed">17697357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncan TJ, Rolland P, Deen S, et al. . Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res 2007;13:4139&#x2013;45. 10.1158/1078-0432.CCR-06-2833</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-2833</ArticleId>
            <ArticleId IdType="pubmed">17634541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Hou D, Wei H, et al. . Lack of interferon-&#x3b3; receptor results in a microenvironment favorable for intestinal tumorigenesis. Oncotarget 2016;7:42099&#x2013;109. 10.18632/oncotarget.9867</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.9867</ArticleId>
            <ArticleId IdType="pmc">PMC5173119</ArticleId>
            <ArticleId IdType="pubmed">27286456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gooch JL, Herrera RE, Yee D. The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells. Cell Growth Differ 2000;11:335&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10910100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller TW, P&#xe9;rez-Torres M, Narasanna A, et al. . Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009;69:4192&#x2013;201. 10.1158/0008-5472.CAN-09-0042</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-0042</ArticleId>
            <ArticleId IdType="pmc">PMC2724871</ArticleId>
            <ArticleId IdType="pubmed">19435893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang B-H, Liu L-Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19&#x2013;65. 10.1016/S0065-230X(09)02002-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0065-230X(09)02002-8</ArticleId>
            <ArticleId IdType="pmc">PMC2933405</ArticleId>
            <ArticleId IdType="pubmed">19595306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGillicuddy FC, Chiquoine EH, Hinkle CC, et al. . Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. J Biol Chem 2009;284:31936&#x2013;44. 10.1074/jbc.M109.061655</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.061655</ArticleId>
            <ArticleId IdType="pmc">PMC2797265</ArticleId>
            <ArticleId IdType="pubmed">19776010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mooney RA, Senn J, Cameron S, et al. . Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 2001;276:25889&#x2013;93. 10.1074/jbc.M010579200</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M010579200</ArticleId>
            <ArticleId IdType="pubmed">11342531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S, Jiang Z, Mortenson ED, et al. . The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010;18:160&#x2013;70. 10.1016/j.ccr.2010.06.014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2010.06.014</ArticleId>
            <ArticleId IdType="pmc">PMC2923645</ArticleId>
            <ArticleId IdType="pubmed">20708157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cecil DL, Holt GE, Park KH, et al. . Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res 2014;74:2710&#x2013;8. 10.1158/0008-5472.CAN-13-3286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-3286</ArticleId>
            <ArticleId IdType="pmc">PMC4037234</ArticleId>
            <ArticleId IdType="pubmed">24778415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knutson KL, Almand B, Dang Y, et al. . Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 2004;64:1146&#x2013;51. 10.1158/0008-5472.CAN-03-0173</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-03-0173</ArticleId>
            <ArticleId IdType="pubmed">14871850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melssen M, Slingluff CL. Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol 2017;47:85&#x2013;92. 10.1016/j.coi.2017.07.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2017.07.004</ArticleId>
            <ArticleId IdType="pmc">PMC5757837</ArticleId>
            <ArticleId IdType="pubmed">28755541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshikawa M, Aoki T, Matsushita H, et al. . Nk cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. Biochem Biophys Res Commun 2018;495:2058&#x2013;65. 10.1016/j.bbrc.2017.12.083</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2017.12.083</ArticleId>
            <ArticleId IdType="pubmed">29253566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adhikary T, Wortmann A, Finkernagel F, et al. . Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics 2017;18:243. 10.1186/s12864-017-3630-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12864-017-3630-9</ArticleId>
            <ArticleId IdType="pmc">PMC5359932</ArticleId>
            <ArticleId IdType="pubmed">28327095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callari M, Musella V, Di Buduo E, et al. . Subtype-Dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. Mol Oncol 2014;8:1278&#x2013;89. 10.1016/j.molonc.2014.04.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2014.04.010</ArticleId>
            <ArticleId IdType="pmc">PMC5528564</ArticleId>
            <ArticleId IdType="pubmed">24853384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayers M, Lunceford J, Nebozhyn M, et al. . IFN-&#x3b3;-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 2017;127:2930&#x2013;40. 10.1172/JCI91190</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI91190</ArticleId>
            <ArticleId IdType="pmc">PMC5531419</ArticleId>
            <ArticleId IdType="pubmed">28650338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sistigu A, Yamazaki T, Vacchelli E, et al. . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014;20:1301&#x2013;9. 10.1038/nm.3708</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3708</ArticleId>
            <ArticleId IdType="pubmed">25344738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kursunel MA, Esendagli G. The untold story of IFN-&#x3b3; in cancer biology. Cytokine Growth Factor Rev 2016;31:73&#x2013;81. 10.1016/j.cytogfr.2016.07.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cytogfr.2016.07.005</ArticleId>
            <ArticleId IdType="pubmed">27502919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroeder BA, Black RG, Spadinger S, et al. . Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. J Immunother Cancer 2020;8:e000247. 10.1136/jitc-2019-000247</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jitc-2019-000247</ArticleId>
            <ArticleId IdType="pmc">PMC7254118</ArticleId>
            <ArticleId IdType="pubmed">32269142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsushita H, Hosoi A, Ueha S, et al. . Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN&#x3b3;-dependent cell-cycle arrest. Cancer Immunol Res 2015;3:26&#x2013;36. 10.1158/2326-6066.CIR-14-0098</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0098</ArticleId>
            <ArticleId IdType="pubmed">25127875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirley JL, Keeler GD, Sherman A, et al. . Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells. Mol Ther 2020;28:758&#x2013;70. 10.1016/j.ymthe.2019.11.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymthe.2019.11.011</ArticleId>
            <ArticleId IdType="pmc">PMC7054715</ArticleId>
            <ArticleId IdType="pubmed">31780366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimco G, Knight RA, Latchman DS, et al. . Stat1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest. Cell Cycle 2010;9:4638&#x2013;49. 10.4161/cc.9.23.13955</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.9.23.13955</ArticleId>
            <ArticleId IdType="pubmed">21084836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apelbaum A, Yarden G, Warszawski S, et al. . Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands. Mol Cell Biol 2013;33:800&#x2013;14. 10.1128/MCB.01430-12</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.01430-12</ArticleId>
            <ArticleId IdType="pmc">PMC3571350</ArticleId>
            <ArticleId IdType="pubmed">23230268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braum&#xfc;ller H, Wieder T, Brenner E, et al. . T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494:361&#x2013;5. 10.1038/nature11824</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11824</ArticleId>
            <ArticleId IdType="pubmed">23376950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duncan SA, Baganizi DR, Sahu R, et al. . Socs proteins as regulators of inflammatory responses induced by bacterial infections: a review. Front Microbiol 2017;8:2431. 10.3389/fmicb.2017.02431</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2017.02431</ArticleId>
            <ArticleId IdType="pmc">PMC5733031</ArticleId>
            <ArticleId IdType="pubmed">29312162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liau NPD, Laktyushin A, Lucet IS, et al. . The molecular basis of JAK/STAT inhibition by SOCS1. Nat Commun 2018;9:1558. 10.1038/s41467-018-04013-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-04013-1</ArticleId>
            <ArticleId IdType="pmc">PMC5908791</ArticleId>
            <ArticleId IdType="pubmed">29674694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkitachalam S, Chueh F-Y, Leong K-F, et al. . Suppressor of cytokine signaling 1 interacts with oncogenic lymphocyte-specific protein tyrosine kinase. Oncol Rep 2011;25:677&#x2013;83. 10.3892/or.2011.1144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2011.1144</ArticleId>
            <ArticleId IdType="pmc">PMC3031786</ArticleId>
            <ArticleId IdType="pubmed">21234523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004;24:5434&#x2013;46. 10.1128/MCB.24.12.5434-5446.2004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.24.12.5434-5446.2004</ArticleId>
            <ArticleId IdType="pmc">PMC419873</ArticleId>
            <ArticleId IdType="pubmed">15169905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez-Vega F, Mina M, Armenia J, et al. . Oncogenic signaling pathways in the cancer genome atlas. Cell 2018;173:321&#x2013;37. 10.1016/j.cell.2018.03.035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.03.035</ArticleId>
            <ArticleId IdType="pmc">PMC6070353</ArticleId>
            <ArticleId IdType="pubmed">29625050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma SV, Fischbach MA, Haber DA, et al. . "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 2006;12:4392s&#x2013;5. 10.1158/1078-0432.CCR-06-0096</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-0096</ArticleId>
            <ArticleId IdType="pubmed">16857816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SE, Lee SH, Ahn JS, et al. . Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol 2018;13:106&#x2013;11. 10.1016/j.jtho.2017.10.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2017.10.011</ArticleId>
            <ArticleId IdType="pubmed">29101058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osterweil N. Salvage chemo for NSCLC more effective after PD-1/PD-L1 inhibitors. Oncology Practice 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Alspach E, Lussier DM, Schreiber RD. Interferon &#x3b3; and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb Perspect Biol 2019;11. 10.1101/cshperspect.a028480. [Epub ahead of print: 01 Mar 2019].</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a028480</ArticleId>
            <ArticleId IdType="pmc">PMC6396335</ArticleId>
            <ArticleId IdType="pubmed">29661791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fridman WH, Pag&#xe8;s F, Saut&#xe8;s-Fridman C, et al. . The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298&#x2013;306. 10.1038/nrc3245</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3245</ArticleId>
            <ArticleId IdType="pubmed">22419253</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33657989</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1793-6853</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>49</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>The American journal of Chinese medicine</Title>
          <ISOAbbreviation>Am J Chin Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Quercetin Induces Apoptosis in Glioblastoma Cells by Suppressing Axl/IL-6/STAT3 Signaling Pathway.</ArticleTitle>
        <Pagination>
          <StartPage>767</StartPage>
          <EndPage>784</EndPage>
          <MedlinePgn>767-784</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1142/S0192415X21500361</ELocationID>
        <Abstract>
          <AbstractText>Gliomas are the mostly observed form of primary brain tumor, and glioblastoma multiforme (GBM) shows the highest incidence. The survival rate of GBM is fairly poor; thus, discovery of effective treatment options is required. Among several suggested targets for therapy, the Axl/IL-6/STAT3 signaling pathway has gained recent interest because of its important role within cancer microenvironment. Quercetin, a plant flavonoid, is well known for its anticancer action. However, the effect of quercetin on Axl has never been reported. Quercetin treatment significantly reduced cell viability in two GBM cell lines of U87MG and U373MG while keeping 85% of normal astrocytes alive. Further western blot assays suggested that quercetin induces apoptosis but does not affect Akt or mitogen-activated protein kinases, factors related to cell proliferation. Quercetin also decreased IL-6 release and phosphorylation of STAT3 in GBM cells. In addition, gene expression, protein expression, and half-life of synthesized Axl protein were all suppressed by quercetin. By applying shRNA for knockdown of Axl, we could confirm that the role of Axl was crucial in the apoptotic effect of quercetin on GBM cells. In conclusion, we suggest quercetin as a potential anticancer agent, which may improve cancer microenvironment of GBM via the Axl/IL-6/STAT3 pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Hyo In</ForeName>
            <Initials>HI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA 02215, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Sol Ji</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Cognition and Sociality Institute for Basic Science, Daejeon 34126, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Yu-Jeong</ForeName>
            <Initials>YJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Science in Korean Medicine, College of Korean Medicine Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Min Jeong</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Science in Korean Medicine, College of Korean Medicine Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Tai Young</ForeName>
            <Initials>TY</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Cognition and Sociality Institute for Basic Science, Daejeon 34126, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ko</LastName>
            <ForeName>Seong-Gyu</ForeName>
            <Initials>SG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Singapore</Country>
        <MedlineTA>Am J Chin Med</MedlineTA>
        <NlmUniqueID>7901431</NlmUniqueID>
        <ISSNLinking>0192-415X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9IKM0I5T1E</RegistryNumber>
          <NameOfSubstance UI="D011794">Quercetin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000094963">Axl Receptor Tyrosine Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000722289">AXL protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="Y">Antineoplastic Agents, Phytogenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008517" MajorTopicYN="N">Phytotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011794" MajorTopicYN="N">Quercetin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020794" MajorTopicYN="N">Receptor Protein-Tyrosine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000094963" MajorTopicYN="N">Axl Receptor Tyrosine Kinase</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Axl</Keyword>
        <Keyword MajorTopicYN="N">Glioblastoma</Keyword>
        <Keyword MajorTopicYN="N">IL-6</Keyword>
        <Keyword MajorTopicYN="N">Quercetin</Keyword>
        <Keyword MajorTopicYN="N">STAT3</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33657989</ArticleId>
        <ArticleId IdType="doi">10.1142/S0192415X21500361</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33656766</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1759-7714</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Thoracic cancer</Title>
          <ISOAbbreviation>Thorac Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Curcumin induces ferroptosis in non-small-cell lung cancer via activating autophagy.</ArticleTitle>
        <Pagination>
          <StartPage>1219</StartPage>
          <EndPage>1230</EndPage>
          <MedlinePgn>1219-1230</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/1759-7714.13904</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Emerging studies showed curcumin can inhibit glioblastoma and breast cancer cells via regulating ferroptosis. However, the role of ferroptosis in the inhibitory effect of curcumin on non-small-cell lung cancer (NSCLC) remains unclear.</AbstractText>
          <AbstractText Label="METHODS">Cell counting kit-8 (CCK-8) assay was used to measure the viability of A549 and H1299 cells under different conditions. Cell proliferation was examined by Ki67 immunofluorescence. The morphological changes of cells and tumor tissues were observed by optical microscope and hematoxylin and eosin (H&amp;E) staining. Intracellular reactive oxygen species (ROS), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), and iron contents were determined by corresponding assay kit. The related protein expression levels were detected by western blot and immunohistochemistry. Transmission electron microscope was used to observe ultrastructure changes of A549 and H1299 cells.</AbstractText>
          <AbstractText Label="RESULTS">Curcumin inhibited tumor growth and cell proliferation, but promoted cell death. Characteristic changes of ferroptosis were observed in curcumin group, including iron overload, GSH depletion and lipid peroxidation. Meanwhile, the protein level of ACSL4 was higher and the levels of SLC7A11 and GPX4 were lower in curcumin group than that in control group. Incubation of ferroptosis inhibitors ferrostatin-1 (Fer-1) or knockdown of iron-responsive element-binding protein 2 (IREB2) notably weakened curcumin-induced anti-tumor effect and ferroptosis in A549 and H1299 cells. Further investigation suggested that curcumin induced mitochondrial membrane rupture and mitochondrial cristae decrease, increased autolysosome, increased the level of Beclin1 and LC3, and decreased the level of P62. Curcumin-induced autophagy and subsequent ferroptosis were both alleviated with autophagy inhibitor chloroquine (CQ) or siBeclin1.</AbstractText>
          <AbstractText Label="CONCLUSION">Curcumin induced ferroptosis via activating autophagy in NSCLC, which enhanced the therapeutic effect of NSCLC.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Tang</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-0372-478X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Ding</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Liang</LastName>
            <ForeName>Maoli</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-5112-0892</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xing</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Yuxia</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Nansheng</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Qianqian</ForeName>
            <Initials>Q</Initials>
            <Identifier Source="ORCID">0000-0002-2879-0310</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-6058-4608</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>2016YFC1304502</GrantID>
            <Agency>National key research and development program of China</Agency>
          </Grant>
          <Grant>
            <GrantID>81670084</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>81970084</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>20YFZCSY00390</GrantID>
            <Agency>Tianjin Key Research and Development Program</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Singapore</Country>
        <MedlineTA>Thorac Cancer</MedlineTA>
        <NlmUniqueID>101531441</NlmUniqueID>
        <ISSNLinking>1759-7706</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IT942ZTH98</RegistryNumber>
          <NameOfSubstance UI="D003474">Curcumin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079403" MajorTopicYN="N">Ferroptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">curcumin</Keyword>
        <Keyword MajorTopicYN="N">ferroptosis</Keyword>
        <Keyword MajorTopicYN="N">non-small-cell lung cancer</Keyword>
      </KeywordList>
      <CoiStatement>The author reports no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>12</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33656766</ArticleId>
        <ArticleId IdType="pmc">PMC8046146</ArticleId>
        <ArticleId IdType="doi">10.1111/1759-7714.13904</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosas G, Ruiz R, Araujo JM, Pinto JA, Mas L. ALK rearrangements: Biology, detection and opportunities of therapy in non&#x2010;small cell lung cancer. Crit Rev Oncol Hematol. 2019;136:48&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30878128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng T, Wei Y, Lee RJ, Zhao L. Liposomal curcumin and its application in cancer. Int J Nanomedicine. 2017;12:6027&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5573051</ArticleId>
            <ArticleId IdType="pubmed">28860764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: Current therapies and new targeted treatments. Lancet. 2017;389:299&#x2013;311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27574741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ III, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12:1425&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4968231</ArticleId>
            <ArticleId IdType="pubmed">27245739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yilong Z, Michael JP, Amy AD, Li H, Eaton JK, Wang W, et al. A GPX4&#x2010;dependent cancer cell state underlies the clear&#x2010;cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10:1617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6453886</ArticleId>
            <ArticleId IdType="pubmed">30962421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torii S, Shintoku R, Kubota C, Yaegashi M, Torii R, Sasaki M, et al. An essential role for functional lysosomes in ferroptosis of cancer cells. Biochem J. 2016;473:769&#x2013;77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26759376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomeh MA, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci. 2019;20:1033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6429287</ArticleId>
            <ArticleId IdType="pubmed">30818786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen TC, Chuang JY, Ko CY, Kao TJ, Yang PY, Yu CH, et al. AR ubiquitination induced by the curcumin analog suppresses growth of temozolomide&#x2010;resistant glioblastoma through disrupting GPX4&#x2010;mediated redox homeostasis. Redox Biol. 2020;30:101413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6940696</ArticleId>
            <ArticleId IdType="pubmed">31896509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R, Zhang J, Zhou Y, Gao Q, Wang R, Fu Y, et al. Transcriptome investigation and in vitro verification of curcumin&#x2010;induced HO&#x2010;1 as a feature of ferroptosis in breast cancer cells. Oxid Med Cell Longev. 2020;2020:3469840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7691002</ArticleId>
            <ArticleId IdType="pubmed">33294119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park E, Chung SW. ROS&#x2010;mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. Cell Death Dis. 2019;10:822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6817894</ArticleId>
            <ArticleId IdType="pubmed">31659150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockwell BR, Friedmann AJP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5685180</ArticleId>
            <ArticleId IdType="pubmed">28985560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei S, Qiu T, Yao X, Wang N, Jiang L, Jia X, et al. Arsenic induces pancreatic dysfunction and ferroptosis via mitochondrial ROS&#x2010;autophagy&#x2010;lysosomal pathway. J Hazard Mater. 2020;384:121390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31735470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C, et al. Ferroptosis: A novel anti&#x2010;tumor action for Cisplatin. Cancer Res Treat. 2018;50:445&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5912137</ArticleId>
            <ArticleId IdType="pubmed">28494534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, et al. RAS&#x2010;RAF&#x2010;MEK&#x2010;dependent oxidative cell death involving voltage&#x2010;dependent anion channels. Nature. 2007;447:864&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3047570</ArticleId>
            <ArticleId IdType="pubmed">17568748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: An iron&#x2010;dependent form of nonapoptotic cell death. Cell. 2012;149:1060&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367386</ArticleId>
            <ArticleId IdType="pubmed">22632970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen P, Wu Q, Feng J, Yan L, Sun Y, Liu S, et al. Erianin, a novel dibenzyl compound in dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin&#x2010;dependent ferroptosis. Signal Transduct Target Ther. 2020;5:51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7205607</ArticleId>
            <ArticleId IdType="pubmed">32382060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia X, Fan X, Zhao M, Zhu P. The relationship between Ferroptosis and tumors: A novel landscape for therapeutic approach. Curr Gene Ther. 2019;19:117&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7046989</ArticleId>
            <ArticleId IdType="pubmed">31264548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta HJ, Patel V, Sadikot RT. Curcumin and lung cancer&#x2013;A review. Target Oncol. 2014;9:295&#x2013;310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24840628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guerrero&#x2010;Hue M, Garcia&#x2010;Caballero C, Palomino&#x2010;Antolin A, Rubio&#x2010;Navarro A, V&#xe1;zquez&#x2010;Carballo C, Herencia C, et al. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis&#x2010;mediated cell death. FASEB J. 2019;33:8961&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31034781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onorati AV, Dyczynski M, Ojha R. Targeting autophagy in cancer. Cancer&#x2010;Am Cancer Soc. 2018;124:3307&#x2013;18.</Citation>
        </Reference>
        <Reference>
          <Citation>Kang R, Tang D. Autophagy and Ferroptosis &#x2010; What's the connection? Curr Pathobiol Rep. 2017;5:153&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5640172</ArticleId>
            <ArticleId IdType="pubmed">29038744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S, Henson ES, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7:e2307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4973350</ArticleId>
            <ArticleId IdType="pubmed">27441659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy&#x2010;dependent cell death. Semin Cancer Biol. 2020;66:89&#x2013;100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30880243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latunde&#x2010;Dada GO. Ferroptosis: Role of lipid peroxidation, iron and ferritinophagy. Biochim Biophys Acta Gen Subj. 1861;2017:1893&#x2013;900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28552631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharifi S, Fathi N, Memar MY, Hosseiniyan Khatibi SM, Khalilov R, Negahdari R, et al. Anti&#x2010;microbial activity of curcumin nanoformulations: New trends and future perspectives. Phytother Res. 2020;34:1926&#x2013;46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32166813</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33508878</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-0261</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular oncology</Title>
          <ISOAbbreviation>Mol Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Small extracellular vesicles deliver TGF-Î²1 and promote adriamycin resistance in breast cancer cells.</ArticleTitle>
        <Pagination>
          <StartPage>1528</StartPage>
          <EndPage>1542</EndPage>
          <MedlinePgn>1528-1542</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/1878-0261.12908</ELocationID>
        <Abstract>
          <AbstractText>Chemotherapeutic resistance is a major obstacle in the control of advanced breast cancer (BCa). We have previously shown that small extracellular vesicles (sEVs) can transmit adriamycin resistance between BCa cells. Here, we describe that sEV-mediated TGF-Î²1 intercellular transfer is involved in the drug-resistant transmission. sEVs were isolated and characterized from both sensitive and resistant cells. sEVs derived from the resistant cells were incubated with the sensitive cells and resulted in transmitting the resistant phenotype to the recipient cells. Cytokine antibody microarray revealed that most metastasis-associated cytokines present at the high levels in sEVs from the resistant cells compared with their levels in sEVs from the sensitive cells, particularly TGF-Î²1 is enriched in sEVs from the resistant cells. The sEV-mediated TGF-Î²1 intercellular transfer led to increasing Smad2 phosphorylation and improving cell survival by suppressing apoptosis and enhancing cell mobility. Furthermore, sEV-mediated drug-resistant transmission by delivering TGF-Î²1 was validated using a zebrafish xenograft tumor model. These results elaborated that sEV-mediated TGF-Î²1 intercellular transfer contributes to adriamycin resistance in BCa.</AbstractText>
          <CopyrightInformation>&#xa9; 2021 The Authors. Molecular Oncology published by John Wiley &amp; Sons Ltd on behalf of Federation of European Biochemical Societies.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Chunli</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Institute of Cancer Research, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, the First Affiliated Hospital with Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Wenbo</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Institute of Cancer Research, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, the First Affiliated Hospital with Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Shuyi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Institute of Cancer Research, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Weizi</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Institute of Cancer Research, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, the First Affiliated Hospital with Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiumei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Institute of Cancer Research, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yanyan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Institute of Cancer Research, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Guangqin</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zibin</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis and Test Center, Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-8361-9970</Identifier>
            <AffiliationInfo>
              <Affiliation>Jiangsu Institute of Cancer Research, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Jinhai</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, the First Affiliated Hospital with Nanjing Medical University, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Oncol</MedlineTA>
        <NlmUniqueID>101308230</NlmUniqueID>
        <ISSNLinking>1574-7891</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508960">TGFB1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004625" MajorTopicYN="N">Embryo, Nonmammalian</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067128" MajorTopicYN="N">Extracellular Vesicles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019899" MajorTopicYN="N">Paracrine Communication</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015027" MajorTopicYN="N">Zebrafish</DescriptorName>
          <QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">EMT</Keyword>
        <Keyword MajorTopicYN="N">TGF-&#x3b2;1</Keyword>
        <Keyword MajorTopicYN="N">adriamycin resistance and breast cancer</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">sEVs</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>20</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33508878</ArticleId>
        <ArticleId IdType="pmc">PMC8096780</ArticleId>
        <ArticleId IdType="doi">10.1002/1878-0261.12908</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet&#x2010;Tieulent J &amp; Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65, 87&#x2013;108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25651787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma CX, Reinert T, Chmielewska I &amp; Ellis MJ (2015) Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer 15, 261&#x2013;275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25907219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y, Wang Y, Kiani MF &amp; Wang B (2016) Classification, treatment strategy, and associated drug resistance in breast cancer. Clin Breast Cancer 16, 335&#x2013;343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27268750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blumenschein GR, DiStefano A, Caderao J, Fristenberg B, Adams J, Schweichler LH &amp; Drinkard L (1997) Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non&#x2010;cross&#x2010;resistance late&#x2010;consolidation chemotherapy. Clin Cancer Res 3, 2633&#x2013;2637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10068266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marinello PC, Panis C, Silva TNX, Binato R, Abdelhay E, Rodrigues JA, Mencalha AL, Lopes NMD, Luiz RC, Cecchini R et al. (2019) Metformin prevention of doxorubicin resistance in MCF&#x2010;7 and MDA&#x2010;MB&#x2010;231 involves oxidative stress generation and modulation of cell adaptation genes. Sci Rep 9, 5864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6458149</ArticleId>
            <ArticleId IdType="pubmed">30971831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>V&#xe9;zian A (2014) Tumor microenvironment and therapeutic resistance process. Med Sci (Paris) 30, 803&#x2013;807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25174759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W &amp; Geuze HJ (2000) Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113 (Pt 19), 3365&#x2013;3374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10984428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin&#x2010;Smith GK et al. (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7, 1535750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6322352</ArticleId>
            <ArticleId IdType="pubmed">30637094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayraktar R, Van Roosbroeck K &amp; Calin GA (2017) Cell&#x2010;to&#x2010;cell communication: microRNAs as hormones. Mol Oncol 11, 1673&#x2013;1686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5709614</ArticleId>
            <ArticleId IdType="pubmed">29024380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Yuan X, Shi H, Wu L, Qian H &amp; Xu W (2015) Exosomes in cancer: small particle, big player. J Hematol Oncol 8, 83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4496882</ArticleId>
            <ArticleId IdType="pubmed">26156517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schorey JS, Cheng Y, Singh PP &amp; Smith VL (2015) Exosomes and other extracellular vesicles in host&#x2010;pathogen interactions. EMBO Rep 16, 24&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4304727</ArticleId>
            <ArticleId IdType="pubmed">25488940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X, Shen B, Liu S, Yan D &amp; Feng J (2017) Cisplatin&#x2010;resistant lung cancer cell&#x2010;derived exosomes increase cisplatin resistance of recipient cells in exosomal miR&#x2010;100&#x2010;5p&#x2010;dependent manner. Int J Nanomedicine 12, 3721&#x2013;3733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5439933</ArticleId>
            <ArticleId IdType="pubmed">28553110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, Li H, Zhu X, Yao L &amp; Zhang J (2014) Exosomal miR&#x2010;221/222 enhances tamoxifen resistance in recipient ER&#x2010;positive breast cancer cells. Breast Cancer Res Treat 147, 423&#x2013;431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25007959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fatima F &amp; Nawaz M (2017) Vesiculated long non&#x2010;coding RNAs: offshore packages deciphering trans&#x2010;regulation between cells, cancer progression and resistance to therapies. Noncoding RNA 3, 10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5831998</ArticleId>
            <ArticleId IdType="pubmed">29657282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, Webb G, McDermott R, Watson W, Crown J et al. (2012) Docetaxel&#x2010;resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One 7, e50999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3519481</ArticleId>
            <ArticleId IdType="pubmed">23251413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P &amp; Rincon M (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61, 8851&#x2013;8858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11751408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilbert LA &amp; Hemann MT (2010) DNA damage&#x2010;mediated induction of a chemoresistant niche. Cell 143, 355&#x2013;366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972353</ArticleId>
            <ArticleId IdType="pubmed">21029859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova&#x2010;Todorova K, Leversha M, Hogg N, Seshan VE et al. (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165&#x2013;178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3528019</ArticleId>
            <ArticleId IdType="pubmed">22770218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asiedu MK, Ingle JN, Behrens MD, Radisky DC &amp; Knutson KL (2011) TGFbeta/TNF(alpha)&#x2010;mediated epithelial&#x2010;mesenchymal transition generates breast cancer stem cells with a claudin&#x2010;low phenotype. Cancer Res 71, 4707&#x2013;4719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3129359</ArticleId>
            <ArticleId IdType="pubmed">21555371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernando RI, Castillo MD, Litzinger M, Hamilton DH &amp; Palena C (2011) IL&#x2010;8 signaling plays a critical role in the epithelial&#x2010;mesenchymal transition of human carcinoma cells. Cancer Res 71, 5296&#x2013;5306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3148346</ArticleId>
            <ArticleId IdType="pubmed">21653678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM &amp; Hall BM (2009) Interleukin&#x2010;6 induces an epithelial&#x2010;mesenchymal transition phenotype in human breast cancer cells. Oncogene 28, 2940&#x2013;2947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5576031</ArticleId>
            <ArticleId IdType="pubmed">19581928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X, Zhang L, He X, Zhang P, Sun C, Xu X, Lu Y &amp; Li F (2018) TGF&#x2010;beta plays a vital role in triple&#x2010;negative breast cancer (TNBC) drug&#x2010;resistance through regulating stemness, EMT and apoptosis. Biochem Biophys Res Commun 502, 160&#x2013;165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29792857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringner M, Morgelin M, Bourseau&#x2010;Guilmain E, Bengzon J &amp; Belting M (2013) Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia&#x2010;dependent activation of vascular cells during tumor development. Proc Natl Acad Sci USA 110, 7312&#x2013;7317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3645587</ArticleId>
            <ArticleId IdType="pubmed">23589885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Languino LR, Singh A, Prisco M, Inman GJ, Luginbuhl A, Curry JM &amp; South AP (2016) Exosome&#x2010;mediated transfer from the tumor microenvironment increases TGFbeta signaling in squamous cell carcinoma. Am J Transl Res 8, 2432&#x2013;2437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4891457</ArticleId>
            <ArticleId IdType="pubmed">27347352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E et al. (2013) BM mesenchymal stromal cell&#x2010;derived exosomes facilitate multiple myeloma progression. J Clin Invest 123, 1542&#x2013;1555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3613927</ArticleId>
            <ArticleId IdType="pubmed">23454749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez VG, O'Neill S, Salimu J, Breslin S, Clayton A, Crown J &amp; O'Driscoll L (2017) Resistance to HER2&#x2010;targeted anti&#x2010;cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles. Oncoimmunology 6, e1362530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5706614</ArticleId>
            <ArticleId IdType="pubmed">29209569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv LL, Feng Y, Wen Y, Wu WJ, Ni HF, Li ZL, Zhou LT, Wang B, Zhang JD, Crowley SD et al. (2018) Exosomal CCL2 from tubular epithelial cells is critical for albumin&#x2010;induced tubulointerstitial inflammation. J Am Soc Nephrol 29, 919&#x2013;935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5827595</ArticleId>
            <ArticleId IdType="pubmed">29295871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ono K, Eguchi T, Sogawa C, Calderwood SK, Futagawa J, Kasai T, Seno M, Okamoto K, Sasaki A &amp; Kozaki KI (2018) HSP&#x2010;enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells. J Cell Biochem 119, 7350&#x2013;7362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29768689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicolini A, Carpi A, Ferrari P, Biava PM &amp; Rossi G (2016) Immunotherapy and hormone&#x2010;therapy in metastatic breast cancer: a review and an update. Curr Drug Targets 17, 1127&#x2013;1139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26844558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K &amp; Sun LZ (2010) Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 5, e10365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2860989</ArticleId>
            <ArticleId IdType="pubmed">20442777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallini P, Lennard T, Kirby J &amp; Meeson A (2014) Epithelial&#x2010;to&#x2010;mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 40, 341&#x2013;348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24090504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skladanowski A &amp; Konopa J (1993) Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 46, 375&#x2013;382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7688510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamato D, Burch ML, Piva TJ, Rezaei HB, Rostam MA, Xu S, Zheng W, Little PJ &amp; Osman N (2013) Transforming growth factor&#x2010;beta signalling: role and consequences of Smad linker region phosphorylation. Cell Signal 25, 2017&#x2013;2024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23770288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Qin Y &amp; Liu S (2018) Cytokines, breast cancer stem cells (BCSCs) and chemoresistance. Clin Transl Med 7, 27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6119679</ArticleId>
            <ArticleId IdType="pubmed">30175384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A &amp; Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741&#x2013;4751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3176718</ArticleId>
            <ArticleId IdType="pubmed">20531305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suarez&#x2010;Carmona M, Lesage J, Cataldo D &amp; Gilles C (2017) EMT and inflammation: inseparable actors of cancer progression. Mol Oncol 11, 805&#x2013;823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5496491</ArticleId>
            <ArticleId IdType="pubmed">28599100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan C, Hu W, He Y, Zhang Y, Zhang G, Xu Y &amp; Tang J (2018) Cytokine&#x2010;mediated therapeutic resistance in breast cancer. Cytokine 108, 151&#x2013;159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29609137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rong L, Li R, Li S &amp; Luo R (2016) Immunosuppression of breast cancer cells mediated by transforming growth factor&#x2010;beta in exosomes from cancer cells. Oncol Lett 11, 500&#x2013;504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4727188</ArticleId>
            <ArticleId IdType="pubmed">26870240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SY, Kim MJ, Park SA, Kim JS, Min KN, Kim DK, Lim W, Nam JS &amp; Sheen YY (2015) Combinatorial TGF&#x2010;beta attenuation with paclitaxel inhibits the epithelial&#x2010;to&#x2010;mesenchymal transition and breast cancer stem&#x2010;like cells. Oncotarget 6, 37526&#x2013;37543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4741946</ArticleId>
            <ArticleId IdType="pubmed">26462028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharieh EA, Awidi AS, Ahram M &amp; Zihlif MA (2016) Alteration of gene expression in MDA&#x2010;MB&#x2010;453 breast cancer cell line in response to continuous exposure to Trastuzumab. Gene 575, 415&#x2013;420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26367328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J, Canaff L, Rajadurai CV, Fils&#x2010;Aime N, Tian J, Dai M, Korah J, Villatoro M, Park M, Ali S et al. (2014) Breast cancer anti&#x2010;estrogen resistance 3 inhibits transforming growth factor beta/Smad signaling and associates with favorable breast cancer disease outcomes. Breast Cancer Res 16, 476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4311507</ArticleId>
            <ArticleId IdType="pubmed">25499443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jabbari N, Nawaz M &amp; Rezaie J (2019) Ionizing radiation increases the activity of exosomal secretory pathway in MCF&#x2010;7 human breast cancer cells: a possible way to communicate resistance against radiotherapy. Int J Mol Sci 20, 3649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6696324</ArticleId>
            <ArticleId IdType="pubmed">31349735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jabbari N, Nawaz M &amp; Rezaie J (2019) Bystander effects of ionizing radiation: conditioned media from X&#x2010;ray irradiated MCF&#x2010;7 cells increases the angiogenic ability of endothelial cells. Cell Commun Signal 17, 165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6912994</ArticleId>
            <ArticleId IdType="pubmed">31842899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ham S, Lima LG, Chai EPZ, Muller A, Lobb RJ, Krumeich S, Wen SW, Wiegmans AP &amp; Moller A (2018) Breast cancer&#x2010;derived exosomes alter macrophage polarization via gp130/STAT3 signaling. Front Immunol 9, 871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5951966</ArticleId>
            <ArticleId IdType="pubmed">29867925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soderberg A, Barral AM, Soderstrom M, Sander B &amp; Rosen A (2007) Redox&#x2010;signaling transmitted in trans to neighboring cells by melanoma&#x2010;derived TNF&#x2010;containing exosomes. Free Radic Biol Med 43, 90&#x2013;99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17561097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, Graner M, Frederick B, Agarwal R &amp; Deep G (2015) Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol Carcinog 54, 554&#x2013;565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4706761</ArticleId>
            <ArticleId IdType="pubmed">24347249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Yi J, Chen X, Zhang Y, Xu M &amp; Yang Z (2016) The regulation of cancer cell migration by lung cancer cell&#x2010;derived exosomes through TGF&#x2010;beta and IL&#x2010;10. Oncol Lett 11, 1527&#x2013;1530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4734314</ArticleId>
            <ArticleId IdType="pubmed">26893774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webber J, Steadman R, Mason MD, Tabi Z &amp; Clayton A (2010) Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 70, 9621&#x2013;9630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21098712</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33237729</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1944-8252</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>49</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS applied materials &amp; interfaces</Title>
          <ISOAbbreviation>ACS Appl Mater Interfaces</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Electric Pulse Responsive Magnetic Nanoclusters Loaded with Indoleamine 2,3-Dioxygenase Inhibitor for Synergistic Immuno-Ablation Cancer Therapy.</ArticleTitle>
        <Pagination>
          <StartPage>54415</StartPage>
          <EndPage>54425</EndPage>
          <MedlinePgn>54415-54425</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acsami.0c15679</ELocationID>
        <Abstract>
          <AbstractText>An overlay of local ablation and immunotherapies could be one of the promising approaches to treat solid tumors, but finding the synergistic combination is still challenging with immune tolerance. Herein, electric pulse responsive iron-oxide-nanocube clusters (IONCs) loaded with indoleamine 2,3-dioxygenase inhibitors (IDOi) are prepared for the enhancement of irreversible electroporation (IRE) cell killing and modulation of the tumor immunosuppressive microenvironment (TIM). IDOi-loaded-IONCs (IDOi-IONCs) show highly responsive movement upon the application of IRE electric pulses inducing local magnetic fields. In vitro and in vivo IRE cell-killing efficiency are significantly enhanced by the IDOi-IONCs. The IRE with IDOi-IONCs also triggers IDOi release from IONCs for TIM modulation. The enhanced cell death and local IDOi release of the IRE with IDOi-IONCs demonstrate a synergistic anticancer effect in vivo with overturning the TIM. The increased infiltration of CD8[+] T cells and the elevated ratio of CD8[+] T cells to regulatory T cells are confirmed after the IRE with IDOi-IONCs. Further, synergistic interaction between IRE and IDOi-modulated TIM resulted in enhanced elimination of primary and secondary tumors. This proof-of-concept work illustrates a robust modality to guide immune-modulating nanoparticle-mediated immuno-ablation cancer therapies that can be easily tailored to improve its therapeutic outcome.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Wentao</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, McCormick School of Engineering, Evanston, Illinois 60208, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwak</LastName>
            <ForeName>Kijung</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, McCormick School of Engineering, Evanston, Illinois 60208, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Hyunjun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Bioengineering, University of Illinois at Chicago, Chicago, Illinois 60607, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Dong-Hyun</ForeName>
            <Initials>DH</Initials>
            <Identifier Source="ORCID">0000-0001-6815-3319</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Bioengineering, University of Illinois at Chicago, Chicago, Illinois 60607, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, McCormick School of Engineering, Evanston, Illinois 60208, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Appl Mater Interfaces</MedlineTA>
        <NlmUniqueID>101504991</NlmUniqueID>
        <ISSNLinking>1944-8244</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050503">Indoleamine-Pyrrole 2,3,-Dioxygenase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018274" MajorTopicYN="Y">Electroporation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050503" MajorTopicYN="N">Indoleamine-Pyrrole 2,3,-Dioxygenase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060526" MajorTopicYN="N">Magnetic Fields</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082662" MajorTopicYN="N">Magnetic Iron Oxide Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">indoleamine 2,3-dioxygenase inhibitor</Keyword>
        <Keyword MajorTopicYN="N">irreversible electroporation</Keyword>
        <Keyword MajorTopicYN="N">local ablation</Keyword>
        <Keyword MajorTopicYN="N">magnetic nanoparticles</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>17</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33237729</ArticleId>
        <ArticleId IdType="doi">10.1021/acsami.0c15679</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33158173</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2073-4425</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Genes</Title>
          <ISOAbbreviation>Genes (Basel)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lymphatic Metastasis of NSCLC Involves Chemotaxis Effects of Lymphatic Endothelial Cells through the CCR7-CCL21 Axis Modulated by TNF-Î±.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1309</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/genes11111309</ELocationID>
        <Abstract>
          <AbstractText>Metastasis and recurrence are the main causes of lung adenocarcinoma patients' death. Lymphatic metastasis is the main way of non-small cell lung cancer (NSCLC) metastasis. C-C chemokine receptor type 7 (CCR7) overexpression has been demonstrated to mediate occurrence and progression of NSCLC. Moreover, Chemokine ligand 21 (CCL21) was used to activate CCR7. The CCR7-CCL21 axis is one of the most common "chemokine-receptor" modes of action in the development and metastasis of multiple tumors. However, the role of the CCR7-CCL21 axis in lymphatic metastasis of NSCLC is poorly understood. The study was conducted to investigate the molecular mechanism underlying CCR7-CCL21 axis-mediated lymphatic metastasis of NSCLC A549 cells. Tumor necrosis factor Î± (TNF-Î±) could regulate the tumor microenvironment balance by promoting chemokine secretion. Our study demonstrated that TNF-Î± promoted CCL21 production in human lymphatic endothelial cells (HLEC). Results further showed that TNF-Î± significantly activated the NF-ÎºB pathway in HLEC. NF-ÎºB pathway inhibition with ammonium pyrrolidinedithiocarbamate (PDTC) caused a significant decrease in CCL21 secretion, suggesting that TNF-Î±-induced CCL21 secretion in HLEC was through NF-ÎºB pathway. Co-culture of A549 cells and TNF-Î±-treated HLEC confirmed that the metastasis of A549 cells was enhanced, meanwhile, apoptosis-related proteins were hardly affected. The data proved that a co-culture system prevented cell apoptosis while inducing the lymphatic metastasis of A549 cells. However, the situation was reversed after neutralizing CCL21 expression, suggesting that TNF-Î±-induced CCL21 secretion in HLEC is involved in A549 cells metastasis. Collectively, our finding demonstrated that NF-ÎºB pathway-controlled CCL21 secretion of HLEC contributing to the lymphatic metastasis of A549 cells via the CCR7-CCL21 axis, validating the CCR7-CCL21 axis as a potential target to inhibit metastasis of NSCLC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shuai</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Hongzheng</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhiyun</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bai</LastName>
            <ForeName>Yongkang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Genes (Basel)</MedlineTA>
        <NlmUniqueID>101551097</NlmUniqueID>
        <ISSNLinking>2073-4425</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515478">CCL21 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515370">CCR7 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054421">Chemokine CCL21</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054400">Receptors, CCR7</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054421" MajorTopicYN="N">Chemokine CCL21</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002633" MajorTopicYN="N">Chemotaxis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054400" MajorTopicYN="N">Receptors, CCR7</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CCL21</Keyword>
        <Keyword MajorTopicYN="N">CCR7</Keyword>
        <Keyword MajorTopicYN="N">NSCLC</Keyword>
        <Keyword MajorTopicYN="N">TNF-&#x3b1;</Keyword>
        <Keyword MajorTopicYN="N">lymphatic metastasis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>7</Day>
          <Hour>1</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33158173</ArticleId>
        <ArticleId IdType="pmc">PMC7694274</ArticleId>
        <ArticleId IdType="doi">10.3390/genes11111309</ArticleId>
        <ArticleId IdType="pii">genes11111309</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Knight S.B., Crosbie P.A., Balata H., Chudziak J., Hussell T., Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7:7. doi: 10.1098/rsob.170070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1098/rsob.170070</ArticleId>
            <ArticleId IdType="pmc">PMC5627048</ArticleId>
            <ArticleId IdType="pubmed">28878044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Facchinetti F., Marabelle A., Rossi G., Soria J.-C., Besse B., Tiseo M. Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. J. Thorac. Oncol. 2016;11:1819&#x2013;1836. doi: 10.1016/j.jtho.2016.05.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2016.05.027</ArticleId>
            <ArticleId IdType="pubmed">27288978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardwicke K. Nursing Standard (Royal College of Nursing (Great Britain): 1987. Vol. 22. Royal College of Nursing; Sunderland, UK: 2008. Lung cancer; p. 59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18727357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris K., Khachaturova I., Azab B., Maniatis T., Murukutla S., Chalhoub M., Hatoum H., Kilkenny T., Elsayegh D., Maroun R. Small Cell Lung Cancer Doubling Time and its Effect on Clinical Presentation: A Concise Review. Clin. Med. Insights Oncol. 2012;6:199&#x2013;203. doi: 10.4137/CMO.S9633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4137/CMO.S9633</ArticleId>
            <ArticleId IdType="pmc">PMC3355865</ArticleId>
            <ArticleId IdType="pubmed">22619563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang C.-F.J., Chan D.Y., Speicher P.J., Gulack B.C., Wang X., Hartwig M.G., Onaitis M.W., Tong B.C., D&#x2019;Amico T.A., Berry M.F. Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. J. Clin. Oncol. 2016;34:1057&#x2013;1064. doi: 10.1200/JCO.2015.63.8171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.63.8171</ArticleId>
            <ArticleId IdType="pmc">PMC4933132</ArticleId>
            <ArticleId IdType="pubmed">26786925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naylor E.C. Adjuvant Therapy for Stage I and II Non&#x2013;Small Cell Lung Cancer. Surg. Oncol. Clin. N. Am. 2016;25:585&#x2013;599. doi: 10.1016/j.soc.2016.03.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.soc.2016.03.003</ArticleId>
            <ArticleId IdType="pubmed">27261917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakeam E., Acuna S., Leighl N., Giuliani M., Finlayson S., Varghese T., Darling G. Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival. Lung Cancer. 2017;109:78&#x2013;88. doi: 10.1016/j.lungcan.2017.04.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2017.04.021</ArticleId>
            <ArticleId IdType="pubmed">28577955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reck M., Heigener D.F., Mok T., Soria J.-C., Rabe K.F. Management of non-small-cell lung cancer: Recent developments. Lancet. 2013;382:709&#x2013;719. doi: 10.1016/S0140-6736(13)61502-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(13)61502-0</ArticleId>
            <ArticleId IdType="pubmed">23972814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popper H.H. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35:75&#x2013;91. doi: 10.1007/s10555-016-9618-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-016-9618-0</ArticleId>
            <ArticleId IdType="pmc">PMC4821869</ArticleId>
            <ArticleId IdType="pubmed">27018053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong M., Gong H., Li T., Li X., Liu J., Zhang H., Liu M., Chen G., Liu H., Chen J. Lymph node metastasis in lung squamous cell carcinoma and identification of metastasis-related genes based on the Cancer Genome Atlas. Cancer Med. 2019;8:6280&#x2013;6294. doi: 10.1002/cam4.2525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.2525</ArticleId>
            <ArticleId IdType="pmc">PMC6797670</ArticleId>
            <ArticleId IdType="pubmed">31482686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsudomi T., Suda K., Yatabe Y. Surgery for NSCLC in the era of personalized medicine. Nat. Rev. Clin. Oncol. 2013;10:235&#x2013;244. doi: 10.1038/nrclinonc.2013.22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2013.22</ArticleId>
            <ArticleId IdType="pubmed">23438759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlsen H.S., Haraldsen G., Brandtzaeg P., Baekkevold E.S. Disparate lymphoid chemokine expression in mice and men: No evidence of CCL21 synthesis by human high endothelial venules. Blood. 2005;106:444&#x2013;446. doi: 10.1182/blood-2004-11-4353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2004-11-4353</ArticleId>
            <ArticleId IdType="pubmed">15863780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zu G., Luo B., Yang Y., Tan Y., Tang T., Zhang Y., Chen X., Sun D. Meta-analysis of the prognostic value of C-C chemokine receptor type 7 in patients with solid tumors. Cancer Manag. Res. 2019;11:1881&#x2013;1892. doi: 10.2147/CMAR.S190510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S190510</ArticleId>
            <ArticleId IdType="pmc">PMC6396671</ArticleId>
            <ArticleId IdType="pubmed">30881115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji R.-C. Lymph Nodes and Cancer Metastasis: New Perspectives on the Role of Intranodal Lymphatic Sinuses. Int. J. Mol. Sci. 2016;18:51. doi: 10.3390/ijms18010051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18010051</ArticleId>
            <ArticleId IdType="pmc">PMC5297686</ArticleId>
            <ArticleId IdType="pubmed">28036019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma H., Gao L., Li S., Qin J., Chen L., Liu X., Xu P., Wang F., Xiao H., Zhou S. CCR7 enhances TGF-beta1-induced epithelial-mesenchymal transition and is associated with lymph node metastasis and poor overall survival in gastric cancer. Oncotarget. 2015;6:24348&#x2013;24360. doi: 10.18632/oncotarget.4484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.4484</ArticleId>
            <ArticleId IdType="pmc">PMC4695190</ArticleId>
            <ArticleId IdType="pubmed">26176983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altorki N.K., Markowitz G.J., Gao D., Port J.L., Saxena A., Stiles B., McGraw T., Mittal V. The lung microenvironment: An important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 2018;19:9&#x2013;31. doi: 10.1038/s41568-018-0081-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-018-0081-9</ArticleId>
            <ArticleId IdType="pmc">PMC6749995</ArticleId>
            <ArticleId IdType="pubmed">30532012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009;1:a001651. doi: 10.1101/cshperspect.a001651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a001651</ArticleId>
            <ArticleId IdType="pmc">PMC2882124</ArticleId>
            <ArticleId IdType="pubmed">20457564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ousterout D.G., Perez-pinera P., Thakore P.I., Kabadi A.M., Brown M.T., Qin X., Fedrigo O., Mouly V., Tremblay J.P., Gersbach C.A. Corrigendum: Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients. Mol. Ther. 2013;21:2130. doi: 10.1038/mt.2013.111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mt.2013.111</ArticleId>
            <ArticleId IdType="pmc">PMC3776627</ArticleId>
            <ArticleId IdType="pubmed">23732986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun S.C. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat. Rev. Immunol. 2017;17:545&#x2013;558. doi: 10.1038/nri.2017.52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2017.52</ArticleId>
            <ArticleId IdType="pmc">PMC5753586</ArticleId>
            <ArticleId IdType="pubmed">28580957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Velasquez C., Mansouri S., Mora C., Nassiri F., Suppiah S., Martino J., Zadeh G., Fernandez-Luna J.L. Molecular and Clinical Insights into the Invasive Capacity of Glioblastoma Cells. J. Oncol. 2019;2019:1740763. doi: 10.1155/2019/1740763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/1740763</ArticleId>
            <ArticleId IdType="pmc">PMC6699388</ArticleId>
            <ArticleId IdType="pubmed">31467533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao C., Xiao G., Piersigilli A., Gou J., Ogunwobi O., Bargonetti J. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Res. 2019;21:5. doi: 10.1186/s13058-018-1094-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-018-1094-8</ArticleId>
            <ArticleId IdType="pmc">PMC6332579</ArticleId>
            <ArticleId IdType="pubmed">30642351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schutze S., Wiegmann K., Machleidt T., Kronke M. TNF-induced activation of NF-kappa B. Immunobiology. 1995;193:193&#x2013;203. doi: 10.1016/S0171-2985(11)80543-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0171-2985(11)80543-7</ArticleId>
            <ArticleId IdType="pubmed">8530143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Xu J., Zhou Y., Liu X., Shen L.E., Zhu Y.U., Li Z., Wang X., Guo Q., Hui H. PLSCR1/IP3R1/Ca(2+) axis contributes to differentiation of primary AML cells induced by wogonoside. Cell Death Dis. 2017;8:e2768. doi: 10.1038/cddis.2017.175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2017.175</ArticleId>
            <ArticleId IdType="pmc">PMC5520700</ArticleId>
            <ArticleId IdType="pubmed">28492556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta G.P., Massagu&#xe9; J. Cancer Metastasis: Building a Framework. Cell. 2006;127:679&#x2013;695. doi: 10.1016/j.cell.2006.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.11.001</ArticleId>
            <ArticleId IdType="pubmed">17110329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liotta L.A. An attractive force in metastasis. Nat. Cell Biol. 2001;410:24&#x2013;25. doi: 10.1038/35065180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35065180</ArticleId>
            <ArticleId IdType="pubmed">11242022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tennant D.A., Dur&#xe1;n R.V., Boulahbel H., Gottlieb E. Metabolic transformation in cancer. Carcinogenesis. 2009;30:1269&#x2013;1280. doi: 10.1093/carcin/bgp070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgp070</ArticleId>
            <ArticleId IdType="pubmed">19321800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balkwill F. The chemokine system and cancer. J. Pathol. 2011;226:148&#x2013;157. doi: 10.1002/path.3029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.3029</ArticleId>
            <ArticleId IdType="pubmed">21989643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis. Int. J. Cancer. 2003;105:186&#x2013;189. doi: 10.1002/ijc.11063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.11063</ArticleId>
            <ArticleId IdType="pubmed">12673677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>G&#xfc;nther K., Leier J., Henning G., Dimmler A., Wei&#xdf;bach R., Hohenberger W., F&#xf6;rster R. Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. Int. J. Cancer. 2005;116:726&#x2013;733. doi: 10.1002/ijc.21123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.21123</ArticleId>
            <ArticleId IdType="pubmed">15828050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng J.C., Huang Y., Tang K., Cui M., Niemann D., Lopez A., Morgello S., Chen S. HIV-1-infected and/or immune-activated macrophages regulate astrocyte CXCL8 production through IL-1beta and TNF-&#x3b1;: Involvement of mitogen-activated protein kinases and protein kinase R. J. Neuroimmunol. 2008;200:100&#x2013;110. doi: 10.1016/j.jneuroim.2008.06.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2008.06.015</ArticleId>
            <ArticleId IdType="pmc">PMC2596956</ArticleId>
            <ArticleId IdType="pubmed">18653246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han Y., He T., Huang D., Pardo C.A., Ransohoff R.M. TNF-&#x3b1; mediates SDF-1&#x3b1;&#x2013;induced NF-&#x3ba;B activation and cytotoxic effects in primary astrocytes. J. Clin. Investig. 2001;108:425&#x2013;435. doi: 10.1172/JCI12629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI12629</ArticleId>
            <ArticleId IdType="pmc">PMC209361</ArticleId>
            <ArticleId IdType="pubmed">11489936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheng W.S., Ni H.T., Rowen T.N., Lokensgard J.R., Peterson P.K., Hu S. TNF- -induced chemokine production and apoptosis in human neural precursor cells. J. Leukoc. Biol. 2005;78:1233&#x2013;1241. doi: 10.1189/jlb.0405221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0405221</ArticleId>
            <ArticleId IdType="pubmed">16314440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vestergaard C., Johansen C., Otkjaer K., Deleuran M., Iversen L. Tumor necrosis factor-&#x3b1;-induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor kappaB. Cytokine. 2005;29:49&#x2013;55. doi: 10.1016/j.cyto.2004.09.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2004.09.008</ArticleId>
            <ArticleId IdType="pubmed">15598438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuesta-Mateos C., L&#xf3;pez-Giral S., Alfonso-P&#xe9;rez M., De Soria V.G.G., Loscertales J., Guasch-Vidal S., Beltr&#xe1;n A.E., Zapata J.M., Mu&#xf1;oz-Calleja C. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia. Exp. Hematol. 2010;38:756&#x2013;764e4. doi: 10.1016/j.exphem.2010.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.exphem.2010.05.003</ArticleId>
            <ArticleId IdType="pubmed">20488224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Till K.J., Lin K., Zuzel M., Cawley J.C. The chemokine receptor CCR7 and &#x3b1;4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 2002;99:2977&#x2013;2984. doi: 10.1182/blood.V99.8.2977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V99.8.2977</ArticleId>
            <ArticleId IdType="pubmed">11929789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishigami S., Natsugoe S., Nakajo A., Tokuda K., Uenosono Y., Arigami T., Matsumoto M., Okumura H., Hokita S., Aikou T. Prognostic value of CCR7 expression in gastric cancer. Hepatogastroenterology. 2007;54:1025&#x2013;1028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17629031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shuyi Y., Juping D., Zhiqun Z., Qiong P., Wuyang J., Ting L., Xiaowen H., Liu X., Yuxiang C. A critical role of CCR7 in invasiveness and metastasis of SW620 colon cancer cell in vitro and in vivo. Cancer Biol. Ther. 2008;7:1037&#x2013;1043. doi: 10.4161/cbt.7.7.6065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cbt.7.7.6065</ArticleId>
            <ArticleId IdType="pubmed">18437055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q., Sun L., Yin L., Ming J., Zhang S., Luo W., Qiu X. CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer. Tumour Biol. 2013;34:2703&#x2013;2708. doi: 10.1007/s13277-013-0822-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-013-0822-z</ArticleId>
            <ArticleId IdType="pubmed">23649655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuwabara T., Tanaka Y., Ishikawa F., Kondo M., Sekiya H., Kakiuchi T. CCR7 ligands up-regulate IL-23 through PI3-kinase and NF-kappa B pathway in dendritic cells. J. Leukoc. Biol. 2012;92:309&#x2013;318. doi: 10.1189/jlb.0811415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0811415</ArticleId>
            <ArticleId IdType="pubmed">22591694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao W., Sun Z., Wang S., Li Z., Zheng L. Wnt1 Participates in Inflammation Induced by Lipopolysaccharide Through Upregulating Scavenger Receptor A and NF-kB. Inflammation. 2015;38:1700&#x2013;1706. doi: 10.1007/s10753-015-0147-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10753-015-0147-8</ArticleId>
            <ArticleId IdType="pmc">PMC4495710</ArticleId>
            <ArticleId IdType="pubmed">25749569</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33130472</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1618-095X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>80</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title>
          <ISOAbbreviation>Phytomedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.</ArticleTitle>
        <Pagination>
          <StartPage>153394</StartPage>
          <MedlinePgn>153394</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2020.153394</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0944-7113(20)30225-7</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Programmed death-ligand 1 (PD-L1), which can be induced by interferon-gamma (IFN-Î³) in the tumor microenvironment, is a critical immune checkpoint in cancer immunotherapy. Natural products which reduce IFN-Î³-induced PD-L1 might be exert immunotherapy effect. Licochalcone A (LCA), a natural compound derived from the root of Glycyrrhiza inflata Batalin. (Fabaceae), was found to interfere IFN-Î³-induced PD-L1.</AbstractText>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of this study is to further clarify the effect and the mechanism of LCA on inhibiting IFN-&#x3b3;-induced PD-L1 in lung cancer cells.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The expression levels of PD-L1 were evaluated by flow cytometry, western blot and qRT-PCR. Click-iT protein synthesis assay and luciferase assay were used to identify the effect of LCA on protein synthesis. Jurkat T cell proliferation and apoptosis in the co-culture system were detected by flow cytometry. Flow cytometry was also applied to evaluate reactive oxygen species (ROS) generation.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">LCA downregulated IFN-&#x3b3;-induced PD-L1 protein expression and membrane localization in human lung cancer cells, regardless of inhibiting PD-L1 mRNA level or promoting its protein degradation. LCA decreased apoptosis and proliferative inhibition of Jurkat T cells caused by IFN-&#x3b3;-induced PD-L1-expressing in A549 cells in the co-culture system. Strikingly, LCA was verified as a protein synthesis inhibitor, which reduced both cap-dependent and -independent translation. LCA inhibited PD-L1 translation, likely due to inhibition of 4EBP1 phosphorylation (Ser 65) and activation of PERK-eIF2&#x3b1; pathway. Furthermore, LCA induced ROS generation in a time-dependent manner in lung cancer cells. N-acetyl-L-cysteine (NAC) not only revered ROS generation triggered by LCA but also restored IFN-&#x3b3;-induced expression of PD-L1. Both the inhibition of 4EBP1 phosphorylation (Ser 65) and activation of PERK-eIF2&#x3b1; axis triggered by LCA was restored by co-treatment with NAC.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LCA abrogated IFN-&#x3b3;-induced PD-L1 expression via ROS generation to abolish the protein translation, indicating that LCA has the potential to be applied in cancer immunotherapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier GmbH. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Luo-Wei</ForeName>
            <Initials>LW</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Xiao-Ming</ForeName>
            <Initials>XM</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Yu-Lian</ForeName>
            <Initials>YL</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Mu-Yang</ForeName>
            <Initials>MY</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yu-Chi</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Wei-Bang</ForeName>
            <Initials>WB</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Min-Xia</ForeName>
            <Initials>MX</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Zi-Han</ForeName>
            <Initials>ZH</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiuping</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yitao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Jin-Jian</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: jinjianlu@um.edu.mo.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Phytomedicine</MedlineTA>
        <NlmUniqueID>9438794</NlmUniqueID>
        <ISSNLinking>0944-7113</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047188">Chalcones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C087000">EIF4EBP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JTV5467968</RegistryNumber>
          <NameOfSubstance UI="C070840">licochalcone A</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047188" MajorTopicYN="N">Chalcones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">IFN-&#x3b3;</Keyword>
        <Keyword MajorTopicYN="N">Licochalcone A</Keyword>
        <Keyword MajorTopicYN="N">Natural products</Keyword>
        <Keyword MajorTopicYN="N">PD-L1</Keyword>
        <Keyword MajorTopicYN="N">Protein synthesis inhibitor</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>20</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33130472</ArticleId>
        <ArticleId IdType="doi">10.1016/j.phymed.2020.153394</ArticleId>
        <ArticleId IdType="pii">S0944-7113(20)30225-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33000204</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1791-244X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>46</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular medicine</Title>
          <ISOAbbreviation>Int J Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>KCNQ1OT1 contributes to sorafenib resistance and programmed deathâligandâ1âmediated immune escape via sponging miRâ506 in hepatocellular carcinoma cells.</ArticleTitle>
        <Pagination>
          <StartPage>1794</StartPage>
          <EndPage>1804</EndPage>
          <MedlinePgn>1794-1804</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/ijmm.2020.4710</ELocationID>
        <Abstract>
          <AbstractText>Drug resistance and immune escape of tumor cells severely compromise the treatment efficiency of hepatocellular carcinoma (HCC). Long nonâcoding RNA KCNQ1 overlapping transcript 1 (lncRNA KCNQ1OT1) has been shown to be involved in drug resistance in several cancers. The aim of the present study was to investigate the role of KCNQ1OT1 in sorafenib resistance and immune escape of HCC cells. Reverse transcriptionâquantitative PCR analysis, western blotting and immunohistochemistry were performed to detect the expression of KCNQ1OT1, miRâ506 and programmed deathâligandâ1 (PDâL1). Cell Counting Kitâ8 assay, flow cytometry and Transwell assays were used to evaluate IC50 value, cell apoptosis and metastasis. ELISA was performed to detect the secretion of cytokines. Dualâluciferase reporter assay was conducted to verify the targeting relationships between miRâ506 and KCNQ1OT1 or PDâL1. KCNQ1OT1 and PDâL1 were found to be upregulated and miRâ506 was downregulated in sorafenibâresistant HCC tissues and cells. Furthermore, KCNQ1OT1 knockdown reduced the IC50 value of sorafenib, suppressed cell metastasis and promoted apoptosis in sorafenibâresistant HCC cells. Moreover, KCNQ1OT1 knockdown changed the tumor microenvironment and Tâcell apoptosis in a sorafenibâresistant HCC/Tâcell coâculture model. In addition, it was demonstrated that KCNQ1OT1 functioned as a competing endogenous RNA of miRâ506 and increased PDâL1 expression in sorafenibâresistant HCC cells. miRâ506 inhibition abolished the effects of KCNQ1OT1 knockdown on sorafenib sensitivity, tumor growth, the tumor microenvironment and Tâcell apoptosis. In conclusion, KCNQ1OT1 knockdown inhibited sorafenib resistance and PDâL1âmediated immune escape by sponging miRâ506 in sorafenibâresistant HCC cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Junli</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medical Laboratory, Sanquan College of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Xiaohui</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Sciences, Sanquan College of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Xiaojuan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medical Laboratory, Sanquan College of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Zengyan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medical Laboratory, Sanquan College of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Miao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medical Laboratory, Sanquan College of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Int J Mol Med</MedlineTA>
        <NlmUniqueID>9810955</NlmUniqueID>
        <ISSNLinking>1107-3756</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C485621">KCNQ1OT1 long non-coding RNA, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C561508">MIRN506 microRNA, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024642">Potassium Channels, Voltage-Gated</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9ZOQ3TZI87</RegistryNumber>
          <NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057131" MajorTopicYN="Y">Immune Evasion</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024642" MajorTopicYN="N">Potassium Channels, Voltage-Gated</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077157" MajorTopicYN="N">Sorafenib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33000204</ArticleId>
        <ArticleId IdType="pmc">PMC7521583</ArticleId>
        <ArticleId IdType="doi">10.3892/ijmm.2020.4710</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bruix J, Sherman M. American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020&#x2013;1022. doi: 10.1002/hep.24199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.24199</ArticleId>
            <ArticleId IdType="pmc">PMC3084991</ArticleId>
            <ArticleId IdType="pubmed">21374666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cidon EU. Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol. 2017;9:797&#x2013;807. doi: 10.4254/wjh.v9.i18.797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4254/wjh.v9.i18.797</ArticleId>
            <ArticleId IdType="pmc">PMC5491402</ArticleId>
            <ArticleId IdType="pubmed">28706578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hollebecque A, Malka D, Fert&#xe9; C, Ducreux M, Boige V. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. Eur J Cancer. 2015;51:327&#x2013;339. doi: 10.1016/j.ejca.2014.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2014.12.005</ArticleId>
            <ArticleId IdType="pubmed">25559615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsueh KC, Lee TY, Kor CT, Chen TM, Chang TM, Yang SF, Hsieh CB. The role of liver transplantation or resection for patients with early hepatocellular carcinoma. Tumour Biol. 2016;37:4193&#x2013;4201. doi: 10.1007/s13277-015-4243-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-015-4243-z</ArticleId>
            <ArticleId IdType="pubmed">26490991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol. 2015;7:1041&#x2013;1053. doi: 10.4254/wjh.v7.i8.1041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4254/wjh.v7.i8.1041</ArticleId>
            <ArticleId IdType="pmc">PMC4450181</ArticleId>
            <ArticleId IdType="pubmed">26052393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chow AK, Ng L, Lam CS, Wong SK, Wan TM, Cheng NS, Yau TC, Poon RT, Pang RW. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 2013;8:e78675. doi: 10.1371/journal.pone.0078675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0078675</ArticleId>
            <ArticleId IdType="pmc">PMC3823841</ArticleId>
            <ArticleId IdType="pubmed">24244338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu B, Cao Y, Jiang H, Mao A. Autophagy facilitates the sorafenib resistance of hepatocellular carcinoma cells. West Indian Med J. 2013;62:698&#x2013;700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25014853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruiz de Galarreta M, Bresnahan E, Molina-S&#xe1;nchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, et al. &#x3b2;-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9:1124&#x2013;1141. doi: 10.1158/2159-8290.CD-19-0074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0074</ArticleId>
            <ArticleId IdType="pmc">PMC6677618</ArticleId>
            <ArticleId IdType="pubmed">31186238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang G, Lu X, Yuan L. LncRNA: A link between RNA and cancer. Biochim Biophys Acta. 2014;1839:1097&#x2013;1109. doi: 10.1016/j.bbagrm.2014.08.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagrm.2014.08.012</ArticleId>
            <ArticleId IdType="pubmed">25159663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fatica A, Bozzoni I. Long non-coding RNAs: New players in cell differentiation and development. Nat Rev Genet. 2014;15:7&#x2013;21. doi: 10.1038/nrg3606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg3606</ArticleId>
            <ArticleId IdType="pubmed">24296535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629&#x2013;641. doi: 10.1016/j.cell.2009.02.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.02.006</ArticleId>
            <ArticleId IdType="pubmed">19239885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:354&#x2013;361. doi: 10.1016/j.tcb.2011.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2011.04.001</ArticleId>
            <ArticleId IdType="pubmed">21550244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Ma H, Zhang D, Xie S, Wang W, Li Q, Lin Z, Wang Y. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018;9:742. doi: 10.1038/s41419-018-0793-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0793-5</ArticleId>
            <ArticleId IdType="pmc">PMC6030066</ArticleId>
            <ArticleId IdType="pubmed">29970910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren K, Xu R, Huang J, Zhao J, Shi W. Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma. Cancer Chemother Pharmacol. 2017;80:243&#x2013;250. doi: 10.1007/s00280-017-3356-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-017-3356-z</ArticleId>
            <ArticleId IdType="pubmed">28600629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang P, Ning S, Zhang Y, Li R, Ye J, Zhao Z, Zhi H, Wang T, Guo Z, Li X. Identification of lncRNA-associated competing triplets reveals global patterns and prognostic markers for cancer. Nucleic Acids Res. 2015;43:3478&#x2013;3489. doi: 10.1093/nar/gkv233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkv233</ArticleId>
            <ArticleId IdType="pmc">PMC4402541</ArticleId>
            <ArticleId IdType="pubmed">25800746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu S, Jin L, Zhang F, Sarnow P, Kay MA. Biological basis for restriction of microRNA targets to the 3&#x2032; untranslated region in mammalian mRNAs. Nat Struct Mol Biol. 2009;16:144&#x2013;150. doi: 10.1038/nsmb.1552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nsmb.1552</ArticleId>
            <ArticleId IdType="pmc">PMC2713750</ArticleId>
            <ArticleId IdType="pubmed">19182800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang M, Xie X, Song X, Gu S, Chang X, Su T, Liang B, Huang D. MiR-506 suppresses colorectal cancer development by inhibiting orphan nuclear receptor NR4A1 expression. J Cancer. 2019;10:3560&#x2013;3570. doi: 10.7150/jca.28272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.28272</ArticleId>
            <ArticleId IdType="pmc">PMC6603418</ArticleId>
            <ArticleId IdType="pubmed">31293661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R, Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, et al. miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer. Oncogene. 2015;34:717&#x2013;725. doi: 10.1038/onc.2014.9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2014.9</ArticleId>
            <ArticleId IdType="pubmed">24608427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, et al. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 2015;235:25&#x2013;36. doi: 10.1002/path.4443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.4443</ArticleId>
            <ArticleId IdType="pmc">PMC4268369</ArticleId>
            <ArticleId IdType="pubmed">25230372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou H, Lin C, Zhang Y, Zhang X, Zhang C, Zhang P, Xie X, Ren Z. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR 1/P-gp expression. Cell Prolif. 2017;50:e12341. doi: 10.1111/cpr.12341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cpr.12341</ArticleId>
            <ArticleId IdType="pmc">PMC6529089</ArticleId>
            <ArticleId IdType="pubmed">28217977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Dai J, Yan J, Zhang Y, Yin Z. Targeting EZH 2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma. J Cell Mol Med. 2019;23:4770&#x2013;4778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6584518</ArticleId>
            <ArticleId IdType="pubmed">31087496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res. 2016;76:3666&#x2013;3670. doi: 10.1158/0008-5472.CAN-16-0359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-0359</ArticleId>
            <ArticleId IdType="pmc">PMC4930690</ArticleId>
            <ArticleId IdType="pubmed">27325641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207&#x2013;212. doi: 10.1016/j.coi.2011.12.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2011.12.009</ArticleId>
            <ArticleId IdType="pmc">PMC3319479</ArticleId>
            <ArticleId IdType="pubmed">22236695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wang L. miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1. Biotechnol Lett. 2017;39:1485&#x2013;1492. doi: 10.1007/s10529-017-2397-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10529-017-2397-z</ArticleId>
            <ArticleId IdType="pubmed">28721584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241. doi: 10.1038/ncomms6241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms6241</ArticleId>
            <ArticleId IdType="pmc">PMC4212319</ArticleId>
            <ArticleId IdType="pubmed">25348003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378&#x2013;390. doi: 10.1056/NEJMoa0708857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0708857</ArticleId>
            <ArticleId IdType="pubmed">18650514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402&#x2013;408. doi: 10.1006/meth.2001.1262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId>
            <ArticleId IdType="pubmed">11846609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Igney FH, Krammer PH. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71:907&#x2013;920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12050175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen QN, Wei CC, Wang ZX, Sun M. Long non-coding RNAs in anti-cancer drug resistance. Oncotarget. 2017;8:1925&#x2013;1936. doi: 10.18632/oncotarget.12461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.12461</ArticleId>
            <ArticleId IdType="pmc">PMC5352108</ArticleId>
            <ArticleId IdType="pubmed">27713133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xian D, Zhao Y. LncRNA KCNQ1OT1 enhanced the methotrexate resistance of colorectal cancer cells by regulating miR-760/PPP1R1B via the cAMP signalling pathway. J Cell Mol Med. 2019;23:3808&#x2013;3823. doi: 10.1111/jcmm.14071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.14071</ArticleId>
            <ArticleId IdType="pmc">PMC6533496</ArticleId>
            <ArticleId IdType="pubmed">30997746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu H, Yang L, Li L, Zeng C. Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis. Biochem Biophys Res Commun. 2018;503:2400&#x2013;2406. doi: 10.1016/j.bbrc.2018.06.168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2018.06.168</ArticleId>
            <ArticleId IdType="pubmed">29966655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong RS. Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:87. doi: 10.1186/1756-9966-30-87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-9966-30-87</ArticleId>
            <ArticleId IdType="pmc">PMC3197541</ArticleId>
            <ArticleId IdType="pubmed">21943236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eccles SA, Box C, Court W. Cell migration/invasion assays and their application in cancer drug discovery. Biotechnol Annu Rev. 2005;11:391&#x2013;421. doi: 10.1016/S1387-2656(05)11013-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1387-2656(05)11013-8</ArticleId>
            <ArticleId IdType="pubmed">16216785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang D, Chen J, Yang L, Ouyang Q, Li J, Lao L, Zhao J, Liu J, Lu Y, Xing Y, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018;19:1112&#x2013;1125. doi: 10.1038/s41590-018-0207-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-018-0207-y</ArticleId>
            <ArticleId IdType="pubmed">30224822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM, Raymond E. Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res. 2014;6:340&#x2013;352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4113496</ArticleId>
            <ArticleId IdType="pubmed">25075251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li KK, Adams DH. Antitumor CD8+ T cells in hepatocellular carcinoma: Present but exhausted. Hepatology. 2014;59:1232&#x2013;1234. doi: 10.1002/hep.26779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.26779</ArticleId>
            <ArticleId IdType="pubmed">24123091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrera L, Montes-Serv&#xed;n E, Barrera A, Ram&#xed;rez-Tirado LA, Salinas-Parra F, Ba&#xf1;ales-M&#xe9;ndez JL, Sandoval-R&#xed;os M, Arrieta &#xd3;. Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. Ann Oncol. 2015;26:428&#x2013;435. doi: 10.1093/annonc/mdu549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdu549</ArticleId>
            <ArticleId IdType="pubmed">25467015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-&#x3b3; and IL-12. Immunity. 2018;49:1148&#x2013;1161. doi: 10.1016/j.immuni.2018.09.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2018.09.024</ArticleId>
            <ArticleId IdType="pmc">PMC6301092</ArticleId>
            <ArticleId IdType="pubmed">30552023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. 2015;6:234&#x2013;242. doi: 10.18632/oncotarget.2703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.2703</ArticleId>
            <ArticleId IdType="pmc">PMC4381591</ArticleId>
            <ArticleId IdType="pubmed">25428917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Liu Y, Meng L, Liu K, Ji B. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep. 2017;38:899&#x2013;907. doi: 10.3892/or.2017.5722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2017.5722</ArticleId>
            <ArticleId IdType="pmc">PMC5561980</ArticleId>
            <ArticleId IdType="pubmed">28627705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. . N Engl J Med. 2012;366:2443&#x2013;2454. doi: 10.1056/NEJMoa1200690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200690</ArticleId>
            <ArticleId IdType="pmc">PMC3544539</ArticleId>
            <ArticleId IdType="pubmed">22658127</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32610185</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2422</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>394</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Experimental cell research</Title>
          <ISOAbbreviation>Exp Cell Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The MyD88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88/GSK-3Î² and MyD88/NF-ÎºB signalling pathways.</ArticleTitle>
        <Pagination>
          <StartPage>112157</StartPage>
          <MedlinePgn>112157</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexcr.2020.112157</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-4827(20)30404-3</ELocationID>
        <Abstract>
          <AbstractText>MyD88 has been implicated in the tumourigenesis, metastasis and recurrence of breast cancer (BC). Here we utilized TJ-M2010-2 (TJ), an inhibitor of MyD88 homodimerimerization, and siMyD88 to suppress the function of MyD88 in MCF-7 and MDA-MB-231 cells. BC cells were treated in vitro and xenografted into nude mice to generate a model in vivo. TJ inhibited BC cell growth by impeding proliferation rather than by promoting apoptosis in vitro. Additionally, TJ and siMyD88 significantly attenuated cell migration and invasion, inhibited EMT-like progression and reduced cytokine (IL-6, IL-8, TGF-Î²1 and TNF-Î±) secretion induced by LPS. In vivo, TJ significantly hindered tumour growth in mice. Notably, TJ also decreased the secretion of IL-6, IL-8, TGF-Î²1, and TNF-Î± and M2 macrophage infiltration in the tumour microenvironment. The expression of MyD88, TRAF6, NF-ÎºB p65, Snail, MMP-2, MMP-9, p-GSK-3Î² and p-Akt was significantly downregulated by TJ in BC cells and tumour tissues. Collectively, these results suggest that a MyD88 inhibitor (TJ) may be a promising therapeutic modality for treating BC patients.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jian-Hua</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Chuang</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ze-Yang</ForeName>
            <Initials>ZY</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Zhi-Miao</ForeName>
            <Initials>ZM</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Dong-Cheng</ForeName>
            <Initials>DC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xue</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuang</LastName>
            <ForeName>Xin-Wen</ForeName>
            <Initials>XW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Zhi-Hong</ForeName>
            <Initials>ZH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Wei-Jie</ForeName>
            <Initials>WJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Ping</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Electronic address: pzhou@tjh.tjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Sheng-Rong</ForeName>
            <Initials>SR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, PR China. Electronic address: sun137@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Exp Cell Res</MedlineTA>
        <NlmUniqueID>0373226</NlmUniqueID>
        <ISSNLinking>0014-4827</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000607343">5-(3-(4-(4-benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl))propanamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053594">Myeloid Differentiation Factor 88</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053594" MajorTopicYN="N">Myeloid Differentiation Factor 88</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Epithelial-mesenchymal transition</Keyword>
        <Keyword MajorTopicYN="N">Metastasis</Keyword>
        <Keyword MajorTopicYN="N">Myeloid differentiation factor 88</Keyword>
        <Keyword MajorTopicYN="N">Tumour microenvironment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32610185</ArticleId>
        <ArticleId IdType="doi">10.1016/j.yexcr.2020.112157</ArticleId>
        <ArticleId IdType="pii">S0014-4827(20)30404-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32495392</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4652</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>236</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cellular physiology</Title>
          <ISOAbbreviation>J Cell Physiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Triptolide decreases tumor-associated macrophages infiltration and M2 polarization to remodel colon cancer immune microenvironment via inhibiting tumor-derived CXCL12.</ArticleTitle>
        <Pagination>
          <StartPage>193</StartPage>
          <EndPage>204</EndPage>
          <MedlinePgn>193-204</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jcp.29833</ELocationID>
        <Abstract>
          <AbstractText>Colon cancer is a common and deadly human digestive tract malignant tumor with poor prognosis. Immunotherapy has elicited tremendous success as a treatment modality for multiple solid tumors. Triptolide is extracted from the traditional Chinese medicine Tripterygium wilfordii Hook. F which shows various pharmacological actions including antitumor, anti-inflammatory, antimicrobial, antifibrosis, and antirheumatic. However, the influence of triptolide treatment on remodeling tumor immune microenvironment is still unknown in colon cancer. This study was aimed to investigate the therapeutic effect of triptolide treatment on colon cancer and the impact on tumor immune microenvironment and its underlying mechanism. We used CT26 subcutaneous tumors to conduct in vivo experiments and HT29, CT16, and Raw264.7 cells to perform in vitro assays. Triptolide had a therapeutic effect against colon cancer in vivo. Triptolide treatment distinctly inhibited the proliferation of colon cancer cells and induced apoptosis in vitro. In colon cancer immune microenvironment, triptolide treatment decreased the infiltration of tumor-associated macrophages through downregulating tumor-derived CXCL12 expression via nuclear factor kappa B and extracellular signal-regulated protein kinases 1 and 2 axis to remodel the immune microenvironment. Triptolide-educated colon cancers retarded the macrophages polarize to anti-inflammatory M2 status by decreasing the expression of Arg-1, CD206, and interleukin-10. Moreover, triptolide inhibited the migration of colon cancer cells via decreasing vascular endothelial growth factor expression. Our results identified the role of triptolide treatment in remodeling colon cancer immune microenvironment along with the distinct cytotoxicity function against colon cancer cells, which may provide the evidence for triptolide treatment in clinical.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Xuan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Hongze District People's Hospital, Hongze, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Guangyi</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Jiasheng</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Huaiyin Hospital of Huai'an City, Huai'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-8395-056X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Cell Physiol</MedlineTA>
        <NlmUniqueID>0050222</NlmUniqueID>
        <ISSNLinking>0021-9541</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515255">CXCL12 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004224">Diterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004852">Epoxy Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010616">Phenanthrenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>19ALD1S53J</RegistryNumber>
          <NameOfSubstance UI="C001899">triptolide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004224" MajorTopicYN="N">Diterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004852" MajorTopicYN="N">Epoxy Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019073" MajorTopicYN="N">HT29 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010616" MajorTopicYN="N">Phenanthrenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067996" MajorTopicYN="N">RAW 264.7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000084582" MajorTopicYN="N">Tumor-Associated Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CXCL12</Keyword>
        <Keyword MajorTopicYN="N">colon cancer</Keyword>
        <Keyword MajorTopicYN="N">triptolide</Keyword>
        <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
        <Keyword MajorTopicYN="N">tumor-associated macrophages</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32495392</ArticleId>
        <ArticleId IdType="doi">10.1002/jcp.29833</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Abajo, A., Bitarte, N., Zarate, R., Boni, V., Lopez, I., Gonzalez-Huarriz, M., &#x2026; Garcia-Foncillas, J. (2012). Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World Journal of Gastroenterology, 18(7), 637-645.</Citation>
        </Reference>
        <Reference>
          <Citation>Arora, N., Alsaied, O., Dauer, P., Majumder, K., Modi, S., Giri, B., &#x2026; Saluja, A. (2017). Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer. PLoS One, 12(2), e0171827.</Citation>
        </Reference>
        <Reference>
          <Citation>Beider, K., Bitner, H., Leiba, M., Gutwein, O., Koren-Michowitz, M., Ostrovsky, O., &#x2026; Nagler, A. (2014). Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget, 5(22), 11283-11296.</Citation>
        </Reference>
        <Reference>
          <Citation>Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., &amp; Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394-424.</Citation>
        </Reference>
        <Reference>
          <Citation>Bu, Y., &amp; Zhao, D. (2020). Luteolin retards CXCL12-induced Jurkat cells migration by disrupting transcription of CXCR4. Experimental and Molecular Pathology, 113, 104370.</Citation>
        </Reference>
        <Reference>
          <Citation>Cardoso, A. P., Pinto, M. L., Pinto, A. T., Oliveira, M. I., Pinto, M. T., Goncalves, R., &#x2026; Oliveira, M. J. (2014). Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity. Oncogene, 33(16), 2123-2133.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, S. R., Dai, Y., Zhao, J., Lin, L., Wang, Y., &amp; Wang, Y. (2018). A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii Hook F. Frontiers in Pharmacology, 9, 104.</Citation>
        </Reference>
        <Reference>
          <Citation>Feng, Q., Chang, W., Mao, Y., He, G., Zheng, P., Tang, W., &#x2026; Xu, J. (2019). Tumor-associated macrophages as prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer. Clinical Cancer Research, 25(13), 3896-3907.</Citation>
        </Reference>
        <Reference>
          <Citation>Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., &amp; Diaz, L. A., Jr. (2019). Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nature Reviews Gastroenterology &amp; Hepatology, 16(6), 361-375.</Citation>
        </Reference>
        <Reference>
          <Citation>Han, Y., Huang, W., Liu, J., Liu, D., Cui, Y., Huang, R., &#x2026; Lei, M. (2017). Triptolide inhibits the AR signaling pathway to suppress the proliferation of enzalutamide resistant prostate cancer cells. Theranostics, 7(7), 1914-1927.</Citation>
        </Reference>
        <Reference>
          <Citation>Hayden, M. S., &amp; Ghosh, S. (2008). Shared principles in NF-kappaB signaling. Cell, 132(3), 344-362.</Citation>
        </Reference>
        <Reference>
          <Citation>Johnson, S. M., Wang, X., &amp; Evers, B. M. (2011). Triptolide inhibits proliferation and migration of colon cancer cells by inhibition of cell cycle regulators and cytokine receptors. The Journal of Surgical Research, 168(2), 197-205.</Citation>
        </Reference>
        <Reference>
          <Citation>Kalyan, A., Kircher, S., Shah, H., Mulcahy, M., &amp; Benson, A. (2018). Updates on immunotherapy for colorectal cancer. Journal of Gastrointestinal Oncology, 9(1), 160-169.</Citation>
        </Reference>
        <Reference>
          <Citation>Kukreja, P., Abdel-Mageed, A. B., Mondal, D., Liu, K., &amp; Agrawal, K. C. (2005). Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: Role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Research, 65(21), 9891-9898.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, J., Shen, M., Yue, Z., Yang, Z., Wang, M., Li, C., &#x2026; Wang, Z. (2012). Triptolide inhibits colon-rectal cancer cells proliferation by induction of G1 phase arrest through upregulation of p21. Phytomedicine, 19(8-9), 756-762.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, W., Xu, J., Wang, M., Wang, Q., Bi, Y., &amp; Han, M. (2011). Tumor-derived vascular endothelial growth factor (VEGF)-A facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. International Journal of Oncology, 39(5), 1213-1220.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, X., Zhao, P., Wang, X., Wang, L., Zhu, Y., &amp; Gao, W. (2019). Triptolide induces glioma cell autophagy and apoptosis via upregulating the ROS/JNK and downregulating the Akt/mTOR signaling pathways. Frontiers in Oncology, 9, 387.</Citation>
        </Reference>
        <Reference>
          <Citation>Madge, L. A., &amp; May, M. J. (2010). Classical NF-kappaB activation negatively regulates noncanonical NF-kappaB-dependent CXCL12 expression. Journal of Biological Chemistry, 285(49), 38069-38077.</Citation>
        </Reference>
        <Reference>
          <Citation>Magalhaes, B., Peleteiro, B., &amp; Lunet, N. (2012). Dietary patterns and colorectal cancer: Systematic review and meta-analysis. European Journal of Cancer Prevention, 21(1), 15-23.</Citation>
        </Reference>
        <Reference>
          <Citation>Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., &amp; Allavena, P. (2017). Tumour-associated macrophages as treatment targets in oncology. Nature Reviews Clinical Oncology, 14(7), 399-416.</Citation>
        </Reference>
        <Reference>
          <Citation>Noel, P., Von Hoff, D. D., Saluja, A. K., Velagapudi, M., Borazanci, E., &amp; Han, H. (2019). Triptolide and its derivatives as cancer therapies. Trends In Pharmacological Sciences, 40(5), 327-341.</Citation>
        </Reference>
        <Reference>
          <Citation>Oliveira, A., Beyer, G., Chugh, R., Skube, S. J., Majumder, K., Banerjee, S., &#x2026; Dudeja, V. (2015). Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F. Laboratory Investigation, 95(6), 648-659.</Citation>
        </Reference>
        <Reference>
          <Citation>Pellino, G., Warren, O., Mills, S., Rasheed, S., Tekkis, P. P., &amp; Kontovounisios, C. (2018). Comparison of Western and Asian guidelines concerning the management of colon cancer. Diseases of the Colon and Rectum, 61(2), 250-259.</Citation>
        </Reference>
        <Reference>
          <Citation>Phillips, P. A., Dudeja, V., McCarroll, J. A., Borja-Cacho, D., Dawra, R. K., Grizzle, W. E., &#x2026; Saluja, A. K. (2007). Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Research, 67(19), 9407-9416.</Citation>
        </Reference>
        <Reference>
          <Citation>Pigneux, A., Mahon, F. X., Uhalde, M., Jeanneteau, M., Lacombe, F., Milpied, N., &#x2026; Belloc, F. (2008). Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Experimental Hematology, 36(12), 1648-1659.</Citation>
        </Reference>
        <Reference>
          <Citation>Reno, T. A., Kim, J. Y., &amp; Raz, D. J. (2015). Triptolide inhibits lung cancer cell migration, invasion, and metastasis. The Annals of Thoracic Surgery, 100(5), 1817-1824.</Citation>
        </Reference>
        <Reference>
          <Citation>Rigo, A., Gottardi, M., Zamo, A., Mauri, P., Bonifacio, M., Krampera, M., &#x2026; Vinante, F. (2010). Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Molecular Cancer, 9, 273.</Citation>
        </Reference>
        <Reference>
          <Citation>Riihimaki, M., Hemminki, A., Sundquist, J., &amp; Hemminki, K. (2016). Patterns of metastasis in colon and rectal cancer. Scientific Reports, 6, 29765.</Citation>
        </Reference>
        <Reference>
          <Citation>Rivard, C., Geller, M., Schnettler, E., Saluja, M., Vogel, R. I., Saluja, A., &amp; Ramakrishnan, S. (2014). Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug. Gynecologic Oncology, 135(2), 318-324.</Citation>
        </Reference>
        <Reference>
          <Citation>Shao, H., Ma, J., Guo, T., &amp; Hu, R. (2014). Triptolide induces apoptosis of breast cancer cells via a mechanism associated with the Wnt/beta-catenin signaling pathway. Experimental and Therapeutic Medicine, 8(2), 505-508.</Citation>
        </Reference>
        <Reference>
          <Citation>Siegel, R., Desantis, C., &amp; Jemal, A. (2014). Colorectal cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64(2), 104-117.</Citation>
        </Reference>
        <Reference>
          <Citation>Simons, M., Gordon, E., &amp; Claesson-Welsh, L. (2016). Mechanisms and regulation of endothelial VEGF receptor signalling. Nature Reviews Molecular Cell Biology, 17(10), 611-625.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, H., Ma, D., Wang, C., Zhao, S., &amp; Liu, C. (2016). Triptolide inhibits invasion and tumorigenesis of hepatocellular carcinoma MHCC-97H cells through NF-kappaB signaling. Medical Science Monitor, 22, 1827-1836.</Citation>
        </Reference>
        <Reference>
          <Citation>Wei, C., Yang, C., Wang, S., Shi, D., Zhang, C., Lin, X., &#x2026; Xiong, B. (2019). Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Molecular Cancer, 18(1), 64.</Citation>
        </Reference>
        <Reference>
          <Citation>Yahaya, M. A. F., Lila, M. A. M., Ismail, S., Zainol, M., &amp; Afizan, N. (2019). Tumour-associated macrophages (TAMs) in colon cancer and how to reeducate them. Journal of Immunology Research, 2019, 2368249.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu, X., Wang, D., Wang, X., Sun, S., Zhang, Y., Wang, S., &#x2026; Qu, X. (2019). CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p. Journal of Experimental &amp; Clinical Cancer Research, 38(1), 32.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang, R., Qi, F., Zhao, F., Li, G., Shao, S., Zhang, X., &#x2026; Feng, Y. (2019). Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. Cell Death &amp; Disease, 10(4), 273.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhu, P., Wu, Y., Yang, A., Fu, X., Mao, M., &amp; Liu, Z. (2017). Catalpol suppressed proliferation, growth and invasion of CT26 colon cancer by inhibiting inflammation and tumor angiogenesis. Biomedicine &amp; Pharmacotherapy, 95, 68-76.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">32106002</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1618-095X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>68</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title>
          <ISOAbbreviation>Phytomedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The dual roles of calycosin in growth inhibition and metastatic progression during pancreatic cancer development: A "TGF-Î² paradox".</ArticleTitle>
        <Pagination>
          <StartPage>153177</StartPage>
          <MedlinePgn>153177</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2020.153177</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0944-7113(20)30010-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Calycosin is a bioactive isoflavonoid of the medicinal plant Astragalus membranaceus that exhibits a wide range of pharmacological properties. In the present study, we have attempted to explore the anti-tumorigenic potential of calycosin in pancreatic cancer.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">MTT assay was used to determine cancer cell viability. Cell cycle analysis and detection of apoptosis were performed using flow cytometry. A wound healing assay was employed to study the migratory activity of cancer cells. Western blotting and RT-PCR were used to explore the mechanism by assessing the target proteins and genes. An orthotopic tumor xenograft mouse model was also used to study the drug effects in vivo.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Calycosin inhibited the growth of pancreatic cancer cells by inducing p21[Waf1/Cip1]-induced cell cycle arrest and caspase-dependent apoptosis. Alternatively, it also promoted MIA PaCa-2 cell migration by eliciting epithelial-mesenchymal transition (EMT) and matrix metalloproteinase activation. In vivo study has confirmed that calycosin would provoke the pro-invasive and angiogenic drive and subsequent EMT in pancreatic tumors. Further mechanistic study suggests that induction of the Raf/MEK/ERK pathway and facilitated polarization of M2 tumor-associated macrophage in the tumor microenvironment both contribute to the pro-metastatic potential of calycosin. These events appear to be associated with increased expression of TGF-&#x3b2;1 at both transcriptional and post-translational levels, which may explain the paradoxical drug actions since TGF-&#x3b2; has been implicated to play dual roles as both tumor suppressor and tumor promoter in pancreatic cancer development.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Findings of this study provide innovative insights about the impact of calycosin in pancreatic cancer progression through induction of cell cycle arrest and apoptosis while possessing certain tumor-promoting property by modulation of the tumor microenvironment.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier GmbH. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Teaching and Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Auyeung</LastName>
            <ForeName>Kathy Ka-Wai</ForeName>
            <Initials>KK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, The University of Hong Kong, Hong Kong SAR, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sze</LastName>
            <ForeName>Stephen Cho-Wing</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Hong Kong Baptist University, Hong Kong SAR, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shiqing</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Hong Kong Baptist University, Hong Kong SAR, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yung</LastName>
            <ForeName>Ken Kin-Lam</ForeName>
            <Initials>KK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Hong Kong Baptist University, Hong Kong SAR, China. Electronic address: kklyung@hkbu.edu.hk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ko</LastName>
            <ForeName>Joshua Ka-Shun</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Teaching and Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China; Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China. Electronic address: jksko@hkbu.edu.hk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>01</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Phytomedicine</MedlineTA>
        <NlmUniqueID>9438794</NlmUniqueID>
        <ISSNLinking>0944-7113</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007529">Isoflavones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508960">TGFB1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>09N3E8P7TA</RegistryNumber>
          <NameOfSubstance UI="C121707">7,3'-dihydroxy-4'-methoxyisoflavone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007529" MajorTopicYN="N">Isoflavones</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067996" MajorTopicYN="N">RAW 264.7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Calycosin</Keyword>
        <Keyword MajorTopicYN="N">ERK</Keyword>
        <Keyword MajorTopicYN="N">Growth inhibition</Keyword>
        <Keyword MajorTopicYN="N">Pancreatic cancer</Keyword>
        <Keyword MajorTopicYN="N">TGF-&#x3b2;</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare no conflicts of interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32106002</ArticleId>
        <ArticleId IdType="doi">10.1016/j.phymed.2020.153177</ArticleId>
        <ArticleId IdType="pii">S0944-7113(20)30010-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32055920</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-0851</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>69</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer immunology, immunotherapy : CII</Title>
          <ISOAbbreviation>Cancer Immunol Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>813</StartPage>
          <EndPage>824</EndPage>
          <MedlinePgn>813-824</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-020-02513-y</ELocationID>
        <Abstract>
          <AbstractText>Despite significant therapeutic improvements chronic lymphocytic leukemia (CLL) remains an incurable disease and there is a persistent pursuit of new treatment alternatives. Lurbinectedin, a selective inhibitor of active transcription of protein-coding genes, is currently in phase II/III clinical trials for solid tumors such as small-cell lung cancer (SCLC). In this study, we aimed to evaluate the activity of Lurbinectedin on circulating mononuclear cells from CLL patients and to determine whether Lurbinectedin could affect the cross-talk between B-CLL cells and the tumor microenvironment. We found that Lurbinectedin induced a dose- and time-dependent death in all cell types evaluated, with B cells, monocytes and monocytic myeloid derived suppressor cells (Mo-MDSC) being the most susceptible populations. At sub-apoptotic doses, Lurbinectedin decreased the expression of CCR7 in B-CLL cells and impaired their migration towards CCL19 and CCL21. Furthermore, low concentrations of Lurbinectedin stimulated the synthesis of pro-IL1Î² in monocytes and nurse-like cells, without inducing the inflammasome activation. Altogether, these results indicate that Lurbinectedin might have antitumor activity in CLL due to its direct action on leukemic cells in combination with its effects on the tumor microenvironment. Our findings encourage further investigation of Lurbinectedin as a potential therapy for CLL.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Risnik</LastName>
            <ForeName>Denise</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-8843-7968</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratorio de InmunologÃ­a OncolÃ³gica, Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina. risnikd@upmc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Colado</LastName>
            <ForeName>Ana</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratorio de InmunologÃ­a OncolÃ³gica, Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Podaza</LastName>
            <ForeName>Enrique</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratorio de InmunologÃ­a OncolÃ³gica, Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>AlmejÃºn</LastName>
            <ForeName>MarÃ­a BelÃ©n</ForeName>
            <Initials>MB</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratorio de InmunologÃ­a OncolÃ³gica, Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>ElÃ­as</LastName>
            <ForeName>Esteban Enrique</ForeName>
            <Initials>EE</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratorio de InmunologÃ­a OncolÃ³gica, Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bezares</LastName>
            <ForeName>Raimundo Fernando</ForeName>
            <Initials>RF</Initials>
            <AffiliationInfo>
              <Affiliation>Servicio de HematologÃ­a, Hospital General de Agudos Dr. Teodoro Ãlvarez, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>FernÃ¡ndez-Grecco</LastName>
            <ForeName>Horacio</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Servicio de HematologÃ­a, Sanatorio Julio MÃ©ndez, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seija</LastName>
            <ForeName>NoÃ©</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratorio de Leucemia LinfocÃ­tica CrÃ³nica, Institut Pasteur Montevideo, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oppezzo</LastName>
            <ForeName>Pablo</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratorio de Leucemia LinfocÃ­tica CrÃ³nica, Institut Pasteur Montevideo, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Borge</LastName>
            <ForeName>Mercedes</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratorio de InmunologÃ­a OncolÃ³gica, Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gamberale</LastName>
            <ForeName>Romina</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratorio de InmunologÃ­a OncolÃ³gica, Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giordano</LastName>
            <ForeName>Mirta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratorio de InmunologÃ­a OncolÃ³gica, Instituto de Medicina Experimental (IMEX), CONICET-Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>PICT 2012/212</GrantID>
            <Agency>Agencia Nacional de Promoci&#xf3;n Cient&#xed;fica y Tecnol&#xf3;gica</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>02</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Cancer Immunol Immunother</MedlineTA>
        <NlmUniqueID>8605732</NlmUniqueID>
        <ISSNLinking>0340-7004</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515460">CCL19 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515478">CCL21 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515370">CCR7 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002243">Carbolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054415">Chemokine CCL19</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054421">Chemokine CCL21</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C568606">PM 01183</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054400">Receptors, CCR7</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054415" MajorTopicYN="N">Chemokine CCL19</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054421" MajorTopicYN="N">Chemokine CCL21</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072737" MajorTopicYN="N">Myeloid-Derived Suppressor Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054400" MajorTopicYN="N">Receptors, CCR7</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CCR7</Keyword>
        <Keyword MajorTopicYN="N">Chronic lymphocytic leukemia (CLL)</Keyword>
        <Keyword MajorTopicYN="N">IL1&#x3b2;</Keyword>
        <Keyword MajorTopicYN="N">Lurbinectedin</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32055920</ArticleId>
        <ArticleId IdType="doi">10.1007/s00262-020-02513-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s00262-020-02513-y</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31996991</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-0851</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>69</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer immunology, immunotherapy : CII</Title>
          <ISOAbbreviation>Cancer Immunol Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>PKCÎ¶ mediated anti-proliferative effect of C2 ceramide on neutralization of the tumor microenvironment and melanoma regression.</ArticleTitle>
        <Pagination>
          <StartPage>611</StartPage>
          <EndPage>627</EndPage>
          <MedlinePgn>611-627</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-020-02492-0</ELocationID>
        <Abstract>
          <AbstractText>Immunotherapy, which has advantages over chemotherapy due to lesser toxicity and higher specificity, is on the rise to treat cancer. Recently, pro-apoptotic glycolipid, ceramide has emerged as a key regulator in cancer immunotherapy. The present study elucidated the potential anti-melanoma efficacy of cell-permeable, exogenous C2 ceramide on cell death and amelioration of tumor microenvironment (TME). We, for the first time, demonstrated that C2 ceramide triggered apoptosis of melanoma cells by augmenting PKCÎ¶ along with pro-inflammatory cytokines and signaling factors. C2 ceramide showed a PKCÎ¶-mediated tumor-suppressive role in melanoma without exhibiting hepatotoxicity and nephrotoxicity. Moreover, PKCÎ¶ was revealed as one of the key regulators of Akt and ceramide during C2 ceramide-mediated apoptosis. C2 ceramide was effective in repolarization of M2 macrophage phenotype and reduction of angiogenic factors such as VEGF, VEGFR1, VEGFR2, HIF1Î±. Interestingly, PKCÎ¶ knockdown attenuated C2 ceramide-mediated inhibition of melanoma progression. Restoration of the Th1 type TME by C2 ceramide enhanced cytotoxic T cell-mediated killing of melanoma cells. Altogether, the study unraveled that C2 ceramide-induced PKCÎ¶ was associated with favorable immune cell functioning in TME leading to melanoma regression. Thus, our findings explored a novel mechanistic insight into C2 ceramide as a promising immunotherapeutic agent in melanoma treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ghosh</LastName>
            <ForeName>Sweta</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Juin</LastName>
            <ForeName>Subir Kumar</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nandi</LastName>
            <ForeName>Partha</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute (CNCI), Kolkata, 700026, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Majumdar</LastName>
            <ForeName>Suchandra Bhattacharyya</ForeName>
            <Initials>SB</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bose</LastName>
            <ForeName>Anamika</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute (CNCI), Kolkata, 700026, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baral</LastName>
            <ForeName>Rathindranath</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute (CNCI), Kolkata, 700026, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sil</LastName>
            <ForeName>Parames C</ForeName>
            <Initials>PC</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Majumdar</LastName>
            <ForeName>Subrata</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India. subrata@jcbose.ac.in.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>Grant No: 09/015(0475)2015-EMR-1</GrantID>
            <Agency>Council of Scientific and Industrial Research (CSIR), India</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>01</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Cancer Immunol Immunother</MedlineTA>
        <NlmUniqueID>8605732</NlmUniqueID>
        <ISSNLinking>0340-7004</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002518">Ceramides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C088238">protein kinase C zeta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.13</RegistryNumber>
          <NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002518" MajorTopicYN="N">Ceramides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067996" MajorTopicYN="N">RAW 264.7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040262" MajorTopicYN="N">Receptors, Vascular Endothelial Growth Factor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">C2 ceramide</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">Melanoma</Keyword>
        <Keyword MajorTopicYN="N">PKC&#x3b6;</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31996991</ArticleId>
        <ArticleId IdType="doi">10.1007/s00262-020-02492-0</ArticleId>
        <ArticleId IdType="pii">10.1007/s00262-020-02492-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31681329</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <PubDate>
              <Year>2019</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.</ArticleTitle>
        <Pagination>
          <StartPage>2455</StartPage>
          <MedlinePgn>2455</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2455</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2019.02455</ELocationID>
        <Abstract>
          <AbstractText>B-cell receptor (BCR)-dependent signaling is central for leukemia B-cell homeostasis, as underscored by the promising clinical results obtained in patients with chronic lymphocytic leukemia (CLL) treated with novel agents targeting components of this pathway. Herein, we demonstrate that the mithralog EC-7072 displays high ex vivo cytotoxic activity against leukemia cells from CLL patients independently from high-risk prognostic markers and IGHV mutational status. EC-7072 was significantly less toxic against T cells and NK cells and did not alter the production of the immune effector molecules IFN-Î³ and perforin. EC-7072 directly triggered caspase-3-dependent CLL cell apoptosis, which was not abrogated by microenvironment-derived factors that sustain leukemia cell survival. RNA-sequencing analyses revealed a dramatic EC-7072-driven reprograming of the transcriptome of CLL cells, including a wide downregulation of multiple components and targets of the BCR signaling pathway. Accordingly, we found decreased levels of phosphorylated signaling nodes downstream of the BCR. Crosslinking-mediated BCR activation antagonized CLL cell death triggered by EC-7072, increased the phosphorylation levels of the abovementioned signaling nodes and upregulated BCL2 expression, suggesting that the mithralog disrupts CLL cell viability by targeting the BCR signaling axis at multiple levels. EC-7072 exerted similar or higher antileukemic activity than that of several available CLL therapies and displayed additive or synergistic interaction with these drugs in killing CLL cells. Overall, our findings provide rationale for future investigation to test whether EC-7072 may be a potential therapeutic option for patients with CLL and other B-cell malignancies.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 Lorenzo-Herrero, Sordo-Bahamonde, Bretones, Payer, Gonz&#xe1;lez-Rodr&#xed;guez, Gonz&#xe1;lez-Garc&#xed;a, P&#xe9;rez-Escuredo, Villa-&#xc1;lvarez, N&#xfa;&#xf1;ez, Mor&#xed;s, Gonzalez and L&#xf3;pez-Soto.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lorenzo-Herrero</LastName>
            <ForeName>Seila</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de BiologÃ­a Funcional, InmunologÃ­a, Universidad de Oviedo, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de OncologÃ­a del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto de InvestigaciÃ³n Sanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sordo-Bahamonde</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de BiologÃ­a Funcional, InmunologÃ­a, Universidad de Oviedo, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de OncologÃ­a del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto de InvestigaciÃ³n Sanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>EntreChem S.L., Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bretones</LastName>
            <ForeName>Gabriel</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de OncologÃ­a del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto de InvestigaciÃ³n Sanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Departamento de BioquÃ­mica y BiologÃ­a Molecular, Universidad de Oviedo, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Payer</LastName>
            <ForeName>Ãngel R</ForeName>
            <Initials>&#xc1;R</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de OncologÃ­a del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto de InvestigaciÃ³n Sanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>GonzÃ¡lez-RodrÃ­guez</LastName>
            <ForeName>Ana P</ForeName>
            <Initials>AP</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de OncologÃ­a del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto de InvestigaciÃ³n Sanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>GonzÃ¡lez-GarcÃ­a</LastName>
            <ForeName>Esther</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Hospital de CabueÃ±es, GijÃ³n, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>PÃ©rez-Escuredo</LastName>
            <ForeName>Jhudit</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>EntreChem S.L., Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Villa-Ãlvarez</LastName>
            <ForeName>MÃ³nica</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de BiologÃ­a Funcional, InmunologÃ­a, Universidad de Oviedo, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de OncologÃ­a del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto de InvestigaciÃ³n Sanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>NÃºÃ±ez</LastName>
            <ForeName>Luz-Elena</ForeName>
            <Initials>LE</Initials>
            <AffiliationInfo>
              <Affiliation>EntreChem S.L., Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>MorÃ­s</LastName>
            <ForeName>Francisco</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>EntreChem S.L., Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonzalez</LastName>
            <ForeName>Segundo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de BiologÃ­a Funcional, InmunologÃ­a, Universidad de Oviedo, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de OncologÃ­a del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto de InvestigaciÃ³n Sanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>LÃ³pez-Soto</LastName>
            <ForeName>Alejandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de BiologÃ­a Funcional, InmunologÃ­a, Universidad de Oviedo, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de OncologÃ­a del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto de InvestigaciÃ³n Sanitaria del Principado de Asturias, Oviedo, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011947">Receptors, Antigen, B-Cell</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C520007">mithramycin SK</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NIJ123W41V</RegistryNumber>
          <NameOfSubstance UI="D008926">Plicamycin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015973" MajorTopicYN="N">Gene Expression Regulation, Leukemic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008926" MajorTopicYN="N">Plicamycin</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011947" MajorTopicYN="N">Receptors, Antigen, B-Cell</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">BCR</Keyword>
        <Keyword MajorTopicYN="N">CLL</Keyword>
        <Keyword MajorTopicYN="N">EC-7072</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">mithralog</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31681329</ArticleId>
        <ArticleId IdType="pmc">PMC6813538</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2019.02455</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Prim. (2017) 3:16096 10.1038/nrdp.2016.96</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2016.96</ArticleId>
            <ArticleId IdType="pmc">PMC5336551</ArticleId>
            <ArticleId IdType="pubmed">28102226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood. (2018) 131:2283&#x2013;96. 10.1182/blood-2017-10-764373</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2017-10-764373</ArticleId>
            <ArticleId IdType="pubmed">29666114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. (2016) 16:145&#x2013;62. 10.1038/nrc.2016.8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2016.8</ArticleId>
            <ArticleId IdType="pubmed">26911189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puente XS, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-Subero JI, et al. . Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. (2015) 526:519&#x2013;24. 10.1038/nature14666</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14666</ArticleId>
            <ArticleId IdType="pubmed">26200345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, et al. . Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. (2011) 44:47&#x2013;52. 10.1038/ng.1032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.1032</ArticleId>
            <ArticleId IdType="pubmed">22158541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi S, Li Z, Zou D, An G, Cui R, Zhong S, et al. . Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med. (2017) 19:182&#x2013;91. 10.1038/gim.2016.81</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gim.2016.81</ArticleId>
            <ArticleId IdType="pubmed">27467457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beekman R, Chapaprieta V, Russinol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, et al. . The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. (2018) 24:868&#x2013;80. 10.1038/s41591-018-0028-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0028-4</ArticleId>
            <ArticleId IdType="pmc">PMC6363101</ArticleId>
            <ArticleId IdType="pubmed">29785028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Brien SM. Highlights in chronic lymphocytic leukemia from the 2018 American Society of Clinical Oncology annual meeting. Clin Adv Hematol Oncol. (2018) 16 (Suppl. 12):1&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30235180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, O'Brien S. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. (2018) 15:510&#x2013;27. 10.1038/s41571-018-0037-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-018-0037-8</ArticleId>
            <ArticleId IdType="pubmed">29777163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, et al. . Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. (1998) 92:1165&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9694704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood. (2015) 126:471&#x2013;7. 10.1182/blood-2015-03-585075</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2015-03-585075</ArticleId>
            <ArticleId IdType="pmc">PMC4513250</ArticleId>
            <ArticleId IdType="pubmed">26065659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. (2012) 120:1175&#x2013;84. 10.1182/blood-2012-02-362624</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2012-02-362624</ArticleId>
            <ArticleId IdType="pmc">PMC3418714</ArticleId>
            <ArticleId IdType="pubmed">22715122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. (2013) 34:592&#x2013;601. 10.1016/j.it.2013.07.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2013.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC3898793</ArticleId>
            <ArticleId IdType="pubmed">23928062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. . Ibrutinib Regimens versus chemoimmunotherapy in older patients with untreated CLL. N Eng J Med. (2018) 379:2517&#x2013;28. 10.1056/NEJMoa1812836</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1812836</ArticleId>
            <ArticleId IdType="pmc">PMC6325637</ArticleId>
            <ArticleId IdType="pubmed">30501481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. . Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. (2011) 117:6287&#x2013;96. 10.1182/blood-2011-01-328484</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-01-328484</ArticleId>
            <ArticleId IdType="pmc">PMC3122947</ArticleId>
            <ArticleId IdType="pubmed">21422473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. . Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. (2010) 116:2078&#x2013;88. 10.1182/blood-2010-02-271171</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2010-02-271171</ArticleId>
            <ArticleId IdType="pmc">PMC2951855</ArticleId>
            <ArticleId IdType="pubmed">20522708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. . Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. (2018) 19:65&#x2013;75. 10.1016/S1470-2045(17)30909-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(17)30909-9</ArticleId>
            <ArticleId IdType="pmc">PMC6027999</ArticleId>
            <ArticleId IdType="pubmed">29246803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Eng J Med. (2018) 378:1107&#x2013;20. 10.1056/NEJMoa1713976</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1713976</ArticleId>
            <ArticleId IdType="pubmed">29562156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. . Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. (2018) 9:342&#x2013;53. 10.1158/2159-8290</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290</ArticleId>
            <ArticleId IdType="pubmed">30514704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol. (2001) 19:940&#x2013;5. 10.1038/nbt1001-940</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt1001-940</ArticleId>
            <ArticleId IdType="pubmed">11581659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green L, Donehower RC. Hepatic toxicity of low doses of mithramycin in hypercalcemia. Cancer treatment reports. (1984) 68:1379&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6238672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Remsing LL, Gonzalez AM, Nur-e-Alam M, Fernandez-Lozano MJ, Brana AF, Rix U, et al. . Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. J Am Chem Soc. (2003) 125:5745&#x2013;53. 10.1021/ja034162h</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ja034162h</ArticleId>
            <ArticleId IdType="pmc">PMC4480629</ArticleId>
            <ArticleId IdType="pubmed">12733914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baig I, Perez M, Brana AF, Gomathinayagam R, Damodaran C, Salas JA, et al. . Mithramycin analogues generated by combinatorial biosynthesis show improved bioactivity. J Nat Prod. (2008) 71:199&#x2013;207. 10.1021/np0705763</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/np0705763</ArticleId>
            <ArticleId IdType="pmc">PMC2442402</ArticleId>
            <ArticleId IdType="pubmed">18197601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez M, Baig I, Brana AF, Salas JA, Rohr J, Mendez C. Generation of new derivatives of the antitumor antibiotic mithramycin by altering the glycosylation pattern through combinatorial biosynthesis. Chembiochem Eur J Chem Biol. (2008) 9:2295&#x2013;304. 10.1002/cbic.200800299</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbic.200800299</ArticleId>
            <ArticleId IdType="pmc">PMC2574993</ArticleId>
            <ArticleId IdType="pubmed">18756551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malek A, Nunez LE, Magistri M, Brambilla L, Jovic S, Carbone GM, et al. . Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS ONE. (2012) 7:e35130. 10.1371/journal.pone.0035130</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0035130</ArticleId>
            <ArticleId IdType="pmc">PMC3334962</ArticleId>
            <ArticleId IdType="pubmed">22545098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, et al. . Identification of mithramycin analogues with improved targeting of the EWS-FLI1 transcription factor. Clin Cancer Res. (2016) 22:4105&#x2013;18. 10.1158/1078-0432.CCR-15-2624</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-2624</ArticleId>
            <ArticleId IdType="pmc">PMC4987166</ArticleId>
            <ArticleId IdType="pubmed">26979396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lissa D, Senovilla L, Rello-Varona S, Vitale I, Michaud M, Pietrocola F, et al. . Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proc Natl Acad Sci USA. (2014) 111:3020&#x2013;5. 10.1073/pnas.1318440111</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1318440111</ArticleId>
            <ArticleId IdType="pmc">PMC3939868</ArticleId>
            <ArticleId IdType="pubmed">24516128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sica V, Maiuri MC, Kroemer G, Galluzzi L. Detection of Apoptotic Versus Autophagic Cell Death by Flow Cytometry. Methods Mol Biol. (2016) 1419:1&#x2013;16. 10.1007/978-1-4939-3581-9_1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-3581-9_1</ArticleId>
            <ArticleId IdType="pubmed">27108427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. (2017) 14:417&#x2013;9. 10.1038/nmeth.4197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.4197</ArticleId>
            <ArticleId IdType="pmc">PMC5600148</ArticleId>
            <ArticleId IdType="pubmed">28263959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. (2014) 15:550. 10.1186/s13059-014-0550-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId>
            <ArticleId IdType="pmc">PMC4302049</ArticleId>
            <ArticleId IdType="pubmed">25516281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulgen E, Ozisik O, Sezerman OU. pathfindR: an R package for pathway enrichment analysis utilizing active subnetworks. bioRxiv. (2018) 272450 10.1101/272450</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/272450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. (2010) 70:440&#x2013;6. 10.1158/0008-5472.CAN-09-1947</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-1947</ArticleId>
            <ArticleId IdType="pubmed">20068163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bijnsdorp IV, Giovannetti E, Peters GJ. Analysis of drug interactions. Methods Mol Biol. (2011) 731:421&#x2013;34. 10.1007/978-1-61779-080-5_34</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-61779-080-5_34</ArticleId>
            <ArticleId IdType="pubmed">21516426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. . iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. (2018) 131:2745&#x2013;60. 10.1182/blood-2017-09-806398</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2017-09-806398</ArticleId>
            <ArticleId IdType="pubmed">29540348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem. (2000) 275:9390&#x2013;5. 10.1074/jbc.275.13.9390</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.275.13.9390</ArticleId>
            <ArticleId IdType="pubmed">10734083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. (2018) 18:148&#x2013;67. 10.1038/nrc.2017.121</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2017.121</ArticleId>
            <ArticleId IdType="pubmed">29348577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia&#x2013;focus on the B-cell receptor. Clin Cancer Res. (2014) 20:548&#x2013;56. 10.1158/1078-0432.CCR-13-0226</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0226</ArticleId>
            <ArticleId IdType="pubmed">24323900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. . Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. (2014) 123:3286&#x2013;95. 10.1182/blood-2014-02-548610</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-02-548610</ArticleId>
            <ArticleId IdType="pmc">PMC4046423</ArticleId>
            <ArticleId IdType="pubmed">24659631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, et al. . Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. (2014) 123:3797&#x2013;802. 10.1182/blood-2013-10-534073</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2013-10-534073</ArticleId>
            <ArticleId IdType="pmc">PMC4055926</ArticleId>
            <ArticleId IdType="pubmed">24778152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. . Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Eng J Med. (2016) 374:311&#x2013;22. 10.1056/NEJMoa1513257</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1513257</ArticleId>
            <ArticleId IdType="pmc">PMC7107002</ArticleId>
            <ArticleId IdType="pubmed">26639348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koehrer S, Burger JA. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clin Adv Hematol Oncol. (2016) 14:55&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27057669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Walchli S, et al. . Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood. (2017) 129:759&#x2013;70. 10.1182/blood-2016-05-718494</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2016-05-718494</ArticleId>
            <ArticleId IdType="pmc">PMC5301824</ArticleId>
            <ArticleId IdType="pubmed">28011673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. . The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. (2016) 127:3215&#x2013;24. 10.1182/blood-2016-01-688796</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2016-01-688796</ArticleId>
            <ArticleId IdType="pmc">PMC4920022</ArticleId>
            <ArticleId IdType="pubmed">27069256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hata AN, Engelman JA, Faber AC. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. (2015) 5:475&#x2013;87. 10.1158/2159-8290.CD-15-0011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-15-0011</ArticleId>
            <ArticleId IdType="pmc">PMC4727530</ArticleId>
            <ArticleId IdType="pubmed">25895919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogler M, Walter HS, Dyer MJS. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment. Br J Haematol. (2017) 178:364&#x2013;79. 10.1111/bjh.14684</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.14684</ArticleId>
            <ArticleId IdType="pubmed">28449207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaher M, Akrout I, Mirshahi M, Kolb JP, Billard C. Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol. Leukemia. (2009) 23:594&#x2013;6. 10.1038/leu.2008.239</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2008.239</ArticleId>
            <ArticleId IdType="pubmed">18784742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baou M, Kohlhaas SL, Butterworth M, Vogler M, Dinsdale D, Walewska R, et al. . Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica. (2010) 95:1510&#x2013;8. 10.3324/haematol.2010.022368</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2010.022368</ArticleId>
            <ArticleId IdType="pmc">PMC2930952</ArticleId>
            <ArticleId IdType="pubmed">20378569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaher M, Mirshahi M, Nuraliev Y, Sharifova M, Bombarda I, Marie JP, et al. . The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, a new plant-derived extract. Int J Oncol. (2011) 39:965&#x2013;72. 10.3892/ijo.2011.1121</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2011.1121</ArticleId>
            <ArticleId IdType="pubmed">21750864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. . High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. (2018) 132:892&#x2013;902. 10.1182/blood-2018-01-826008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-01-826008</ArticleId>
            <ArticleId IdType="pubmed">29997221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. . Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Eng J Med. (2014) 370:2286&#x2013;94. 10.1056/NEJMoa1400029</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1400029</ArticleId>
            <ArticleId IdType="pmc">PMC4144824</ArticleId>
            <ArticleId IdType="pubmed">24869598</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31552695</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1521-3773</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>58</Volume>
            <Issue>48</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>Angewandte Chemie (International ed. in English)</Title>
          <ISOAbbreviation>Angew Chem Int Ed Engl</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Artificial Enzyme Catalyzed Cascade Reactions: Antitumor Immunotherapy Reinforced by NIR-II Light.</ArticleTitle>
        <Pagination>
          <StartPage>17425</StartPage>
          <EndPage>17432</EndPage>
          <MedlinePgn>17425-17432</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/anie.201909729</ELocationID>
        <Abstract>
          <AbstractText>Current cancer therapy is seriously challenged by tumor metastasis and recurrence. One promising solution to these problems is to build antitumor immunity. However, immunotherapeutic efficacy is highly impeded by the immunosuppressive state of the tumors. Here a new strategy is presented, catalytic immunotherapy based on artificial enzymes. Cu2-x Te nanoparticles exhibit tunable enzyme-mimicking activity (including glutathione oxidase and peroxidase) under near-infrared-II (NIR-II) light. The cascade reactions catalyzed by the Cu2-x Te artificial enzyme gradually elevates intratumor oxidative stress to induce immunogenic cell death. Meanwhile, the continuously generated oxidative stress by the Cu2-x Te artificial enzyme reverses the immunosuppressive tumor microenvironment, and boosts antitumor immune responses to eradicate both primary and distant metastatic tumors. Moreover, immunological memory effect is successfully acquired after treatment with the Cu2-x Te artificial enzyme to suppress tumor relapse.</AbstractText>
          <CopyrightInformation>&#xa9; 2019 Wiley-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Mei</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-6147-7633</Identifier>
            <AffiliationInfo>
              <Affiliation>College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan, 410083, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory for Powder Metallurgy, Central South University, Changsha, Hunan, 410083, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ouyang</LastName>
            <ForeName>Jiang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan, 410083, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory for Powder Metallurgy, Central South University, Changsha, Hunan, 410083, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Chuanwan</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>College of Chemistry and Chemical Engineering, University of South China, Hengyang, Hunan, 421001, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan, 410083, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Wansong</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-3426-2653</Identifier>
            <AffiliationInfo>
              <Affiliation>College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan, 410083, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory for Powder Metallurgy, Central South University, Changsha, Hunan, 410083, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>You-Nian</ForeName>
            <Initials>YN</Initials>
            <Identifier Source="ORCID">0000-0002-7078-5937</Identifier>
            <AffiliationInfo>
              <Affiliation>College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan, 410083, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory for Powder Metallurgy, Central South University, Changsha, Hunan, 410083, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>21636010</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>21807117</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>2018JJ3631</GrantID>
            <Agency>Hunan Provincial Natural Science Foundation of China</Agency>
            <Country>International</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Angew Chem Int Ed Engl</MedlineTA>
        <NlmUniqueID>0370543</NlmUniqueID>
        <ISSNLinking>1433-7851</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>789U1901C5</RegistryNumber>
          <NameOfSubstance UI="D003300">Copper</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.-</RegistryNumber>
          <NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.7</RegistryNumber>
          <NameOfSubstance UI="D009195">Peroxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.8.4.-</RegistryNumber>
          <NameOfSubstance UI="C020667">glutathione oxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NQA0O090ZJ</RegistryNumber>
          <NameOfSubstance UI="D013691">Tellurium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040761" MajorTopicYN="N">Biomimetic Materials</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002384" MajorTopicYN="N">Catalysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007259" MajorTopicYN="N">Infrared Rays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053768" MajorTopicYN="N">Metal Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009374" MajorTopicYN="N">Neoplasms, Experimental</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010088" MajorTopicYN="N">Oxidoreductases</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009195" MajorTopicYN="N">Peroxidase</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013691" MajorTopicYN="N">Tellurium</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anticancer</Keyword>
        <Keyword MajorTopicYN="N">enzymes</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">nanoparticles</Keyword>
        <Keyword MajorTopicYN="N">oxidative stress</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31552695</ArticleId>
        <ArticleId IdType="doi">10.1002/anie.201909729</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Z. Hu, J. Ding, Z. Ma, R. Sun, J. A. Seoane, J. S. Shaffer, C. J. Suarez, A. S. Berghoff, C. Cremolini, A. Falcone, F. Loupakis, P. Birner, M. Preusser, H. J. Lenz, C. Curtis, Nat. Genet. 2019, 51, 1113-1122.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Xia, J. Wu, W. Wei, Y. Du, T. Wan, X. Ma, W. An, A. Guo, C. Miao, H. Yue, S. Li, X. Cao, Z. Su, G. Ma, Nat. Mater. 2018, 17, 187;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Yang, J. Tang, P. L. Abbaraju, M. Jambhrunkar, H. Song, M. Zhang, C. Lei, J. Fu, Z. Gu, Y. Liu, C. Yu, Angew. Chem. Int. Ed. 2018, 57, 11764-11769;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2018, 130, 11938-11943.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Shi, T. Lammers, Acc. Chem. Res. 2019, 52, 1543-1554;</Citation>
        </Reference>
        <Reference>
          <Citation>W. Song, J. Kuang, C.-X. Li, M. Zhang, D. Zheng, X. Zeng, C. Liu, X.-Z. Zhang, ACS Nano 2018, 12, 1978-1989.</Citation>
        </Reference>
        <Reference>
          <Citation>H. Phuengkham, L. Ren, I. W. Shin, Y. T. Lim, Adv. Mater. 2019, 31, 1803322.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>J. Li, D. Cui, J. Huang, S. He, Z. Yang, Y. Zhang, Y. Luo, K. Pu, Angew. Chem. Int. Ed. 2019, 58, 12680-12687;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2019, 131, 12810-12817;</Citation>
        </Reference>
        <Reference>
          <Citation>C. W. Ng, J. Li, K. Pu, Adv. Funct. Mater. 2018, 28, 1804688.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>J. Li, J. Huang, Y. Lyu, J. Huang, Y. Jiang, C. Xie, K. Pu, J. Am. Chem. Soc. 2019, 141, 4073-4079;</Citation>
        </Reference>
        <Reference>
          <Citation>B. Xu, H. Wang, W. Wang, L. Gao, S. Li, X. Pan, H. Wang, H. Yang, X. Meng, Q. Wu, L. Zheng, S. Chen, X. Shi, K. Fan, X. Yan, H. Liu, Angew. Chem. Int. Ed. 2019, 58, 4911-4916;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2019, 131, 4965-4970;</Citation>
        </Reference>
        <Reference>
          <Citation>M. Huo, L. Wang, Y. Wang, Y. Chen, J. Shi, ACS Nano 2019, 13, 2643-2653;</Citation>
        </Reference>
        <Reference>
          <Citation>X. Wang, C. Wei, J.-H. Su, B. He, G.-B. Wen, Y.-W. Lin, Y. Zhang, Angew. Chem. Int. Ed. 2018, 57, 3504-3508;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2018, 130, 3562-3566;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Zhang, J. Ge, Z. Liu, ACS Catal. 2015, 5, 4503-4513.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>K. Fan, J. Xi, L. Fan, P. Wang, C. Zhu, Y. Tang, X. Xu, M. Liang, B. Jiang, X. Yan, L. Gao, Nat. Commun. 2018, 9, 1440;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Lin, J. Ren, X. Qu, Acc. Chem. Res. 2014, 47, 1097-1105.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>H. Wang, K. Wan, X. Shi, Adv. Mater. 2018, 30, 1805368;</Citation>
        </Reference>
        <Reference>
          <Citation>H. Lin, Y. Chen, J. Shi, Chem. Soc. Rev. 2018, 47, 1938-1958;</Citation>
        </Reference>
        <Reference>
          <Citation>B. Yang, Y. Chen, J. Shi, Adv. Mater. 2019, 31, 1901778.</Citation>
        </Reference>
        <Reference>
          <Citation>S. Gao, H. Lin, H. Zhang, H. Yao, Y. Chen, J. Shi, Adv. Sci. 2019, 6, 1801733.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>Q. Yang, Z. Hu, S. Zhu, R. Ma, H. Ma, Z. Ma, H. Wan, T. Zhu, Z. Jiang, W. Liu, L. Jiao, H. Sun, Y. Liang, H. Dai, J. Am. Chem. Soc. 2018, 140, 1715-1724;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Jiang, P. K. Upputuri, C. Xie, Z. Zeng, A. Sharma, X. Zhen, J. Li, J. Huang, M. Pramanik, K. Pu, Adv. Mater. 2019, 31, 1808166;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. Jiang, J. Li, X. Zhen, C. Xie, K. Pu, Adv. Mater. 2018, 30, 1705980.</Citation>
        </Reference>
        <Reference>
          <Citation>W. Chen, J. Ouyang, X. Yi, Y. Xu, C. Niu, W. Zhang, L. Wang, J. Sheng, L. Deng, Y. N. Liu, S. Guo, Adv. Mater. 2018, 30, 1703458.</Citation>
        </Reference>
        <Reference>
          <Citation>L. Liu, D. Jiang, A. McDonald, Y. Hao, G. L. Millhauser, F. Zhou, J. Am. Chem. Soc. 2011, 133, 12229-12237.</Citation>
        </Reference>
        <Reference>
          <Citation>W. Chen, Q. Huang, W. Ou, Y. Hao, L. Wang, K. Zeng, H. Guo, J. Li, Y.-N. Liu, Small 2014, 10, 1261-1265.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Ouyang, Y. Deng, W. Chen, Q. Xu, L. Wang, Z. Liu, F.-Y. Tang, L. Deng, Y.-N. Liu, J. Mater. Chem. B 2018, 6, 2057-2064.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>W. Chen, K. Zeng, H. Liu, J. Ouyang, L. Q. Wang, Y. Liu, H. Wang, L. Deng, Y. N. Liu, Adv. Funct. Mater. 2017, 27, 1605795;</Citation>
        </Reference>
        <Reference>
          <Citation>J. Ouyang, L. Wang, W. Chen, K. Zeng, Y. Han, Y. Xu, Q. Xu, L. Deng, Y. N. Liu, Chem. Commun. 2018, 54, 3468-3471.</Citation>
        </Reference>
        <Reference>
          <Citation>J. Ouyang, M. Wen, W. Chen, Y. Tan, Z. Liu, Q. Xu, K. Zeng, L. Deng, Y. N. Liu, Chem. Commun. 2019, 55, 4877-4880.</Citation>
        </Reference>
        <Reference>
          <Citation>A. Sermeus, C. Michiels, Cell Death Dis. 2011, 2, e164.</Citation>
        </Reference>
        <Reference>
          <Citation>F. Zhou, B. Feng, H. Yu, D. Wang, T. Wang, Y. Ma, S. Wang, Y. Li, Adv. Mater. 2019, 31, 1805888.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>R. Kuai, W. Yuan, S. Son, J. Nam, Y. Xu, Y. Fan, A. Schwendeman, J. J. Moon, Sci. Adv. 2018, 4, eaao1736;</Citation>
        </Reference>
        <Reference>
          <Citation>G.-T. Yu, L. Rao, H. Wu, L.-L. Yang, L.-L. Bu, W.-W. Deng, L. Wu, X. Nan, W.-F. Zhang, X.-Z. Zhao, W. Liu, Z.-J. Sun, Adv. Funct. Mater. 2018, 28, 1801389.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>J. Lu, X. Liu, Y.-P. Liao, X. Wang, A. Ahmed, W. Jiang, Y. Ji, H. Meng, A. E. Nel, ACS Nano 2018, 12, 11041-11061;</Citation>
        </Reference>
        <Reference>
          <Citation>Y. W. Choo, M. Kang, H. Y. Kim, J. Han, S. Kang, J.-R. Lee, G.-J. Jeong, S. P. Kwon, S. Y. Song, S. Go, M. Jung, J. Hong, B.-S. Kim, ACS Nano 2018, 12, 8977-8993;</Citation>
        </Reference>
        <Reference>
          <Citation>M. Ovais, M. Guo, C. Chen, Adv. Mater. 2019, 31, 1808303.</Citation>
        </Reference>
        <Reference>
          <Citation>Q. Fan, Z. Chen, C. Wang, Z. Liu, Adv. Funct. Mater. 2018, 28, 1802540.</Citation>
        </Reference>
        <Reference>
          <Citation>&#xa0;</Citation>
        </Reference>
        <Reference>
          <Citation>S. Zanganeh, G. Hutter, R. Spitler, O. Lenkov, M. Mahmoudi, A. Shaw, J. S. Pajarinen, H. Nejadnik, S. Goodman, M. Moseley, L. M. Coussens, H. E. Daldrup-Link, Nat. Nanotechnol. 2016, 11, 986-994;</Citation>
        </Reference>
        <Reference>
          <Citation>C. Shi, T. Liu, Z. Guo, R. Zhuang, X. Zhang, X. Chen, Nano Lett. 2018, 18, 7330-7342.</Citation>
        </Reference>
        <Reference>
          <Citation>P. P. Tak, G. S. Firestein, J. Clin. Invest. 2001, 107, 7-11.</Citation>
        </Reference>
        <Reference>
          <Citation>B. Zhang, F. Wang, H. Zhou, D. Gao, Z. Yuan, C. Wu, X. Zhang, Angew. Chem. Int. Ed. 2019, 58, 2744-2748;</Citation>
        </Reference>
        <Reference>
          <Citation>Angew. Chem. 2019, 131, 2770-2774.</Citation>
        </Reference>
        <Reference>
          <Citation>X. Hu, T. Wu, Y. Bao, Z. Zhang, J. Controlled Release 2017, 256, 26-45.</Citation>
        </Reference>
        <Reference>
          <Citation>A. V. Kroll, R. H. Fang, Y. Jiang, J. Zhou, X. Wei, C. L. Yu, J. Gao, B. T. Luk, D. Dehaini, W. Gao, L. Zhang, Adv. Mater. 2017, 29, 1703969.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30420335</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>442</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>Feb</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A20-mediated deubiquitination of ERÎ± in the microenvironment of CD163[+] macrophages sensitizes endometrial cancer cells to estrogen.</ArticleTitle>
        <Pagination>
          <StartPage>137</StartPage>
          <EndPage>147</EndPage>
          <MedlinePgn>137-147</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2018.10.019</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(18)30633-5</ELocationID>
        <Abstract>
          <AbstractText>Continuous estrogen signaling is thought to be the main mechanism causing endometrial cancer (EC). Studies have demonstrated that CD163[+] macrophages could promote the development of estrogen-dependent EC, but the mechanisms involved remain unclear. We found that CD163[+] macrophages were the dominant macrophages in atypical endometrial hyperplasia and cancer, and their infiltration was positively associated with ERÎ± expression. CD163[+] macrophages mainly increased ERÎ± protein levels but with little upregulatory effect on ESR1 (ERÎ± coding gene) transcripts. The ubiquitin-editing enzyme A20, screened from the endometrial microarray obtained from mice receiving a high-fat diet and sustained estrogen-intervened, was highly expressed in endometrial lesions rich with CD163[+] macrophages, and positively correlated with ERÎ± expression. Similarly, A20 and ERÎ± were both upregulated by CD163[+] macrophages via cytokines such as IL1Î±, IL17A and TNFÎ±. Mechanistically, A20 overexpression in EC cells prolonged ERÎ± protein half-life without affecting ESR1 transcripts. A20 increased functional ERÎ± protein levels and enhanced estrogen-driven EC cell proliferation through preventing ERÎ± protein degradation by its deubiquitinase activity. Our study revealed that A20-mediated deubiquitination of ERÎ± might be an important mechanism by which CD163[+] macrophages sensitize EC cells to estrogen.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2018 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Qiaoying</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: lvqiaoying@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Liying</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: chengyali123001@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Yali</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: xieliying11@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: Yshi@iau.edu.lc.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shan</LastName>
            <ForeName>Weiwei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: fdsww1024@sina.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ning</LastName>
            <ForeName>Chengcheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: justcarolyn@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Bingying</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: 13818814056@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Bingyi</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: xiaomihaoku@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Xuezhen</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: xuezhenluo2013@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Qizhi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200000, People's Republic of China. Electronic address: qizhihe2013@51mch.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: zhuq1215@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yingli</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecologic Oncology, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou, 310022, China. Electronic address: pandazhang@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zhenbo</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200080, People's Republic of China. Electronic address: zhangzhenbozzb@aliyun.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chenji</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, 200438, People's Republic of China. Electronic address: chenjiwang@fudan.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiaojun</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: xiaojunchen2013@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Congjian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, People's Republic of China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai, 200011, People's Republic of China. Electronic address: xucongjian@fudan.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015214">Antigens, Differentiation, Myelomonocytic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C085464">CD163 antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C506487">ESR1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4TI98Z838E</RegistryNumber>
          <NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.19.12</RegistryNumber>
          <NameOfSubstance UI="C076529">TNFAIP3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.19.12</RegistryNumber>
          <NameOfSubstance UI="D000072598">Tumor Necrosis Factor alpha-Induced Protein 3</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015214" MajorTopicYN="N">Antigens, Differentiation, Myelomonocytic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047628" MajorTopicYN="N">Estrogen Receptor alpha</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072598" MajorTopicYN="N">Tumor Necrosis Factor alpha-Induced Protein 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">A20</Keyword>
        <Keyword MajorTopicYN="N">CD163(+) macrophages</Keyword>
        <Keyword MajorTopicYN="N">Deubiquitination</Keyword>
        <Keyword MajorTopicYN="N">ER&#x3b1;</Keyword>
        <Keyword MajorTopicYN="N">Endometrial cancer</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30420335</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2018.10.019</ArticleId>
        <ArticleId IdType="pii">S0304-3835(18)30633-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30352911</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-3265</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Feb</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
          <ISOAbbreviation>Clin Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>1113</StartPage>
          <EndPage>1124</EndPage>
          <MedlinePgn>1113-1124</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-17-3852</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">Adaptive antitumor immunity following ablative radiotherapy (ART) is attenuated by host myeloid-derived suppressor cell (MDSC), tumor-associated macrophage (TAM), and regulatory T-cell (Treg) infiltrates. We hypothesized treatment with ART and a secondary mitochondrial-derived activators of caspase (SMAC) mimetic could reverse the immunosuppressive lung cancer microenvironment to favor adaptive immunity.</AbstractText>
          <AbstractText Label="EXPERIMENTAL DESIGN">To evaluate for synergy between ART and the SMAC mimetic Debio 1143 and the dependence upon CD8[+] T cells and TNF&#x3b1;, we used LLC-OVA syngeneic mouse model of lung cancer and treated them with Debio 1143 and/or ART (30 Gy) with or without anti-CD8, anti-TNF&#x3b1;, or anti-IFN&#x3b3; antibodies. Tumor-infiltrating OVA-specific CD8[+] T cells, Tc1 effector cells, MDSCs, TAMs, and Tregs, were quantified by flow cytometry. Tc1-promoting cytokines TNF&#x3b1;, IFN&#x3b3;, and IL1&#x3b2; and the immunosuppressive IL10 and Arg-1 within LLC-OVA tumor tissue or mouse serum were measured by RT-PCR and ELISA.</AbstractText>
          <AbstractText Label="RESULTS">ART delayed tumor growth, and the addition of Debio 1143 greatly enhanced its efficacy, which included several complete responses. These complete responders rejected an LLC-OVA tumor rechallenge. ART and Debio 1143 synergistically induced a tumor-specific, Tc1 cellular and cytokine response while eliminating immunosuppressive cells and cytokines from the tumor microenvironment. Depletion of CD8[+] cells, TNF&#x3b1;, and IFN&#x3b3; with blocking antibody abrogated synergy between ART and Debio 1143 and partially restored tumor-infiltrating MDSCs.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Debio 1143 augments the tumor-specific adaptive immunity induced by ART, while reversing host immunosuppressive cell infiltrates in the tumor microenvironment in a TNF&#x3b1;, IFN&#x3b3;, and CD8[+] T-cell-dependent manner. This provides a novel strategy to enhance the immunogenicity of ART.</AbstractText>
          <CopyrightInformation>&#xa9;2018 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Tao</LastName>
            <ForeName>Zhen</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology and Cyberknife Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>McCall</LastName>
            <ForeName>Neal S</ForeName>
            <Initials>NS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wiedemann</LastName>
            <ForeName>Norbert</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Debiopharm International SA, Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vuagniaux</LastName>
            <ForeName>GrÃ©goire</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Debiopharm International SA, Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Zhiyong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology and Cyberknife Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. bo.lu@jefferson.edu zhiyong0524@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania. bo.lu@jefferson.edu zhiyong0524@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Clin Cancer Res</MedlineTA>
        <NlmUniqueID>9502500</NlmUniqueID>
        <ISSNLinking>1078-0432</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001392">Azocines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C412403">DIABLO protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C559144">N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001392" MajorTopicYN="N">Azocines</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001559" MajorTopicYN="N">Benzhydryl Compounds</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040761" MajorTopicYN="N">Biomimetic Materials</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018827" MajorTopicYN="N">Carcinoma, Lewis Lung</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072737" MajorTopicYN="N">Myeloid-Derived Suppressor Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011878" MajorTopicYN="N">Radiotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30352911</ArticleId>
        <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-3852</ArticleId>
        <ArticleId IdType="pii">1078-0432.CCR-17-3852</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29915309</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Jun</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CXCR1/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis.</ArticleTitle>
        <Pagination>
          <StartPage>714</StartPage>
          <MedlinePgn>714</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">714</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-018-0745-0</ELocationID>
        <Abstract>
          <AbstractText>The loss of appropriate cell adhesion normally induces apoptosis via a process termed anoikis. The aim of this study was to investigate the effects of mesenchymal stem cells (MSCs) in the cancer microenvironment on the anoikis resistance and pulmonary metastasis of osteosarcoma (OS) cells, and to evaluate the critical role of the interleukin (IL)-8/C-X-C chemokine receptor (CXCR) 1/Akt-signaling pathway in these processes. Metastatic OS subtype cells, which did or did not interact with MSC-conditioned medium (MSC-CM) in vitro, were isolated from the pulmonary site and named Saos2-lung-M. Both MSC-CM and IL-8 treatment increased the anoikis resistance of Saos2 cells in vitro. Moreover, exogenous MSC-CM promoted the survival and metastasis of Saos2 cells in nude mice. Saos2-lung-M cells were more malignant and resistant to anoikis than parental cells. MSCs secreted IL-8, thereby protecting OS cells from anoikis. Blocking the IL-8/CXCR1/Akt pathway via CXCR1 knockdown inhibited the pulmonary metastasis of Saos2-lung-MSCs and prolonged the survival of tumor-bearing mice. In conclusion, MSCs enhanced OS cell resistance to anoikis and pulmonary metastasis via regulation of the IL-8/CXCR1/Akt pathway. These findings suggest that MSCs can "select for" OS cells with high metastatic potential in vivo, and highlight CXCR1 as a key target in the regulation of pulmonary metastasis of OS cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Orthopaedic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Xiu-Guo</ForeName>
            <Initials>XG</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tu</LastName>
            <ForeName>Bing</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopaedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Min-Qi</ForeName>
            <Initials>MQ</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiao</LastName>
            <ForeName>Han</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shu-Hong</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Qi-Ming</ForeName>
            <Initials>QM</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. chillow@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Ting-Ting</ForeName>
            <Initials>TT</Initials>
            <Identifier Source="ORCID">0000-0002-1670-7452</Identifier>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ttt@sjtu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>81672205</GrantID>
            <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>81502326</GrantID>
            <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
            <Country>International</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>06</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D023062">Receptors, Interleukin-8A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023102" MajorTopicYN="N">Anoikis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012516" MajorTopicYN="N">Osteosarcoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023062" MajorTopicYN="N">Receptors, Interleukin-8A</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29915309</ArticleId>
        <ArticleId IdType="pmc">PMC6006172</ArticleId>
        <ArticleId IdType="doi">10.1038/s41419-018-0745-0</ArticleId>
        <ArticleId IdType="pii">10.1038/s41419-018-0745-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lettieri CK, et al. Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy. 2016;8:1233&#x2013;1244. doi: 10.2217/imt-2016-0048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt-2016-0048</ArticleId>
            <ArticleId IdType="pubmed">27605071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat. Res. 2009;152:3&#x2013;13. doi: 10.1007/978-1-4419-0284-9_1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4419-0284-9_1</ArticleId>
            <ArticleId IdType="pubmed">20213383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, et al. Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res. 2018;6:11. doi: 10.1038/s41413-018-0009-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41413-018-0009-8</ArticleId>
            <ArticleId IdType="pmc">PMC5884797</ArticleId>
            <ArticleId IdType="pubmed">29644114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones KB. Osteosarcomagenesis: modeling cancer initiation in the mouse. Sarcoma. 2011;2011:694136. doi: 10.1155/2011/694136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2011/694136</ArticleId>
            <ArticleId IdType="pmc">PMC3043296</ArticleId>
            <ArticleId IdType="pubmed">21403899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaikh AB, et al. Present advances and future perspectives of molecular targeted therapy for osteosarcoma. Int. J. Mol. Sci. 2016;17:506. doi: 10.3390/ijms17040506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17040506</ArticleId>
            <ArticleId IdType="pmc">PMC4848962</ArticleId>
            <ArticleId IdType="pubmed">27058531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis IJ, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J. Natl. Cancer Inst. 2007;99:112&#x2013;128. doi: 10.1093/jnci/djk015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djk015</ArticleId>
            <ArticleId IdType="pubmed">17227995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu PK, et al. Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients. Jpn J. Clin. Oncol. 2009;39:514&#x2013;522. doi: 10.1093/jjco/hyp057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jjco/hyp057</ArticleId>
            <ArticleId IdType="pubmed">19525290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan GN, Lv YF, Guo QN. Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. Cancer Lett. 2016;370:268&#x2013;274. doi: 10.1016/j.canlet.2015.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2015.11.003</ArticleId>
            <ArticleId IdType="pubmed">26571463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272:177&#x2013;185. doi: 10.1016/j.canlet.2008.05.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2008.05.029</ArticleId>
            <ArticleId IdType="pubmed">18579285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiao H, Tang T. Engineering 3D approaches to model the dynamic microenvironments of cancer bone metastasis. Bone Res. 2018;6:3. doi: 10.1038/s41413-018-0008-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41413-018-0008-9</ArticleId>
            <ArticleId IdType="pmc">PMC5826951</ArticleId>
            <ArticleId IdType="pubmed">29507817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Montero CM, Wygant JN, McIntyre BW. PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur. J. Cancer. 2006;42:1491&#x2013;1500. doi: 10.1016/j.ejca.2006.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2006.03.007</ArticleId>
            <ArticleId IdType="pubmed">16759849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortini M, Avnet S, Baldini N. Mesenchymal stroma: role in osteosarcoma progression. Cancer Lett. 2017;405:90&#x2013;99. doi: 10.1016/j.canlet.2017.07.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2017.07.024</ArticleId>
            <ArticleId IdType="pubmed">28774797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mutsaers AJ, Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone. 2014;62:56&#x2013;63. doi: 10.1016/j.bone.2014.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bone.2014.02.003</ArticleId>
            <ArticleId IdType="pubmed">24530473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tewari D, et al. Ovariectomized rats with established osteopenia have diminished mesenchymal stem cells in the bone marrow and impaired homing, osteoinduction and bone regeneration at the fracture site. Stem Cell Rev. 2015;11:309&#x2013;321. doi: 10.1007/s12015-014-9573-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12015-014-9573-5</ArticleId>
            <ArticleId IdType="pubmed">25433862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsukamoto S, et al. Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model. Int. J. Oncol. 2012;40:163&#x2013;169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21971610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bian ZY, Fan QM, Li G, Xu WT, Tang TT. Human mesenchymal stem cells promote growth of osteosarcoma: involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. Cancer Sci. 2010;101:2554&#x2013;2560. doi: 10.1111/j.1349-7006.2010.01731.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2010.01731.x</ArticleId>
            <ArticleId IdType="pubmed">20874851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu WT, Bian ZY, Fan QM, Li G, Tang TT. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 2009;281:32&#x2013;41. doi: 10.1016/j.canlet.2009.02.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2009.02.022</ArticleId>
            <ArticleId IdType="pubmed">19342158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008;8:726&#x2013;736. doi: 10.1038/nri2395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2395</ArticleId>
            <ArticleId IdType="pubmed">19172693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcellos-de-Souza P, Gori V, Bambi F, Chiarugi P. Tumor microenvironment: bone marrow-mesenchymal stem cells as key players. Biochim. Biophys. Acta. 1836;321-335:2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24183942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gales D, Clark C, Manne U, Samuel T. The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol. 2013;2013:859154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3810054</ArticleId>
            <ArticleId IdType="pubmed">24224100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdul-Aziz AM, et al. MIF-induced stromal PKCbeta/IL8 is essential in human acute myeloid leukemia. Cancer Res. 2017;77:303&#x2013;311. doi: 10.1158/0008-5472.CAN-16-1095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-1095</ArticleId>
            <ArticleId IdType="pubmed">27872094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avnet S, et al. Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-kappaB activation. Int. J. Cancer. 2017;140:1331&#x2013;1345. doi: 10.1002/ijc.30540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.30540</ArticleId>
            <ArticleId IdType="pmc">PMC5272857</ArticleId>
            <ArticleId IdType="pubmed">27888521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang H, Wang X, Miao W, Wang B, Qiu Y. CXCL8 promotes the invasion of human osteosarcoma cells by regulation of PI3K/Akt signaling pathway. APMIS. 2017;125:773&#x2013;780. doi: 10.1111/apm.12721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apm.12721</ArticleId>
            <ArticleId IdType="pubmed">28736978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du L, Fan Q, Tu B, Yan W, Tang T. Establishment and characterization of a new highly metastatic human osteosarcoma cell line derived from Saos2. Int. J. Clin. Exp. Pathol. 2014;7:2871&#x2013;2882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4097260</ArticleId>
            <ArticleId IdType="pubmed">25031706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han XG, et al. CXCR1 knockdown improves the sensitivity of osteosarcoma to cisplatin. Cancer Lett. 2015;369:405&#x2013;415. doi: 10.1016/j.canlet.2015.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2015.09.002</ArticleId>
            <ArticleId IdType="pubmed">26391645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du L, et al. Tumorigenesis and spontaneous metastasis by luciferase-labeled human xenograft osteosarcoma cells in nude mice. Chin. Med. J. (Engl.). 2012;125:4022&#x2013;4030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23158137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorlick R, Khanna C. Osteosarcoma. J. Bone Miner. Res. 2010;25:683&#x2013;691. doi: 10.1002/jbmr.77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbmr.77</ArticleId>
            <ArticleId IdType="pubmed">20205169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb. Exp. Pharmacol. 2007;180:263&#x2013;283. doi: 10.1007/978-3-540-68976-8_12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-540-68976-8_12</ArticleId>
            <ArticleId IdType="pubmed">17554513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi F, Gong L. Secretion of interleukin-6 by bone marrow mesenchymal stem cells promotes metastasis in hepatocellular carcinoma. Biosci. Rep. 2017;37:4. doi: 10.1042/BSR20170181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BSR20170181</ArticleId>
            <ArticleId IdType="pmc">PMC5567045</ArticleId>
            <ArticleId IdType="pubmed">28659496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol. Res. 2014;2:1125&#x2013;1131. doi: 10.1158/2326-6066.CIR-14-0160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0160</ArticleId>
            <ArticleId IdType="pmc">PMC4258879</ArticleId>
            <ArticleId IdType="pubmed">25480554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, et al. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 2016;31:61&#x2013;71. doi: 10.1016/j.cytogfr.2016.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cytogfr.2016.08.002</ArticleId>
            <ArticleId IdType="pmc">PMC6142815</ArticleId>
            <ArticleId IdType="pubmed">27578214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carnero A. The PKB/AKT pathway in cancer. Curr. Pharm. Des. 2010;16:34&#x2013;44. doi: 10.2174/138161210789941865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138161210789941865</ArticleId>
            <ArticleId IdType="pubmed">20214616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer. 2009;9:550&#x2013;562. doi: 10.1038/nrc2664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2664</ArticleId>
            <ArticleId IdType="pubmed">19629070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008;14:6735&#x2013;6741. doi: 10.1158/1078-0432.CCR-07-4843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-07-4843</ArticleId>
            <ArticleId IdType="pubmed">18980965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu B, Du L, Fan QM, Tang Z, Tang TT. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett. 2012;325:80&#x2013;88. doi: 10.1016/j.canlet.2012.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2012.06.006</ArticleId>
            <ArticleId IdType="pubmed">22743617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiratsuka S, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 2008;10:1349&#x2013;1355. doi: 10.1038/ncb1794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1794</ArticleId>
            <ArticleId IdType="pubmed">18820689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folkman J, Moscona A. Role of cell shape in growth control. Nature. 1978;273:345&#x2013;349. doi: 10.1038/273345a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/273345a0</ArticleId>
            <ArticleId IdType="pubmed">661946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 1994;124:619&#x2013;626. doi: 10.1083/jcb.124.4.619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.124.4.619</ArticleId>
            <ArticleId IdType="pmc">PMC2119917</ArticleId>
            <ArticleId IdType="pubmed">8106557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu C, et al. Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci. 2017;108:1347&#x2013;1356. doi: 10.1111/cas.13256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.13256</ArticleId>
            <ArticleId IdType="pmc">PMC5497929</ArticleId>
            <ArticleId IdType="pubmed">28406574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, et al. CHIP regulates bone mass by targeting multiple TRAF family members in bone marrow stromal cells. Bone Res. 2018;6:10. doi: 10.1038/s41413-018-0010-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41413-018-0010-2</ArticleId>
            <ArticleId IdType="pmc">PMC5874245</ArticleId>
            <ArticleId IdType="pubmed">29619270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu B, et al. Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-beta/Smad2/3 pathway. Exp. Cell Res. 2014;320:164&#x2013;173. doi: 10.1016/j.yexcr.2013.10.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2013.10.013</ArticleId>
            <ArticleId IdType="pubmed">24183998</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29642007</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2211-1247</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Apr</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell reports</Title>
          <ISOAbbreviation>Cell Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>How Biophysical Forces Regulate Human B Cell Lymphomas.</ArticleTitle>
        <Pagination>
          <StartPage>499</StartPage>
          <EndPage>511</EndPage>
          <MedlinePgn>499-511</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2018.03.069</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2211-1247(18)30430-3</ELocationID>
        <Abstract>
          <AbstractText>The role of microenvironment-mediated biophysical forces in human lymphomas remains elusive. Diffuse large B cell lymphomas (DLBCLs) are heterogeneous tumors, which originate from highly proliferative germinal center B cells. These tumors, their associated neo-vessels, and lymphatics presumably expose cells to particular fluid flow and survival signals. Here, we show that fluid flow enhances proliferation and modulates response of DLBCLs to specific therapeutic agents. Fluid flow upregulates surface expression of B cell receptors (BCRs) and integrin receptors in subsets of ABC-DLBCLs with either CD79A/B mutations or WT BCRs, similar to what is observed with xenografted human tumors in mice. Fluid flow differentially upregulates signaling targets, such as SYK and p70S6K, in ABC-DLBCLs. By selective knockdown of CD79B and inhibition of signaling targets, we provide mechanistic insights into how fluid flow mechanomodulates BCRs and integrins in ABC-DLBCLs. These findings redefine microenvironment factors that regulate lymphoma-drug interactions and will be critical for testing targeted therapies.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Apoorva</LastName>
            <ForeName>F</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY 14853, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Loiben</LastName>
            <ForeName>Alexander M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Shivem B</ForeName>
            <Initials>SB</Initials>
            <AffiliationInfo>
              <Affiliation>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Purwada</LastName>
            <ForeName>Alberto</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fontan</LastName>
            <ForeName>Lorena</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10021, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goldstein</LastName>
            <ForeName>Rebecca</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10021, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kirby</LastName>
            <ForeName>Brian J</ForeName>
            <Initials>BJ</Initials>
            <AffiliationInfo>
              <Affiliation>Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY 14853, USA; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10021, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Melnick</LastName>
            <ForeName>Ari M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10021, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cosgrove</LastName>
            <ForeName>Benjamin D</ForeName>
            <Initials>BD</Initials>
            <AffiliationInfo>
              <Affiliation>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Ankur</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY 14853, USA; Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA; Englander Institute for Precision Medicine, Weill Cornell Medical College, New York, NY 10021, USA. Electronic address: as2833@cornell.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R00 AG042491</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AI132738</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA187492</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R33 CA212968</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Rep</MedlineTA>
        <NlmUniqueID>101573691</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051925">CD79 Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016023">Integrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011947">Receptors, Antigen, B-Cell</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="C060902">lyn protein-tyrosine kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051925" MajorTopicYN="N">CD79 Antigens</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016023" MajorTopicYN="N">Integrins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016403" MajorTopicYN="N">Lymphoma, Large B-Cell, Diffuse</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044085" MajorTopicYN="N">Microfluidics</DescriptorName>
          <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011947" MajorTopicYN="N">Receptors, Antigen, B-Cell</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033081" MajorTopicYN="N">Shear Strength</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019061" MajorTopicYN="N">src-Family Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">B cell receptor</Keyword>
        <Keyword MajorTopicYN="Y">chemotherapy</Keyword>
        <Keyword MajorTopicYN="Y">fluid</Keyword>
        <Keyword MajorTopicYN="Y">integrin</Keyword>
        <Keyword MajorTopicYN="Y">lymph node</Keyword>
        <Keyword MajorTopicYN="Y">lymphatics</Keyword>
        <Keyword MajorTopicYN="Y">mechanomodulation</Keyword>
        <Keyword MajorTopicYN="Y">mutation</Keyword>
        <Keyword MajorTopicYN="Y">shear stress</Keyword>
        <Keyword MajorTopicYN="Y">signaling</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29642007</ArticleId>
        <ArticleId IdType="mid">NIHMS961959</ArticleId>
        <ArticleId IdType="pmc">PMC5965297</ArticleId>
        <ArticleId IdType="doi">10.1016/j.celrep.2018.03.069</ArticleId>
        <ArticleId IdType="pii">S2211-1247(18)30430-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503&#x2013;511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10676951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apoorva FNU, Tian YF, Pierpont TM, Bassen DM, Cerchietti L, Butcher JT, Weiss RS, Singh A. Award Winner in the Young Investigator Category, 2017 Society for Biomaterials Annual Meeting and Exposition, Minneapolis, MN, April 05&#x2013;08, 2017: Lymph node stiffness-mimicking hydrogels regulate human B-cell lymphoma growth and cell surface receptor expression in a molecular subtype-specific manner. J Biomed Mater Res A. 2017;105:1833&#x2013;1844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28177577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blonska M, Zhu Y, Chuang HH, You MJ, Kunkalla K, Vega F, Lin X. Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. Blood. 2015;125:981&#x2013;991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4319238</ArticleId>
            <ArticleId IdType="pubmed">25533033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brower V. Ibrutinib promising in subtype of DLBCL. Lancet Oncol. 2015;16:e428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26212869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18:148&#x2013;167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29348577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cayrol F, D&#xed;az Flaqu&#xe9; MC, Fernando T, Yang SN, Sterle HA, Bolontrade M, Amor&#xf3;s M, Isse B, Far&#xed;as RN, Ahn H, et al. Integrin &#x3b1;v&#x3b2;3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood. 2015;125:841&#x2013;851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4311229</ArticleId>
            <ArticleId IdType="pubmed">25488971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235&#x2013;242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11807147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cosgrove BD, Alexopoulos LG, Hang TC, Hendriks BS, Sorger PK, Griffith LG, Lauffenburger DA. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol Biosyst. 2010;6:1195&#x2013;1206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2943488</ArticleId>
            <ArticleId IdType="pubmed">20361094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai B, Zhao XF, Hagner P, Shapiro P, Mazan-Mamczarz K, Zhao S, Natkunam Y, Gartenhaus RB. Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma. Cancer Res. 2009;69:7835&#x2013;7843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2839501</ArticleId>
            <ArticleId IdType="pubmed">19789340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861&#x2013;1874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2193582</ArticleId>
            <ArticleId IdType="pubmed">11748286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2845535</ArticleId>
            <ArticleId IdType="pubmed">20054396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai DY, Barbosa IA, Kwon JS, Guan Y, et al. An optimized micro-RNA backbone for effective single-copy RNAi. Cell Rep. 2013;5:1704&#x2013;1713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24332856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Font&#xe1;n L, Melnick A. Molecular pathways: targeting MALT1 para-caspase activity in lymphoma. Clin Cancer Res. 2013;19:6662&#x2013;6668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24004675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell. 2012;22:812&#x2013;824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3984478</ArticleId>
            <ArticleId IdType="pubmed">23238016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005;65:4320&#x2013;4333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15899824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology (Am Soc Hematol Educ Program) 2011;2011:498&#x2013;505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22160081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015;27:409&#x2013;425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4618684</ArticleId>
            <ArticleId IdType="pubmed">25759025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, et al. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. J Clin Invest. 2015;125:4559&#x2013;4571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4665772</ArticleId>
            <ArticleId IdType="pubmed">26529251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41:2502&#x2013;2512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16199153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jafarnejad M, Woodruff MC, Zawieja DC, Carroll MC, Moore JE., Jr Modeling lymph flow and fluid exchange with blood vessels in lymph nodes. Lymphat Res Biol. 2015;13:234&#x2013;247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4685511</ArticleId>
            <ArticleId IdType="pubmed">26683026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3258060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K&#xfc;ppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251&#x2013;262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15803153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kappaB pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111:3701&#x2013;3713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2275028</ArticleId>
            <ArticleId IdType="pubmed">18160665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lecault V, Vaninsberghe M, Sekulovic S, Knapp DJ, Wohrer S, Bowden W, Viel F, McLaughlin T, Jarandehei A, Miller M, et al. High-throughput analysis of single hematopoietic stem cell proliferation in microfluidic cell culture arrays. Nat Methods. 2011;8:581&#x2013;586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21602799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee DY, Li YS, Chang SF, Zhou J, Ho HM, Chiu JJ, Chien S. Oscillatory flow-induced proliferation of osteoblast-like cells is mediated by alphavbeta3 and beta1 integrins through synergistic interactions of focal adhesion kinase and Shc with phosphatidylinositol 3-kinase and the Akt/mTOR/p70S6K pathway. J Biol Chem. 2010;285:30&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2804177</ArticleId>
            <ArticleId IdType="pubmed">19889638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008a;319:1676&#x2013;1679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18323416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, et al. Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008b;359:2313&#x2013;2323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19038878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li D, Tang T, Lu J, Dai K. Effects of flow shear stress and mass transport on the construction of a large-scale tissue-engineered bone in a perfusion bioreactor. Tissue Eng Part A. 2009;15:2773&#x2013;2783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19226211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLaughlin P, Grillo-L&#xf3;pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825&#x2013;2833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9704735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakao Y, Kimura H, Sakai Y, Fujii T. Bile canaliculi formation by aligning rat primary hepatocytes in a microfluidic device. Biomicrofluidics. 2011;5:22212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3145237</ArticleId>
            <ArticleId IdType="pubmed">21799718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115&#x2013;119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5024568</ArticleId>
            <ArticleId IdType="pubmed">21179087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, Grant S. Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leuk Res. 2010;34:379&#x2013;386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3150480</ArticleId>
            <ArticleId IdType="pubmed">20117835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poincloux R, Collin O, Liz&#xe1;rraga F, Romao M, Debray M, Piel M, Chavrier P. Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel. Proc Natl Acad Sci USA. 2011;108:1943&#x2013;1948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3033302</ArticleId>
            <ArticleId IdType="pubmed">21245302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11:12&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7709161</ArticleId>
            <ArticleId IdType="pubmed">24217204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and anti-angiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol. 2009;20:413&#x2013;424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2733074</ArticleId>
            <ArticleId IdType="pubmed">19088170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 2013;121:5192&#x2013;5202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3695363</ArticleId>
            <ArticleId IdType="pubmed">23632889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14:517&#x2013;534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25008267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A, Brito I, Lammerding J. Beyond tissue stiffness and bio-adhesivity: advanced biomaterials to model tumor microenvironments and drug resistance. Trends Cancer. 2018 Published online March 10, 2018. https://doi.org/10.1016/j.trecan.2018.01.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trecan.2018.01.008</ArticleId>
            <ArticleId IdType="pmc">PMC5884450</ArticleId>
            <ArticleId IdType="pubmed">29606313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013;344:378&#x2013;387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3558816</ArticleId>
            <ArticleId IdType="pubmed">23220742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian YF, Ahn H, Schneider RS, Yang SN, Roman-Gonzalez L, Melnick AM, Cerchietti L, Singh A. Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials. 2015;73:110&#x2013;119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4623826</ArticleId>
            <ArticleId IdType="pubmed">26406451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tjin EP, Groen RW, Vogelzang I, Derksen PW, Klok MD, Meijer HP, van Eeden S, Pals ST, Spaargaren M. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood. 2006;107:760&#x2013;768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16189274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tzima E, del Pozo MA, Shattil SJ, Chien S, Schwartz MA. Activation of integrins in endothelial cells by fluid shear stress mediates Rho-dependent cytoskeletal alignment. EMBO J. 2001;20:4639&#x2013;4647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC125600</ArticleId>
            <ArticleId IdType="pubmed">11532928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922&#x2013;926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26193343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojciechowski W, Li H, Marshall S, Dell'Agnola C, Espinoza-Delgado I. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms. J Immunol. 2005;174:7859&#x2013;7868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15944291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Shaffer AL, 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21:723&#x2013;737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4059833</ArticleId>
            <ArticleId IdType="pubmed">22698399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yee C, Biondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, Wong GG, Clark SC, Messner HA, Minden MD. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989;74:798&#x2013;804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2787680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon SO, Zhang X, Freedman AS, Zahrieh D, Lossos IS, Li L, Choi YS. Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas. Am J Pathol. 2010;177:377&#x2013;386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2893680</ArticleId>
            <ArticleId IdType="pubmed">20566742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu W, Qu H, Hu G, Zhang Q, Song K, Guan H, Liu T, Qin J. A microfluidic-based multi-shear device for investigating the effects of low fluid-induced stresses on osteoblasts. PLoS One. 2014;9:e89966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3937402</ArticleId>
            <ArticleId IdType="pubmed">24587156</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29592953</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>08</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1091-6490</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>115</Volume>
            <Issue>16</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Apr</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.</ArticleTitle>
        <Pagination>
          <StartPage>E3673</StartPage>
          <EndPage>E3681</EndPage>
          <MedlinePgn>E3673-E3681</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1803291115</ELocationID>
        <Abstract>
          <AbstractText>Metastases constitute the greatest causes of deaths from cancer. However, no effective therapeutic options currently exist for cancer patients with metastasis. Estrogen receptor Î² (ERÎ²), as a member of the nuclear receptor superfamily, shows potent tumor-suppressive activities in many cancers. To investigate whether modulation of ERÎ² could serve as a therapeutic strategy for cancer metastasis, we examined whether the selective ERÎ² agonist LY500307 could suppress lung metastasis of triple-negative breast cancer (TNBC) and melanoma. Mechanistically, while we observed that LY500307 potently induced cell death of cancer cells metastasized to lung in vivo, it does not mediate apoptosis of cancer cells in vitro, indicating that the cell death-inducing effects of LY500307 might be mediated by the tumor microenvironment. Pathological examination combined with flow cytometry assays indicated that LY500307 treatment induced significant infiltration of neutrophils in the metastatic niche. Functional experiments demonstrated that LY500307-treated cancer cells show chemotactic effects for neutrophils and that in vivo neutrophil depletion by Ly6G antibody administration could reverse the effects of LY500307-mediated metastasis suppression. RNA sequencing analysis showed that LY500307 could induce up-regulation of IL-1Î² in TNBC and melanoma cells, which further triggered antitumor neutrophil chemotaxis. However, the therapeutic effects of LY500307 treatment for suppression of lung metastasis was attenuated in IL1B[-/-] murine models, due to failure to induce antitumor neutrophil infiltration in the metastatic niche. Collectively, our study demonstrated that pharmacological activation of ERÎ² could augment innate immunity to suppress cancer metastatic colonization to lung, thus providing alternative therapeutic options for cancer patients with metastasis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Linjie</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Shuang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mei</LastName>
            <ForeName>Shenglin</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai Key Laboratory of Tuberculosis, Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University, 200433 Shanghai, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Zhengnan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Lian</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, West China Second Hospital of Sichuan University, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Nianxin</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Qilian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Qiuhong</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, City University of Hong Kong, 999077 Kowloon Tong, Hong Kong, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Le</LastName>
            <ForeName>Xiaobing</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lau</LastName>
            <ForeName>Wayne Bond</ForeName>
            <Initials>WB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lau</LastName>
            <ForeName>Bonnie</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Emergency Medicine, Kaiser Permanente Santa Clara Medical Center (affiliate of Stanford University), Santa Clara, CA 95051.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, City University of Hong Kong, 999077 Kowloon Tong, Hong Kong, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yi</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Xia</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Yuquan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Warner</LastName>
            <ForeName>Margaret</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77204.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biosciences and Nutrition, Novum, Karolinska Institute, 14186 Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gustafsson</LastName>
            <ForeName>Jan-Ãke</ForeName>
            <Initials>J&#xc5;</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77204; jgustafs@central.uh.edu taotaovip2005@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biosciences and Nutrition, Novum, Karolinska Institute, 14186 Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Shengtao</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-8322-5536</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University and Collaborative Innovation Center, 610041 Chengdu, People's Republic of China; jgustafs@central.uh.edu taotaovip2005@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>03</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001578">Benzopyrans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020847">Estrogen Receptor Modulators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047629">Estrogen Receptor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004967">Estrogens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C587672">IL1B protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2ZUL6758TZ</RegistryNumber>
          <NameOfSubstance UI="C000592024">erteberel</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001578" MajorTopicYN="N">Benzopyrans</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020847" MajorTopicYN="N">Estrogen Receptor Modulators</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047629" MajorTopicYN="N">Estrogen Receptor beta</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName>
          <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008325" MajorTopicYN="N">Mammary Neoplasms, Experimental</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009376" MajorTopicYN="N">Neoplasms, Hormone-Dependent</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020556" MajorTopicYN="N">Neutrophil Infiltration</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013047" MajorTopicYN="N">Specific Pathogen-Free Organisms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ER&#x3b2;</Keyword>
        <Keyword MajorTopicYN="N">IL-1&#x3b2;</Keyword>
        <Keyword MajorTopicYN="N">LY500307</Keyword>
        <Keyword MajorTopicYN="N">cancer metastasis</Keyword>
        <Keyword MajorTopicYN="N">neutrophil</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29592953</ArticleId>
        <ArticleId IdType="pmc">PMC5910874</ArticleId>
        <ArticleId IdType="doi">10.1073/pnas.1803291115</ArticleId>
        <ArticleId IdType="pii">1803291115</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16:201&#x2013;218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7055530</ArticleId>
            <ArticleId IdType="pubmed">27009393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov. 2011;10:778&#x2013;792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21921919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597&#x2013;608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21779010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations&#x2014;A mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573&#x2013;583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4911210</ArticleId>
            <ArticleId IdType="pubmed">26122181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674&#x2013;690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5461122</ArticleId>
            <ArticleId IdType="pubmed">27184417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warner M, Huang B, Gustafsson JA. Estrogen receptor &#x3b2; as a pharmaceutical target. Trends Pharmacol Sci. 2017;38:92&#x2013;99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27979317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bado I, Gugala Z, Fuqua SAW, Zhang XH. Estrogen receptors in breast and bone: From virtue of remodeling to vileness of metastasis. Oncogene. 2017;36:4527&#x2013;4537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5552443</ArticleId>
            <ArticleId IdType="pubmed">28368409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Giorgi V, et al. Estrogens, estrogen receptors and melanoma. Expert Rev Anticancer Ther. 2011;11:739&#x2013;747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21554049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marzagalli M, et al. Estrogen receptor beta in melanoma: From molecular insights to potential clinical utility. Front Endocrinol (Lausanne) 2016;7:140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5080294</ArticleId>
            <ArticleId IdType="pubmed">27833586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18:128&#x2013;134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29326430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katt ME, Wong AD, Searson PC. Dissemination from a solid tumor: Examining the multiple parallel pathways. Trends Cancer. 2018;4:20&#x2013;37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5806201</ArticleId>
            <ArticleId IdType="pubmed">29413419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braeuer RR, et al. Why is melanoma so metastatic? Pigment Cell Melanoma Res. 2014;27:19&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24106873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Press DJ, Miller ME, Liederbach E, Yao K, Huo D. De novo metastasis in breast cancer: Occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis. 2017 doi: 10.1007/s10585-017-9871-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10585-017-9871-9</ArticleId>
            <ArticleId IdType="pubmed">29288366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajikar SS, et al. Tumor-suppressor inactivation of GDF11 occurs by precursor sequestration in triple-negative breast cancer. Dev Cell. 2017;43:418&#x2013;435.e413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5726799</ArticleId>
            <ArticleId IdType="pubmed">29161592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ossio R, Rold&#xe1;n-Mar&#xed;n R, Mart&#xed;nez-Said H, Adams DJ, Robles-Espinoza CD. Melanoma: A global perspective. Nat Rev Cancer. 2017;17:393&#x2013;394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28450704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mann S, et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol. 2001;32:113&#x2013;118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11172304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma R, et al. Estrogen receptor beta as a therapeutic target in breast cancer stem cells. J Natl Cancer Inst. 2017;109:1&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5441302</ArticleId>
            <ArticleId IdType="pubmed">28376210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renoir JM, Marsaud V, Lazennec G. Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol. 2013;85:449&#x2013;465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23103568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honma N, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol. 2008;26:3727&#x2013;3734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18669459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinsche O, Girgert R, Emons G, Gr&#xfc;ndker C. Estrogen receptor &#x3b2; selective agonists reduce invasiveness of triple-negative breast cancer cells. Int J Oncol. 2015;46:878&#x2013;884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25420519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruddy SC, et al. Preferential estrogen receptor &#x3b2; ligands reduce Bcl-2 expression in hormone-resistant breast cancer cells to increase autophagy. Mol Cancer Ther. 2014;13:1882&#x2013;1893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24785256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cotrim CZ, et al. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene. 2013;32:2390&#x2013;2402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22751110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marzagalli M, Casati L, Moretti RM, Montagnani Marelli M, Limonta P. Estrogen receptor beta agonists differentially affect the growth of human melanoma cell lines. PLoS One. 2015;10:e0134396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4520550</ArticleId>
            <ArticleId IdType="pubmed">26225426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18:134&#x2013;147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28990587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sch&#xfc;rmann N, et al. Myeloperoxidase targets oxidative host attacks to Salmonella and prevents collateral tissue damage. Nat Microbiol. 2017;2:16268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28112722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harbort CJ, et al. Neutrophil oxidative burst activates ATM to regulate cytokine production and apoptosis. Blood. 2015;126:2842&#x2013;2851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4692144</ArticleId>
            <ArticleId IdType="pubmed">26491069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: Neutral no more. Nat Rev Cancer. 2016;16:431&#x2013;446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27282249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mouchemore KA, Anderson RL, Hamilton JA. Neutrophils, G-CSF and their contribution to breast cancer metastasis. FEBS J. 2018;285:665&#x2013;679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28834401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dissemond J, et al. Activated neutrophils exert antitumor activity against human melanoma cells: Reactive oxygen species-induced mechanisms and their modulation by granulocyte-macrophage-colony-stimulating factor. J Invest Dermatol. 2003;121:936&#x2013;938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14632216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Granot Z, et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011;20:300&#x2013;314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3172582</ArticleId>
            <ArticleId IdType="pubmed">21907922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andzinski L, et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. 2016;138:1982&#x2013;1993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26619320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finisguerra V, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015;522:349&#x2013;353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4594765</ArticleId>
            <ArticleId IdType="pubmed">25985180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou S, et al. Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics. 2012;11:M112.017988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3394960</ArticleId>
            <ArticleId IdType="pubmed">22493182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai Y, et al. VEGF-targeted short hairpin RNA inhibits intraperitoneal ovarian cancer growth in nude mice. Oncology. 2009;77:385&#x2013;394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20130421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Partida-Sanchez S, et al. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by adp-ribose, the major product generated by the CD38 enzyme reaction. J Immunol. 2007;179:7827&#x2013;7839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18025229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao L, et al. Long noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. Cancer Res. 2017;77:1369&#x2013;1382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28087599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao L, et al. An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis. Oncogene. 2017;36:3384&#x2013;3396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28114283</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29587825</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1756-9966</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Mar</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of experimental &amp; clinical cancer research : CR</Title>
          <ISOAbbreviation>J Exp Clin Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inflammatory interferon activates HIF-1Î±-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway.</ArticleTitle>
        <Pagination>
          <StartPage>70</StartPage>
          <MedlinePgn>70</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">70</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13046-018-0730-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tumor microenvironments (TMEs) activate various axes/pathways, predominantly inflammatory and hypoxic responses, impact tumorigenesis, metastasis and therapeutic resistance significantly. Although molecular pathways of individual TME are extensively studied, evidence showing interaction and crosstalk between hypoxia and inflammation remain unclear. Thus, we examined whether interferon (IFN) could modulate both inflammatory and hypoxic responses under normoxia and its relation with cancer development.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">IFN was used to induce inflammation response and HIF-1&#x3b1; expression in various cancer cell lines. Corresponding signaling pathways were then analyzed by a combination of pharmacological inhibitors, immunoblotting, GST-Raf pull-down assays, dominant-negative and short-hairpin RNA-mediated knockdown approaches. Specifically, roles of functional HIF-1&#x3b1; in the IFN-induced epithelial-mesenchymal transition (EMT) and other tumorigenic propensities were examined by knockdown, pharmacological inhibition, luciferase reporter, clonogenic, anchorage-independent growth, wound-healing, vasculogenic mimicry, invasion and sphere-formation assays as well as cellular morphology observation.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We showed for the first time that IFN induced functional HIF-1&#x3b1; expression in a time- and dose- dependent manner in various cancer cell lines under both hypoxic and normoxic conditions, and then leading to an activated HIF-1&#x3b1; pathway in an IFN-mediated pro-inflammatory TME. IFN regulates anti-apoptosis activity, cellular metastasis, EMT and vasculogenic mimicry by a novel mechanism through mainly the activation of PI3K/AKT/mTOR axis. Subsequently, pharmacological and genetic modulations of HIF-1&#x3b1;, JAK, PI3K/AKT/mTOR or p38 pathways efficiently abrogate above IFN-induced tumorigenic propensities. Moreover, HIF-1&#x3b1; is required for the IFN-induced invasiveness, tumorigenesis and vasculogenic mimicry. Further supports for the HIF-1&#x3b1;-dependent tumorigenesis were obtained from results of xenograft mouse model and sphere-formation assay.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our mechanistic study showed an induction of HIF-1&#x3b1; and EMT ability in an IFN-mediated inflammatory TME and thus demonstrating a novel interaction between inflammatory and hypoxic TMEs. Moreover, targeting HIF-1&#x3b1; may be a potential target for inhibiting tumor tumorigenesis and EMT by decreasing cancer cells wound healing and anchorage-independent colony growth. Our results also lead to rationale guidance for developing new therapeutic strategies to prevent relapse via targeting TME-providing IFN signaling and HIF-1&#x3b1; programming.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yeh</LastName>
            <ForeName>Yen-Hsiu</ForeName>
            <Initials>YH</Initials>
            <AffiliationInfo>
              <Affiliation>Department and Graduate Institute of Microbiology, College of Medicine, Taipei, Taiwan, Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsiao</LastName>
            <ForeName>Ho-Fu</ForeName>
            <Initials>HF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Emergency Medicine, Sijhih Cathay General Hospital, New Taipei City, Taiwan, Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yeh</LastName>
            <ForeName>Yen-Cheng</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Tien-Wen</ForeName>
            <Initials>TW</Initials>
            <AffiliationInfo>
              <Affiliation>Department and Graduate Institute of Microbiology, College of Medicine, Taipei, Taiwan, Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Tsai-Kun</ForeName>
            <Initials>TK</Initials>
            <AffiliationInfo>
              <Affiliation>Department and Graduate Institute of Microbiology, College of Medicine, Taipei, Taiwan, Republic of China. tsaikunli@ntu.edu.tw.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Biotechnology, National Taiwan University, Taipei, Taiwan, Republic of China. tsaikunli@ntu.edu.tw.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Genomic Medicine, National Taiwan University, Taipei, Taiwan, Republic of China. tsaikunli@ntu.edu.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>MOST 103-2320-B-002-063-MY3; 105-2325-B-002-018; 106-2320-B-002-049-MY3</GrantID>
            <Agency>Ministry of Science and Technology, Taiwan</Agency>
          </Grant>
          <Grant>
            <GrantID>MOST 105-2811-B-002-069; 106-2811-B-002-095</GrantID>
            <Agency>Ministry of Science and Technology, Taiwan</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>03</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Exp Clin Cancer Res</MedlineTA>
        <NlmUniqueID>8308647</NlmUniqueID>
        <ISSNLinking>0392-9078</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9008-11-1</RegistryNumber>
          <NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="D018631">ras Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="Y">Epithelial-Mesenchymal Transition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051795" MajorTopicYN="N">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018631" MajorTopicYN="N">ras Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Epithelial-to-mesenchymal transition</Keyword>
        <Keyword MajorTopicYN="N">HIF-1&#x3b1;</Keyword>
        <Keyword MajorTopicYN="N">Inflammatory hypoxia</Keyword>
        <Keyword MajorTopicYN="N">Interferon</Keyword>
        <Keyword MajorTopicYN="N">Oncogenesis</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>COMPETING INTERESTS: The authors declare that they have no competing interest. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29587825</ArticleId>
        <ArticleId IdType="pmc">PMC5870508</ArticleId>
        <ArticleId IdType="doi">10.1186/s13046-018-0730-6</ArticleId>
        <ArticleId IdType="pii">10.1186/s13046-018-0730-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Baron B, Kitagawa T, Nakamura K, Kuramitsu Y. Isolation of a growth factor stress-induced pancreatic Cancer sub-population: insight into changes due to micro-environment. Cancer Genomics Proteomics. 2015;12:49&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25770187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol. 2008;586:4055&#x2013;4059. doi: 10.1113/jphysiol.2008.157669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.2008.157669</ArticleId>
            <ArticleId IdType="pmc">PMC2652186</ArticleId>
            <ArticleId IdType="pubmed">18599532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436&#x2013;444. doi: 10.1038/nature07205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07205</ArticleId>
            <ArticleId IdType="pubmed">18650914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datar I, Schalper KA. Epithelial-mesenchymal transition and immune evasion during lung Cancer progression: the chicken or the egg? Clin Cancer Res. 2016;22:3422&#x2013;3424. doi: 10.1158/1078-0432.CCR-16-0336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-0336</ArticleId>
            <ArticleId IdType="pmc">PMC4947415</ArticleId>
            <ArticleId IdType="pubmed">27076625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res. 2015;21:680&#x2013;686. doi: 10.1158/1078-0432.CCR-14-2198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2198</ArticleId>
            <ArticleId IdType="pmc">PMC4333734</ArticleId>
            <ArticleId IdType="pubmed">25691772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh SR, Rameshwar P, Siegel P. Targeting tumor microenvironment in cancer therapy. Cancer Lett. 2016;380:203&#x2013;204. doi: 10.1016/j.canlet.2016.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2016.04.009</ArticleId>
            <ArticleId IdType="pubmed">27060765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly M, Yang Y, et al. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One. 2013;8:e67054. doi: 10.1371/journal.pone.0067054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0067054</ArticleId>
            <ArticleId IdType="pmc">PMC3677922</ArticleId>
            <ArticleId IdType="pubmed">23785517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Creighton CJ, Gibbons DL, Kurie JM. The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res. 2013;5:187&#x2013;195. doi: 10.2147/CMAR.S35171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S35171</ArticleId>
            <ArticleId IdType="pmc">PMC3754282</ArticleId>
            <ArticleId IdType="pubmed">23986650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, et al. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015;6:8755. doi: 10.1038/ncomms9755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms9755</ArticleId>
            <ArticleId IdType="pmc">PMC4659938</ArticleId>
            <ArticleId IdType="pubmed">26530832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Wu X, Chen S, Chen S, Xiang N, Chen Y, Guo D. Ubiquitin ligase Fbw7 restricts the replication of hepatitis C virus by targeting NS5B for ubiquitination and degradation. Biochem Biophys Res Commun. 2016;470:697&#x2013;703. doi: 10.1016/j.bbrc.2016.01.076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.01.076</ArticleId>
            <ArticleId IdType="pubmed">26774344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren H, Jia L, Zhao T, Zhang H, Chen J, Yang S, Liu J, Yu M, Hao J. Hypoxia inducible factor (HIF)-1alpha directly activates leptin receptor (Ob-R) in pancreatic cancer cells. Cancer Lett. 2014;354:172&#x2013;180. doi: 10.1016/j.canlet.2014.08.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2014.08.001</ArticleId>
            <ArticleId IdType="pubmed">25130171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646&#x2013;674. doi: 10.1016/j.cell.2011.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.02.013</ArticleId>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palazon A, Aragones J, Morales-Kastresana A, de Landazuri MO, Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res. 2012;18:1207&#x2013;1213. doi: 10.1158/1078-0432.CCR-11-1591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-1591</ArticleId>
            <ArticleId IdType="pubmed">22205687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol. 2011;27:347&#x2013;376. doi: 10.1146/annurev-cellbio-092910-154036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-cellbio-092910-154036</ArticleId>
            <ArticleId IdType="pubmed">21740232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leggat JA, Gibbons DL, Haque SF, Smith AL, Wells JW, Choy K, Lloyd CM, Hayday AC, Noble A. Innate responsiveness of CD8 memory T-cell populations nonspecifically inhibits allergic sensitization. J Allergy Clin Immunol. 2008;122:1014&#x2013;1021. doi: 10.1016/j.jaci.2008.08.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2008.08.011</ArticleId>
            <ArticleId IdType="pmc">PMC3389734</ArticleId>
            <ArticleId IdType="pubmed">18804851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrarotto R, Goonatilake R, Young Yoo S, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, et al. Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung Cancer. Clin Cancer Res. 2016;22:1674&#x2013;1686. doi: 10.1158/1078-0432.CCR-14-2890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2890</ArticleId>
            <ArticleId IdType="pmc">PMC4818738</ArticleId>
            <ArticleId IdType="pubmed">26597303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364:656&#x2013;665. doi: 10.1056/NEJMra0910283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra0910283</ArticleId>
            <ArticleId IdType="pmc">PMC3930928</ArticleId>
            <ArticleId IdType="pubmed">21323543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung HY, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res. 2015;21:962&#x2013;968. doi: 10.1158/1078-0432.CCR-13-3173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-3173</ArticleId>
            <ArticleId IdType="pmc">PMC4320988</ArticleId>
            <ArticleId IdType="pubmed">25107915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, et al. A patient-derived, Pan-Cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res. 2016;22:609&#x2013;620. doi: 10.1158/1078-0432.CCR-15-0876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0876</ArticleId>
            <ArticleId IdType="pmc">PMC4737991</ArticleId>
            <ArticleId IdType="pubmed">26420858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res. 2016;22:3630&#x2013;3642. doi: 10.1158/1078-0432.CCR-15-1434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1434</ArticleId>
            <ArticleId IdType="pmc">PMC4947453</ArticleId>
            <ArticleId IdType="pubmed">26851185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, Pertsemlidis A, Gregory PA, Wright JA, Goodall GJ, et al. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest. 2012;122:3170&#x2013;3183. doi: 10.1172/JCI63608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI63608</ArticleId>
            <ArticleId IdType="pmc">PMC3428095</ArticleId>
            <ArticleId IdType="pubmed">22850877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, et al. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res. 2011;71:7670&#x2013;7682. doi: 10.1158/0008-5472.CAN-11-0964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-0964</ArticleId>
            <ArticleId IdType="pmc">PMC3419137</ArticleId>
            <ArticleId IdType="pubmed">21987723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3:276&#x2013;285. doi: 10.1038/nrc1046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1046</ArticleId>
            <ArticleId IdType="pubmed">12671666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang YC, Chou HY, Shen TL, Chang WJ, Tai PH, Li TK. Topoisomerase II-mediated DNA cleavage and mutagenesis activated by nitric oxide underlie the inflammation-associated tumorigenesis. Antioxid Redox Signal. 2013;18:1129&#x2013;1140. doi: 10.1089/ars.2012.4620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2012.4620</ArticleId>
            <ArticleId IdType="pubmed">22998676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibbons DL, Spencer J. Mouse and human intestinal immunity: same ballpark, different players; different rules, same score. Mucosal Immunol. 2011;4:148&#x2013;157. doi: 10.1038/mi.2010.85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2010.85</ArticleId>
            <ArticleId IdType="pubmed">21228770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073&#x2013;1081. doi: 10.1093/carcin/bgp127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgp127</ArticleId>
            <ArticleId IdType="pubmed">19468060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan WC, Lee YR, Huang SF, Lin YM, Chen TY, Chung HC, Tsai CH, Chen HY, Chiang CT, Lai CK, et al. A Cullin3-KLHL20 ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell. 2011;20:214&#x2013;228. doi: 10.1016/j.ccr.2011.07.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2011.07.008</ArticleId>
            <ArticleId IdType="pubmed">21840486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, Kaelin WG., Jr Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov. 2011;1:222&#x2013;235. doi: 10.1158/2159-8290.CD-11-0098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-11-0098</ArticleId>
            <ArticleId IdType="pmc">PMC3202343</ArticleId>
            <ArticleId IdType="pubmed">22037472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123:3664&#x2013;3671. doi: 10.1172/JCI67230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI67230</ArticleId>
            <ArticleId IdType="pmc">PMC3754249</ArticleId>
            <ArticleId IdType="pubmed">23999440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisinger-Mathason TS, Zhang M, Qiu Q, Skuli N, Nakazawa MS, Karakasheva T, Mucaj V, Shay JE, Stangenberg L, Sadri N, et al. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 2013;3:1190&#x2013;1205. doi: 10.1158/2159-8290.CD-13-0118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-0118</ArticleId>
            <ArticleId IdType="pmc">PMC3822914</ArticleId>
            <ArticleId IdType="pubmed">23906982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoo YG, Christensen J, Gu J, Huang LE. HIF-1alpha mediates tumor hypoxia to confer a perpetual mesenchymal phenotype for malignant progression. Sci Signal. 2011;4:pt4. doi: 10.1126/scisignal.2002072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2002072</ArticleId>
            <ArticleId IdType="pubmed">21693763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, Cha SY, Ryu JK, Choi YJ, Kim J, et al. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol. 2006;8:1398&#x2013;1406. doi: 10.1038/ncb1508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1508</ArticleId>
            <ArticleId IdType="pubmed">17072303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3&#x2032;-kinase/Akt signaling pathway. Cancer Res. 2001;61:7349&#x2013;7355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11585776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorlach A, Bonello S. The cross-talk between NF-kappaB and HIF-1: further evidence for a significant liaison. Biochem J. 2008;412:e17&#x2013;e19. doi: 10.1042/BJ20080920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20080920</ArticleId>
            <ArticleId IdType="pubmed">18498249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doe MR, Ascano JM, Kaur M, Cole MD. Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res. 2012;72:949&#x2013;957. doi: 10.1158/0008-5472.CAN-11-2371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-2371</ArticleId>
            <ArticleId IdType="pmc">PMC3288382</ArticleId>
            <ArticleId IdType="pubmed">22186139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh YH, Yang YC, Hsieh MY, Yeh YC, Li TK. A negative feedback of the HIF-1alpha pathway via interferon-stimulated gene 15 and ISGylation. Clin Cancer Res. 2013;19:5927&#x2013;5939. doi: 10.1158/1078-0432.CCR-13-0018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0018</ArticleId>
            <ArticleId IdType="pubmed">24056783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joseph JV, Conroy S, Pavlov K, Sontakke P, Tomar T, Eggens-Meijer E, Balasubramaniyan V, Wagemakers M, den Dunnen WF, Kruyt FA. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1alpha-ZEB1 axis. Cancer Lett. 2015;359:107&#x2013;116. doi: 10.1016/j.canlet.2015.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2015.01.010</ArticleId>
            <ArticleId IdType="pubmed">25592037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung WW, Chu YC, Chen PR, Liao MH, Lee JW. Positive regulation of HIF-1A expression by EBV oncoprotein LMP1 in nasopharyngeal carcinoma cells. Cancer Lett. 2016;382:21&#x2013;31. doi: 10.1016/j.canlet.2016.08.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2016.08.021</ArticleId>
            <ArticleId IdType="pubmed">27567526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanharanta S, Massague J. Hypoxia signaling--license to metastasize. Cancer Discov. 2013;3:1103&#x2013;1104. doi: 10.1158/2159-8290.CD-13-0481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-0481</ArticleId>
            <ArticleId IdType="pmc">PMC3889127</ArticleId>
            <ArticleId IdType="pubmed">24124230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012;18:5585&#x2013;5594. doi: 10.1158/1078-0432.CCR-12-0858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-0858</ArticleId>
            <ArticleId IdType="pubmed">23071360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding C, Luo J, Li L, Li S, Yang L, Pan H, Liu Q, Qin H, Chen C, Feng J. Gab2 facilitates epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling in colorectal cancer. J Exp Clin Cancer Res. 2016;35:5. doi: 10.1186/s13046-015-0280-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-015-0280-0</ArticleId>
            <ArticleId IdType="pmc">PMC4709914</ArticleId>
            <ArticleId IdType="pubmed">26754532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei L, Li K, Pang X, Guo B, Su M, Huang Y, Wang N, Ji F, Zhong C, Yang J, et al. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2. J Exp Clin Cancer Res. 2016;35:166. doi: 10.1186/s13046-016-0446-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-016-0446-4</ArticleId>
            <ArticleId IdType="pmc">PMC5073421</ArticleId>
            <ArticleId IdType="pubmed">27769315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, Li J, Zhang Q. Resveratrol reverses doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer. J Exp Clin Cancer Res. 2017;36:19. doi: 10.1186/s13046-016-0487-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-016-0487-8</ArticleId>
            <ArticleId IdType="pmc">PMC5270306</ArticleId>
            <ArticleId IdType="pubmed">28126034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson CL, Jurk D, Fullard N, Banks P, Page A, Luli S, Elsharkawy AM, Gieling RG, Chakraborty JB, Fox C, et al. NFkappaB1 is a suppressor of neutrophil-driven hepatocellular carcinoma. Nat Commun. 2015;6:6818. doi: 10.1038/ncomms7818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms7818</ArticleId>
            <ArticleId IdType="pmc">PMC4410629</ArticleId>
            <ArticleId IdType="pubmed">25879839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17:2115&#x2013;2117. doi: 10.1096/fj.03-0329fje.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.03-0329fje</ArticleId>
            <ArticleId IdType="pubmed">12958148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibbons DL, Shashikant C, Hayday AC. A comparative analysis of RNA targeting strategies in the thymosin beta 4 gene. J Mol Biol. 2004;342:1069&#x2013;1076. doi: 10.1016/j.jmb.2004.07.081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jmb.2004.07.081</ArticleId>
            <ArticleId IdType="pubmed">15351635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishii K, Kabarowski JH, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene. 1996;13:2225&#x2013;2234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8950990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams LM, Gibbons DL, Gearing A, Maini RN, Feldmann M, Brennan FM. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest. 1996;97:2833&#x2013;2841. doi: 10.1172/JCI118739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI118739</ArticleId>
            <ArticleId IdType="pmc">PMC507377</ArticleId>
            <ArticleId IdType="pubmed">8675695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005;24:5552&#x2013;5560. doi: 10.1038/sj.onc.1208719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1208719</ArticleId>
            <ArticleId IdType="pubmed">16007214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, et al. Multifaceted roles of GSK-3 and Wnt/beta-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia. 2014;28:15&#x2013;33. doi: 10.1038/leu.2013.184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2013.184</ArticleId>
            <ArticleId IdType="pmc">PMC3887408</ArticleId>
            <ArticleId IdType="pubmed">23778311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albrengues J, Bertero T, Grasset E, Bonan S, Maiel M, Bourget I, Philippe C, Herraiz Serrano C, Benamar S, Croce O, et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun. 2015;6:10204. doi: 10.1038/ncomms10204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10204</ArticleId>
            <ArticleId IdType="pmc">PMC4682161</ArticleId>
            <ArticleId IdType="pubmed">26667266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendez O, Zavadil J, Esencay M, Lukyanov Y, Santovasi D, Wang SC, Newcomb EW, Zagzag D. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer. 2010;9:133. doi: 10.1186/1476-4598-9-133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-9-133</ArticleId>
            <ArticleId IdType="pmc">PMC2896954</ArticleId>
            <ArticleId IdType="pubmed">20515450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798&#x2013;809. doi: 10.1038/nrc2734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2734</ArticleId>
            <ArticleId IdType="pmc">PMC4856025</ArticleId>
            <ArticleId IdType="pubmed">19851315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuxe J, Karlsson MC. TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol. 2012;22:455&#x2013;461. doi: 10.1016/j.semcancer.2012.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2012.05.004</ArticleId>
            <ArticleId IdType="pubmed">22627188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016;15:18. doi: 10.1186/s12943-016-0502-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-016-0502-x</ArticleId>
            <ArticleId IdType="pmc">PMC4765192</ArticleId>
            <ArticleId IdType="pubmed">26905733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16:717&#x2013;727. doi: 10.1038/ncb3015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3015</ArticleId>
            <ArticleId IdType="pmc">PMC6220424</ArticleId>
            <ArticleId IdType="pubmed">25082194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindsey S, Langhans SA. Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. Front Oncol. 2014;4:358. doi: 10.3389/fonc.2014.00358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2014.00358</ArticleId>
            <ArticleId IdType="pmc">PMC4263086</ArticleId>
            <ArticleId IdType="pubmed">25566498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J. IL-1beta promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol Cancer. 2012;11:87. doi: 10.1186/1476-4598-11-87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-11-87</ArticleId>
            <ArticleId IdType="pmc">PMC3532073</ArticleId>
            <ArticleId IdType="pubmed">23174018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomes M, Teixeira AL, Coelho A, Araujo A, Medeiros R. The role of inflammation in lung cancer. Adv Exp Med Biol. 2014;816:1&#x2013;23. doi: 10.1007/978-3-0348-0837-8_1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-0348-0837-8_1</ArticleId>
            <ArticleId IdType="pubmed">24818717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008;15:678&#x2013;685. doi: 10.1038/cdd.2008.21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2008.21</ArticleId>
            <ArticleId IdType="pmc">PMC3050610</ArticleId>
            <ArticleId IdType="pubmed">18259193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014;4:1310&#x2013;1325. doi: 10.1158/2159-8290.CD-13-1010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-1010</ArticleId>
            <ArticleId IdType="pmc">PMC4409786</ArticleId>
            <ArticleId IdType="pubmed">25122198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bottos A, Gotthardt D, Gill JW, Gattelli A, Frei A, Tzankov A, Sexl V, Wodnar-Filipowicz A, Hynes NE. Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat Commun. 2016;7:12258. doi: 10.1038/ncomms12258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms12258</ArticleId>
            <ArticleId IdType="pmc">PMC4947169</ArticleId>
            <ArticleId IdType="pubmed">27406745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakanishi K, Sakamoto M, Yasuda J, Takamura M, Fujita N, Tsuruo T, Todo S, Hirohashi S. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res. 2002;62:2971&#x2013;2975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12019180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov. 2014;9:1&#x2013;20. doi: 10.2174/15748928113089990031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/15748928113089990031</ArticleId>
            <ArticleId IdType="pubmed">23312026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soga S, Akinaga S, Shiotsu Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des. 2013;19:366&#x2013;376. doi: 10.2174/138161213804143617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138161213804143617</ArticleId>
            <ArticleId IdType="pubmed">22920907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Wei L, Chen Q, Terek RM. CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol Cancer. 2010;9:17. doi: 10.1186/1476-4598-9-17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-9-17</ArticleId>
            <ArticleId IdType="pmc">PMC2825244</ArticleId>
            <ArticleId IdType="pubmed">20102637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brooks DL, Schwab LP, Krutilina R, Parke DN, Sethuraman A, Hoogewijs D, Schorg A, Gotwald L, Fan M, Wenger RH, Seagroves TN. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Mol Cancer. 2016;15:26. doi: 10.1186/s12943-016-0510-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-016-0510-x</ArticleId>
            <ArticleId IdType="pmc">PMC4802728</ArticleId>
            <ArticleId IdType="pubmed">27001172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williamson SC, Metcalf RL, Trapani F, Mohan S, Antonello J, Abbott B, Leong HS, Chester CP, Simms N, Polanski R, et al. Vasculogenic mimicry in small cell lung cancer. Nat Commun. 2016;7:13322. doi: 10.1038/ncomms13322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms13322</ArticleId>
            <ArticleId IdType="pmc">PMC5105195</ArticleId>
            <ArticleId IdType="pubmed">27827359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh YH, Wang SW, Yeh YC, Hsiao HF, Li TK. Rhapontigenin inhibits TGF-beta-mediated epithelialmesenchymal transition via the PI3K/AKT/mTOR pathway and is not associated with HIF-1alpha degradation. Oncol Rep. 2016;35:2887&#x2013;2895. doi: 10.3892/or.2016.4664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2016.4664</ArticleId>
            <ArticleId IdType="pubmed">26986649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeon YJ, Jo MG, Yoo HM, Hong SH, Park JM, Ka SH, Oh KH, Seol JH, Jung YK, Chung CH. Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. J Clin Invest. 2012;122(7):2622&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3386819</ArticleId>
            <ArticleId IdType="pubmed">22706304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, Scott GL, Giovanella BC, Liu LF. ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther. 2008;7:1430&#x2013;1439. doi: 10.1158/1535-7163.MCT-07-2345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-07-2345</ArticleId>
            <ArticleId IdType="pmc">PMC2561335</ArticleId>
            <ArticleId IdType="pubmed">18566215</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29486738</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>10</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2407</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC cancer</Title>
          <ISOAbbreviation>BMC Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.</ArticleTitle>
        <Pagination>
          <StartPage>231</StartPage>
          <MedlinePgn>231</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">231</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-018-4155-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Paclitaxel (PTX) is a potent anti-cancer drug commonly used for the treatment of advanced breast cancer (BCA) and melanoma. Toll-like receptor 4 (TLR4) promotes the production of pro-inflammatory cytokines associated with cancer chemoresistance. This study aims to explore the effect of TLR4 in PTX resistance in triple-negative BCA and advanced melanoma and the effect of compound A (CpdA) to attenuate this resistance.</AbstractText>
          <AbstractText Label="METHODS">BCA and melanoma cell lines were checked for the response to PTX by cytotoxic assay. The response to PTX of TLR4-transient knockdown cells by siRNA transfection was evaluated compared to the control cells. Levels of pro-inflammatory cytokines, IL-6 and IL-8, and anti-apoptotic protein, XIAP were measured by real-time PCR whereas the secreted IL-8 was quantitated by ELISA in TLR4-transient knockdown cancer cells with or without CpdA treatment. The apoptotic cells after adding PTX alone or in combination with CpdA were detected by caspase-3/7 assay.</AbstractText>
          <AbstractText Label="RESULTS">PTX could markedly induce TLR4 expression in both MDA-MB-231 BCA and MDA-MB-435 melanoma cell lines having a basal level of TLR4 whereas no significant induction in TLR4-transient knockdown cells occurred. The siTLR4-treated BCA cells revealed more dead cells after PTX treatment than that of mock control cells. IL-6, IL-8 and XIAP showed increased expressions in PTX-treated cells and this over-production effect was inhibited in TLR4-transient knockdown cells. Apoptotic cells were detected higher when PTX and CpdA were combined than PTX treatment alone. Isobologram exhibited the synergistic effect of CpdA and PTX. CpdA could significantly decrease expressions of IL-6, XIAP and IL-8, as well as excreted IL-8 levels together with reduced cancer viability after PTX treatment.</AbstractText>
          <AbstractText Label="CONCLUSIONS">The acquired TLR4-mediated PTX resistance in BCA and melanoma is explained partly by the paracrine effect of IL-6 and IL-8 released into the tumor microenvironment and over-production of anti-apoptotic protein, XIAP, in BCA cells and importantly CpdA could reduce this effect and sensitize PTX-induced apoptosis in a synergistic manner. In conclusion, the possible impact of TLR4-dependent signaling pathway in PTX resistance in BCA and melanoma is proposed and using PTX in combination with CpdA may attenuate TLR4-mediated PTX resistance in the treatment of the patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sootichote</LastName>
            <ForeName>Rochanawan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate Program in Immunology, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thuwajit</LastName>
            <ForeName>Peti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singsuksawat</LastName>
            <ForeName>Ekapot</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Warnnissorn</LastName>
            <ForeName>Malee</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yenchitsomanus</LastName>
            <ForeName>Pa-Thai</ForeName>
            <Initials>PT</Initials>
            <AffiliationInfo>
              <Affiliation>Siriraj Centre of Research Excellence for Cancer Immunotherapy, Division of Molecular Medicine, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ithimakin</LastName>
            <ForeName>Suthinee</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Oncology, Department of Internal Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chantharasamee</LastName>
            <ForeName>Jomjit</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Oncology, Department of Internal Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thuwajit</LastName>
            <ForeName>Chanitra</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. cthuwajit@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>02</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>BMC Cancer</MedlineTA>
        <NlmUniqueID>100967800</NlmUniqueID>
        <ISSNLinking>1471-2407</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C104564">2-(4-acetoxyphenyl)-2-chloro-N-methylethylamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495345">TLR4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>X8ZC7V0OX3</RegistryNumber>
          <NameOfSubstance UI="D014439">Tyramine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014439" MajorTopicYN="N">Tyramine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Compound A</Keyword>
        <Keyword MajorTopicYN="N">Melanoma</Keyword>
        <Keyword MajorTopicYN="N">Paclitaxel</Keyword>
        <Keyword MajorTopicYN="N">TLR4</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>ETHICS APPROVAL AND CONSENT TO PARTICIPATE: No human and animal ethics approval was required. CONSENT FOR PUBLICATION: Not applicable COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29486738</ArticleId>
        <ArticleId IdType="pmc">PMC5830047</ArticleId>
        <ArticleId IdType="doi">10.1186/s12885-018-4155-6</ArticleId>
        <ArticleId IdType="pii">10.1186/s12885-018-4155-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Attasara P, Buasom R. Hospital-based cancer registry 2011/NCI Thailand. 2012. pp. 1&#x2013;55.</Citation>
        </Reference>
        <Reference>
          <Citation>Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep. 2007;9(1):22&#x2013;30. doi: 10.1007/BF02951422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02951422</ArticleId>
            <ArticleId IdType="pubmed">17164044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, Chan S, Welcher R, Liu D. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage breast cancer. Clin Cancer Res. 2013;19(6):1587&#x2013;1595. doi: 10.1158/1078-0432.CCR-12-1359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1359</ArticleId>
            <ArticleId IdType="pubmed">23340299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzarito T, Venturi G, Cesolini A, Fais S. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett. 2015;356(2 Pt B):697&#x2013;703. doi: 10.1016/j.canlet.2014.10.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2014.10.017</ArticleId>
            <ArticleId IdType="pubmed">25449440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Guan M, Wong PF, Yu H, Dong J, Xu J. Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway. Food Chem Toxicol. 2012;50(9):3019&#x2013;3024. doi: 10.1016/j.fct.2012.06.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fct.2012.06.027</ArticleId>
            <ArticleId IdType="pubmed">22743248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Yin J, Shen W, Gao R, Liu Y, Chen Y, Li X, Liu C, Xiang R, Luo N. TLR4 promotes breast cancer metastasis via Akt/GSK3beta/beta-catenin pathway upon LPS stimulation. Anat Rec (Hoboken) 2017;300(7):1219&#x2013;1229. doi: 10.1002/ar.23590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ar.23590</ArticleId>
            <ArticleId IdType="pubmed">28296189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato Y, Goto Y, Narita N, Hoon DS. Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2009;2(Suppl 1):205&#x2013;214. doi: 10.1007/s12307-009-0022-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12307-009-0022-y</ArticleId>
            <ArticleId IdType="pmc">PMC2756339</ArticleId>
            <ArticleId IdType="pubmed">19685283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding AH, Porteu F, Sanchez E, Nathan CF. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science. 1990;248(4953):370&#x2013;372. doi: 10.1126/science.1970196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1970196</ArticleId>
            <ArticleId IdType="pubmed">1970196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66(7):3859&#x2013;3868. doi: 10.1158/0008-5472.CAN-05-3948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-3948</ArticleId>
            <ArticleId IdType="pubmed">16585214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang AC, Su QB, Wu FX, Zhang XL, Liu PS. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur J Clin Investig. 2009;39(2):157&#x2013;164. doi: 10.1111/j.1365-2362.2008.02070.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2362.2008.02070.x</ArticleId>
            <ArticleId IdType="pubmed">19200169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, Spaczynski M, Whiteside TL. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009;28(49):4353&#x2013;4363. doi: 10.1038/onc.2009.289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2009.289</ArticleId>
            <ArticleId IdType="pmc">PMC2794996</ArticleId>
            <ArticleId IdType="pubmed">19826413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang AC, Ma YB, Wu FX, Ma ZF, Liu NF, Gao R, Gao YS, Sheng XG. TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma. Oncol Lett. 2014;7(3):871&#x2013;877. doi: 10.3892/ol.2013.1759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2013.1759</ArticleId>
            <ArticleId IdType="pmc">PMC3919821</ArticleId>
            <ArticleId IdType="pubmed">24527095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther. 2013;12(8):1676&#x2013;1687. doi: 10.1158/1535-7163.MCT-12-1019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-12-1019</ArticleId>
            <ArticleId IdType="pmc">PMC3742631</ArticleId>
            <ArticleId IdType="pubmed">23720768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lesovaya EA, Yemelyanov AY, Kirsanov KI, Yakubovskaya MG, Budunova IV. Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562. Biochemistry (Mosc) 2011;76(11):1242&#x2013;1252. doi: 10.1134/S000629791111006X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1134/S000629791111006X</ArticleId>
            <ArticleId IdType="pubmed">22117551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lesovaya E, Yemelyanov A, Kirsanov K, Popa A, Belitsky G, Yakubovskaya M, Gordon LI, Rosen ST, Budunova I. Combination of a selective activator of the glucocorticoid receptor compound a with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies. Cell Cycle. 2013;12(1):133&#x2013;144. doi: 10.4161/cc.23048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.23048</ArticleId>
            <ArticleId IdType="pmc">PMC3570502</ArticleId>
            <ArticleId IdType="pubmed">23255118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yemelyanov A, Bhalla P, Yang X, Ugolkov A, Iwadate K, Karseladze A, Budunova I. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality. Cell Cycle. 2012;11(2):395&#x2013;406. doi: 10.4161/cc.11.2.18945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.11.2.18945</ArticleId>
            <ArticleId IdType="pmc">PMC3356826</ArticleId>
            <ArticleId IdType="pubmed">22223138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671&#x2013;675. doi: 10.1038/nmeth.2089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.2089</ArticleId>
            <ArticleId IdType="pmc">PMC5554542</ArticleId>
            <ArticleId IdType="pubmed">22930834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007;44(11):2850&#x2013;2859. doi: 10.1016/j.molimm.2007.01.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2007.01.022</ArticleId>
            <ArticleId IdType="pubmed">17328955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, Schwartz P, Rutherford T, Azodi M, Mor G. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med. 2006;79(3&#x2013;4):153&#x2013;163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1994803</ArticleId>
            <ArticleId IdType="pubmed">17940625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML, Gonzalez-Quintana JM, Vizoso FJ. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665. doi: 10.1186/1471-2407-10-665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-10-665</ArticleId>
            <ArticleId IdType="pmc">PMC3009680</ArticleId>
            <ArticleId IdType="pubmed">21129170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, Aguirre A, Suarez A, Gonzalez JM, Escaff S, Vizoso FJ. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother. 2011;60(2):217&#x2013;226. doi: 10.1007/s00262-010-0931-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-010-0931-0</ArticleId>
            <ArticleId IdType="pubmed">20978888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, Shen H, Zhu X. Reduced expression of toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 2010;29:92. doi: 10.1186/1756-9966-29-92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-9966-29-92</ArticleId>
            <ArticleId IdType="pmc">PMC2913950</ArticleId>
            <ArticleId IdType="pubmed">20618976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu F, Wang F, Yang T, Sheng Y, Zhong T, Chen Y. Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell Int. 2014;14(1):538. doi: 10.1186/s12935-014-0142-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-014-0142-4</ArticleId>
            <ArticleId IdType="pmc">PMC4279688</ArticleId>
            <ArticleId IdType="pubmed">25550688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001;6(2):133&#x2013;146. doi: 10.1634/theoncologist.6-2-133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.6-2-133</ArticleId>
            <ArticleId IdType="pubmed">11306725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CH, Wu CL, Shiau AL. Toll-like receptor 4 signaling promotes tumor growth. J Immunother. 2010;33(1):73&#x2013;82. doi: 10.1097/CJI.0b013e3181b7a0a4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0b013e3181b7a0a4</ArticleId>
            <ArticleId IdType="pubmed">19952954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge X, Cao Z, Gu Y, Wang F, Li J, Han M, Xia W, Yu Z, Lyu P. PFKFB3 potentially contributes to paclitaxel resistance in breast cancer cells through TLR4 activation by stimulating lactate production. Cell Mol Biol (Noisy-le-grand) 2016;62(6):119&#x2013;125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27262815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan ZQ. Regulation of TLR4 expression is a tale about tail. Arterioscler Thromb Vasc Biol. 2006;26(12):2582&#x2013;2584. doi: 10.1161/01.ATV.0000250933.92917.dd.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.ATV.0000250933.92917.dd</ArticleId>
            <ArticleId IdType="pubmed">17110607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao SJ, Zhou YH, Yuan Y, Li D, Wu FH, Wang Q, Zhu JH, Yan B, Wei JJ, Zhang GM, et al. Triggering of toll-like receptor 4 on metastatic breast cancer cells promotes alphavbeta3-mediated adhesion and invasive migration. Breast Cancer Res Treat. 2012;133(3):853&#x2013;863. doi: 10.1007/s10549-011-1844-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-011-1844-0</ArticleId>
            <ArticleId IdType="pubmed">22042369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Zhu R, Huang Z, Li H, Zhu H. Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci. 2013;58(8):2223&#x2013;2236. doi: 10.1007/s10620-013-2745-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-013-2745-3</ArticleId>
            <ArticleId IdType="pubmed">23828139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003;48:82&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14737948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25(3):94&#x2013;102. doi: 10.1016/j.cyto.2003.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2003.10.004</ArticleId>
            <ArticleId IdType="pubmed">14698135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 1999;5(11):3445&#x2013;3453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10589757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kars MD, Iseri OD, Gunduz U. A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells. Eur J Pharmacol. 2011;657(1&#x2013;3):4&#x2013;9. doi: 10.1016/j.ejphar.2011.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2011.02.001</ArticleId>
            <ArticleId IdType="pubmed">21320484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003;22(10):1517&#x2013;1527. doi: 10.1038/sj.onc.1206226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1206226</ArticleId>
            <ArticleId IdType="pubmed">12629515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250(2):607&#x2013;610. doi: 10.1016/0014-5793(89)80805-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-5793(89)80805-1</ArticleId>
            <ArticleId IdType="pubmed">2787758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Z, Yang WM, Chen LP, Yang DH, Zhou Q, Zhu J, Chen JJ, Huang RC, Chen ZS, Huang RP. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res Treat. 2012;135(3):737&#x2013;747. doi: 10.1007/s10549-012-2196-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-012-2196-0</ArticleId>
            <ArticleId IdType="pubmed">22923236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer. 2007;56(1):25&#x2013;33. doi: 10.1016/j.lungcan.2006.11.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2006.11.014</ArticleId>
            <ArticleId IdType="pubmed">17175059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, Shang H, Cui L, Zhang Z, Zhang Y, Li Y, Wu J, Li RK, Xie J. Targeted blockade of interleukin-8 abrogates its promotion of cervical cancer growth and metastasis. Mol Cell Biochem. 2013;375(1&#x2013;2):69&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23247723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, Meng XY. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 2012;59(1):145&#x2013;155. doi: 10.1016/j.cyto.2012.04.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2012.04.013</ArticleId>
            <ArticleId IdType="pubmed">22579115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10(21):7157&#x2013;7162. doi: 10.1158/1078-0432.CCR-04-0812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-0812</ArticleId>
            <ArticleId IdType="pubmed">15534087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho YA, Sung MK, Yeon JY, Ro J, Kim J. Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype. Cancer Res Treat. 2013;45(3):210&#x2013;219. doi: 10.4143/crt.2013.45.3.210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4143/crt.2013.45.3.210</ArticleId>
            <ArticleId IdType="pmc">PMC3804733</ArticleId>
            <ArticleId IdType="pubmed">24155680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D, Ran S. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res. 2014;74(19):5421&#x2013;5434. doi: 10.1158/0008-5472.CAN-14-0067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-0067</ArticleId>
            <ArticleId IdType="pmc">PMC4185415</ArticleId>
            <ArticleId IdType="pubmed">25274031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kashkar H. X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin Cancer Res. 2010;16(18):4496&#x2013;4502. doi: 10.1158/1078-0432.CCR-10-1664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-1664</ArticleId>
            <ArticleId IdType="pubmed">20682709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Wu X, Sun Y, Chen F. Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer. J Int Med Res. 2011;39(5):1682&#x2013;1692. doi: 10.1177/147323001103900510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/147323001103900510</ArticleId>
            <ArticleId IdType="pubmed">22117968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Wang Y, Gao W, Zhang R, Han X, Jia M, Guan W. Transfer of siRNA against XIAP induces apoptosis and reduces tumor cells growth potential in human breast cancer in vitro and in vivo. Breast Cancer Res Treat. 2006;96(3):267&#x2013;277. doi: 10.1007/s10549-005-9080-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-005-9080-0</ArticleId>
            <ArticleId IdType="pubmed">16341821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, Libert C, Staels B, Louw A, Haegeman G. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A. 2005;102(44):15827&#x2013;15832. doi: 10.1073/pnas.0505554102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0505554102</ArticleId>
            <ArticleId IdType="pmc">PMC1276063</ArticleId>
            <ArticleId IdType="pubmed">16243974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y, Ishiguro H, Ide H, Inoue S, Kashiwagi E, Kawahara T, Jalalizadeh M, Reis LO, Miyamoto H, Compound A. Inhibits bladder cancer growth predominantly via glucocorticoid receptor Transrepression. Mol Endocrinol. 2015;29(10):1486&#x2013;1497. doi: 10.1210/me.2015-1128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/me.2015-1128</ArticleId>
            <ArticleId IdType="pmc">PMC5414678</ArticleId>
            <ArticleId IdType="pubmed">26322830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, et al. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood. 2008;111(9):4690&#x2013;4699. doi: 10.1182/blood-2007-09-112904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2007-09-112904</ArticleId>
            <ArticleId IdType="pmc">PMC2343599</ArticleId>
            <ArticleId IdType="pubmed">18305219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT, Jr, Budunova I. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells. Cancer Res. 2008;68(12):4763&#x2013;4773. doi: 10.1158/0008-5472.CAN-07-6104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-6104</ArticleId>
            <ArticleId IdType="pubmed">18559523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schettini F, Giuliano M, De Placido S, Arpino G. Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives. Cancer Treat Rev. 2016;50:129&#x2013;141. doi: 10.1016/j.ctrv.2016.09.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2016.09.004</ArticleId>
            <ArticleId IdType="pubmed">27665540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kottschade LA, Suman VJ, Amatruda T, 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a north central cancer treatment group study, N057E(1) Cancer. 2011;117(8):1704&#x2013;1710. doi: 10.1002/cncr.25659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.25659</ArticleId>
            <ArticleId IdType="pmc">PMC3116030</ArticleId>
            <ArticleId IdType="pubmed">21472717</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29436393</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1540-9538</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>215</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Mar</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of experimental medicine</Title>
          <ISOAbbreviation>J Exp Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.</ArticleTitle>
        <Pagination>
          <StartPage>895</StartPage>
          <EndPage>910</EndPage>
          <MedlinePgn>895-910</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20171818</ELocationID>
        <Abstract>
          <AbstractText>Drug resistance to approved systemic therapies in estrogen receptor-positive (ER+) breast cancer remains common. We hypothesized that factors present in the human tumor microenvironment (TME) drive drug resistance. Screening of a library of recombinant secreted microenvironmental proteins revealed fibroblast growth factor 2 (FGF2) as a potent mediator of resistance to anti-estrogens, mTORC1 inhibition, and phosphatidylinositol 3-kinase inhibition in ER+ breast cancer. Phosphoproteomic analyses identified ERK1/2 as a major output of FGF2 signaling via FGF receptors (FGFRs), with consequent up-regulation of Cyclin D1 and down-regulation of Bim as mediators of drug resistance. FGF2-driven drug resistance in anti-estrogen-sensitive and -resistant models, including patient-derived xenografts, was reverted by neutralizing FGF2 or FGFRs. A transcriptomic signature of FGF2 signaling in primary tumors predicted shorter recurrence-free survival independently of age, grade, stage, and FGFR amplification status. These findings delineate FGF2 signaling as a ligand-based drug resistance mechanism and highlights an underdeveloped aspect of precision oncology: characterizing and treating patients according to their TME constitution.</AbstractText>
          <CopyrightInformation>&#xa9; 2018 Shee et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shee</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hinds</LastName>
            <ForeName>John W</ForeName>
            <Initials>JW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hampsch</LastName>
            <ForeName>Riley A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Varn</LastName>
            <ForeName>Frederick S</ForeName>
            <Initials>FS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Traphagen</LastName>
            <ForeName>Nicole A</ForeName>
            <Initials>NA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Kishan</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-5002-3417</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jenkins</LastName>
            <ForeName>Nicole P</ForeName>
            <Initials>NP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Cell Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kettenbach</LastName>
            <ForeName>Arminja N</ForeName>
            <Initials>AN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Cell Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Demidenko</LastName>
            <ForeName>Eugene</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Owens</LastName>
            <ForeName>Philip</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Medicine, Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Faber</LastName>
            <ForeName>Anthony C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>VCU Philips Institute for Oral Health Research, School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Golub</LastName>
            <ForeName>Todd R</ForeName>
            <Initials>TR</Initials>
            <AffiliationInfo>
              <Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Straussman</LastName>
            <ForeName>Ravid</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miller</LastName>
            <ForeName>Todd W</ForeName>
            <Initials>TW</Initials>
            <Identifier Source="ORCID">0000-0001-8912-2909</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH todd.w.miller@dartmouth.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Comprehensive Breast Program, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA200994</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>IK2 BX002929</GrantID>
            <Acronym>BX</Acronym>
            <Agency>BLRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA023108</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>F30 CA216966</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA211869</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 GM119455</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>02</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Exp Med</MedlineTA>
        <NlmUniqueID>2985109R</NlmUniqueID>
        <ISSNLinking>0022-1007</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000072224">Bcl-2-Like Protein 11</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017468">Receptors, Fibroblast Growth Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>103107-01-3</RegistryNumber>
          <NameOfSubstance UI="D016222">Fibroblast Growth Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>136601-57-5</RegistryNumber>
          <NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072224" MajorTopicYN="N">Bcl-2-Like Protein 11</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019938" MajorTopicYN="N">Cyclin D1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016222" MajorTopicYN="N">Fibroblast Growth Factor 2</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017468" MajorTopicYN="N">Receptors, Fibroblast Growth Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29436393</ArticleId>
        <ArticleId IdType="pmc">PMC5839765</ArticleId>
        <ArticleId IdType="doi">10.1084/jem.20171818</ArticleId>
        <ArticleId IdType="pii">jem.20171818</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Akl M.R., Nagpal P., Ayoub N.M., Tai B., Prabhu S.A., Capac C.M., Gliksman M., Goy A., and Suh K.S.. 2016. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 7:44735&#x2013;44762. 10.18632/oncotarget.8203</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8203</ArticleId>
            <ArticleId IdType="pmc">PMC5190132</ArticleId>
            <ArticleId IdType="pubmed">27007053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altucci L., Addeo R., Cicatiello L., Dauvois S., Parker M.G., Truss M., Beato M., Sica V., Bresciani F., and Weisz A.. 1996. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene. 12:2315&#x2013;2324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8649771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Cancer Society 2015. Cancer Facts &amp; Figures 2015. American Cancer Society, Atlanta, GA. 56 pp.</Citation>
        </Reference>
        <Reference>
          <Citation>Andr&#xe9; F., Bachelot T., Campone M., Dalenc F., Perez-Garcia J.M., Hurvitz S.A., Turner N., Rugo H., Smith J.W., Deudon S., et al. . 2013. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin. Cancer Res. 19:3693&#x2013;3702. 10.1158/1078-0432.CCR-13-0190</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0190</ArticleId>
            <ArticleId IdType="pubmed">23658459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bosco E.E., Wang Y., Xu H., Zilfou J.T., Knudsen K.E., Aronow B.J., Lowe S.W., and Knudsen E.S.. 2007. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J. Clin. Invest. 117:218&#x2013;228. 10.1172/JCI28803</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI28803</ArticleId>
            <ArticleId IdType="pmc">PMC1679964</ArticleId>
            <ArticleId IdType="pubmed">17160137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Network 2012. Comprehensive molecular portraits of human breast tumours. Nature. 490:61&#x2013;70. 10.1038/nature11412</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11412</ArticleId>
            <ArticleId IdType="pmc">PMC3465532</ArticleId>
            <ArticleId IdType="pubmed">23000897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caunt C.J., Sale M.J., Smith P.D., and Cook S.J.. 2015. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat. Rev. Cancer. 15:577&#x2013;592. 10.1038/nrc4000</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc4000</ArticleId>
            <ArticleId IdType="pubmed">26399658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Zhang Y., Yin Y., Gao G., Li S., Jiang Y., Gu X., and Luo J.. 2005. SPD--a web-based secreted protein database. Nucleic Acids Res. 33:D169&#x2013;D173. 10.1093/nar/gki093</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gki093</ArticleId>
            <ArticleId IdType="pmc">PMC540047</ArticleId>
            <ArticleId IdType="pubmed">15608170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng C., Yan X., Sun F., and Li L.M.. 2007. Inferring activity changes of transcription factors by binding association with sorted expression profiles. BMC Bioinformatics. 8:452 10.1186/1471-2105-8-452</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2105-8-452</ArticleId>
            <ArticleId IdType="pmc">PMC2194743</ArticleId>
            <ArticleId IdType="pubmed">18021409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. METABRIC Group . 2012. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346&#x2013;352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3440846</ArticleId>
            <ArticleId IdType="pubmed">22522925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demidenko E. 2006. The assessment of tumour response to treatment. Appl. Stat. 55:365&#x2013;377.</Citation>
        </Reference>
        <Reference>
          <Citation>Demidenko E. 2010. Three endpoints of in vivo tumour radiobiology and their statistical estimation. Int. J. Radiat. Biol. 86:164&#x2013;173. 10.3109/09553000903419304</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/09553000903419304</ArticleId>
            <ArticleId IdType="pmc">PMC2900851</ArticleId>
            <ArticleId IdType="pubmed">20148701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demidenko E. 2013. Mixed Models: Theory and Applications with R. John Wiley &amp; Sons, Hoboken, NJ. 717 pp.</Citation>
        </Reference>
        <Reference>
          <Citation>Dephoure N., Zhou C., Vill&#xe9;n J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., and Gygi S.P.. 2008. A quantitative atlas of mitotic phosphorylation. Proc. Natl. Acad. Sci. USA. 105:10762&#x2013;10767. 10.1073/pnas.0805139105</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0805139105</ArticleId>
            <ArticleId IdType="pmc">PMC2504835</ArticleId>
            <ArticleId IdType="pubmed">18669648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeRose Y.S., Wang G., Lin Y.C., Bernard P.S., Buys S.S., Ebbert M.T., Factor R., Matsen C., Milash B.A., Nelson E., et al. . 2011. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17:1514&#x2013;1520. 10.1038/nm.2454</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.2454</ArticleId>
            <ArticleId IdType="pmc">PMC3553601</ArticleId>
            <ArticleId IdType="pubmed">22019887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeRose Y.S., Gligorich K.M., Wang G., Georgelas A., Bowman P., Courdy S.J., Welm A.L., and Welm B.E.. 2013. Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr. Protoc. Pharmacol. Chapter 14:Unit14.23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3630511</ArticleId>
            <ArticleId IdType="pubmed">23456611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., and Gingeras T.R.. 2013. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 29:15&#x2013;21. 10.1093/bioinformatics/bts635</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId>
            <ArticleId IdType="pmc">PMC3530905</ArticleId>
            <ArticleId IdType="pubmed">23104886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Early Breast Cancer Trialists&#x2019; Collaborative Group (EBCTCG), Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., McGale P., Pan H.C., Taylor C., Wang Y.C., et al. . 2011. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378:771&#x2013;784. 10.1016/S0140-6736(11)60993-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(11)60993-8</ArticleId>
            <ArticleId IdType="pmc">PMC3163848</ArticleId>
            <ArticleId IdType="pubmed">21802721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., and Parkin D.M.. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 127:2893&#x2013;2917. 10.1002/ijc.25516</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.25516</ArticleId>
            <ArticleId IdType="pubmed">21351269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., and Bray F.. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 136:E359&#x2013;E386. 10.1002/ijc.29210</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29210</ArticleId>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fidler I.J., Wilmanns C., Staroselsky A., Radinsky R., Dong Z., and Fan D.. 1994. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev. 13:209&#x2013;222. 10.1007/BF00689637</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00689637</ArticleId>
            <ArticleId IdType="pubmed">7923551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K., Harbeck N., Lipatov O.N., Walshe J.M., Moulder S., et al. . 2016. Palbociclib and Letrozole in Advanced Breast Cancer. N. Engl. J. Med. 375:1925&#x2013;1936. 10.1056/NEJMoa1607303</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1607303</ArticleId>
            <ArticleId IdType="pubmed">27959613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foster J.S., Henley D.C., Bukovsky A., Seth P., and Wimalasena J.. 2001. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol. Cell. Biol. 21:794&#x2013;810. 10.1128/MCB.21.3.794-810.2001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.21.3.794-810.2001</ArticleId>
            <ArticleId IdType="pmc">PMC86671</ArticleId>
            <ArticleId IdType="pubmed">11154267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giulianelli S., Cerliani J.P., Lamb C.A., Fabris V.T., Bottino M.C., Gorostiaga M.A., Novaro V., G&#xf3;ngora A., Baldi A., Molinolo A., and Lanari C.. 2008. Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int. J. Cancer. 123:2518&#x2013;2531. 10.1002/ijc.23802</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.23802</ArticleId>
            <ArticleId IdType="pubmed">18767044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>GTEx Consortium 2015. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 348:648&#x2013;660. 10.1126/science.1262110</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1262110</ArticleId>
            <ArticleId IdType="pmc">PMC4547484</ArticleId>
            <ArticleId IdType="pubmed">25954001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guzm&#xe1;n C., Bagga M., Kaur A., Westermarck J., and Abankwa D.. 2014. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One. 9:e92444 10.1371/journal.pone.0092444</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0092444</ArticleId>
            <ArticleId IdType="pmc">PMC3960247</ArticleId>
            <ArticleId IdType="pubmed">24647355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hay M., Thomas D.W., Craighead J.L., Economides C., and Rosenthal J.. 2014. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32:40&#x2013;51. 10.1038/nbt.2786</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.2786</ArticleId>
            <ArticleId IdType="pubmed">24406927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang D.C., and Strasser A.. 2000. BH3-Only proteins-essential initiators of apoptotic cell death. Cell. 103:839&#x2013;842. 10.1016/S0092-8674(00)00187-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(00)00187-2</ArticleId>
            <ArticleId IdType="pubmed">11136969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang H., and Tindall D.J.. 2007. Dynamic FoxO transcription factors. J. Cell Sci. 120:2479&#x2013;2487. 10.1242/jcs.001222</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.001222</ArticleId>
            <ArticleId IdType="pubmed">17646672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>H&#xfc;bner A., Barrett T., Flavell R.A., and Davis R.J.. 2008. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol. Cell. 30:415&#x2013;425. 10.1016/j.molcel.2008.03.025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2008.03.025</ArticleId>
            <ArticleId IdType="pmc">PMC2453504</ArticleId>
            <ArticleId IdType="pubmed">18498746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H., and Chambon P.. 1990. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 9:1603&#x2013;1614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC551856</ArticleId>
            <ArticleId IdType="pubmed">2328727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsouri L., Ashraf A., Birch A.M., Lee K.K., Mirzaei N., and Sastre M.. 2015. Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice. Neurobiol. Aging. 36:821&#x2013;831. 10.1016/j.neurobiolaging.2014.10.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.10.004</ArticleId>
            <ArticleId IdType="pubmed">25457554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klemm F., and Joyce J.A.. 2015. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 25:198&#x2013;213. 10.1016/j.tcb.2014.11.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2014.11.006</ArticleId>
            <ArticleId IdType="pmc">PMC5424264</ArticleId>
            <ArticleId IdType="pubmed">25540894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kodack D.P., Askoxylakis V., Ferraro G.B., Sheng Q., Badeaux M., Goel S., Qi X., Shankaraiah R., Cao Z.A., Ramjiawan R.R., et al. . 2017. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Sci. Transl. Med. 9:eaal4682 10.1126/scitranslmed.aal4682</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aal4682</ArticleId>
            <ArticleId IdType="pmc">PMC5917603</ArticleId>
            <ArticleId IdType="pubmed">28539475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kouhara H., Hadari Y.R., Spivak-Kroizman T., Schilling J., Bar-Sagi D., Lax I., and Schlessinger J.. 1997. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 89:693&#x2013;702. 10.1016/S0092-8674(00)80252-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(00)80252-4</ArticleId>
            <ArticleId IdType="pubmed">9182757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krop I.E., Mayer I.A., Ganju V., Dickler M., Johnston S., Morales S., Yardley D.A., Melichar B., Forero-Torres A., Lee S.C., et al. . 2016. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 17:811&#x2013;821. 10.1016/S1470-2045(16)00106-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(16)00106-6</ArticleId>
            <ArticleId IdType="pmc">PMC5524539</ArticleId>
            <ArticleId IdType="pubmed">27155741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larsen S.S., Egeblad M., J&#xe4;&#xe4;ttel&#xe4; M., and Lykkesfeldt A.E.. 1999. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. Breast Cancer Res. Treat. 58:41&#x2013;56. 10.1023/A:1006232830161</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1006232830161</ArticleId>
            <ArticleId IdType="pubmed">10634517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linder C., Bystr&#xf6;m P., Engel G., Auer G., Aspenblad U., Strander H., and Linder S.. 1998. Correlation between basic fibroblast growth factor immunostaining of stromal cells and stromelysin-3 mRNA expression in human breast carcinoma. Br. J. Cancer. 77:941&#x2013;945. 10.1038/bjc.1998.155</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.1998.155</ArticleId>
            <ArticleId IdType="pmc">PMC2150112</ArticleId>
            <ArticleId IdType="pubmed">9528838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loi S., Haibe-Kains B., Desmedt C., Wirapati P., Lallemand F., Tutt A.M., Gillet C., Ellis P., Ryder K., Reid J.F., et al. . 2008. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics. 9:239 10.1186/1471-2164-9-239</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2164-9-239</ArticleId>
            <ArticleId IdType="pmc">PMC2423197</ArticleId>
            <ArticleId IdType="pubmed">18498629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C.X., Reinert T., Chmielewska I., and Ellis M.J.. 2015. Mechanisms of aromatase inhibitor resistance. Nat. Rev. Cancer. 15:261&#x2013;275. 10.1038/nrc3920</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3920</ArticleId>
            <ArticleId IdType="pubmed">25907219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller T.W., Balko J.M., and Arteaga C.L.. 2011. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J. Clin. Oncol. 29:4452&#x2013;4461. 10.1200/JCO.2010.34.4879</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.34.4879</ArticleId>
            <ArticleId IdType="pmc">PMC3221526</ArticleId>
            <ArticleId IdType="pubmed">22010023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Musolino A., Campone M., Neven P., Denduluri N., Barrios C.H., Cortes J., Blackwell K., Soliman H., Kahan Z., Bonnefoi H., et al. . 2017. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 19:18 10.1186/s13058-017-0807-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-017-0807-8</ArticleId>
            <ArticleId IdType="pmc">PMC5301372</ArticleId>
            <ArticleId IdType="pubmed">28183331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owens P., Engelking E., Han G., Haeger S.M., and Wang X.J.. 2010. Epidermal Smad4 deletion results in aberrant wound healing. Am. J. Pathol. 176:122&#x2013;133. 10.2353/ajpath.2010.090081</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2010.090081</ArticleId>
            <ArticleId IdType="pmc">PMC2797875</ArticleId>
            <ArticleId IdType="pubmed">19959815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrone A., Adamo M.E., Cheng C., and Kettenbach A.N.. 2016. Identification of Candidate Cyclin-dependent kinase 1 (Cdk1) Substrates in Mitosis by Quantitative Phosphoproteomics. Mol. Cell. Proteomics. 15:2448&#x2013;2461. 10.1074/mcp.M116.059394</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M116.059394</ArticleId>
            <ArticleId IdType="pmc">PMC4937516</ArticleId>
            <ArticleId IdType="pubmed">27134283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quail D.F., and Joyce J.A.. 2013. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19:1423&#x2013;1437. 10.1038/nm.3394</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3394</ArticleId>
            <ArticleId IdType="pmc">PMC3954707</ArticleId>
            <ArticleId IdType="pubmed">24202395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis-Filho J.S., Simpson P.T., Turner N.C., Lambros M.B., Jones C., Mackay A., Grigoriadis A., Sarrio D., Savage K., Dexter T., et al. . 2006. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 12:6652&#x2013;6662. 10.1158/1078-0432.CCR-06-1164</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-1164</ArticleId>
            <ArticleId IdType="pubmed">17121884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson M.D., and Oshlack A.. 2010. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11:R25 10.1186/gb-2010-11-3-r25</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/gb-2010-11-3-r25</ArticleId>
            <ArticleId IdType="pmc">PMC2864565</ArticleId>
            <ArticleId IdType="pubmed">20196867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rudas M., Lehnert M., Huynh A., Jakesz R., Singer C., Lax S., Schippinger W., Dietze O., Greil R., Stiglbauer W., et al. Austrian Breast and Colorectal Cancer Study Group . 2008. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin. Cancer Res. 14:1767&#x2013;1774. 10.1158/1078-0432.CCR-07-4122</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-07-4122</ArticleId>
            <ArticleId IdType="pubmed">18347178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seghezzi G., Patel S., Ren C.J., Gualandris A., Pintucci G., Robbins E.S., Shapiro R.L., Galloway A.C., Rifkin D.B., and Mignatti P.. 1998. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 141:1659&#x2013;1673. 10.1083/jcb.141.7.1659</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.141.7.1659</ArticleId>
            <ArticleId IdType="pmc">PMC2132998</ArticleId>
            <ArticleId IdType="pubmed">9647657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., et al. . 2012. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62:220&#x2013;241. 10.3322/caac.21149</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21149</ArticleId>
            <ArticleId IdType="pubmed">22700443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith K., Fox S.B., Whitehouse R., Taylor M., Greenall M., Clarke J., and Harris A.L.. 1999. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann. Oncol. 10:707&#x2013;713. 10.1023/A:1008303614441</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1008303614441</ArticleId>
            <ArticleId IdType="pubmed">10442194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., et al. . 2012. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487:500&#x2013;504. 10.1038/nature11183</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11183</ArticleId>
            <ArticleId IdType="pmc">PMC3711467</ArticleId>
            <ArticleId IdType="pubmed">22763439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., and Mesirov J.P.. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102:15545&#x2013;15550. 10.1073/pnas.0506580102</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId>
            <ArticleId IdType="pmc">PMC1239896</ArticleId>
            <ArticleId IdType="pubmed">16199517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Symmans W.F., Hatzis C., Sotiriou C., Andre F., Peintinger F., Regitnig P., Daxenbichler G., Desmedt C., Domont J., Marth C., et al. . 2010. Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol. 28:4111&#x2013;4119. 10.1200/JCO.2010.28.4273</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.28.4273</ArticleId>
            <ArticleId IdType="pmc">PMC2953969</ArticleId>
            <ArticleId IdType="pubmed">20697068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teicher B.A., Herman T.S., Holden S.A., Wang Y.Y., Pfeffer M.R., Crawford J.W., and Frei E. III. 1990. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 247:1457&#x2013;1461. 10.1126/science.2108497</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.2108497</ArticleId>
            <ArticleId IdType="pubmed">2108497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tivari S., Korah R., Lindy M., and Wieder R.. 2015. An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation. J. Vis. Exp. 100:e52672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4652423</ArticleId>
            <ArticleId IdType="pubmed">26168083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M.A., Natrajan R., Marchio C., Iorns E., Mackay A., et al. . 2010. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70:2085&#x2013;2094. 10.1158/0008-5472.CAN-09-3746</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-3746</ArticleId>
            <ArticleId IdType="pmc">PMC2832818</ArticleId>
            <ArticleId IdType="pubmed">20179196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner N.C., Ro J., Andr&#xe9; F., Loi S., Verma S., Iwata H., Harbeck N., Loibl S., Huang Bartlett C., Zhang K., et al. PALOMA3 Study Group . 2015. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N. Engl. J. Med. 373:209&#x2013;219. 10.1056/NEJMoa1505270</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1505270</ArticleId>
            <ArticleId IdType="pubmed">26030518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uhl&#xe9;n M., Fagerberg L., Hallstr&#xf6;m B.M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson &#xc5;., Kampf C., Sj&#xf6;stedt E., Asplund A., et al. . 2015. Proteomics. Tissue-based map of the human proteome. Science. 347:1260419 10.1126/science.1260419</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1260419</ArticleId>
            <ArticleId IdType="pubmed">25613900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaillant F., Merino D., Lee L., Breslin K., Pal B., Ritchie M.E., Smyth G.K., Christie M., Phillipson L.J., Burns C.J., et al. . 2013. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 24:120&#x2013;129. 10.1016/j.ccr.2013.06.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.06.002</ArticleId>
            <ArticleId IdType="pubmed">23845444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van de Vijver M.J., He Y.D., van&#x2019;t Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., et al. . 2002. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999&#x2013;2009. 10.1056/NEJMoa021967</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa021967</ArticleId>
            <ArticleId IdType="pubmed">12490681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varn F.S., Ung M.H., Lou S.K., and Cheng C.. 2015. Integrative analysis of survival-associated gene sets in breast cancer. BMC Med. Genomics. 8:11 10.1186/s12920-015-0086-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12920-015-0086-0</ArticleId>
            <ArticleId IdType="pmc">PMC4359519</ArticleId>
            <ArticleId IdType="pubmed">25881247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L., Park H., Chhim S., Ding Y., Jiang W., Queen C., and Kim K.J.. 2012a A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol. Cancer Ther. 11:864&#x2013;872. 10.1158/1535-7163.MCT-11-0813</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-11-0813</ArticleId>
            <ArticleId IdType="pmc">PMC3324641</ArticleId>
            <ArticleId IdType="pubmed">22351746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T., Kettenbach A.N., Gerber S.A., and Bailey-Kellogg C.. 2012b MMFPh: a maximal motif finder for phosphoproteomics datasets. Bioinformatics. 28:1562&#x2013;1570. 10.1093/bioinformatics/bts195</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/bts195</ArticleId>
            <ArticleId IdType="pmc">PMC3371830</ArticleId>
            <ArticleId IdType="pubmed">22531218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilcken N.R., Prall O.W., Musgrove E.A., and Sutherland R.L.. 1997. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res. 3:849&#x2013;854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9815758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., et al. . 2012. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487:505&#x2013;509. 10.1038/nature11249</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11249</ArticleId>
            <ArticleId IdType="pmc">PMC3724525</ArticleId>
            <ArticleId IdType="pubmed">22763448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing Y., Yu T., Wu Y.N., Roy M., Kim J., and Lee C.. 2006. An expectation-maximization algorithm for probabilistic reconstructions of full-length isoforms from splice graphs. Nucleic Acids Res. 34:3150&#x2013;3160. 10.1093/nar/gkl396</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkl396</ArticleId>
            <ArticleId IdType="pmc">PMC1475746</ArticleId>
            <ArticleId IdType="pubmed">16757580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Q., Geng Y., and Sicinski P.. 2001. Specific protection against breast cancers by cyclin D1 ablation. Nature. 411:1017&#x2013;1021. 10.1038/35082500</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35082500</ArticleId>
            <ArticleId IdType="pubmed">11429595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Q., Sicinska E., Geng Y., Ahnstr&#xf6;m M., Zagozdzon A., Kong Y., Gardner H., Kiyokawa H., Harris L.N., St&#xe5;l O., and Sicinski P.. 2006. Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 9:23&#x2013;32. 10.1016/j.ccr.2005.12.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2005.12.012</ArticleId>
            <ArticleId IdType="pubmed">16413469</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29408569</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>04</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-0012</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>154</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Gastroenterology</Title>
          <ISOAbbreviation>Gastroenterology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.</ArticleTitle>
        <Pagination>
          <StartPage>1024</StartPage>
          <EndPage>1036.e9</EndPage>
          <MedlinePgn>1024-1036.e9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2017.10.050</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0016-5085(18)30099-4</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND &amp; AIMS">Ceramide, a sphingolipid metabolite, affects T-cell signaling, induces apoptosis of cancer cells, and slows tumor growth in mice. However, it has not been used as a chemotherapeutic agent because of its cell impermeability and precipitation in aqueous solution. We developed a nanoliposome-loaded C6-ceremide (LipC6) to overcome this limitation and investigated its effects in mice with liver tumors.</AbstractText>
          <AbstractText Label="METHODS">Immune competent C57BL/6 mice received intraperitoneal injections of carbon tetrachloride and intra-splenic injections of oncogenic hepatocytes. As a&#xa0;result, tumors resembling human hepatocellular carcinomas developed in a fibrotic liver setting. After tumors formed, mice were given an injection of LipC6 or vehicle via tail vein every other&#xa0;day for 2 weeks. This was followed by administration, also via tail vein, of tumor antigen-specific (TAS) CD8[+] T cells isolated from the spleens of line 416 mice, and subsequent immunization by intraperitoneal injection of tumor antigen-expressing B6/WT-19 cells. Tumor growth was monitored with magnetic resonance imaging. Tumor apoptosis, proliferation, and AKT expression were analyzed using immunohistochemistry and immunoblots. Cytokine production, phenotype, and function of TAS CD8[+] T&#xa0;cells and tumor-associated macrophages (TAMs) were studied with flow cytometry, real-time polymerase chain reaction (PCR), and ELISA. Reactive oxygen species (ROS) in TAMs and bone marrow-derived macrophages, induced by colony stimulating factor 2 (GMCSF or CSF2) or colony stimulating factor 1 (MCSF or CSF1), were detected using a&#xa0;luminescent assay.</AbstractText>
          <AbstractText Label="RESULTS">Injection of LipC6 slowed tumor growth by reducing tumor cell proliferation and phosphorylation of AKT, and increasing tumor cell apoptosis, compared with vehicle. Tumors grew more slowly in mice given the combination of LipC6 injection and TAS CD8[+] T cells followed by immunization compared with mice given vehicle,&#xa0;LipC6, the T cells, or immunization alone. LipC6 injection also reduced numbers of TAMs and their&#xa0;production of ROS. LipC6 induced TAMs to differentiate into an M1 phenotype, which reduced immune suppression and increased activity of CD8[+] T cells. These results were validated by experiments with bone marrow-derived macrophages induced by GMCSF or MCSF.</AbstractText>
          <AbstractText Label="CONCLUSIONS">In mice with liver tumors,&#xa0;injection of LipC6 reduces the number of TAMs and the ability of TAMs to suppress the anti-tumor immune response. LipC6 also increases the anti-tumor effects of TAS&#xa0;CD8[+] T cells. LipC6 might therefore increase the efficacy&#xa0;of&#xa0;immune therapy in patients with hepatocellular carcinoma.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Guangfu</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Missouri-Columbia, Columbia, Missouri; Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, Missouri; Department of Molecular Microbiology and Immunology, University of Missouri-Columbia, Columbia, Missouri. Electronic address: liguan@health.missouri.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Dai</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Missouri-Columbia, Columbia, Missouri; Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, Missouri.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kimchi</LastName>
            <ForeName>Eric T</ForeName>
            <Initials>ET</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Missouri-Columbia, Columbia, Missouri; Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, Missouri.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaifi</LastName>
            <ForeName>Jussuf T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Missouri-Columbia, Columbia, Missouri; Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, Missouri.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Xiaoqiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Missouri-Columbia, Columbia, Missouri; Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, Missouri.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manjunath</LastName>
            <ForeName>Yariswamy</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Missouri-Columbia, Columbia, Missouri; Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, Missouri.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xinjian</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Missouri-Columbia, Columbia, Missouri; Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, Missouri.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deering</LastName>
            <ForeName>Tye</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, University of Virginia, Charlottesville, Virginia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Avella</LastName>
            <ForeName>Diego M</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Missouri-Columbia, Columbia, Missouri; Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, Missouri.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fox</LastName>
            <ForeName>Todd</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, University of Virginia, Charlottesville, Virginia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rockey</LastName>
            <ForeName>Don C</ForeName>
            <Initials>DC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schell</LastName>
            <ForeName>Todd D</ForeName>
            <Initials>TD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kester</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Staveley-O'Carroll</LastName>
            <ForeName>Kevin F</ForeName>
            <Initials>KF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University of Missouri-Columbia, Columbia, Missouri; Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, Missouri. Electronic address: ocarrollk@health.missouri.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA164335</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA208396</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>01</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Gastroenterology</MedlineTA>
        <NlmUniqueID>0374630</NlmUniqueID>
        <ISSNLinking>0016-5085</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000952">Antigens, Polyomavirus Transforming</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002518">Ceramides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C035737">major urinary proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>038753E78J</RegistryNumber>
          <NameOfSubstance UI="C101954">N-caproylsphingosine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Gastroenterology. 2018 Aug;155(2):579-580</RefSource>
          <PMID Version="1">30064723</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000952" MajorTopicYN="N">Antigens, Polyomavirus Transforming</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002518" MajorTopicYN="N">Ceramides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016219" MajorTopicYN="N">Immunotherapy, Adoptive</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">HCC Model</Keyword>
        <Keyword MajorTopicYN="N">Immune Regulation</Keyword>
        <Keyword MajorTopicYN="N">Liver Cancer</Keyword>
        <Keyword MajorTopicYN="N">Nanotechnology</Keyword>
        <Keyword MajorTopicYN="N">Tumor Microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>Conflicts of interest. The authors declare no conflicts. Competing financial interests. The Penn State Research Foundation has licensed ceramide nanoliposomes and other nonliposomal nanotechnology to Keystone Nano Inc (State College, PA). Dr Mark Kester is the Chief Medical Officer of Keystone Nano Inc.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29408569</ArticleId>
        <ArticleId IdType="mid">NIHMS953697</ArticleId>
        <ArticleId IdType="pmc">PMC5908238</ArticleId>
        <ArticleId IdType="doi">10.1053/j.gastro.2017.10.050</ArticleId>
        <ArticleId IdType="pii">S0016-5085(18)30099-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245&#x2013;1255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22353262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014&#x2013;1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4118725</ArticleId>
            <ArticleId IdType="pubmed">24048123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller KL. Cancer immunology and immunotherapy. Realizing the promise. Introduction Science. 2015;348:54&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25838372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niu LZ, Li JL, Zeng JY, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol. 2013;19:3473&#x2013;3480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3683687</ArticleId>
            <ArticleId IdType="pubmed">23801841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajewski TF, Schumacher T. Cancer immunotherapy. Curr Opin Immunol. 2013;25:259&#x2013;260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23587868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, Wolchok JD. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol. 2013;25:291&#x2013;296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3672064</ArticleId>
            <ArticleId IdType="pubmed">23561594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pembrolizumab superior to ipilimumab in melanoma. Cancer Discov. 2015;5:568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25895921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol. 2011;54:830&#x2013;834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21145836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D, Staveley-O&#x2019;Carroll KF, Li G. Immune-based therapy clinical trials in hepatocellular carcinoma. J Clin Cell Immunol. 2015:6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4750497</ArticleId>
            <ArticleId IdType="pubmed">26877890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider C, Teufel A, Yevsa T, et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut. 2012;61:1733&#x2013;1743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4533880</ArticleId>
            <ArticleId IdType="pubmed">22267597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut. 2015;64:842&#x2013;848.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6311419</ArticleId>
            <ArticleId IdType="pubmed">25666193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morad SA, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 2013;13:51&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23235911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morales A, Lee H, Goni FM, et al. Sphingolipids and cell death. Apoptosis. 2007;12:923&#x2013;939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17294080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta. 2002;1585:114&#x2013;125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12531544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoffel B, Bauer P, Nix M, et al. Ceramide-independent CD28 and TCR signaling but reduced IL-2 secretion in T cells of acid sphingomyelinase-deficient mice. Eur J Immunol. 1998;28:874&#x2013;880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9541582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagaram HR, Divittore NA, Barth BM, et al. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut. 2011;60:695&#x2013;701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21193455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G, Liu D, Cooper TK, et al. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol. 2017;66:75&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5167655</ArticleId>
            <ArticleId IdType="pubmed">27520877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kester M, Bassler J, Fox TE, et al. Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic. Biol Chem. 2015;396:737&#x2013;747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25838296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Ryland L, Yang J, et al. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood. 2010;116:4192&#x2013;4201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2993625</ArticleId>
            <ArticleId IdType="pubmed">20671121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zolnik BS, Stern ST, Kaiser JM, et al. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos. 2008;36:1709&#x2013;1715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18490436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology. 2014;59:2034&#x2013;2042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24115204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Choksi S, Chen K, et al. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res. 2013;23:898&#x2013;914.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3698641</ArticleId>
            <ArticleId IdType="pubmed">23752925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Held WA, Mullins JJ, Kuhn NJ, et al. T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein/SV40 T antigen hybrid gene. EMBO J. 1989;8:183&#x2013;191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC400788</ArticleId>
            <ArticleId IdType="pubmed">2714250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Staveley-O&#x2019;Carroll K, Schell TD, Jimenez M, et al. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol. 2003;171:697&#x2013;707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12847236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avella DM, Li G, Schell TD, et al. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology. 2012;55:141&#x2013;152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3243781</ArticleId>
            <ArticleId IdType="pubmed">21898502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duluc D, Delneste Y, Tan F, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007;110:4319&#x2013;4330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17848619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263&#x2013;274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15776005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleetwood AJ, Dinh H, Cook AD, et al. GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J Leukoc Biol. 2009;86:411&#x2013;421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19406830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303&#x2013;7311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17082649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emens LA. Chemoimmunotherapy. Cancer J. 2010;16:295&#x2013;303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2919833</ArticleId>
            <ArticleId IdType="pubmed">20693839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004;22:1136&#x2013;1151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15020616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melief CJ, Toes RE, Medema JP, et al. Strategies for immunotherapy of cancer. Adv Immunol. 2000;75:235&#x2013;282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10879286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P, Wagner K, Wolchok JD, et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805&#x2013;812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3426440</ArticleId>
            <ArticleId IdType="pubmed">22020206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 2011;11:403&#x2013;415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3368251</ArticleId>
            <ArticleId IdType="pubmed">21546914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watters RJ, Fox TE, Tan SF, et al. Targeting gluco-sylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. Leuk Lymphoma. 2013;54:1288&#x2013;1296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4296321</ArticleId>
            <ArticleId IdType="pubmed">23181473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y, DiVittore NA, Kaiser JM, et al. Combinatorial therapies improve the therapeutic efficacy of nano-liposomal ceramide for pancreatic cancer. Cancer Biol Ther. 2011;12:574&#x2013;585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3218384</ArticleId>
            <ArticleId IdType="pubmed">21795855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pritzl CJ, Seo YJ, Xia C, et al. A ceramide analogue stimulates dendritic cells to promote T cell responses upon virus infections. J Immunol. 2015;194:4339&#x2013;4349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4402267</ArticleId>
            <ArticleId IdType="pubmed">25810392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herz J, Pardo J, Kashkar H, et al. Acid sphingomyelinase is a key regulator of cytotoxic granule secretion by primary T lymphocytes. Nat Immunol. 2009;10:761&#x2013;768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19525969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sallusto F, Nicolo C, De Maria R, et al. Ceramide inhibits antigen uptake and presentation by dendritic cells. J Exp Med. 1996;184:2411&#x2013;2416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2196395</ArticleId>
            <ArticleId IdType="pubmed">8976196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moghimi SM, Patel HM. Modulation of murine liver macrophage clearance of liposomes by diethylstilbestrol. The effect of vesicle surface charge and a role for the complement receptor Mac-1 (CD11b/CD18) of newly recruited macrophages in liposome recognition. J Control Release. 2002;78:55&#x2013;65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11772449</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29124315</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-0851</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>67</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer immunology, immunotherapy : CII</Title>
          <ISOAbbreviation>Cancer Immunol Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.</ArticleTitle>
        <Pagination>
          <StartPage>381</StartPage>
          <EndPage>392</EndPage>
          <MedlinePgn>381-392</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-017-2091-y</ELocationID>
        <Abstract>
          <AbstractText>Checkpoint inhibitor therapy has led to major treatment advances for several cancers including non-small cell lung cancer (NSCLC). Despite this, a significant percentage of patients do not respond or develop resistance. Potential mechanisms of resistance include lack of expression of programmed death ligand 1 (PD-L1), decreased capacity to present tumor antigens, and the presence of an immunosuppressive tumor microenvironment. Mocetinostat is a spectrum-selective inhibitor of class I/IV histone deacetylases (HDACs), a family of proteins implicated in epigenetic silencing of immune regulatory genes in tumor and immune cells. Mocetinostat upregulated PD-L1 and antigen presentation genes including class I and II human leukocyte antigen (HLA) family members in a panel of NSCLC cell lines in vitro. Mocetinostat target gene promoters were occupied by a class I HDAC and exhibited increased active histone marks after mocetinostat treatment. Mocetinostat synergized with interferon Î³ (IFN-Î³) in regulating class II transactivator (CIITA), a master regulator of class II HLA gene expression. In a syngeneic tumor model, mocetinostat decreased intratumoral T-regulatory cells (Tregs) and potentially myeloid-derived suppressor cell (MDSC) populations and increased intratumoral CD8+ populations. In ex vivo assays, patient-derived, mocetinostat-treated Tregs also showed significant down regulation of FOXP3 and HELIOS. The combination of mocetinostat and a murine PD-L1 antibody antagonist demonstrated increased anti-tumor activity compared to either therapy alone in two syngeneic tumor models. Together, these data provide evidence that mocetinostat modulates immune-related genes in tumor cells as well as immune cell types in the tumor microenvironment and enhances checkpoint inhibitor therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Briere</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Mirati Therapeutics, Inc., 9393 Towne Center Dr, Suite 200, San Diego, CA, 92121, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sudhakar</LastName>
            <ForeName>Niranjan</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Mirati Therapeutics, Inc., 9393 Towne Center Dr, Suite 200, San Diego, CA, 92121, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woods</LastName>
            <ForeName>David M</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>NYU Langone Medical Center, New York, NY, 10016, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hallin</LastName>
            <ForeName>Jill</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Mirati Therapeutics, Inc., 9393 Towne Center Dr, Suite 200, San Diego, CA, 92121, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Engstrom</LastName>
            <ForeName>Lars D</ForeName>
            <Initials>LD</Initials>
            <AffiliationInfo>
              <Affiliation>Mirati Therapeutics, Inc., 9393 Towne Center Dr, Suite 200, San Diego, CA, 92121, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aranda</LastName>
            <ForeName>Ruth</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Mirati Therapeutics, Inc., 9393 Towne Center Dr, Suite 200, San Diego, CA, 92121, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chiang</LastName>
            <ForeName>Harrah</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Mirati Therapeutics, Inc., 9393 Towne Center Dr, Suite 200, San Diego, CA, 92121, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>SodrÃ©</LastName>
            <ForeName>Andressa L</ForeName>
            <Initials>AL</Initials>
            <AffiliationInfo>
              <Affiliation>NYU Langone Medical Center, New York, NY, 10016, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olson</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Mirati Therapeutics, Inc., 9393 Towne Center Dr, Suite 200, San Diego, CA, 92121, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weber</LastName>
            <ForeName>Jeffrey S</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>NYU Langone Medical Center, New York, NY, 10016, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Christensen</LastName>
            <ForeName>James G</ForeName>
            <Initials>JG</Initials>
            <AffiliationInfo>
              <Affiliation>Mirati Therapeutics, Inc., 9393 Towne Center Dr, Suite 200, San Diego, CA, 92121, USA. christensenj@mirati.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Cancer Immunol Immunother</MedlineTA>
        <NlmUniqueID>8605732</NlmUniqueID>
        <ISSNLinking>0340-7004</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>A6GWB8T96J</RegistryNumber>
          <NameOfSubstance UI="C523184">mocetinostat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.98</RegistryNumber>
          <NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017951" MajorTopicYN="N">Antigen Presentation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006655" MajorTopicYN="N">Histone Deacetylases</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Chromatin immunoprecipitation</Keyword>
        <Keyword MajorTopicYN="N">Epigenetics</Keyword>
        <Keyword MajorTopicYN="N">Histone deacetylase</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">T regulatory cells</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29124315</ArticleId>
        <ArticleId IdType="doi">10.1007/s00262-017-2091-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s00262-017-2091-y</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28683469</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>09</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-1827</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>117</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Aug</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>British journal of cancer</Title>
          <ISOAbbreviation>Br J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.</ArticleTitle>
        <Pagination>
          <StartPage>628</StartPage>
          <EndPage>638</EndPage>
          <MedlinePgn>628-638</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2017.205</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lurbinectedin is a novel anticancer agent currently undergoing late-stage (Phase II /III) clinical evaluation in platinum-resistant ovarian, BRCA1/2-mutated breast and small-cell lung cancer. Lurbinectedin is structurally related to trabectedin and it inhibits active transcription and the DNA repair machinery in tumour cells.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this study we investigated whether lurbinectedin has the ability to modulate the inflammatory microenvironment and the viability of myeloid cells in tumour-bearing mice.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Administration of lurbinectedin significantly and selectively decreased the number of circulating monocytes and, in tumour tissues, that of macrophages and vessels. Similar findings were observed when a lurbinectedin-resistant tumour variant was used, indicating a direct effect of lurbinectedin on the tumour microenviroment. In vitro, lurbinectedin induced caspase-8-dependent apoptosis of human purified monocytes, whereas at low doses it significantly inhibited the production of inflammatory/growth factors (CCL2, CXCL8 and VEGF) and dramatically impaired monocyte adhesion and migration ability. These findings were supported by the strong inhibition of genes of the Rho-GTPase family in lurbinectedin-treated monocytes.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results illustrate that lurbinectedin affects at multiple levels the inflammatory microenvironment by acting on the viability and functional activity of mononuclear phagocytes. These peculiar effects, combined with its intrinsic activity against cancer cells, make lurbinectedin a compound of particular interest in oncology.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Belgiovine</LastName>
            <ForeName>Cristina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, 20089 Rozzano, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bello</LastName>
            <ForeName>Ezia</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liguori</LastName>
            <ForeName>Manuela</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Craparotta</LastName>
            <ForeName>Ilaria</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mannarino</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paracchini</LastName>
            <ForeName>Lara</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beltrame</LastName>
            <ForeName>Luca</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marchini</LastName>
            <ForeName>Sergio</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galmarini</LastName>
            <ForeName>Carlos M</ForeName>
            <Initials>CM</Initials>
            <AffiliationInfo>
              <Affiliation>Cell Biology and Pharmacogenomics Department, Pharmamar, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mantovani</LastName>
            <ForeName>Alberto</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, Humanitas University, Via Manzoni 113, 20089 Rozzano, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frapolli</LastName>
            <ForeName>Roberta</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Allavena</LastName>
            <ForeName>Paola</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'Incalci</LastName>
            <ForeName>Maurizio</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>15-1346</GrantID>
            <Acronym>AICR_</Acronym>
            <Agency>Worldwide Cancer Research</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>07</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Cancer</MedlineTA>
        <NlmUniqueID>0370635</NlmUniqueID>
        <ISSNLinking>0007-0920</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018906">Antineoplastic Agents, Alkylating</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C111835">CCL2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508606">CXCL8 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002243">Carbolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018932">Chemokine CCL2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004149">Dioxoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C568606">PM 01183</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D044005">Tetrahydroisoquinolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053181">Caspase 8</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="D020741">rho GTP-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>ID0YZQ2TCP</RegistryNumber>
          <NameOfSubstance UI="D000077606">Trabectedin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018906" MajorTopicYN="N">Antineoplastic Agents, Alkylating</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053181" MajorTopicYN="N">Caspase 8</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018932" MajorTopicYN="N">Chemokine CCL2</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004149" MajorTopicYN="N">Dioxoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005354" MajorTopicYN="N">Fibrosarcoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018922" MajorTopicYN="N">HL-60 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="Y">Macrophages</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044005" MajorTopicYN="N">Tetrahydroisoquinolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077606" MajorTopicYN="N">Trabectedin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020298" MajorTopicYN="N">U937 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020741" MajorTopicYN="N">rho GTP-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28683469</ArticleId>
        <ArticleId IdType="pmc">PMC5572168</ArticleId>
        <ArticleId IdType="doi">10.1038/bjc.2017.205</ArticleId>
        <ArticleId IdType="pii">bjc2017205</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Allavena P, Mantovani A (2012) Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 167(2): 195&#x2013;205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3278685</ArticleId>
            <ArticleId IdType="pubmed">22235995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belgiovine C, D&#x2019;Incalci M, Allavena P, Frapolli R (2016) Tumor-associated macrophages and anti-tumor therapies: complex links. Cell Mol Life Sci 73(13): 2411&#x2013;2424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26956893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol) 57(1): 289&#x2013;300.</Citation>
        </Reference>
        <Reference>
          <Citation>Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT (2013) Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 19(12): 3165&#x2013;3175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3742575</ArticleId>
            <ArticleId IdType="pubmed">23613317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breitling R, Armengaud P, Amtmann A, Herzyk P (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573(1&#x2013;3): 83&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15327980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>C&#xe9;spedes MV, Guill&#xe9;n MJ, L&#xf3;pez-Casas PP, Sarno F, Gallardo A, &#xc1;lamo P, Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Avil&#xe9;s P, Mangues R (2016) Lurbinectedin induces depletion of tumor-associated macrophages (TAM), an essential component of its in vivo synergism with gemcitabine. Dis Model Mech 9: 1461&#x2013;1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5200894</ArticleId>
            <ArticleId IdType="pubmed">27780828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339(6117): 286&#x2013;291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3591506</ArticleId>
            <ArticleId IdType="pubmed">23329041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Palma M, Lewis CE (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23(3): 277&#x2013;286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23518347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstr&#xf6;m K, West BL, Coussens LM (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1(1): 54&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3203524</ArticleId>
            <ArticleId IdType="pubmed">22039576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C, Romero R (2007) A systems biology approach for pathway level analysis. Genome Res 17(10): 1537&#x2013;1545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1987343</ArticleId>
            <ArticleId IdType="pubmed">17785539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ (2014) First-in-human phase I study of lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res 20(8): 2205&#x2013;2214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24563480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420(6916): 629&#x2013;635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12478284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqu&#xe9; A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fu&#x10d;&#xed;kov&#xe1; J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, J&#xe4;ger D, Kalinski P, K&#xe4;rre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Saut&#xe8;s-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G (2014) Classification of current anticancer immunotherapies. Oncotarget 5(24): 12472&#x2013;12508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4350348</ArticleId>
            <ArticleId IdType="pubmed">25537519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galmarini CM, Mackey JR, Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3(7): 415&#x2013;424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12142171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23(2): 249&#x2013;262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23410977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P (2010) Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 70(6): 2235&#x2013;2244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20215499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646&#x2013;674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528): 563&#x2013;567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4836193</ArticleId>
            <ArticleId IdType="pubmed">25428504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hume DA, MacDonald KPA (2011) Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119(8): 1810&#x2013;1820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22186992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knowles HJ, Harris AL (2007) Macrophages and the hypoxic tumour microenvironment. Front Biosci 12: 4298&#x2013;4314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17485376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203(4): 871&#x2013;881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118300</ArticleId>
            <ArticleId IdType="pubmed">16606666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuang D-M, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206(6): 1327&#x2013;1337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2715058</ArticleId>
            <ArticleId IdType="pubmed">19451266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liguori M, Buracchi C, Pasqualini F, Bergomas F, Pesce S, Sironi M, Grizzi F, Mantovani A, Belgiovine C, Allavena P (2016) Functional TRAIL receptors in monocytes and tumor-associated macrophages: a possible targeting pathway in the tumor microenvironment. Oncotarget 7(27): 41662&#x2013;41676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5173086</ArticleId>
            <ArticleId IdType="pubmed">27191500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Allavena P (2015) The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 212(4): 435&#x2013;445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4387285</ArticleId>
            <ArticleId IdType="pubmed">25753580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203): 436&#x2013;444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18650914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A, Sica A, Locati M (2005) Macrophage polarization comes of age. Immunity 23(4): 344&#x2013;346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16226499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massazza G, Tomasoni A, Lucchini V, Allavena P, Erba E, Colombo N, Mantovani A, D'Incalci M, Mangioni C, Giavazzi R (1989) Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer 44(3): 494&#x2013;500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2777413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moneo V, Martinez P, de Castro B, Cascajares S, Avila S, Garcia-Fernandez LF, Galmarini M (2014) Abstract A174: Comparison of the antitumor activity of Trabectedin, Lurbinectedin, Zalypsis and PM00128 in a panel of human cells deficient in transcription/NER repair factors. Mol Cancer Ther 12(11_Supplement): A174.</Citation>
        </Reference>
        <Reference>
          <Citation>Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1): 49&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4137410</ArticleId>
            <ArticleId IdType="pubmed">25035953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, Cesca M, Scanziani E, Belotti D, Giavazzi R (2012) Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. Br J Cancer 107(2): 360&#x2013;369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3394985</ArticleId>
            <ArticleId IdType="pubmed">22713663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paz-Ares L, Forster M, Boni V, Szyldergemajn S, Corral J, Turnbull S, Cubillo A, Teruel CF, Calderero IL, Siguero M, Bohan P, Calvo E (2017) Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors. Invest New Drugs 206(2): 198&#x2013;206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27873130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pernice T, Bishop AG, Guillen MJ, Cuevas C, Aviles P (2016) Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma. J Pharm Biomed Anal 123: 37&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26871278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, Wu L (2010) Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 115(7): 1461&#x2013;1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2826767</ArticleId>
            <ArticleId IdType="pubmed">20008303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW, Sutton JC, Holland EC, Daniel D, Joyce JA (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19(10): 1264&#x2013;1272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3840724</ArticleId>
            <ArticleId IdType="pubmed">24056773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu Q-X, Huang Q, Shen Y, Zhu Y-B, Zhang X-G (2016) The increase of circulating PD-L1-expressing CD68+ macrophage in ovarian cancer. Tumor Biol 37(4): 5031&#x2013;5037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26541760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, R&#xfc;ttinger D (2014) Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25(6): 846&#x2013;859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24898549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, Garc&#xed;a-Fern&#xe1;ndez LF, Cuevas C, Allavena P, Erba E, D'Incalci M (2013) Comparison ofin vitroandin vivobiological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis (PM00104). Int J Cancer 133(9): 2024&#x2013;2033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23588839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sales G, Calura E, Cavalieri D, Romualdi C (2012) graphite&#x2014;a Bioconductor package to convert pathway topology to gene network. BMC Bioinformatics 13(1): 20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3296647</ArticleId>
            <ArticleId IdType="pubmed">22292714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santamaria Nunez G, Robles CMG, Giraudon C, Mart&#xed;nez-Leal JF, Compe E, Coin F, Aviles P, Galmarini CM, Egly JM (2016) Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther 15(10): 2399&#x2013;2412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27630271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528): 568&#x2013;571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4246418</ArticleId>
            <ArticleId IdType="pubmed">25428505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA Committee of the National Cancer Research Institute (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102(11): 1555&#x2013;1577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2883160</ArticleId>
            <ArticleId IdType="pubmed">20502460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yona S, Kim K-W, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guilliams M, Misharin A, Hume DA, Perlman H, Malissen B, Zelzer E, Jung S (2013) Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38(1): 79&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3908543</ArticleId>
            <ArticleId IdType="pubmed">23273845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeisberger SM, Odermatt B, Marty C, Zehnder-Fj&#xe4;llman AH, Ballmer-Hofer K, Schwendener RA (2006) Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95(3): 272&#x2013;281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2360657</ArticleId>
            <ArticleId IdType="pubmed">16832418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74(18): 5057&#x2013;5069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4182950</ArticleId>
            <ArticleId IdType="pubmed">25082815</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28591705</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>04</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1949-2553</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>27</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Jul</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncotarget</Title>
          <ISOAbbreviation>Oncotarget</ISOAbbreviation>
        </Journal>
        <ArticleTitle>M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>44465</StartPage>
          <EndPage>44476</EndPage>
          <MedlinePgn>44465-44476</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.17973</ELocationID>
        <Abstract>
          <AbstractText>M2 macrophages are a major component of the tumor microenvironment and are important promoters of tumor occurrence and progression. In this study, we detected large numbers of M2 macrophages in hepatocellular carcinoma tissues using immunohistochemistry and immunofluorescence. Moreover, upon oxaliplatin treatment, the M2 macrophages overexpressed interleukin-17, an important inflammatory cytokine, and thus inhibited oxaliplatin-induced apoptosis. By knocking down the interleukin-17 receptor and lysosome-associated membrane protein 2A (a key protein in chaperone-mediated autophagy) in hepatocellular carcinoma cells, we found that interleukin-17 stimulated chaperone-mediated autophagy, which further suppressed apoptosis upon oxaliplatin treatment. Chaperone-mediated autophagy induced tolerance to oxaliplatin treatment by reducing cyclin D1 expression; thus, cyclin D1 overexpression stimulated oxaliplatin-induced apoptosis. In addition, cyclin D1 expression was inhibited by interleukin-17, but increased when the interleukin-17 receptor was knocked down. Thus M2 macrophages in the hepatocellular carcinoma microenvironment generate large amounts of interleukin-17, which suppress oxaliplatin-induced tumor cell apoptosis by activating chaperone-mediated autophagy and in turn reducing cyclin D1 expression. These findings may facilitate the development of novel therapeutic strategies for chemorefractory liver cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Leilei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Jiapei</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Aidong</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Jinghua</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Haixin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Hospital of Traditional Chinese Medicine of Tangshan City, Tangshan, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pang</LastName>
            <ForeName>Dequan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Hebei Medical University Second Hospital, Shijiazhuang, Hebei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oncotarget</MedlineTA>
        <NlmUniqueID>101532965</NlmUniqueID>
        <ISSNLinking>1949-2553</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D052119">Lysosomal-Associated Membrane Protein 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053722">Receptors, Interleukin-17</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>04ZR38536J</RegistryNumber>
          <NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>136601-57-5</RegistryNumber>
          <NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019938" MajorTopicYN="N">Cyclin D1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052119" MajorTopicYN="N">Lysosomal-Associated Membrane Protein 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009944" MajorTopicYN="N">Organoplatinum Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077150" MajorTopicYN="N">Oxaliplatin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053722" MajorTopicYN="N">Receptors, Interleukin-17</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">M2 tumor-associated macrophages</Keyword>
        <Keyword MajorTopicYN="N">chaperone-mediated autophagy</Keyword>
        <Keyword MajorTopicYN="N">cyclin D1</Keyword>
        <Keyword MajorTopicYN="N">hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">interleukin-17</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICTS OF INTEREST. All authors declare that there is no conflicts interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28591705</ArticleId>
        <ArticleId IdType="pmc">PMC5546494</ArticleId>
        <ArticleId IdType="doi">10.18632/oncotarget.17973</ArticleId>
        <ArticleId IdType="pii">17973</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Marrero JA. Current Treatment Approaches in HCC. Clin Adv Hematol Oncol. 2013;11:15&#x2013;18.</Citation>
        </Reference>
        <Reference>
          <Citation>Bruix J, Sherman M. American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update Hepatology. 2011;53:1020&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3084991</ArticleId>
            <ArticleId IdType="pubmed">21374666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143:355&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972353</ArticleId>
            <ArticleId IdType="pubmed">21029859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castells M, Thibault B, Delord JP, Couderc B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci. 2012;13:9545&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3431813</ArticleId>
            <ArticleId IdType="pubmed">22949815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18:349&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18467122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F. Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol. 2011;2011:184&#x2013;186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3227419</ArticleId>
            <ArticleId IdType="pubmed">22162712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4036716</ArticleId>
            <ArticleId IdType="pubmed">24901008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L. Increased intratumor IL-17-producing cells correlate with poor surviral in hepatocelluar carcinoma patients. J Hepatol. 2009;50:980&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19329213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orosz L, Papanicolaou EG, Sepr&#xe9;nyi G, Megyeri K. IL-17A and IL-17F induce autophagy in RAW 264.7 macrophages. Biomed Pharmacother. 2016;77:129&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26796276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carew JS, Medina EC, Esquivel JA, 2nd, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med. 2010;14:2448&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2891399</ArticleId>
            <ArticleId IdType="pubmed">19583815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Hou N, Faried A, Tsutsumi S, Takeuchi T, Kuwano H, Faried A, Tsutsumi S, Takeuchi T, Kuwano H. Inhibition of autophagy by 3-MA enhances the effect of 5-FU induced apoptosis in colon cancer cells. Ann Surg Oncol. 2009;16:761&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19116755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie W, Zhang L, Jiao H, Guan L, Zha J, Li X, Wu M, Wang Z, Han J, You H. Chaperone-mediated autophagy prevents apoptosis by degrading BBC3/PUMA. Autophagy. 2015;11:1623&#x2013;35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4590652</ArticleId>
            <ArticleId IdType="pubmed">26212789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011;25:795&#x2013;800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3078705</ArticleId>
            <ArticleId IdType="pubmed">21498569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubbi ME, Semenza GL. An essential role for chaperone-mediated autophagy in cell cycle progression. Autophagy. 2015;11:850&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4509436</ArticleId>
            <ArticleId IdType="pubmed">25945892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pflaum J, Schlosser S, M&#xfc;ller M. p53 Family and Cellular Stress Responses in Cancer. Front Oncol. 2014;4:285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4204435</ArticleId>
            <ArticleId IdType="pubmed">25374842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng YM, Feng CW, Chen SY, Hsieh HY, Chen YH, Hsu CD. Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. BMC Cancer. 2015;15:134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4383201</ArticleId>
            <ArticleId IdType="pubmed">25886177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertoli C, de Bruin RA. Turning cell cycle entry on its head. eLife. 2014;3:e03475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076868</ArticleId>
            <ArticleId IdType="pubmed">24986860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li CX, Ng KT, Forbes SJ, Guan XY, Poon RT, Fan ST, Man K. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol. 2015;62:607&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25450711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luedde T, Schwabe RF. NF-&#x3ba;B in the liver&#x2014;linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:108&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3295539</ArticleId>
            <ArticleId IdType="pubmed">21293511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumor promoter in inflammation-associated cancer. Nature. 2004;431:461&#x2013;466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15329734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimura K, Oyamada A, Iwamoto Y, Yoshikai Y, Yamada H. CD4 T cell-intrinsic IL-2 signaling differentially affects Th1 and Th17 development. J Leukoc Biol. 2013;94:271&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23715742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada H. Current perspectives on the role of IL-17 in autoimmune disease. J Inflamm Res. 2010;3:33&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3218730</ArticleId>
            <ArticleId IdType="pubmed">22096355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine. 2008;41:92&#x2013;104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2667118</ArticleId>
            <ArticleId IdType="pubmed">18178098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011;23:613&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3190066</ArticleId>
            <ArticleId IdType="pubmed">21852080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Napolitano G, Johnson JL, He J, Rocca CJ, Monfregola J, Pestonjamasp K, Cherqui S, Catz SD. Impairment of chaperone-mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis. EMBO Mol Med. 2015;7:158&#x2013;74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4328646</ArticleId>
            <ArticleId IdType="pubmed">25586965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther. 2004;3:169&#x2013;78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14985457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013;4:e838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3824660</ArticleId>
            <ArticleId IdType="pubmed">24113172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa NL, Valadares MC, Souza PP, Mendon&#xe7;a EF, Oliveira JC, Silva TA, Batista AC. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol. 2013;49:216&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23089461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 2010;10:112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2851690</ArticleId>
            <ArticleId IdType="pubmed">20338029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F. Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol. 2011;2011:565187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3227419</ArticleId>
            <ArticleId IdType="pubmed">22162712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sica A. Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol. 2010;32:153&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21403610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sica A, Porta C, Morlacchi S, Banfi S, Strauss L, Rimoldi M, Totaro MG, Riboldi E. Origin and functions of tumor-associated myeloid cells (TAMCs) Cancer Microenviron. 2012;5:133&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3399067</ArticleId>
            <ArticleId IdType="pubmed">21948460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu YL, Jahangiri A, Delay M, Aghi MK. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res. 2012;72:4294&#x2013;99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3432684</ArticleId>
            <ArticleId IdType="pubmed">22915758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li GG, Guo ZZ, Ma XF, Cao N, Geng SN, Zheng YQ, Meng MJ, Lin HH, Han G, Du GJ. The M2 macrophages induce autophagic vascular disorder and promote mouse sensitivity to urethane-related lung carcinogenesis. Dev Comp Immunol. 2016;59:89&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26806760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez G, Delattre O, Auboeuf D, Dutertre M. Coupled alteration of transcription and splicing by a single oncogene: boosting the effect on cyclin D1 activity. Cell Cycle. 2008;7:2299&#x2013;305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18677114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19:6173&#x2013;82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3844928</ArticleId>
            <ArticleId IdType="pubmed">24045179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H, Sicinski P. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012;22:438&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3487466</ArticleId>
            <ArticleId IdType="pubmed">23079655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang BK, Cohen J, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, Palena CM. The T-box transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to chemotherapy and radiation. Cancer Res. 2013;73:1489&#x2013;1489.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu Y, Beland FA, Chen S, Liu F, Guo L, Fang JL. Mechanisms of tolvaptan-induced toxicity in HepG2 cells. Biochem Pharmacol. 2015;95:324&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5894093</ArticleId>
            <ArticleId IdType="pubmed">25858412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng YF, Shi YH, Ding ZB, Ke AW, Gu CY, Hui B, Zhou J, Qiu SJ, Dai Z, Fan J. Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. Autophagy. 2013;9:2056&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24157892</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28534943</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>07</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1791-2423</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>51</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of oncology</Title>
          <ISOAbbreviation>Int J Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.</ArticleTitle>
        <Pagination>
          <StartPage>25</StartPage>
          <EndPage>38</EndPage>
          <MedlinePgn>25-38</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/ijo.2017.4014</ELocationID>
        <Abstract>
          <AbstractText>Macrophages play a pivotal role in tumor microenvironment. Bu-Fei Decoction (BFD) is a classical formula of traditional Chinese medicine (TCM) to alleviate lung cancer related symptoms, whether it has antitumor effect or could influence cancer microenvironment deserves further study. The aim of the present study was to examine the antitumor effect of BFD on non-small cell lung cancer (NSCLC), and to investigate the underlying mechanisms through tumor associated macrophages (TAMs). M2-polarized TAMs were induced by Phorbol 12-myristate 13-acetate (PMA) and interleukin 4 (IL-4). The antitumor activity of BFD in vitro was investigated in A549 and H1975 cells using MTT assay. The in vivo anticancer effect of BFD was evaluated in athymic nude mouse xenograft model. The invasive and migration properties of NSCLC cells were measured using Transwell. The protein expression was assessed using western blotting, ELISA and immunohistochemistry. The gene expression was examined using RT-PCR. TAMs was successfully established. Conditioned medium from TAMs increased cell proliferation, migration and invasion in NSCLC cells (p&lt;0.05). BFD showed dose-dependent inhibitory effect on cell proliferation, migration and invasion abilities induced by TAMs. TAMs and rhIL-10 promoted the mRNA and protein expression of PD-L1 in NSCLC cells (p&lt;0.01). AntiâILâ10 antibodies inhibited the elevated PD-L1 expression induced by TAMs. In vitro, the expression of PD-L1 and IL-10 was inhibited by BFD dose-dependently. In vivo, BFD suppressed A549 and H1975 tumor growth and decreased the expression of IL-10, PD-L1 and CD206. The results showed that TAMs play an important role in tumor progression of NSCLC, which was associated with tumor proliferation, migration, invasion and immunosuppression. Moreover, the antitumor mechanism of BFD is related to interruption of the link between TAMs and cancer cells by inhibiting the expression of IL-10 and PD-L1 in vitro and in vivo. Our results demonstrated BFD's potential as a novel treatment for NSCLC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pang</LastName>
            <ForeName>Lina</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Shuyan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiao</LastName>
            <ForeName>Yanna</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Shantong</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Xiran</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Pingping</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>05</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Int J Oncol</MedlineTA>
        <NlmUniqueID>9306042</NlmUniqueID>
        <ISSNLinking>1019-6439</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508609">IL10 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000626333">bu-fei decoction</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>130068-27-8</RegistryNumber>
          <NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28534943</ArticleId>
        <ArticleId IdType="pmc">PMC5467788</ArticleId>
        <ArticleId IdType="doi">10.3892/ijo.2017.4014</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87&#x2013;108. doi: 10.3322/caac.21262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21262</ArticleId>
            <ArticleId IdType="pubmed">25651787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howlader N, Noone AM, Krapcho M, Miler D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al., editors. SEER Cancer Statistics Review, 1975&#x2013;2013. National Cancer Institute; Bethesda, MD: seer.cancer.gov/csr/1975_2013/(based on November 2015 SEER data submission, posted to the SEER web site, April 2016)</Citation>
        </Reference>
        <Reference>
          <Citation>Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271&#x2013;289. doi: 10.3322/caac.21349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21349</ArticleId>
            <ArticleId IdType="pubmed">27253694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gardiner RE, Jahangeer S, Forde P, Ariffin AB, Bird B, Soden D, Hinchion J. Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role? Cancer Metastasis Rev. 2015;34:129&#x2013;144. doi: 10.1007/s10555-015-9550-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-015-9550-8</ArticleId>
            <ArticleId IdType="pubmed">25726003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327:656&#x2013;661. doi: 10.1126/science.1178331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1178331</ArticleId>
            <ArticleId IdType="pmc">PMC2887389</ArticleId>
            <ArticleId IdType="pubmed">20133564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065&#x2013;1073. doi: 10.1189/jlb.0609385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0609385</ArticleId>
            <ArticleId IdType="pubmed">19741157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taniguchi K, Hikiji H, Okinaga T, Hashidate-Yoshida T, Shindou H, Ariyoshi W, Shimizu T, Tominaga K, Nishihara T. Essential role of lysophosphatidylcholine acyltransferase 3 in the induction of macrophage polarization in PMA-treated U937 cells. J Cell Biochem. 2015;116:2840&#x2013;2848. doi: 10.1002/jcb.25230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.25230</ArticleId>
            <ArticleId IdType="pubmed">25994902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. Biochim Biophys Acta. 2009;1796:11&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19269310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zwadlo G, Voegeli R, Schulze Osthoff K, Sorg C. A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol. 1987;55:295&#x2013;304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3450546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JH, Lee GT, Woo SH, Ha YS, Kwon SJ, Kim WJ, Kim IY. BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. Cancer Res. 2013;73:3604&#x2013;3614. doi: 10.1158/0008-5472.CAN-12-4563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-4563</ArticleId>
            <ArticleId IdType="pubmed">23633487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C-Y, Xu J-Y, Shi X-Y, Huang W, Ruan T-Y, Xie P, Ding J-L. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Invest. 2013;93:844&#x2013;854. doi: 10.1038/labinvest.2013.69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.2013.69</ArticleId>
            <ArticleId IdType="pubmed">23752129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, Liu S, Qin Y, Chen H. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer. 2011;74:188&#x2013;196. doi: 10.1016/j.lungcan.2011.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2011.04.009</ArticleId>
            <ArticleId IdType="pubmed">21601305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 2009;129:1016&#x2013;1025. doi: 10.1038/jid.2008.310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2008.310</ArticleId>
            <ArticleId IdType="pubmed">18843292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li CC, Hou YC, Yeh CL, Yeh SL. Effects of eicosapentaenoic acid and docosahexaenoic acid on prostate cancer cell migration and invasion induced by tumor-associated macrophages. PLoS One. 2014;9:e99630. doi: 10.1371/journal.pone.0099630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0099630</ArticleId>
            <ArticleId IdType="pmc">PMC4055683</ArticleId>
            <ArticleId IdType="pubmed">24925287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263&#x2013;266. doi: 10.1016/j.cell.2006.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.01.007</ArticleId>
            <ArticleId IdType="pubmed">16439202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, Sakoda M, Ueno S, Natsugoe S, Takao S. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2011;167:e211&#x2013;e219. doi: 10.1016/j.jss.2009.05.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jss.2009.05.026</ArticleId>
            <ArticleId IdType="pubmed">19765725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mellor AL, Munn DH. Creating immune privilege: Active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8:74&#x2013;80. doi: 10.1038/nri2233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2233</ArticleId>
            <ArticleId IdType="pubmed">18064049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Q-M, Jing Y-Y, Yu GF, Kou XR, Ye F, Gao L, Li R, Zhao QD, Yang Y, Lu ZH, et al. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett. 2014;352:160&#x2013;168. doi: 10.1016/j.canlet.2014.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2014.05.008</ArticleId>
            <ArticleId IdType="pubmed">24892648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71&#x2013;78. doi: 10.1038/nrc1256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1256</ArticleId>
            <ArticleId IdType="pubmed">14708027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727&#x2013;740. doi: 10.1084/jem.193.6.727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.193.6.727</ArticleId>
            <ArticleId IdType="pmc">PMC2193412</ArticleId>
            <ArticleId IdType="pubmed">11257139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G. Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front Immunol. 2014;5:489. doi: 10.3389/fimmu.2014.00489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2014.00489</ArticleId>
            <ArticleId IdType="pmc">PMC4188035</ArticleId>
            <ArticleId IdType="pubmed">25339957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 2003;63:8360&#x2013;8365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14678997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD, Ran S. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer. 2007;121:2181&#x2013;2191. doi: 10.1002/ijc.22937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.22937</ArticleId>
            <ArticleId IdType="pubmed">17597103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames DS, Beck AW, Barnett CC, Fleming JB, Brekken RA. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res. 2008;68:4340&#x2013;4346. doi: 10.1158/0008-5472.CAN-07-6705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-6705</ArticleId>
            <ArticleId IdType="pubmed">18519694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rauh MJ, Sly LM, Kalesnikoff J, Hughes MR, Cao LP, Lam V, Krystal G. The role of SHIP1 in macrophage programming and activation. Biochem Soc Trans. 2004;32:785&#x2013;788. doi: 10.1042/BST0320785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BST0320785</ArticleId>
            <ArticleId IdType="pubmed">15494015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torisu-Itakura H, Lee JH, Huynh Y, Ye X, Essner R, Morton DL. Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother. 2007;30:831&#x2013;838. doi: 10.1097/CJI.0b013e318158795b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0b013e318158795b</ArticleId>
            <ArticleId IdType="pubmed">18049335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206:1327&#x2013;1337. doi: 10.1084/jem.20082173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20082173</ArticleId>
            <ArticleId IdType="pmc">PMC2715058</ArticleId>
            <ArticleId IdType="pubmed">19451266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia Y, Wang Y, Yang J, Song K. Study on effects of Bufei Decoction on &#x3b1;-SMA in lung tissue of pulmonary fibrosis rats. Zhonghua Zhongyiyao Xuekan. 2014;23:1916&#x2013;1918. In Chinese.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang H, Xia YL, Yang J, Song K. Study on effects of Bufei Decoction on MMP-9 and TIMP-1 in lung tissue of pulmonary fibrosis rats. Zhonghua Zhongyiyao Xuekan. 2011;29:2673&#x2013;2679.</Citation>
        </Reference>
        <Reference>
          <Citation>Du X, Du X, Zhang K, Wang J, Guo G, Wang R. The clinical trials to observe the effect of Astragalus injection combine with chemotherapy in patients with malignant tumor. Shanghai Med Pharm J. 2010;2:16.</Citation>
        </Reference>
        <Reference>
          <Citation>Chiu PY, Lam PY, Yan CW, Ko KM. Schisandrin B protects against solar irradiation-induced oxidative injury in BJ human fibroblasts. Fitoterapia. 2011;82:682&#x2013;691. doi: 10.1016/j.fitote.2011.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fitote.2011.02.010</ArticleId>
            <ArticleId IdType="pubmed">21356279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi D, Huang Q. PhD thesis. Southern Medical University; Guangzhou: 2008. The effect of Fructus schisandrae B element to vascular endothelial growth factor in human glioma. In Chinese.</Citation>
        </Reference>
        <Reference>
          <Citation>Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659&#x2013;661. doi: 10.1096/fj.07-9574LSF.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.07-9574LSF</ArticleId>
            <ArticleId IdType="pubmed">17942826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng L, Huang D, Liu J, Qian Y, Deng J, Li D, Hu Z, Zhang J, Jiang G, Zheng S. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol. 2008;134:1021&#x2013;1027. doi: 10.1007/s00432-008-0364-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-008-0364-8</ArticleId>
            <ArticleId IdType="pubmed">18347814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: From mechanisms to therapeutic implications. Trends Immunol. 2015;36:229&#x2013;239. doi: 10.1016/j.it.2015.02.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2015.02.004</ArticleId>
            <ArticleId IdType="pubmed">25770924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Shen Y, Qu QX, Chen XQ, Zhang XG, Huang JA. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp Cell Res. 2013;319:96&#x2013;102. doi: 10.1016/j.yexcr.2012.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2012.09.006</ArticleId>
            <ArticleId IdType="pubmed">22999863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei H, Ju DW, Yu Y, Tao Q, Chen G, Gu S, Hamada H, Cao X. Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon-&#x3b3;. Gene Ther. 2000;7:707&#x2013;713. doi: 10.1038/sj.gt.3301162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.gt.3301162</ArticleId>
            <ArticleId IdType="pubmed">10800095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salazar-Onfray F. Interleukin-10: A cytokine used by tumors to escape immunosurveillance. Med Oncol. 1999;16:86&#x2013;94. doi: 10.1007/BF02785841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02785841</ArticleId>
            <ArticleId IdType="pubmed">10456656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y, Chen H. Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res. 2011;30:62. doi: 10.1186/1756-9966-30-62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-9966-30-62</ArticleId>
            <ArticleId IdType="pmc">PMC3117740</ArticleId>
            <ArticleId IdType="pubmed">21595995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274) FEBS Lett. 2006;580:755&#x2013;762. doi: 10.1016/j.febslet.2005.12.093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2005.12.093</ArticleId>
            <ArticleId IdType="pubmed">16413538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8:793&#x2013;800. doi: 10.1038/nm0902-1039c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0902-1039c</ArticleId>
            <ArticleId IdType="pubmed">12091876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682&#x2013;687. doi: 10.1038/nature04444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature04444</ArticleId>
            <ArticleId IdType="pubmed">16382236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Li G, Meng H, Fan Y, Song Y, Wang S, Zhu F, Guo C, Zhang L, Shi Y. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother. 2012;61:101&#x2013;108. doi: 10.1007/s00262-011-1094-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-011-1094-3</ArticleId>
            <ArticleId IdType="pubmed">21853301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19:3165&#x2013;3175. doi: 10.1158/1078-0432.CCR-12-3314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-3314</ArticleId>
            <ArticleId IdType="pmc">PMC3742575</ArticleId>
            <ArticleId IdType="pubmed">23613317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen LP, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94:107&#x2013;116. doi: 10.1038/labinvest.2013.130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.2013.130</ArticleId>
            <ArticleId IdType="pmc">PMC6125250</ArticleId>
            <ArticleId IdType="pubmed">24217091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 2014;6:1670&#x2013;1690. doi: 10.3390/cancers6031670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers6031670</ArticleId>
            <ArticleId IdType="pmc">PMC4190561</ArticleId>
            <ArticleId IdType="pubmed">25125485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol. 2000;11:815&#x2013;819. doi: 10.1023/A:1008375208574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1008375208574</ArticleId>
            <ArticleId IdType="pubmed">10997808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin M, Zhao K, Huang Q, Shang P. Structural features and biological activities of the polysaccharides from Astragalus membranaceus. Int J Biol Macromol. 2014;64:257&#x2013;266. doi: 10.1016/j.ijbiomac.2013.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijbiomac.2013.12.002</ArticleId>
            <ArticleId IdType="pubmed">24325861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Sun YN, Yan XT, Yang SY, Song SB, Lee YM, Kim YH. NF-&#x3ba;B inhibitory activity of sucrose fatty acid esters and related constituents from Astragalus membranaceus. J Agric Food Chem. 2013;61:7081&#x2013;7088. doi: 10.1021/jf4017509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jf4017509</ArticleId>
            <ArticleId IdType="pubmed">23815760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, May B, Di YM, Zhang AL, Lu C, Xue CC, Lin L. Oral Chinese herbal medicine combined with pharmacotherapy for stable COPD: A systematic review of effect on BODE index and six minute walk test. PLoS One. 2014;9:e91830. doi: 10.1371/journal.pone.0091830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0091830</ArticleId>
            <ArticleId IdType="pmc">PMC3951501</ArticleId>
            <ArticleId IdType="pubmed">24622390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Sun Y, Jin L, Xu Y, Wang L, Ren T, Wang K. Enhancement of non-specific immune response in sea cucumber (Apostichopus japonicus) by Astragalus membranaceus and its polysaccharides. Fish Shellfish Immunol. 2009;27:757&#x2013;762. doi: 10.1016/j.fsi.2009.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fsi.2009.09.002</ArticleId>
            <ArticleId IdType="pubmed">19748588</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28455246</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>08</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>04</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>400</Volume>
            <PubDate>
              <Year>2017</Year>
              <Month>Aug</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Fn14Â·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.</ArticleTitle>
        <Pagination>
          <StartPage>99</StartPage>
          <EndPage>109</EndPage>
          <MedlinePgn>99-109</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2017.04.026</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(17)30287-2</ELocationID>
        <Abstract>
          <AbstractText>Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) demonstrates specific anti-cancer activity, but insufficient efficacy in patients. A fusion protein Fn14Â·TRAIL, that combines soluble TRAIL molecule with a specific TWEAK receptor Fn14, is a better apoptosis-inducer for hepatocellular carcinomas than soluble TRAIL. However, Fn14Â·TRAIL does not effectively induce apoptosis in tumors of the lymphoid origin. As malignant cell apoptosis is strongly enhanced by secondary oligomerization of TRAIL, we tested the hypothesis that soluble Fn14Â·TRAIL can be oligomerized and become more active by adding TWEAK, a cytokine secreted in the tumor environment. We revealed that TWEAK and Fn14Â·TRAIL spontaneously formed a stable complex that induced apoptosis of malignant lymphoblasts earlier and more efficiently than TRAIL. The TWEAK-modified Fn14Â·TRAIL oligomer bound to target cells and delivered apoptotic signaling via TRAIL receptors. The oligomer induced faster and stronger cleavage of procaspase-8, -9, and -3; BID; poly-ADP ribose polymerase; and RIP compared to TRAIL. The oligomer also reduced expression of the anti-apoptotic proteins c-FLIP short and cIAP-1. Our data indicate that Fn14Â·TRAIL can be converted into a highly effective TRAIL oligomer upon binding to TWEAK.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2017 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Prigozhina</LastName>
            <ForeName>Tatyana B</ForeName>
            <Initials>TB</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology and Hypertension Department, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Szafer</LastName>
            <ForeName>Fanny</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>KAHR Medical Ltd, Jerusalem 91120, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aronin</LastName>
            <ForeName>Alexandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology and Hypertension Department, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tzdaka</LastName>
            <ForeName>Kobi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>KAHR Medical Ltd, Jerusalem 91120, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amsili</LastName>
            <ForeName>Shira</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>KAHR Medical Ltd, Jerusalem 91120, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Makdasi</LastName>
            <ForeName>Efi</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>KAHR Medical Ltd, Jerusalem 91120, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shani</LastName>
            <ForeName>Noam</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>KAHR Medical Ltd, Jerusalem 91120, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dranitzki Elhalel</LastName>
            <ForeName>Michal</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology and Hypertension Department, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel. Electronic address: michale@hadassah.org.il.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>04</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074049">Cytokine TWEAK</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000622071">Fn14-TRAIL fusion protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053220">Receptors, TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C109743">TNFSF12 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048069">Tumor Necrosis Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074049" MajorTopicYN="N">Cytokine TWEAK</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015458" MajorTopicYN="N">Leukemia, T-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053220" MajorTopicYN="N">Receptors, TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053221" MajorTopicYN="N">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048069" MajorTopicYN="N">Tumor Necrosis Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Fn14&#xb7;TRAIL</Keyword>
        <Keyword MajorTopicYN="N">Fusion protein</Keyword>
        <Keyword MajorTopicYN="N">Oligomerization</Keyword>
        <Keyword MajorTopicYN="N">TWEAK</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28455246</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2017.04.026</ArticleId>
        <ArticleId IdType="pii">S0304-3835(17)30287-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28129639</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>10</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1949-2553</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Feb</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncotarget</Title>
          <ISOAbbreviation>Oncotarget</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>14428</StartPage>
          <EndPage>14442</EndPage>
          <MedlinePgn>14428-14442</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.14803</ELocationID>
        <Abstract>
          <AbstractText>CXCR1 and CXCR2 chemokine receptors and their ligands (CXCL1/2/3/7/8) play an important role in tumor progression. Tested to date CXCR1/2 antagonists and chemokine-targeted antibodies were reported to affect malignant cells in vitro and in animal models. Yet, redundancy of chemotactic signals and toxicity hinder further clinical development of these approaches. In this pre-clinical study we investigated the capacity of a novel small molecule dual CXCR1/2 inhibitor, Ladarixin (LDX), to attenuate progression of experimental human melanomas. Our data showed that LDX-mediated inhibition of CXCR1/2 abrogated motility and induced apoptosis in cultured cutaneous and uveal melanoma cells and xenografts independently of the molecular defects associated with the malignant phenotype. These effects were mediated by the inhibition of AKT and NF-kB signaling pathways. Moreover, systemic treatment of melanoma-bearing mice with LDX also polarized intratumoral macrophages to M1 phenotype, abrogated intratumoral de novo angiogenesis and inhibited melanoma self-renewal. Collectively, these studies outlined the pre-requisites of the successful CXCR1/2 inhibition on malignant cells and demonstrated multifactorial effects of Ladarixin on cutaneous and uveal melanomas, suggesting therapeutic utility of LDX in treatment of various melanoma types.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kemp</LastName>
            <ForeName>Daria Marley</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pidich</LastName>
            <ForeName>Alyson</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Larijani</LastName>
            <ForeName>Mary</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jonas</LastName>
            <ForeName>Rebecca</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lash</LastName>
            <ForeName>Elizabeth</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>Takami</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Terai</LastName>
            <ForeName>Mizue</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Pizzol</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>DompÃ© Farmaceutici SpA, Via Campo di Pile, L'Aquila, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Allegretti</LastName>
            <ForeName>Marcello</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>DompÃ© Farmaceutici SpA, Via Campo di Pile, L'Aquila, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Igoucheva</LastName>
            <ForeName>Olga</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alexeev</LastName>
            <ForeName>Vitali</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oncotarget</MedlineTA>
        <NlmUniqueID>101532965</NlmUniqueID>
        <ISSNLinking>1949-2553</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C511776">2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D023062">Receptors, Interleukin-8A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D023063">Receptors, Interleukin-8B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002633" MajorTopicYN="N">Chemotaxis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023062" MajorTopicYN="N">Receptors, Interleukin-8A</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023063" MajorTopicYN="N">Receptors, Interleukin-8B</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CXCR1/2 inhibitor</Keyword>
        <Keyword MajorTopicYN="N">melanoma</Keyword>
        <Keyword MajorTopicYN="N">melanoma apoptosis</Keyword>
        <Keyword MajorTopicYN="N">tumor growth inhibition</Keyword>
        <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICTS OF INTEREST. Authors declare no conflict of interest in relation to the work described in this manuscript.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28129639</ArticleId>
        <ArticleId IdType="pmc">PMC5362416</ArticleId>
        <ArticleId IdType="doi">10.18632/oncotarget.14803</ArticleId>
        <ArticleId IdType="pii">14803</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Richmond A, Yang J, Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment cell &amp; melanoma research. 2009;22(2):175&#x2013;186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2848967</ArticleId>
            <ArticleId IdType="pubmed">19222802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balentien E, Mufson BE, Shattuck RL, Derynck R, Richmond A. Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene. 1991;6(7):1115&#x2013;1124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1861861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R, Richmond A. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. Journal of leukocyte biology. 2000;67(1):53&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2669312</ArticleId>
            <ArticleId IdType="pubmed">10647998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owen JD, Strieter R, Burdick M, Haghnegahdar H, Nanney L, Shattuck-Brandt R, Richmond A. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. International journal of cancer Journal international du cancer. 1997;73(1):94&#x2013;103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9334815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer research. 2006;66(8):4125&#x2013;4132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16618733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. Journal of leukocyte biology. 2002;72(1):9&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2668262</ArticleId>
            <ArticleId IdType="pubmed">12101257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Richmond A. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer research. 2001;61(12):4901&#x2013;4909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11406569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science. 1991;253(5025):1278&#x2013;1280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1840701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nature immunology. 2001;2(2):123&#x2013;128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11175804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-oncology. 2005;7(2):122&#x2013;133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1871893</ArticleId>
            <ArticleId IdType="pubmed">15831231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma B, Singh S, Varney ML, Singh RK. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert opinion on therapeutic targets. 2010;14(4):435&#x2013;442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4229031</ArticleId>
            <ArticleId IdType="pubmed">20230195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur M, Singh D. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. The Journal of pharmacology and experimental therapeutics. 2013;347(1):173&#x2013;180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23912333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garau A, Bertini R, Mosca M, Bizzarri C, Anacardio R, Triulzi S, Allegretti M, Ghezzi P, Villa P. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat. European cytokine network. 2006;17(1):35&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16613761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, Matsushima K, Herlyn M. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. International journal of cancer Journal international du cancer. 2003;103(3):335&#x2013;343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12471616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herlyn D, Iliopoulos D, Jensen PJ, Parmiter A, Baird J, Hotta H, Adachi K, Ross AH, Jambrosic J, Koprowski H, In Herlyn M. vitro properties of human melanoma cells metastatic in nude mice. Cancer research. 1990;50(8):2296&#x2013;2302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2156614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE. Genetic analysis of the &#x2018;uveal melanoma&#x2019; C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment cell &amp; melanoma research. 2015;28(3):357&#x2013;359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25515650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozaki S, Vuyyuru R, Kageyama K, Terai M, Ohara M, Cheng H, Manser T, Mastrangelo MJ, Aplin AE, Sato T. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. The American journal of pathology. 2016;186(1):43&#x2013;56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4715216</ArticleId>
            <ArticleId IdType="pubmed">26613897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Igoucheva O, Kelly A, Uitto J, Alexeev V. Protein therapeutics for junctional epidermolysis bullosa: incorporation of recombinant beta3 chain into laminin 332 in beta3&#x2212;/&#x2212; keratinocytes in vitro. The Journal of investigative dermatology. 2008;128(6):1476&#x2013;1486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3357058</ArticleId>
            <ArticleId IdType="pubmed">18079746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smythe WR, Williams JP, Wheelock MJ, Johnson KR, Kaiser LR, Albelda SM. Cadherin and catenin expression in normal human bronchial epithelium and non-small cell lung cancer. Lung Cancer. 1999;24(3):157&#x2013;168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10460003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams HK, Sanders DS, Jankowski JA, Landini G, Brown AM. Expression of cadherins and catenins in oral epithelial dysplasia and squamous cell carcinoma. Journal of oral pathology &amp; medicine. 1998;27(7):308&#x2013;317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9725568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Molecular and cellular biology. 1999;19(7):4798&#x2013;4805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC84278</ArticleId>
            <ArticleId IdType="pubmed">10373529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer metastasis reviews. 2005;24(2):315&#x2013;327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15986140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N de la Iglesia, Konopka G, Lim KL, Nutt CL, Bromberg JF, Frank DA, Mischel PS, Louis DN, Bonni A. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. The Journal of neuroscience. 2008;28(23):5870&#x2013;5878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2700037</ArticleId>
            <ArticleId IdType="pubmed">18524891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, Palmqvist R. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PloS one. 2012;7(10):e47045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3471949</ArticleId>
            <ArticleId IdType="pubmed">23077543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. American journal of clinical pathology. 2006;125(2):209&#x2013;216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16393674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boonyaratanakornkit JB, Yue L, Strachan LR, Scalapino KJ, LeBoit PE, Lu Y, Leong SP, Smith JE, Ghadially R. Selection of tumorigenic melanoma cells using ALDH. The Journal of investigative dermatology. 2010;130(12):2799&#x2013;2808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5621840</ArticleId>
            <ArticleId IdType="pubmed">20739950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012;30(10):2100&#x2013;2113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3448863</ArticleId>
            <ArticleId IdType="pubmed">22887839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P, Liu L. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Scientific reports. 2014;4:5911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4118151</ArticleId>
            <ArticleId IdType="pubmed">25081383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. The Journal of clinical investigation. 2010;120(2):485&#x2013;497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2810075</ArticleId>
            <ArticleId IdType="pubmed">20051626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon JR, Li F, Zhang X, Wang W, Zhao X, Nayyar A. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals. Journal of leukocyte biology. 2005;78(6):1265&#x2013;1272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16204619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneberger D, Gordon JR, DeVasure JM, Boten JA, Heires AJ, Romberger DJ, Wyatt TA. CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks lung inflammation in swine barn dust-instilled mice. Pulmonary pharmacology &amp; therapeutics. 2015;31:55&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4396599</ArticleId>
            <ArticleId IdType="pubmed">25681618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R, Singh RK. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res. 2009;15(7):2380&#x2013;2386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4232212</ArticleId>
            <ArticleId IdType="pubmed">19293256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. The Journal of pharmacology and experimental therapeutics. 2007;322(2):477&#x2013;485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17496166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, Gonsiorek W, Billah MM, Fine JS, Hey JA. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. The Journal of pharmacology and experimental therapeutics. 2007;322(2):486&#x2013;493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17496165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, Tsai M, Sadeh J, Magnussen H. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. The European respiratory journal. 2010;35(3):564&#x2013;570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19643947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nair KK, Pillai HS, Thajudeen A, Tharakan J, Titus T, Valaparambil A, Sivasubramonian S, Mahadevan KK, Namboodiri N, Sasidharan B, Ganapathi S. Comparative study on safety, efficacy, and midterm results of balloon mitral valvotomy performed with triple lumen and double lumen mitral valvotomy catheters. Catheterization and cardiovascular interventions. 2012;80(6):978&#x2013;986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22566347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O&#x2019;Byrne PM, Stryszak P, Gann L, Sadeh J, Chanez P. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clinical and experimental allergy. 2012;42(7):1097&#x2013;1103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22702508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertini R, Barcelos LS, Beccari AR, Cavalieri B, Moriconi A, Bizzarri C, Di Benedetto P, Di Giacinto C, Gloaguen I, Galliera E, Corsi MM, Russo RC, Andrade SP, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. British journal of pharmacology. 2012;165(2):436&#x2013;454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3268197</ArticleId>
            <ArticleId IdType="pubmed">21718305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hattermann K, Holzenburg E, Hans F, Lucius R, Held-Feindt J, Mentlein R. Effects of the chemokine CXCL12 and combined internalization of its receptors CXCR4 and CXCR7 in human MCF-7 breast cancer cells. Cell and tissue research. 2014;357(1):253&#x2013;266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4077318</ArticleId>
            <ArticleId IdType="pubmed">24770893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villa P, Triulzi S, Cavalieri B, Di Bitondo R, Bertini R, Barbera S, Bigini P, Mennini T, Gelosa P, Tremoli E, Sironi L, Ghezzi P. The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol Med. 2007;13(3-4):125&#x2013;133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1892761</ArticleId>
            <ArticleId IdType="pubmed">17592546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. The New England journal of medicine. 1991;324(1):1&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1701519</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27855523</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1525-6014</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug and chemical toxicology</Title>
          <ISOAbbreviation>Drug Chem Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immunomodulatory and cellular anti-oxidant activities of caffeic, ferulic, and p-coumaric phenolic acids: a structure-activity relationship study.</ArticleTitle>
        <Pagination>
          <StartPage>416</StartPage>
          <EndPage>424</EndPage>
          <MedlinePgn>416-424</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/01480545.2016.1252919</ELocationID>
        <Abstract>
          <AbstractText>Many studies have been performed to assess the potential utility of natural products as immunomodulatory agents to enhance host responses and to reduce damage to the human body. To determine whether phenolic compounds (caffeic, ferulic, and p-coumaric acids) have immunomodulatory effects and clarify which types of immune effector cells are stimulated in vitro, we evaluated their effect on splenocyte proliferation and lysosomal enzyme activity. We also investigated the activity of natural killer (NK) cells and cytotoxic T lymphocytes (CTL). In addition, induction of the cellular antioxidant activity in splenocytes, macrophages, and red blood cells was determined by measuring the ï¬uorescence of the DCF product. The study first results indicated that caï¬eic, ferulic, and p-coumaric acids significantly promote LPS-stimulated splenocyte proliferation, suggesting a potential activation of B cells, and enhanced humoral immune response in hosts treated by the tested natural products. Phenolic acids significantly enhanced the killing activity of isolated NK and CTL cells but had negligible effects on mitogen-induced proliferation of splenic T cells. We showed that caffeic acid enhances lysosomal enzyme activity in murine peritoneal macrophages, suggesting a potential role in activating such cells. Immunomodulatory activity was concomitant with the cellular antioxidant effect in macrophages and splenocytes of caffeic and ferulic acids. We conclude from this study that caï¬eic, ferulic, and p-coumaric acids exhibited an immunomodulatory effect which could be ascribed, in part, to their cytoprotective effect via their antioxidant capacity. Furthermore, these results suggest that these natural products could be potentially used to modulate immune cell functions in physiological and pathological conditions.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kilani-Jaziri</LastName>
            <ForeName>Soumaya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>a Laboratory of Cellular and Molecular Biology , Faculty of Dental Medicine, University of Monastir , Monastir , Tunisia and.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>b Unit of Bioactive and Natural Substances and Biotechnology UR12ES12, Faculty of Pharmacy, University of Monastir , Monastir , Tunisia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mokdad-Bzeouich</LastName>
            <ForeName>Imen</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>a Laboratory of Cellular and Molecular Biology , Faculty of Dental Medicine, University of Monastir , Monastir , Tunisia and.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>b Unit of Bioactive and Natural Substances and Biotechnology UR12ES12, Faculty of Pharmacy, University of Monastir , Monastir , Tunisia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Krifa</LastName>
            <ForeName>Mounira</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>a Laboratory of Cellular and Molecular Biology , Faculty of Dental Medicine, University of Monastir , Monastir , Tunisia and.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>b Unit of Bioactive and Natural Substances and Biotechnology UR12ES12, Faculty of Pharmacy, University of Monastir , Monastir , Tunisia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasr</LastName>
            <ForeName>Nouha</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>a Laboratory of Cellular and Molecular Biology , Faculty of Dental Medicine, University of Monastir , Monastir , Tunisia and.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>b Unit of Bioactive and Natural Substances and Biotechnology UR12ES12, Faculty of Pharmacy, University of Monastir , Monastir , Tunisia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghedira</LastName>
            <ForeName>Kamel</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>b Unit of Bioactive and Natural Substances and Biotechnology UR12ES12, Faculty of Pharmacy, University of Monastir , Monastir , Tunisia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chekir-Ghedira</LastName>
            <ForeName>Leila</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>a Laboratory of Cellular and Molecular Biology , Faculty of Dental Medicine, University of Monastir , Monastir , Tunisia and.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>b Unit of Bioactive and Natural Substances and Biotechnology UR12ES12, Faculty of Pharmacy, University of Monastir , Monastir , Tunisia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Drug Chem Toxicol</MedlineTA>
        <NlmUniqueID>7801723</NlmUniqueID>
        <ISSNLinking>0148-0545</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002109">Caffeic Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003373">Coumaric Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008934">Mitogens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011422">Propionates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>AVM951ZWST</RegistryNumber>
          <NameOfSubstance UI="C004999">ferulic acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IBS9D1EU3J</RegistryNumber>
          <NameOfSubstance UI="C495469">p-coumaric acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>U2S3A33KVM</RegistryNumber>
          <NameOfSubstance UI="C040048">caffeic acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002109" MajorTopicYN="N">Caffeic Acids</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003373" MajorTopicYN="N">Coumaric Acids</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019587" MajorTopicYN="N">Dietary Supplements</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017737" MajorTopicYN="N">Macrophages, Peritoneal</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008934" MajorTopicYN="N">Mitogens</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011422" MajorTopicYN="N">Propionates</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CTL activity</Keyword>
        <Keyword MajorTopicYN="N">Hydroxycinnamic acids</Keyword>
        <Keyword MajorTopicYN="N">antioxidant activity</Keyword>
        <Keyword MajorTopicYN="N">immunomodulation</Keyword>
        <Keyword MajorTopicYN="N">natural killer cell</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27855523</ArticleId>
        <ArticleId IdType="doi">10.1080/01480545.2016.1252919</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27732933</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1949-2553</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>48</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Nov</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncotarget</Title>
          <ISOAbbreviation>Oncotarget</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.</ArticleTitle>
        <Pagination>
          <StartPage>78605</StartPage>
          <EndPage>78618</EndPage>
          <MedlinePgn>78605-78618</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.12522</ELocationID>
        <Abstract>
          <AbstractText>The bone marrow microenvironment plays a decisive role in multiple myeloma progression and drug resistance. Chemokines are soluble mediators of cell migration, proliferation and survival and essentially modulate tumor progression and drug resistance. Here we investigated bone marrow-derived chemokines of naive and therapy-refractory myeloma patients and discovered that high levels of the chemokine CCL27, known so far for its role in skin inflammatory processes, correlated with worse overall survival of the patients. In addition, chemokine levels were significantly higher in samples from patients who became refractory to bortezomib at first line treatment compared to resistance at later treatment lines.In vitro as well as in an in vivo model we could show that CCL27 triggers bortezomib-resistance of myeloma cells. This effect was strictly dependent on the expression of the respective receptor, CCR10, on stroma cells and involved the modulation of IL-10 expression, activation of myeloma survival pathways, and modulation of proteasomal activity. Drug resistance could be totally reversed by blocking CCR10 by siRNA as well as blocking IL-10 and its receptor.From our data we suggest that blocking the CCR10/CCL27/IL-10 myeloma-stroma crosstalk is a novel therapeutic target that could be especially relevant in early refractory myeloma patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thangavadivel</LastName>
            <ForeName>Shanmugapriya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Tyrolean Cancer Research Institute, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zelle-Rieser</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Tyrolean Cancer Research Institute, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olivier</LastName>
            <ForeName>Angelika</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Tyrolean Cancer Research Institute, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Postert</LastName>
            <ForeName>Benno</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Tyrolean Cancer Research Institute, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Untergasser</LastName>
            <ForeName>Gerold</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Tyrolean Cancer Research Institute, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Angiogenesis and Tumorbiology, Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kern</LastName>
            <ForeName>Johann</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Angiogenesis and Tumorbiology, Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brunner</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Medical University Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gunsilius</LastName>
            <ForeName>Eberhard</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Angiogenesis and Tumorbiology, Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Biedermann</LastName>
            <ForeName>Rainer</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedic Surgery, Medical University Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hajek</LastName>
            <ForeName>Roman</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hematooncology, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pour</LastName>
            <ForeName>Ludek</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hematooncology, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Willenbacher</LastName>
            <ForeName>Wolfgang</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine V, University Hospital Innsbruck, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Greil</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Tyrolean Cancer Research Institute, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Salzburg Cancer Research Institute-Laboratory of Immunological and Molecular Cancer Research, Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Third Medical Department at The Paracelsus Medical University Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Cluster Salzburg (CCS), Salzburg, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>JÃ¶hrer</LastName>
            <ForeName>Karin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Tyrolean Cancer Research Institute, Innsbruck, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oncotarget</MedlineTA>
        <NlmUniqueID>101532965</NlmUniqueID>
        <ISSNLinking>1949-2553</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C492276">CCL27 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515706">CCR10 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054425">Chemokine CCL27</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508609">IL10 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061988">Proteasome Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054447">Receptors, CCR10</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053701">Receptors, Interleukin-10</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>130068-27-8</RegistryNumber>
          <NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>69G8BD63PP</RegistryNumber>
          <NameOfSubstance UI="D000069286">Bortezomib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.25.1</RegistryNumber>
          <NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069286" MajorTopicYN="N">Bortezomib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054425" MajorTopicYN="N">Chemokine CCL27</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061988" MajorTopicYN="N">Proteasome Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020239" MajorTopicYN="N">Receptor Cross-Talk</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054447" MajorTopicYN="N">Receptors, CCR10</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053701" MajorTopicYN="N">Receptors, Interleukin-10</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CCL27</Keyword>
        <Keyword MajorTopicYN="N">CCR10</Keyword>
        <Keyword MajorTopicYN="N">drug resistance</Keyword>
        <Keyword MajorTopicYN="N">myeloma</Keyword>
        <Keyword MajorTopicYN="N">stroma cells</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICTS OF INTEREST. The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27732933</ArticleId>
        <ArticleId IdType="pmc">PMC5346663</ArticleId>
        <ArticleId IdType="doi">10.18632/oncotarget.12522</ArticleId>
        <ArticleId IdType="pii">12522</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049&#x2013;3058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4432002</ArticleId>
            <ArticleId IdType="pubmed">25838343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004;22:891&#x2013;928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15032599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonecchi R, Locati M, Mantovani A. Chemokines and cancer: a fatal attraction. Cancer Cell. 2011;19:434&#x2013;435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21481784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2016;35:816&#x2013;826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25961926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaacoub K, Pedeux R, Tarte K, Guillaudeux T. Role of the tumor microenvironment in regulating apoptosis and cancer progression. Cancer Lett. 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27224890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119:2026&#x2013;2029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16671092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, Anderson KC. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002;1:539&#x2013;544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12479272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johrer K, Janke K, Krugmann J, Fiegl M, Greil R. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res. 2004;10:1901&#x2013;1910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15041705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vande Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B, Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer. 2003;88:855&#x2013;862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2377079</ArticleId>
            <ArticleId IdType="pubmed">12644822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100:2195&#x2013;2202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12200385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Bunemann E, Lehto M, Wolff H, Yen D, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002;8:157&#x2013;165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11821900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morales J, Homey B, Vicari AP, Hudak S, Oldham E, Hedrick J, Orozco R, Copeland NG, Jenkins NA, McEvoy LM, Zlotnik A. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA. 1999;96:14470&#x2013;14475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC24460</ArticleId>
            <ArticleId IdType="pubmed">10588729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C, Knol E. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol. 2004;113:334&#x2013;340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14767451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Asano N, Mitsui H, Tada Y, Wakugawa M, Watanabe T, Torii H, Komine M, Asahina A, Nakamura K, et al. Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol. 2003;111:592&#x2013;597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12642842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hieshima K, Kawasaki Y, Hanamoto H, Nakayama T, Nagakubo D, Kanamaru A, Yoshie O. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol. 2004;173:3668&#x2013;3675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15356112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lazarus NH, Kunkel EJ, Johnston B, Wilson E, Youngman KR, Butcher EC. A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol. 2003;170:3799&#x2013;3805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12646646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan J, Kunkel EJ, Gosslar U, Lazarus N, Langdon P, Broadwell K, Vierra MA, Genovese MC, Butcher EC, Soler D. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J Immunol. 2000;165:2943&#x2013;2949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10975800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scanlon KM, Hawksworth RJ, Lane SJ, Mahon BP. IL-17A induces CCL28, supporting the chemotaxis of IgE-secreting B cells. Int Arch Allergy Immunol. 2011;156:51&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21447959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu S, Yang K, Yang J, Li M, Xiong N. Critical roles of chemokine receptor CCR10 in regulating memory IgA responses in intestines. Proc Natl Acad Sci USA. 2011;108:E1035&#x2013;1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3215018</ArticleId>
            <ArticleId IdType="pubmed">21969568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunkel EJ, Kim CH, Lazarus NH, Vierra MA, Soler D, Bowman EP, Butcher EC. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest. 2003;111:1001&#x2013;1010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC152588</ArticleId>
            <ArticleId IdType="pubmed">12671049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karlsson C, Baudet A, Miharada N, Soneji S, Gupta R, Magnusson M, Enver T, Karlsson G, Larsson J. Identification of the chemokine CCL28 as a growth and survival factor for human hematopoietic stem and progenitor cells. Blood. 2013;121:3838&#x2013;3842. s3831&#x2013;3815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23509159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexeev V, Donahue A, Uitto J, Igoucheva O. Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues. Cytotherapy. 2013;15:171&#x2013;184. e171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3551218</ArticleId>
            <ArticleId IdType="pubmed">23321329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inokuma D, Abe R, Fujita Y, Sasaki M, Shibaki A, Nakamura H, McMillan JR, Shimizu T, Shimizu H. CTACK/CCL27 accelerates skin regeneration via accumulation of bone marrow-derived keratinocytes. Stem cells. 2006;24:2810&#x2013;2816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16931770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol. 2003;170:1136&#x2013;1140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12538668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome biology. 2006;7:243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1794421</ArticleId>
            <ArticleId IdType="pubmed">17201934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johrer K, Obkircher M, Neureiter D, Parteli J, Zelle-Rieser C, Maizner E, Kern J, Hermann M, Hamacher F, Merkel O, Wacht N, Zidorn C, Scheideler M, et al. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target. Journal of molecular medicine (Berlin, Germany) 2012;90:681&#x2013;693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22205266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martowicz A, Kern J, Gunsilius E, Untergasser G. Establishment of a human multiple myeloma xenograft model in the chicken to study tumor growth, invasion and angiogenesis. Journal of visualized experiments : JoVE. 2015:e52665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4542136</ArticleId>
            <ArticleId IdType="pubmed">25993267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker J, Covelo-Fernandez A, von Bonin F, Kube D, Wilting J. Specific tumor-stroma interactions of EBV-positive Burkitt's lymphoma cells in the chick chorioallantoic membrane. Vascular cell. 2012;4:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3325879</ArticleId>
            <ArticleId IdType="pubmed">22404859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klingenberg M, Becker J, Eberth S, Kube D, Wilting J. The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma. BMC cancer. 2014;14:339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4036709</ArticleId>
            <ArticleId IdType="pubmed">24884418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu ZJ, Costes V, Lu ZY, Zhang XG, Pitard V, Moreau JF, Bataille R, Wijdenes J, Rossi JF, Klein B. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood. 1996;88:3972&#x2013;3986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8916964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem cells (Dayton, Ohio) 2012;30:266&#x2013;279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22102554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang TP, Poltoratsky V, Vancurova I. Bortezomib inhibits expression of TGF-beta1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. Journal of immunology (Baltimore, Md : 1950) 2015;194:2942&#x2013;2953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4355060</ArticleId>
            <ArticleId IdType="pubmed">25681335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar S, Rajkumar SV. Many facets of bortezomib resistance/susceptibility. Blood. 2008;112:2177&#x2013;2178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18779399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947&#x2013;959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4123429</ArticleId>
            <ArticleId IdType="pubmed">22645181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veldkamp CT, Seibert C, Peterson FC, De la Cruz NB, Haugner JC, 3rd, Basnet H, Sakmar TP, Volkman BF. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal. 2008;1:ra4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2692298</ArticleId>
            <ArticleId IdType="pubmed">18799424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jansma AL, Kirkpatrick JP, Hsu AR, Handel TM, Nietlispach D. NMR analysis of the structure, dynamics, and unique oligomerization properties of the chemokine CCL27. J Biol Chem. 2010;285:14424&#x2013;14437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2863231</ArticleId>
            <ArticleId IdType="pubmed">20200157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawano Y, Moschetta M, Manier S, Glavey S, Gorgun GT, Roccaro AM, Anderson KC, Ghobrial IM. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263:160&#x2013;172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25510276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daubeuf F, Jung F, Douglas GJ, Chevalier E, Frossard N. Protective effect of a Protein Epitope Mimetic CCR10 antagonist, POL7085, in a model of allergic eosinophilic airway inflammation. Respir Res. 2015;16:77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4490744</ArticleId>
            <ArticleId IdType="pubmed">26112287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia M, Hu S, Fu Y, Jin W, Yi Q, Matsui Y, Yang J, McDowell MA, Sarkar S, Kalia V, Xiong N. CCR10 regulates balanced maintenance and function of resident regulatory and effector T cells to promote immune homeostasis in the skin. J Allergy Clin Immunol. 2014;134:634&#x2013;644. e610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4149943</ArticleId>
            <ArticleId IdType="pubmed">24767879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riis JL, Johansen C, Vestergaard C, Otkjaer K, Kragballe K, Iversen L. CCL27 expression is regulated by both p38 MAPK and IKKbeta signalling pathways. Cytokine. 2011;56:699&#x2013;707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21993219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagami S, Saeki H, Komine M, Kakinuma T, Nakamura K, Tsunemi Y, Sasaki K, Asahina A, Tamaki K. CCL28 production in HaCaT cells was mediated by different signal pathways from CCL27. Exp Dermatol. 2006;15:95&#x2013;100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16433680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B, Harousseau JL, Bataille R, Rossi JF, Klein B. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood. 1995;85:2521&#x2013;2527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7727780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26188281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stasi R, Brunetti M, Bussa S, Pagano A. Serum interleukin-10 in plasma-cell dyscrasias. Am J Hematol. 1997;54:335&#x2013;337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9092693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zingone A, Wang W, Corrigan-Cummins M, Wu SP, Plyler R, Korde N, Kwok M, Manasanch EE, Tageja N, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, et al. Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. Cytokine. 2014;69:294&#x2013;297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4148078</ArticleId>
            <ArticleId IdType="pubmed">25043675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramsey DM, McAlpine SR. Halting metastasis through CXCR4 inhibition. Bioorg Med Chem Lett. 2013;23:20&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23211868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zollner S, Vonhoff S, Mishima Y, Maiso P, Reagan MR, Lonardi S, et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep. 2014;9:118&#x2013;128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4194173</ArticleId>
            <ArticleId IdType="pubmed">25263552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST. Characterization of the MM. 1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003;31:271&#x2013;282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12691914</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27651484</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>01</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1091-6490</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>113</Volume>
            <Issue>40</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Oct</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF.</ArticleTitle>
        <Pagination>
          <StartPage>11300</StartPage>
          <EndPage>11305</EndPage>
          <MedlinePgn>11300-11305</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Radiation therapy (RT), a major modality for treating localized tumors, can induce tumor regression outside the radiation field through an abscopal effect that is thought to involve the immune system. Our studies were designed to understand the early immunological effects of RT in the tumor microenvironment using several syngeneic mouse tumor models. We observed that RT induced sterile inflammation with a rapid and transient infiltration of CD11b[+]Gr-1[high+] neutrophils into the tumors. RT-recruited tumor-associated neutrophils (RT-Ns) exhibited an increased production of reactive oxygen species and induced apoptosis of tumor cells. Tumor infiltration of RT-Ns resulted in sterile inflammation and, eventually, the activation of tumor-specific cytotoxic T cells, their recruitment into the tumor site, and tumor regression. Finally, the concurrent administration of granulocyte colony-stimulating factor (G-CSF) enhanced RT-mediated antitumor activity by activating RT-Ns. Our results suggest that the combination of RT and G-CSF should be further evaluated in preclinical and clinical settings.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Takeshima</LastName>
            <ForeName>Tsuguhide</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pop</LastName>
            <ForeName>Laurentiu M</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Laine</LastName>
            <ForeName>Aaron</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iyengar</LastName>
            <ForeName>Puneeth</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vitetta</LastName>
            <ForeName>Ellen S</ForeName>
            <Initials>ES</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390; Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390 raquibul.hannan@utsouthwestern.edu ellen.vitetta@utsouthwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hannan</LastName>
            <ForeName>Raquibul</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390; raquibul.hannan@utsouthwestern.edu ellen.vitetta@utsouthwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>HHSN272201300006C</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>09</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D039481">CD11b Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018925">Chemokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>143011-72-7</RegistryNumber>
          <NameOfSubstance UI="D016179">Granulocyte Colony-Stimulating Factor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D039481" MajorTopicYN="N">CD11b Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016179" MajorTopicYN="N">Granulocyte Colony-Stimulating Factor</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007274" MajorTopicYN="N">Injections, Intraperitoneal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011836" MajorTopicYN="N">Radiation Tolerance</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">G-CSF</Keyword>
        <Keyword MajorTopicYN="N">radiation therapy</Keyword>
        <Keyword MajorTopicYN="N">tumor-associated neutrophils</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27651484</ArticleId>
        <ArticleId IdType="pmc">PMC5056034</ArticleId>
        <ArticleId IdType="doi">10.1073/pnas.1613187113</ArticleId>
        <ArticleId IdType="pii">1613187113</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Timmerman R, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070&#x2013;1076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2907644</ArticleId>
            <ArticleId IdType="pubmed">20233825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325&#x2013;1332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26270858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res. 1992;58:143&#x2013;175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1532109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houghton AM. The paradox of tumor-associated neutrophils: Fueling tumor growth with cytotoxic substances. Cell Cycle. 2010;9(9):1732&#x2013;1737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20404546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccard H, Muschel RJ, Opdenakker G. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol. 2012;82(3):296&#x2013;309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21798756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol. 2013;35(2):163&#x2013;176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23007469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fridlender ZG, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: &#x201c;N1&#x201d; versus &#x201c;N2&#x201d; TAN. Cancer Cell. 2009;16(3):183&#x2013;194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2754404</ArticleId>
            <ArticleId IdType="pubmed">19732719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest. 2010;120(4):1151&#x2013;1164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2846036</ArticleId>
            <ArticleId IdType="pubmed">20237412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eruslanov EB, et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest. 2014;124(12):5466&#x2013;5480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4348966</ArticleId>
            <ArticleId IdType="pubmed">25384214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8(4):279&#x2013;289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2763408</ArticleId>
            <ArticleId IdType="pubmed">18340345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159&#x2013;175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23435331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lorimore SA, Coates PJ, Scobie GE, Milne G, Wright EG. Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects? Oncogene. 2001;20(48):7085&#x2013;7095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11704832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakayama E, Shiratsuchi Y, Kobayashi Y, Nagata K. The importance of infiltrating neutrophils in SDF-1 production leading to regeneration of the thymus after whole-body X-irradiation. Cell Immunol. 2011;268(1):24&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21320703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fran&#xe7;ois A, Milliat F, Guipaud O, Benderitter M. Inflammation and immunity in radiation damage to the gut mucosa. BioMed Res Int. 2013;2013:123241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3614034</ArticleId>
            <ArticleId IdType="pubmed">23586015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140(6):798&#x2013;804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20303871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huebener P, et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest. 2015;125(2):539&#x2013;550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4319429</ArticleId>
            <ArticleId IdType="pubmed">25562324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadik CD, Kim ND, Luster AD. Neutrophils cascading their way to inflammation. Trends Immunol. 2011;32(10):452&#x2013;460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3470857</ArticleId>
            <ArticleId IdType="pubmed">21839682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sumida K, et al. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol. 2012;42(8):2060&#x2013;2072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22653638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol. 2008;83(1):64&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17884993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sim S, et al. NADPH oxidase-derived reactive oxygen species-mediated activation of ERK1/2 is required for apoptosis of human neutrophils induced by Entamoeba histolytica. J Immunol. 2005;174(7):4279&#x2013;4288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15778391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauernfeind F, et al. Cutting edge: Reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol. 2011;187(2):613&#x2013;617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3131480</ArticleId>
            <ArticleId IdType="pubmed">21677136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roots R, Okada S. Estimation of life times and diffusion distances of radicals involved in x-ray-induced DNA strand breaks of killing of mammalian cells. Radiat Res. 1975;64(2):306&#x2013;320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1197641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikkelsen RB, Wardman P. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene. 2003;22(37):5734&#x2013;5754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12947383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoue Y, et al. NLRP3 regulates neutrophil functions and contributes to hepatic ischemia-reperfusion injury independently of inflammasomes. J Immunol. 2014;192(9):4342&#x2013;4351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24696236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothe G, Oser A, Valet G. Dihydrorhodamine 123: A new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes. Naturwissenschaften. 1988;75(7):354&#x2013;355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3211206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lugade AA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516&#x2013;7523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15944250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaue D, et al. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res. 2008;14(15):4883&#x2013;4890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2748652</ArticleId>
            <ArticleId IdType="pubmed">18676762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood. 2009;114(3):589&#x2013;595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2713472</ArticleId>
            <ArticleId IdType="pubmed">19349616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeshima T, et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: Its potentiation by combination with Th1 cell therapy. Cancer Res. 2010;70(7):2697&#x2013;2706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20215523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apetoh L, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17979839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marabelle A, Filatenkov A, Sagiv-Barfi I, Kohrt H. Radiotherapy and toll-like receptor agonists. Semin Radiat Oncol. 2015;25(1):34&#x2013;39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25481264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jablonska J, Wu CF, Andzinski L, Leschner S, Weiss S. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-&#x3b2;. Int J Cancer. 2014;134(6):1346&#x2013;1358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24154944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andzinski L, et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. 2016;138(8):1982&#x2013;1993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26619320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishalian I, et al. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother. 2013;62(11):1745&#x2013;1756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24092389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>H&#xe5;kansson L, et al. Effects of in vivo administration of G-CSF on neutrophil and eosinophil adhesion. Br J Haematol. 1997;98(3):603&#x2013;611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9332315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demers M, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA. 2012;109(32):13076&#x2013;13081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3420209</ArticleId>
            <ArticleId IdType="pubmed">22826226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>L&#xf6;wenberg B, et al. Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8):743&#x2013;752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12930926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bottoni U, et al. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Jpn J Clin Oncol. 2005;35(9):507&#x2013;513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16120623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Staar S, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50(5):1161&#x2013;1171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11483325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voloshin T, et al. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: Prevention by a CXCR4 antagonist. Blood. 2011;118(12):3426&#x2013;3435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3179406</ArticleId>
            <ArticleId IdType="pubmed">21685373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheikh H, et al. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung Cancer. 2011;74(1):75&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21353720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki T, et al. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol. 2006;18(1):1&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16352631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA. 2009;106(16):6742&#x2013;6747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2665197</ArticleId>
            <ArticleId IdType="pubmed">19346489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JS, et al. Administration of granulocyte colony-stimulating factor with radiotherapy promotes tumor growth by stimulating vascularization in tumor-bearing mice. Oncol Rep. 2015;34(1):147&#x2013;154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25976379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belletti B, et al. Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res. 2008;14(5):1325&#x2013;1332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18316551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannan R, et al. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer Immunol Immunother. 2012;61(12):2227&#x2013;2238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22644735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfaro C, et al. Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes. PLoS One. 2011;6(12):e29300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3243708</ArticleId>
            <ArticleId IdType="pubmed">22206007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singhal S, et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell. 2016;30(1):120&#x2013;135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4945447</ArticleId>
            <ArticleId IdType="pubmed">27374224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim K, et al. Neutrophil trails guide influenza-specific CD8&#x207a; T cells in the airways. Science. 2015;349(6252):aaa4352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4809646</ArticleId>
            <ArticleId IdType="pubmed">26339033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pidikiti R, et al. Dosimetric characterization of an image-guided stereotactic small animal irradiator. Phys Med Biol. 2011;56(8):2585&#x2013;2599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21444969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shehan DC, Hrapchak BB. Theory and Practice of Histotechnology. 2nd Ed Battelle Press; Columbus, OH: 1980.</Citation>
        </Reference>
        <Reference>
          <Citation>Woods AE, Ellis RC. Laboratory Histopathology, A Complete Reference. Churchill Livingstone; London: 1996.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27349166</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>07</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>380</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Sep</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/Î²-catenin pathway.</ArticleTitle>
        <Pagination>
          <StartPage>134</StartPage>
          <EndPage>143</EndPage>
          <MedlinePgn>134-43</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2016.06.020</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(16)30380-9</ELocationID>
        <Abstract>
          <AbstractText>Combretastatin A-1 phosphate (CA1P) is a microtubule polymerization inhibitor that binds to the colchicine-binding site of tubulin. We demonstrated that CA1P has outstanding anti-cancer activity against hepatocellular carcinoma (HCC) in vitro and in vivo. As determined by fluorescence staining and western blots (WBs), CA1P induced reactive oxygen species (ROS) accumulation and apoptosis in HepG2 cells with a down-regulation of Mcl-1. Additional studies indicated that CA1P induced microtubule depolymerization-mediated AKT inactivation, which resulted in GSK-3Î² activation, Wnt/Î²-Catenin pathway inhibition, and Mcl-1 down-regulation. The induction of HepG2 cell apoptosis by CA1P was prevented by a GSK-3Î²-specific inhibitor. Furthermore, immunohistochemistry studies on hepatocellular carcinoma mouse models showed that CA1P had activity against tumor-associated macrophages (TAMs). CA1P induced TAM apoptosis in vitro through the same mechanism observed with HepG2 cells, and it eliminated TAMs in the tumor microenvironment (TME) in vivo. In TME, the expression of TGF-Î² and TNF-Î± was also altered. The adoptive transfer of macrophages partly rescued the growth of tumor inhibited by CA1P. These findings indicate that CA1P has great potential to impact both cancer cells and the microenvironment, and our results should accelerate the application of CA1P for HCC therapy in clinic.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Duowei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhuo</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xianjing</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duan</LastName>
            <ForeName>Jingjing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Hongbao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>You</LastName>
            <ForeName>Linjun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bian</LastName>
            <ForeName>Jinsong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhen</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China. Electronic address: cz@cpu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China. Electronic address: yy@cpu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>06</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C579095">MCL1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050257">Tubulin Modulators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2222ATS339</RegistryNumber>
          <NameOfSubstance UI="C063690">combretastatin A-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C000605506">GSK3B protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064549" MajorTopicYN="N">Myeloid Cell Leukemia Sequence 1 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013267" MajorTopicYN="N">Stilbenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050257" MajorTopicYN="N">Tubulin Modulators</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Combretastatin A-1 phosphate</Keyword>
        <Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
        <Keyword MajorTopicYN="N">Tumor-associated macrophage</Keyword>
        <Keyword MajorTopicYN="N">Wnt/&#x3b2;-catenin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27349166</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2016.06.020</ArticleId>
        <ArticleId IdType="pii">S0304-3835(16)30380-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27253488</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>01</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-0023</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>84</Volume>
            <PubDate>
              <Year>2016</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cytokine</Title>
          <ISOAbbreviation>Cytokine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis.</ArticleTitle>
        <Pagination>
          <StartPage>74</StartPage>
          <EndPage>87</EndPage>
          <MedlinePgn>74-87</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cyto.2016.05.014</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1043-4666(16)30098-9</ELocationID>
        <Abstract>
          <AbstractText>Butyrate is a histone deacetylase inhibitor implicated in many studies as a potential therapy for various forms of cancer. High concentrations of butyrate (&gt;1.5mM) have been shown to activate apoptosis in several cancer cell lines including prostate, breast, and leukemia. Butyrate is also known to influence multiple signaling pathways that are mediators of cytokine production. The purpose of this study was to evaluate the impact of high concentrations of butyrate on the cancer microenvironment vis-Ã -vis apoptosis, cellular migration, and capacity to modulate cytokine expression in cancer cells. The results indicate that high concentrations of butyrate induced a 2-fold activation of caspase-3 and reduced cell viability by 60% in U937 leukemia cells. Within 24h, butyrate significantly decreased the levels of chemokines CCL2 and CCL5 in HL-60 and U937 cells, and decreased CCL5 in THP-1 leukemia cells. Differential effects were observed in treatments with valproic acid for CCL2 and CCL5 indicating butyrate-specificity. Many of the biological effects examined in this study are linked to activation of the AKT and MAPK signaling pathways; therefore, we investigated whether butyrate alters the levels of phosphorylated forms of these signaling proteins and how it correlated with the expression of chemokines. The results show that butyrate may partially regulate CCL5 production via p38 MAPK. The decrease in p-ERK1/2 and p-AKT levels correlated with the decrease in CCL2 production. These data suggest that while promoting apoptosis, butyrate has the potential to influence the cancer microenvironment by inducing differential expression of cytokines.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pulliam</LastName>
            <ForeName>Stephanie R</ForeName>
            <Initials>SR</Initials>
            <AffiliationInfo>
              <Affiliation>School of Graduate Studies and Research, Meharry Medical College, 1005 Dr. DB Todd, Jr. Blvd., Nashville, TN 37208, USA; Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, 1005 Dr. DB Todd, Jr. Blvd., Nashville, TN 37208, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pellom</LastName>
            <ForeName>Samuel T</ForeName>
            <Initials>ST</Initials>
            <Suffix>Jr</Suffix>
            <AffiliationInfo>
              <Affiliation>School of Graduate Studies and Research, Meharry Medical College, 1005 Dr. DB Todd, Jr. Blvd., Nashville, TN 37208, USA; Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, 1005 Dr. DB Todd, Jr. Blvd., Nashville, TN 37208, USA; Department of Microbiology and Immunology, School of Medicine, Meharry Medical College, 1005 Dr. DB Todd, Jr. Blvd., Nashville, TN 37208, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shanker</LastName>
            <ForeName>Anil</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>School of Graduate Studies and Research, Meharry Medical College, 1005 Dr. DB Todd, Jr. Blvd., Nashville, TN 37208, USA; Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, 1005 Dr. DB Todd, Jr. Blvd., Nashville, TN 37208, USA; Host-Tumor Interactions Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adunyah</LastName>
            <ForeName>Samuel E</ForeName>
            <Initials>SE</Initials>
            <AffiliationInfo>
              <Affiliation>School of Graduate Studies and Research, Meharry Medical College, 1005 Dr. DB Todd, Jr. Blvd., Nashville, TN 37208, USA; Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, 1005 Dr. DB Todd, Jr. Blvd., Nashville, TN 37208, USA. Electronic address: sadunyah@mmc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>T32 HL007737</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 TR000445</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>G12 MD007586</GrantID>
            <Acronym>MD</Acronym>
            <Agency>NIMHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>SC1 CA182843</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA175370</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>S06 GM008037</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50 CA090949</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 MD007593</GrantID>
            <Acronym>MD</Acronym>
            <Agency>NIMHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R25 GM059994</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 HL007735</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 RR026140</GrantID>
            <Acronym>RR</Acronym>
            <Agency>NCRR NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 CA163069</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 CA091408</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>05</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cytokine</MedlineTA>
        <NlmUniqueID>9005353</NlmUniqueID>
        <ISSNLinking>1043-4666</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002087">Butyrates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018946">Chemokine CCL5</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018925">Chemokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>614OI1Z5WI</RegistryNumber>
          <NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002087" MajorTopicYN="N">Butyrates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018946" MajorTopicYN="N">Chemokine CCL5</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018922" MajorTopicYN="N">HL-60 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007938" MajorTopicYN="N">Leukemia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020298" MajorTopicYN="N">U937 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acute myeloid leukemia</Keyword>
        <Keyword MajorTopicYN="N">Butyrate</Keyword>
        <Keyword MajorTopicYN="N">Cytokines</Keyword>
        <Keyword MajorTopicYN="N">Inflammation</Keyword>
        <Keyword MajorTopicYN="N">Migration</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27253488</ArticleId>
        <ArticleId IdType="mid">NIHMS793084</ArticleId>
        <ArticleId IdType="pmc">PMC4943848</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cyto.2016.05.014</ArticleId>
        <ArticleId IdType="pii">S1043-4666(16)30098-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem. 2002;277:29355&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12072446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liongue C, O'Sullivan LA, Trengove MC, Ward AC. Evolution of JAK-STAT Pathway Components: Mechanisms and Role in Immune System Development. PLoS One. 2012;7:e32777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3296744</ArticleId>
            <ArticleId IdType="pubmed">22412924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul WE. Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. Cell. 1989;57:521&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2497989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chai EZ, Siveen KS, Shanmugam MK, Arfuso F, Sethi G. Analysis of the intricate relationship between chronic inflammation and cancer. Biochem J. 2015;468:1&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25940732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, et al. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget. 2015;6:1359&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4359300</ArticleId>
            <ArticleId IdType="pubmed">25682197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chow MT, Luster AD. Chemokines in cancer. Cancer immunology research. 2014;2:1125&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4258879</ArticleId>
            <ArticleId IdType="pubmed">25480554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pulliam SR, Uzhachenko RV, Adunyah SE, Shanker A. Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunology letters. 2016;169:61&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4710466</ArticleId>
            <ArticleId IdType="pubmed">26597610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummings JH. Short chain fatty acids in the human colon. Gut. 1981;22:763&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1419865</ArticleId>
            <ArticleId IdType="pubmed">7028579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. 1980;21:793&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1419533</ArticleId>
            <ArticleId IdType="pubmed">7429343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boffa LC, Vidali G, Mann RS, Allfrey VG. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem. 1978;253:3364&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">649576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davie JR. Inhibition of histone deacetylase activity by butyrate. The Journal of nutrition. 2003;133:2485S&#x2013;93S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12840228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu J, Gao Z, Shima H. Growth of human prostate cancer cells is significantly suppressed in vitro with sodium butyrate through apoptosis. Oncol Rep. 2012;27:160&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21947091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal M, Kumar R. Bcl-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells. Cell growth &amp; differentiation : the molecular biology journal of the American Association for Cancer Research. 1996;7:311&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8838861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajak B, Orzechowski A, Gajkowska B. Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells. Advances in medical sciences. 2007;52:83&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18217395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17:1519&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3070119</ArticleId>
            <ArticleId IdType="pubmed">21472114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi YH. Apoptosis of U937 human leukemic cells by sodium butyrate is associated with inhibition of telomerase activity. International journal of oncology. 2006;29:1207&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17016653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calabresse C, Venturini L, Ronco G, Villa P, Chomienne C, Belpomme D. Butyric acid and its monosaccharide ester induce apoptosis in the HL-60 cell line. Biochemical and biophysical research communications. 1993;195:31&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8363611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, et al. The p21(Cip1) and p27(Kip1) CDK &#x2018;inhibitors&#x2019; are essential activators of cyclin D-dependent kinases in murine fibroblasts. The EMBO journal. 1999;18:1571&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1171245</ArticleId>
            <ArticleId IdType="pubmed">10075928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosato RR, Almenara JA, Cartee L, Betts V, Chellappan SP, Grant S. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol Cancer Ther. 2002;1:253&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12467221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai Y, Rahmani M, Grant S. An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells. Cell Cycle. 2003;2:467&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12963846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem. 1997;272:22199&#x2013;206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9268365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene. 2004;23:6304&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15318170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han S, Lu J, Zhang Y, Cheng C, Li L, Han L, et al. HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region. Immunology letters. 2007;108:143&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17270283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen KA, Cao Y, Chen JR, Townsend CM, Jr, Ko TC. Dietary fiber enhances a tumor suppressor signaling pathway in the gut. Annals of surgery. 2006;243:619&#x2013;25. discussion 25-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1570539</ArticleId>
            <ArticleId IdType="pubmed">16632996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampson JJ, 3rd, Donkor IO, Huang TL, Adunyah SE. Novel piperazine induces apoptosis in U937 cells. Int J Biochem Mol Biol. 2011;2:78&#x2013;88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3180031</ArticleId>
            <ArticleId IdType="pubmed">21968418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apoptosis: Applied Reagents and Technologies. San Diego: PharMingen; 1998.</Citation>
        </Reference>
        <Reference>
          <Citation>Koumangoye RB, Sakwe AM, Goodwin JS, Patel T, Ochieng J. Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading. PloS one. 2011;6:e24234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3167827</ArticleId>
            <ArticleId IdType="pubmed">21915303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernhard D, Ausserlechner MJ, Tonko M, Loffler M, Hartmann BL, Csordas A, et al. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 1999;13:1991&#x2013;2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10544182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris P, Ralph P. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. Journal of leukocyte biology. 1985;37:407&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3855947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birnie GD. The HL60 cell line: a model system for studying human myeloid cell differentiation. The British journal of cancer Supplement. 1988;9:41&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2149104</ArticleId>
            <ArticleId IdType="pubmed">3076064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin Z. The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature. Atherosclerosis. 2012;221:2&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21978918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schildberger A, Rossmanith E, Eichhorn T, Strassl K, Weber V. Monocytes, peripheral blood mononuclear cells, and THP-1 cells exhibit different cytokine expression patterns following stimulation with lipopolysaccharide. Mediators of inflammation. 2013;2013:697972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3681313</ArticleId>
            <ArticleId IdType="pubmed">23818743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaddi K, Newton RC. Comparison of biological responses of human monocytes and THP-1 cells to chemokines of the intercrine-beta family. Journal of leukocyte biology. 1994;55:756&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7515094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altieri DC, Edgington TS. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem. 1988;263:7007&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2835359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res. 2002;26:495&#x2013;502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11916526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. The EMBO journal. 2001;20:6969&#x2013;78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC125788</ArticleId>
            <ArticleId IdType="pubmed">11742974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer treatment reviews. 2008;34:206&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18226465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van de Loosdrecht AA, Ossenkoppele GJ, Beelen RH, Broekhoven MG, Langenhuijsen MM. Cell cycle specific effects of tumor necrosis factor alpha in monocyte mediated leukemic cell death and the role of beta 2-integrins. Cancer Res. 1993;53:4399&#x2013;407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7689934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22:238&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20171075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borsig L, Wolf MJ, Roblek M, Lorentzen A, Heikenwalder M. Inflammatory chemokines and metastasis--tracing the accessory. Oncogene. 2014;33:3217&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23851506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004;23:2838&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15077147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geest CR, Coffer PJ. MAPK signaling pathways in the regulation of hematopoiesis. Journal of leukocyte biology. 2009;86:237&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19498045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang P, Han J, Hui L. MAPK signaling in inflammation-associated cancer development. Protein &amp; cell. 2010;1:218&#x2013;26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4875080</ArticleId>
            <ArticleId IdType="pubmed">21203968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fransecky L, Mochmann LH, Baldus CD. Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Molecular and cellular therapies. 2015;3:2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4452048</ArticleId>
            <ArticleId IdType="pubmed">26056603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramakrishnan V, Pace BS. Regulation of gamma-globin gene expression involves signaling through the p38 MAPK/CREB1 pathway. Blood cells, molecules &amp; diseases. 2011;47:12&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3695476</ArticleId>
            <ArticleId IdType="pubmed">21497119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung JW, Cho SD, Ahn NS, Yang SR, Park JS, Jo EH, et al. Augmentation of sodium butyrate-induced apoptosis by p38 MAP kinase inhibition in rat liver epithelial cells. Antioxid Redox Signal. 2005;7:1767&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16356138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho SD, Ahn NS, Jung JW, Yang SR, Park JS, Lee YS, et al. Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation. 2006;15:57&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16374231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang XZ, Li ZR, Zhu LB, Huang HY, Hou LL, Lin J. Inhibition of p38 mitogen-activated protein kinase attenuates butyrate-induced intestinal barrier impairment in a Caco-2 cell monolayer model. Journal of pediatric gastroenterology and nutrition. 2014;59:264&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24625969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe K. Butyric acid induces apoptosis in both human monocytes and lymphocytes equivalently. J Oral Sci. 2012;54:7&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22466881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalousek I, Brodska B, Otevrelova P, Roselova P. BimEL-dependent apoptosis induced in peripheral blood lymphocytes with n-butyric acid is moderated by variation in expression of c-myc and p21(WAF1) Cell biochemistry and function. 2008;26:509&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18348176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res. 1998;4:629&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9533530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. Journal of leukocyte biology. 2011;89:31&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20628066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004;25:75&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15102366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4994190</ArticleId>
            <ArticleId IdType="pubmed">20371344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HW, Choi HJ, Ha SJ, Lee KT, Kwon YG. Recruitment of monocytes/macrophages in different tumor microenvironments. Biochimica et biophysica acta. 2013;1835:170&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23287570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. The Journal of clinical investigation. 1995;95:2391&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC295866</ArticleId>
            <ArticleId IdType="pubmed">7738202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000;6:3282&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10955814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SR, Burdick MD, et al. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer immunology, immunotherapy : CII. 2000;49:63&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10823415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Svensson S, Abrahamsson A, Vazquez Rodriguez G, Olsson AK, Jensen L, Cao Y, et al. CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25901081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators of inflammation. 2014;2014:292376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3910068</ArticleId>
            <ArticleId IdType="pubmed">24523569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue G, Zippelius A, Wicki A, Mandala M, Tang F, Massi D, et al. Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. Journal of the National Cancer Institute. 2015;107</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26071042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai Z, Zhang Z, Ye Y, Wang S. Sodium butyrate induces differentiation of gastric cancer cells to intestinal cells via the PTEN/phosphoinositide 3-kinase pathway. Cell biology international. 2010;34:1141&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20718712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Zhou Y, Jackson LN, Johnson SM, Chow CW, Evers BM. Nuclear factor of activated T cells (NFAT) signaling regulates PTEN expression and intestinal cell differentiation. Molecular biology of the cell. 2011;22:412&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3031470</ArticleId>
            <ArticleId IdType="pubmed">21148296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu TC, Lin PM, Chang JG, Lee JP, Chen TP, Lin SF. Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. American journal of hematology. 2000;63:170&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10706759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer cell. 2009;15:195&#x2013;206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19249678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahmani M, Yu C, Reese E, Ahmed W, Hirsch K, Dent P, et al. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene. 2003;22:6231&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13679862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diakos C, Prieschl EE, Saemann MD, Bohmig GA, Csonga R, Sobanov Y, et al. n-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine transcription in mast cells. Biochemical and biophysical research communications. 2006;349:863&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16949031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivero JA, Adunyah SE. Sodium butyrate induces tyrosine phosphorylation and activation of MAP kinase (ERK-1) in human K562 cells. Biochemical and biophysical research communications. 1996;224:796&#x2013;801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8713125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood. 2000;95:2391&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10733512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung JW, Cho SD, Ahn NS, Yang SR, Park JS, Jo EH, et al. Ras/MAP kinase pathways are involved in Ras specific apoptosis induced by sodium butyrate. Cancer letters. 2005;225:199&#x2013;206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15978324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott DW, Longpre JM, Loo G. Upregulation of GADD153 by butyrate: involvement of MAPK. DNA and cell biology. 2008;27:607&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18767967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurita-Ochiai T, Amano S, Fukushima K, Ochiai K. Cellular events involved in butyric acid-induced T cell apoptosis. J Immunol. 2003;171:3576&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14500654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Zhou L, Bao YL, Wu Y, Yu CL, Huang YX, et al. Butyrate induces cell apoptosis through activation of JNK MAP kinase pathway in human colon cancer RKO cells. Chemico-biological interactions. 2010;185:174&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20346929</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27241844</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2326-6074</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer immunology research</Title>
          <ISOAbbreviation>Cancer Immunol Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>688</StartPage>
          <EndPage>697</EndPage>
          <MedlinePgn>688-97</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/2326-6066.CIR-15-0203</ELocationID>
        <Abstract>
          <AbstractText>The development of targeted therapies that affect multiple signaling pathways and stimulate antitumor immunity is greatly needed. About 20% of patients with breast cancer overexpress HER2. Small molecules and antibodies targeting HER2 convey some survival benefits; however, patients with advanced disease succumb to the disease under these treatment regimens, possibly because HER2 is not completely necessary for the survival of the targeted cancer cells. In the present study, we show that a polyinosine/polycytosine (pIC) HER2-homing chemical vector induced the demise of HER2-overexpressing breast cancer cells, including trastuzumab-resistant cells. Targeting pIC to the tumor evoked a number of cell-killing mechanisms, as well as strong bystander effects. These bystander mechanisms included type I IFN induction, immune cell recruitment, and activation. The HER2-targeted pIC strongly inhibited the growth of HER2-overexpressing tumors in immunocompetent mice. The data presented here could open additional avenues in the treatment of HER2-positive breast cancer. Cancer Immunol Res; 4(8); 688-97. Â©2016 AACR.</AbstractText>
          <CopyrightInformation>&#xa9;2016 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zigler</LastName>
            <ForeName>Maya</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shir</LastName>
            <ForeName>Alexei</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joubran</LastName>
            <ForeName>Salim</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sagalov</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klein</LastName>
            <ForeName>Shoshana</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Edinger</LastName>
            <ForeName>Nufar</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lau</LastName>
            <ForeName>Jeffrey</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Oncology Department, Genentech Inc., South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Shang-Fan</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>Translational Oncology Department, Genentech Inc., South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mizraji</LastName>
            <ForeName>Gabriel</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Dental Sciences, Faculty of Dental Medicine, Hebrew University, Jerusalem, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Globerson Levin</LastName>
            <ForeName>Anat</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovoth, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sliwkowski</LastName>
            <ForeName>Mark X</ForeName>
            <Initials>MX</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Oncology Department, Genentech, Inc. South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Levitzki</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel. alex.levitzki@mail.huji.ac.il.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>05</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Immunol Res</MedlineTA>
        <NlmUniqueID>101614637</NlmUniqueID>
        <ISSNLinking>2326-6066</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O84C90HH2L</RegistryNumber>
          <NameOfSubstance UI="D011070">Poly I-C</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011070" MajorTopicYN="N">Poly I-C</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27241844</ArticleId>
        <ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0203</ArticleId>
        <ArticleId IdType="pii">2326-6066.CIR-15-0203</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27235608</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>07</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2017</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>379</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Aug</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.</ArticleTitle>
        <Pagination>
          <StartPage>32</StartPage>
          <EndPage>38</EndPage>
          <MedlinePgn>32-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2016.05.025</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(16)30338-X</ELocationID>
        <Abstract>
          <AbstractText>Therapeutic anticancer vaccine development must address a number of barriers to achieve successful tumor specific killing, including effective antigen presentation and antigen-specific T-cell activation to mediate cytotoxic cellular effects, inhibition of an immune-suppressive tumor microenvironment in order to facilitate and enhance CTL activity, and induction of memory T-cells to prolong tumor rejection. While traditional as well as modern vaccines rely upon delivery of both antigen and adjuvant, a variety of clinically relevant cancers lack ideal immunogenic antigens. Building upon recent efforts, we instead chose to exploit chemotherapy-induced apoptosis to allow for in situ antigen generation in a combination, nanomedicine-based approach. Specifically, lipid-coated cisplatin nanoparticles (LPC) and CpG-encapsulated liposomes (CpG-Lipo) were prepared for the temporally-controlled and multifaceted treatment of an advanced in vivo model of melanoma. Such combination therapy established strong synergistic effects, both in apoptotic extent and subsequent abrogation of tumor growth, which were due largely to both an enhanced cytotoxic T-cell recruitment and a reduction of immune-suppressive mediators in the microenvironments of both spleens and tumor. These results underlie a prolonged host lifespan in the combination approach (45 days) as compared with control (25 days, p &lt; 0.02), providing promise toward a personalized approach to nanomedicine by establishing effect synergy in host-specific immunotherapy following chemotherapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2016. Published by Elsevier Ireland Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Yao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Nanotechnology in Drug Delivery, Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; School of Pharmacy, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yuhua</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Nanotechnology in Drug Delivery, Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miao</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Nanotechnology in Drug Delivery, Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haynes</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Nanotechnology in Drug Delivery, Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiang</LastName>
            <ForeName>Guangya</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Electronic address: gyxiang1968@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Leaf</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>The Center for Nanotechnology in Drug Delivery, Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: leafh@unc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>05</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018899" MajorTopicYN="Y">CpG Islands</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050997" MajorTopicYN="N">Nanomedicine</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Chemotherapy</Keyword>
        <Keyword MajorTopicYN="N">Cisplatin nanoparticle</Keyword>
        <Keyword MajorTopicYN="N">CpG-ODN</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">Melanoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27235608</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2016.05.025</ArticleId>
        <ArticleId IdType="pii">S0304-3835(16)30338-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27070705</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>09</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>11</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1878-3686</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Apr</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer cell</Title>
          <ISOAbbreviation>Cancer Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients.</ArticleTitle>
        <Pagination>
          <StartPage>587</StartPage>
          <EndPage>601</EndPage>
          <MedlinePgn>587-601</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ccell.2016.03.005</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1535-6108(16)30087-3</ELocationID>
        <Abstract>
          <AbstractText>The immune response influences the clinical course of colorectal cancer (CRC). Analyzing the invasive margin of human CRC liver metastases, we identified a mechanism of immune cell exploitation by tumor cells. While two distinct subsets of myeloid cells induce an influx of T cells into the invasive margin via CXCL9/CXCL10, CCL5 is produced by these T cells and stimulates pro-tumoral effects via CCR5. CCR5 blockade in patient-derived functional in vitro organotypic culture models showed a macrophage repolarization with anti-tumoral effects. These anti-tumoral effects were then confirmed in a phase I trial with a CCR5 antagonist in patients with liver metastases of advanced refractory CRC. Mitigation of tumor-promoting inflammation within the tumor tissue and objective tumor responses in CRC were observed.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Halama</LastName>
            <ForeName>Niels</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg, 69120 Heidelberg, Germany; Institute for Immunology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Electronic address: niels.halama@nct-heidelberg.de.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zoernig</LastName>
            <ForeName>Inka</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Berthel</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kahlert</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany; Department of Surgery, University Hospital Dresden, 01307 Dresden, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klupp</LastName>
            <ForeName>Fee</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suarez-Carmona</LastName>
            <ForeName>Meggy</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suetterlin</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brand</LastName>
            <ForeName>Karsten</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Krauss</LastName>
            <ForeName>Juergen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lasitschka</LastName>
            <ForeName>Felix</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lerchl</LastName>
            <ForeName>Tina</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luckner-Minden</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ulrich</LastName>
            <ForeName>Alexis</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koch</LastName>
            <ForeName>Moritz</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University Hospital Dresden, 01307 Dresden, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weitz</LastName>
            <ForeName>Juergen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University Hospital Dresden, 01307 Dresden, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schneider</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buechler</LastName>
            <ForeName>Markus W</ForeName>
            <Initials>MW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zitvogel</LastName>
            <ForeName>Laurence</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM U1015, Institut Gustave Roussy (IGR), 94805 Villejuif, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herrmann</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine I, Klinikum Idar-Oberstein, 55743 Idar Oberstein, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Benner</LastName>
            <ForeName>Axel</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kunz</LastName>
            <ForeName>Christina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luecke</LastName>
            <ForeName>Stephan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Springfeld</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grabe</LastName>
            <ForeName>Niels</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Falk</LastName>
            <ForeName>Christine S</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Transplant Immunology, Integrated Research and Treatment Center Transplantation, Hannover Medical School, 30625 Hannover, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jaeger</LastName>
            <ForeName>Dirk</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany; Tissue Imaging and Analysis Center, National Center for Tumor Diseases, BIOQUANT, University of Heidelberg, 69120 Heidelberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Cell</MedlineTA>
        <NlmUniqueID>101130617</NlmUniqueID>
        <ISSNLinking>1535-6108</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C483024">CCL5 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C584933">CCR5 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018946">Chemokine CCL5</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018925">Chemokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003510">Cyclohexanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019713">Receptors, CCR5</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0813BZ6866</RegistryNumber>
          <NameOfSubstance UI="D004002">Clodronic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>24T2A1DOYB</RegistryNumber>
          <NameOfSubstance UI="C559147">regorafenib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>MD6P741W8A</RegistryNumber>
          <NameOfSubstance UI="D000077592">Maraviroc</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>V55S2QJN2X</RegistryNumber>
          <NameOfSubstance UI="D019331">NG-Nitroarginine Methyl Ester</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Cancer Cell. 2016 Apr 11;29(4):437-9</RefSource>
          <PMID Version="1">27070698</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018946" MajorTopicYN="N">Chemokine CCL5</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002633" MajorTopicYN="N">Chemotaxis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004002" MajorTopicYN="N">Clodronic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003510" MajorTopicYN="N">Cyclohexanes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077592" MajorTopicYN="N">Maraviroc</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019331" MajorTopicYN="N">NG-Nitroarginine Methyl Ester</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019713" MajorTopicYN="N">Receptors, CCR5</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27070705</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ccell.2016.03.005</ArticleId>
        <ArticleId IdType="pii">S1535-6108(16)30087-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26956049</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>01</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1949-2553</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>15</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Apr</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncotarget</Title>
          <ISOAbbreviation>Oncotarget</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFÎºB/IL1Î² signaling network.</ArticleTitle>
        <Pagination>
          <StartPage>20054</StartPage>
          <EndPage>20067</EndPage>
          <MedlinePgn>20054-67</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.7911</ELocationID>
        <Abstract>
          <AbstractText>To better understand how the apoptosis repressor with caspase recruitment domain (ARC) protein confers drug resistance in acute myeloid leukemia (AML), we investigated the role of ARC in regulating leukemia-mesenchymal stromal cell (MSC) interactions. In addition to the previously reported effect on AML apoptosis, we have demonstrated that ARC enhances migration and adhesion of leukemia cells to MSCs both in vitro and in a novel human extramedullary bone/bone marrow mouse model. Mechanistic studies revealed that ARC induces IL1Î² expression in AML cells and increases CCL2, CCL4, and CXCL12 expression in MSCs, both through ARC-mediated activation of NFÎºB. Expression of these chemokines in MSCs increased by AML cells in an ARC/IL1Î²-dependent manner; likewise, IL1Î² expression was elevated when leukemia cells were co-cultured with MSCs. Further, cells from AML patients expressed the receptors for and migrated toward CCL2, CCL4, and CXCL12. Inhibition of IL1Î² suppressed AML cell migration and sensitized the cells co-cultured with MSCs to chemotherapy. Our results suggest the existence of a complex ARC-regulated circuit that maintains intimate connection of AML with the tumor microenvironment through NFÎºB/IL1Î²-regulated chemokine receptor/ligand axes and reciprocal crosstalk resulting in cytoprotection. The data implicate ARC as a promising drug target to potentially sensitize AML cells to chemotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Carter</LastName>
            <ForeName>Bing Z</ForeName>
            <Initials>BZ</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mak</LastName>
            <ForeName>Po Yee</ForeName>
            <Initials>PY</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Ye</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mak</LastName>
            <ForeName>Duncan H</ForeName>
            <Initials>DH</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mu</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacamo</LastName>
            <ForeName>Rodrigo</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruvolo</LastName>
            <ForeName>Vivian</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arold</LastName>
            <ForeName>Stefan T</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>King Abdullah University of Science and Technology (KAUST), Computational Bioscience Research Center, Division of Biological and Environmental Sciences and Engineering, Thuwal, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ladbury</LastName>
            <ForeName>John E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology and Center for Biomolecular Structure and Function, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burks</LastName>
            <ForeName>Jared K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kornblau</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andreeff</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 CA055164</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA016672</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oncotarget</MedlineTA>
        <NlmUniqueID>101532965</NlmUniqueID>
        <ISSNLinking>1949-2553</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508585">IL1B protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C092069">activity regulated cytoskeletal-associated protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015470" MajorTopicYN="N">Leukemia, Myeloid, Acute</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AML</Keyword>
        <Keyword MajorTopicYN="N">ARC</Keyword>
        <Keyword MajorTopicYN="N">NF&#x3ba;B</Keyword>
        <Keyword MajorTopicYN="N">chemoresistance</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICTS OF INTEREST. The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26956049</ArticleId>
        <ArticleId IdType="pmc">PMC4991438</ArticleId>
        <ArticleId IdType="doi">10.18632/oncotarget.7911</ArticleId>
        <ArticleId IdType="pii">7911</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell. 2008;132:598&#x2013;611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4505728</ArticleId>
            <ArticleId IdType="pubmed">18295578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat. 2009;12:103&#x2013;113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3640296</ArticleId>
            <ArticleId IdType="pubmed">19632887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voermans C, van Heese WP, de Jong I, Gerritsen WR, van der Schoot CE. Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia. 2002;16:650&#x2013;657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11960346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Spoo A, Dwenger A, Burger M, Behringer D. CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis) Br J Haematol. 2003;122:579&#x2013;589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12899713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, Shemtov N, Deutsch V, Naparstek E, Nagler A, Lapidot T. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Ca Res. 2004;64:2817&#x2013;2824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15087398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S, Kollet O, Hershkoviz R, Alon R, Hardan I, Ben-Hur H, Naor D, Nagler A, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood. 2004;103:2981&#x2013;2989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15070674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12:1167&#x2013;1174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16998484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007;109:1152&#x2013;1156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17315232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spoo AC, Lubbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109:786&#x2013;791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16888090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalinkovich A, Tavor S, Avigdor A, Kahn J, Brill A, Petit I, Goichberg P, Tesio M, Netzer N, Naparstek E, Hardan I, Nagler A, Resnick I, et al. Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells. Cancer Res. 2006;66:11013&#x2013;11020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17108140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong X, Jiang F, Kalkanis SN, Zhang ZG, Zhang XP, DeCarvalho AC, Katakowski M, Bobbitt K, Mikkelsen T, Chopp M. SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion. Cancer Lett. 2006;236:39&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15967572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, Hail N, Jr, Konopleva M, Andreeff M. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS One. 2013;8:e58426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3590173</ArticleId>
            <ArticleId IdType="pubmed">23484027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng ZH, Shi YX, Samudio IJ, Wang RY, Ling XY, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113:6215&#x2013;6224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699240</ArticleId>
            <ArticleId IdType="pubmed">18955566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119:3917&#x2013;3924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3350358</ArticleId>
            <ArticleId IdType="pubmed">22308295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreeff M, Zeng Z, Kelly MA, Wang R-Y, McQueen TJ, Duvvuri S, Nowshad G, Borthakur G, Burger JA, Kida TM, Jabbour E, Cortes JE, Kantarjian H, et al. Targeting microenvironment-mediated resistance in leukemias: Phase I trial of mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/g-CSF/sorafenib. J Clin Oncol. 2012;30 (suppl; abstr TPS6635)</Citation>
        </Reference>
        <Reference>
          <Citation>Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206&#x2013;6214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699239</ArticleId>
            <ArticleId IdType="pubmed">19050309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591&#x2013;599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4874213</ArticleId>
            <ArticleId IdType="pubmed">21220598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heikaus S, Kempf T, Mahotka C, Gabbert HE, Ramp U. Caspase-8 and its inhibitors in RCCs in vivo: the prominent role of ARC. Apoptosis. 2008;13:938&#x2013;949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18516683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koseki T, Inohara N, Chen S, Nunez G. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc Natl Acad Sci USA. 1998;95:5156&#x2013;5160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC20230</ArticleId>
            <ArticleId IdType="pubmed">9560245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nam YJ, Mani K, Ashton AW, Peng CF, Krishnamurthy B, Hayakawa Y, Lee P, Korsmeyer SJ, Kitsis RN. Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions. Mol Cell. 2004;15:901&#x2013;912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15383280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gustafsson AB, Tsai JG, Logue SE, Crow MT, Gottlieb RA. Apoptosis repressor with caspase recruitment domain protects against cell death by interfering with Bax activation. J Biol Chem. 2004;279:21233&#x2013;21238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15004034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foo RS, Chan LK, Kitsis RN, Bennett MR. Ubiquitination and degradation of the anti-apoptotic protein ARC by MDM2. J Biol Chem. 2007;282:5529&#x2013;5535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17142834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Qanungo S, Crow MT, Watanabe M, Nieminen AL. Apoptosis repressor with caspase recruitment domain (ARC) is expressed in cancer cells and localizes to nuclei. FEBS Lett. 2005;579:2411&#x2013;2415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15848180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mercier I, Vuolo M, Jasmin JF, Medina CM, Williams M, Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP, Kitsis RN. ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle. 2008;7:1640&#x2013;1647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18469522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziegler DS, Wright RD, Kesari S, Lemieux ME, Tran MA, Jain M, Zawel L, Kung AL. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest. 2008;118:3109&#x2013;3122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2491457</ArticleId>
            <ArticleId IdType="pubmed">18677408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mercier I, Vuolo M, Madan R, Xue X, Levalley AJ, Ashton AW, Jasmin JF, Czaja MT, Lin EY, Armstrong RC, Pollard JW, Kitsis RN. ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance. Cell Death Differ. 2005;12:682&#x2013;686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15861191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011;117:780&#x2013;787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3035072</ArticleId>
            <ArticleId IdType="pubmed">21041716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis. 2014;19:698&#x2013;707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3943601</ArticleId>
            <ArticleId IdType="pubmed">24337870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mak PY, Mak DH, Kojima K, Dilip A, Ruvolo VR, Jacamo R, Andreeff M, Carter BZ. ARC suppresses cell death by antagonizing p53 function and suppressing TRAIL in AML cells. ASH. New Orleans. 2013</Citation>
        </Reference>
        <Reference>
          <Citation>Chen Y, Jacamo R, Shi YX, Wang RY, Battula VL, Konoplev S, Strunk D, Hofmann NA, Reinisch A, Konopleva M, Andreeff M. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood. 2012;119:4971&#x2013;4980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367899</ArticleId>
            <ArticleId IdType="pubmed">22490334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damiano JS, Reed JC. CARD proteins as therapeutic targets in cancer. Curr Drug Targets. 2004;5:367&#x2013;374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15134219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang C, Lin X. Regulation of NF-kappaB by the CARD proteins. Immunol Rev. 2012;246:141&#x2013;153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3339759</ArticleId>
            <ArticleId IdType="pubmed">22435552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang TH, Kim SH, Jeong JH, Kim S, Kim YG, Park HH. Crystal structure of caspase recruiting domain (CARD) of apoptosis repressor with CARD (ARC) and its implication in inhibition of apoptosis. Sci Rep. 2015;5:9847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4453921</ArticleId>
            <ArticleId IdType="pubmed">26038885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medina-Ramirez CM, Goswami S, Smirnova T, Bamira D, Benson B, Ferrick N, Segall J, Pollard JW, Kitsis RN. Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance. Cancer Res. 2011;71:7705&#x2013;7715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3245742</ArticleId>
            <ArticleId IdType="pubmed">22037876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamoto E, Tada M, Murakawa K, Takada M, Shindo G, Teramoto K, Matsunaga A, Komuro K, Kanai M, Kawakami A, Fujiwara Y, Kobayashi N, Shirata K, et al. Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. Clin Cancer Res. 2004;10:3629&#x2013;3638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15173069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, Wang Y, Battula VL, Mak PY, Schallmoser K, Ruvolo P, Schober WD, Shpall EJ, et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-kappaB mediates chemoresistance. Blood. 2014;123:2691&#x2013;2702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3999754</ArticleId>
            <ArticleId IdType="pubmed">24599548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6853&#x2013;6866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10602461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Napetschnig J, Wu H. Molecular basis of NF-kappaB signaling. Annu Rev Biophys. 2013;42:443&#x2013;468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3678348</ArticleId>
            <ArticleId IdType="pubmed">23495970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turzanski J, Grundy M, Russell NH, Pallis M. Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia. 2004;18:1662&#x2013;1670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15306822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012;120:1290&#x2013;1298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3418722</ArticleId>
            <ArticleId IdType="pubmed">22723552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Askmyr M, Agerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, Juliusson G, Richter J, Jaras M, Fioretos T. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709&#x2013;3713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23479569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301&#x2013;2307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11588023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchibori R, Tsukahara T, Mizuguchi H, Saga Y, Urabe M, Mizukami H, Kume A, Ozawa K. NF-kappaB Activity regulates mesenchymal stem cell accumulation at tumor sites. Cancer Res. 2013;73:364&#x2013;372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23066037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002;62:3603&#x2013;3608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12097260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Br J Haematol. 2014;167:376&#x2013;384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4357400</ArticleId>
            <ArticleId IdType="pubmed">25079338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carter BZ, Mak DH, Wang Z, Ma W, Mak PY, Andreeff M, Davis RE. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. Leukemia Res. 2013;37:974&#x2013;979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3700666</ArticleId>
            <ArticleId IdType="pubmed">23669290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, Bhatia R. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood. 2013;121:1824&#x2013;1838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3591802</ArticleId>
            <ArticleId IdType="pubmed">23299311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, et al. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015;87:346&#x2013;356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4388314</ArticleId>
            <ArticleId IdType="pubmed">25598437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amir el AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, Shenfeld DK, Krishnaswamy S, Nolan GP, Pe'er D. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol. 2013;31:545&#x2013;552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4076922</ArticleId>
            <ArticleId IdType="pubmed">23685480</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26398122</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>08</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1791-2431</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Oncology reports</Title>
          <ISOAbbreviation>Oncol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>2880</StartPage>
          <EndPage>2888</EndPage>
          <MedlinePgn>2880-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/or.2015.4297</ELocationID>
        <Abstract>
          <AbstractText>The bone marrow microenvironment (BMM) provides a protective niche that supports growth and survival of normal and leukemic hematopoietic stem cells. The SDF-1/CXCR4 interaction is critical for regulation of homing to and retention of hematopoietic cells in the bone marrow (BM), which leads to increased chemoresistance. SDF-1/CXCR4 plays pivotal roles in cross-interactions between blasts and the BMM to prevent retention and mobilization of leukemic cells, as well as in normal hematopoiesis including the development of immune cells. We show that the CXCR4 antagonist, plerixafor, decreased the level of CXCR4 expression and inhibited SDF-1-induced migration of leukemic cells. Further, the inhibition of the interaction between leukemic cells and the BMM by the plerixafor enhanced cytotoxic activity of immune cells as a result of increased susceptibility of leukemic cells to chemotherapeutic agents such as cytosine arabinoside (Ara-C) in a mouse model of acute myeloid leukemia (AML), suggesting biological effects of the BMM through immune cell activation. Because alterations in the BMM promote retention and survival of leukemic cells, targeting the niche is regarded as an advanced strategy to eradicate drug-resistant leukemic blasts. This study demonstrates that the effects of CXCR4 inhibition on blast suppression and immune cell function in the tumor microenvironment and chemotherapy with plerixafor represents an advanced therapeutic strategy of targeting the leukemic niche.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>A-Reum</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Ji Yoon</ForeName>
            <Initials>JY</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Hee-Je</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Min</LastName>
            <ForeName>Woo-Sung</ForeName>
            <Initials>WS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Gyeongsin</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Se-Hoon</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>09</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Oncol Rep</MedlineTA>
        <NlmUniqueID>9422756</NlmUniqueID>
        <ISSNLinking>1021-335X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001596">Benzylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515255">CXCL12 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000080027">Cyclams</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006571">Heterocyclic Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>04079A1RDZ</RegistryNumber>
          <NameOfSubstance UI="D003561">Cytarabine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S915P5499N</RegistryNumber>
          <NameOfSubstance UI="C088327">plerixafor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001596" MajorTopicYN="N">Benzylamines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080027" MajorTopicYN="N">Cyclams</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003561" MajorTopicYN="N">Cytarabine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006412" MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006571" MajorTopicYN="N">Heterocyclic Compounds</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015470" MajorTopicYN="N">Leukemia, Myeloid, Acute</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009374" MajorTopicYN="N">Neoplasms, Experimental</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019718" MajorTopicYN="N">Receptors, CXCR4</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26398122</ArticleId>
        <ArticleId IdType="doi">10.3892/or.2015.4297</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26152356</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1476-5586</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neoplasia (New York, N.Y.)</Title>
          <ISOAbbreviation>Neoplasia</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Smac Mimetic-Induced Upregulation of CCL2/MCP-1 Triggers Migration and Invasion of Glioblastoma Cells and Influences the Tumor Microenvironment in a Paracrine Manner.</ArticleTitle>
        <Pagination>
          <StartPage>481</StartPage>
          <EndPage>489</EndPage>
          <MedlinePgn>481-9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neo.2015.05.002</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1476-5586(15)00068-8</ELocationID>
        <Abstract>
          <AbstractText>Second mitochondria-derived activator of caspase (Smac) mimetics are considered as promising anticancer therapeutics that are currently under investigation in early clinical trials. They induce apoptosis by antagonizing inhibitor of apoptosis proteins, which are frequently overexpressed in cancer. We previously reported that Smac mimetics, such as BV6, additionally exert non-apoptotic functions in glioblastoma (GBM) cells by stimulating migration and invasion in a nuclear factor kappa B (NF-ÎºB)-dependent manner. Because NF-ÎºB target genes mediating these effects are largely unknown, we performed whole-genome expression analyses. Here, we identify chemokine (C-C motif) ligand 2 (CCL2) as the top-listed NF-ÎºB-regulated gene being upregulated upon BV6 treatment in GBM cells. BV6-induced upregulation and secretion of CCL2 are required for migration and invasion of GBM cells because knockdown of CCL2 in GBM cells abolishes these effects. Co-culture experiments of GBM cells with non-malignant astroglial cells reveal that BV6-stimulated secretion of CCL2 by GBM cells into the supernatant triggers migration of astroglial cells toward GBM cells because CCL2 knockdown in BV6-treated GBM cells impedes BV6-stimulated migration of astroglial cells. In conclusion, we identify CCL2 as a BV6-induced NF-ÎºB target gene that triggers migration and invasion of GBM cells and exerts paracrine effects on the GBM's microenvironment by stimulating migration of astroglial cells. These findings provide novel insights into the biological functions of Smac mimetics with important implications for the development of Smac mimetics as cancer therapeutics.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2014 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lindemann</LastName>
            <ForeName>Carina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marschall</LastName>
            <ForeName>Viola</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weigert</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biochemistry I, Goethe-University, Frankfurt, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klingebiel</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Hematology and Oncology, University Children's Hospital, Goethe-University, Frankfurt, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fulda</LastName>
            <ForeName>Simone</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Germany; German Cancer Consortium (DKTK) Heidelberg, Germany; German Cancer Research Center (DKFZ) Heidelberg, Germany. Electronic address: simone.fulda@kgu.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neoplasia</MedlineTA>
        <NlmUniqueID>100886622</NlmUniqueID>
        <ISSNLinking>1476-5586</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C111835">CCL2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018932">Chemokine CCL2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C412403">DIABLO protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032701" MajorTopicYN="N">Biomimetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018932" MajorTopicYN="N">Chemokine CCL2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019899" MajorTopicYN="N">Paracrine Communication</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26152356</ArticleId>
        <ArticleId IdType="pmc">PMC4719005</ArticleId>
        <ArticleId IdType="doi">10.1016/j.neo.2015.05.002</ArticleId>
        <ArticleId IdType="pii">S1476-5586(15)00068-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97&#x2013;109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1929165</ArticleId>
            <ArticleId IdType="pubmed">17618441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009;124:511&#x2013;515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19003982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug&#x2013;induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8:808&#x2013;815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12118245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giese A., Bjerkvig R., Berens M.E., Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21:1624&#x2013;1636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12697889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11:109&#x2013;124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22293567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S. Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists. Oncogene. 2014;33:671&#x2013;676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23474760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S. Novel promising IAP antagonist on the horizon for clinical translation. J Med Chem. 2012;55:4099&#x2013;4100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22515144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wagner L., Marschall V., Karl S., Cristofanon S., Zobel K., Deshayes K., Vucic D., Debatin K.M., Fulda S. Smac mimetic sensitizes glioblastoma cells to temozolomide-induced apoptosis in a RIP1- and NF-kappaB&#x2013;dependent manner. Oncogene. 2013;32:988&#x2013;997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22469979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houghton P.J., Kang M.H., Reynolds C.P., Morton C.L., Kolb E.A., Gorlick R., Keir S.T., Carol H., Lock R., Maris J.M. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012;58:636&#x2013;639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3253328</ArticleId>
            <ArticleId IdType="pubmed">21681929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berger R., Jennewein C., Marschall V., Karl S., Cristofanon S., Wagner L., Vellanki S.H., Hehlgans S., Rodel F., Debatin K.M. NF-{kappa}B is required for Smac mimetic&#x2013;mediated sensitization of glioblastoma cells for {gamma}-irradiation&#x2013;induced apoptosis. Mol Cancer Ther. 2011;10:1867&#x2013;1875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21859841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchoghandjian A., Jennewein C., Eckhardt I., Rajalingam K., Fulda S. Identification of non-canonical NF-kappaB signaling as a critical mediator of Smac mimetic&#x2013;stimulated migration and invasion of glioblastoma cells. Cell Death Dis. 2013;4:e564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3615728</ArticleId>
            <ArticleId IdType="pubmed">23538445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonoda Y., Ozawa T., Hirose Y., Aldape K.D., McMahon M., Berger M.S., Pieper R.O. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. 2001;61:4956&#x2013;4960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11431323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Major E.O., Miller A.E., Mourrain P., Traub R.G., de Widt E., Sever J. Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci U S A. 1985;82:1257&#x2013;1261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC397234</ArticleId>
            <ArticleId IdType="pubmed">2983332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., Zobel K., Dynek J.N., Elliott L.O., Wallweber H.J. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669&#x2013;681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18022362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karl S., Pritschow Y., Volcic M., Hacker S., Baumann B., Wiesmuller L., Debatin K.M., Fulda S. Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response. J Cell Mol Med. 2009;13:4239&#x2013;4256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4496130</ArticleId>
            <ArticleId IdType="pubmed">19725919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckhardt I., Roesler S., Fulda S. Identification of DR5 as a critical, NF-kappaB-regulated mediator of Smac-induced apoptosis. Cell Death Dis. 2013;4:e936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3847333</ArticleId>
            <ArticleId IdType="pubmed">24287697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogler M., Durr K., Jovanovic M., Debatin K.M., Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene. 2007;26:248&#x2013;257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16832350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loberg R.D., Day L.L., Harwood J., Ying C., St John L.N., Giles R., Neeley C.K., Pienta K.J. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 2006;8:578&#x2013;586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1601934</ArticleId>
            <ArticleId IdType="pubmed">16867220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang C.H., Tsai C.C. CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-kappaB signaling pathway. Biochem Pharmacol. 2012;83:335&#x2013;344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22138288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., Benetatos C.A., Chunduru S.K., Condon S.M., McKinlay M. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131:682&#x2013;693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18022363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L., Du F., Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133:693&#x2013;703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18485876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein&#x2013;1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29:313&#x2013;326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2755091</ArticleId>
            <ArticleId IdType="pubmed">19441883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueda A., Okuda K., Ohno S., Shirai A., Igarashi T., Matsunaga K., Fukushima J., Kawamoto S., Ishigatsubo Y., Okubo T. NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol. 1994;153:2052&#x2013;2063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8051410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeshima H., Kuratsu J., Takeya M., Yoshimura T., Ushio Y. Expression and localization of messenger RNA and protein for monocyte chemoattractant protein&#x2013;1 in human malignant glioma. J Neurosurg. 1994;80:1056&#x2013;1062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8189261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desbaillets I., Tada M., de Tribolet N., Diserens A.C., Hamou M.F., Van Meir E.G. Human astrocytomas and glioblastomas express monocyte chemoattractant protein&#x2013;1 (MCP-1) in vivo and in vitro. Int J Cancer. 1994;58:240&#x2013;247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7517920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuratsu J., Yoshizato K., Yoshimura T., Leonard E.J., Takeshima H., Ushio Y. Quantitative study of monocyte chemoattractant protein&#x2013;1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst. 1993;85:1836&#x2013;1839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8230263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Platten M., Kretz A., Naumann U., Aulwurm S., Egashira K., Isenmann S., Weller M. Monocyte chemoattractant protein&#x2013;1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol. 2003;54:388&#x2013;392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12953273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu X., Fujita M., Snyder L.A., Okada H. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol. 2011;104:83&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3068234</ArticleId>
            <ArticleId IdType="pubmed">21116835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Sarkar S., Cua R., Zhou Y., Hader W., Yong V.W. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis. 2012;33:312&#x2013;319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22159219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161&#x2013;174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11990853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanderkerken K., Vande Broek I., Eizirik D.L., Van Valckenborgh E., Asosingh K., Van Riet I., Van Camp B. Monocyte chemoattractant protein&#x2013;1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis. 2002;19:87&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11918087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youngs S.J., Ali S.A., Taub D.D., Rees R.C. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer. 1997;71:257&#x2013;266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9139852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Craig M.J., Loberg R.D. CCL2 (monocyte chemoattractant protein&#x2013;1) in cancer bone metastases. Cancer Metastasis Rev. 2006;25:611&#x2013;619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17160712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ridet J.L., Malhotra S.K., Privat A., Gage F.H. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1997;20:570&#x2013;577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9416670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchoghandjian A., Jennewein C., Eckhardt I., Momma S., Figarella-Branger D., Fulda S. Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-kappaB. Cell Death Differ. 2014;21:735&#x2013;747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3978303</ArticleId>
            <ArticleId IdType="pubmed">24488095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckhardt I., Weigert A., Fulda S. Identification of IRF1 as critical dual regulator of Smac mimetic-induced apoptosis and inflammatory cytokine response. Cell Death Dis. 2014;5:e1562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4454156</ArticleId>
            <ArticleId IdType="pubmed">25501823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dogan T., Harms G.S., Hekman M., Karreman C., Oberoi T.K., Alnemri E.S., Rapp U.R., Rajalingam K. X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat Cell Biol. 2008;10:1447&#x2013;1455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19011619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oberoi T.K., Dogan T., Hocking J.C., Scholz R.P., Mooz J., Anderson C.L., Karreman C., Meyer zu Heringdorf D., Schmidt G., Ruonala M. IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation. EMBO J. 2012;31:14&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3252583</ArticleId>
            <ArticleId IdType="pubmed">22117219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J., Ahn S., Ko Y.G., Boo Y.C., Chi S.G., Ni C.W., Go Y.M., Jo H., Park H. X-linked inhibitor of apoptosis protein controls alpha5-integrin-mediated cell adhesion and migration. Am J Physiol Heart Circ Physiol. 2010;299:H300&#x2013;H309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8868572</ArticleId>
            <ArticleId IdType="pubmed">20472758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehrotra S., Languino L.R., Raskett C.M., Mercurio A.M., Dohi T., Altieri D.C. IAP regulation of metastasis. Cancer Cell. 2010;17:53&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2818597</ArticleId>
            <ArticleId IdType="pubmed">20129247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez J., John S.W., Tenev T., Rautureau G.J., Hinds M.G., Francalanci F., Wilson R., Broemer M., Santoro M.M., Day C.L. CARD-mediated autoinhibition of cIAP1's E3 ligase activity suppresses cell proliferation and migration. Mol Cell. 2011;42:569&#x2013;583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21549626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S. Molecular pathways: targeting inhibitor of apoptosis proteins in cancer&#x2013;from molecular mechanism to therapeutic application. Clin Cancer Res. 2014;20:289&#x2013;295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24270683</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25312253</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <PubDate>
              <Year>2014</Year>
              <Month>Oct</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo.</ArticleTitle>
        <Pagination>
          <StartPage>6610</StartPage>
          <MedlinePgn>6610</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">6610</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/srep06610</ELocationID>
        <Abstract>
          <AbstractText>Leukemia cells highly expressing chemokine receptor CXCR4 can actively response to stroma derived factor 1Î± (CXCL12), trafficking and homing to the marrow microenvironment, which causes poor prognosis and relapse. Here we demonstrate that a novel designed peptide (E5) targeting CXCR4 inhibits CXCL12- and stroma-induced activation in multiple acute myelocytic leukemia (AML) cell lines and displays anti-AML activity. We show that E5 has high affinity to multiple AML cells with high CXCR4 level in a concentration dependent manner. E5 significantly inhibits CXCL12- or murine stromal cell (MS-5)-induced migration of leukemia cells and prevents the cells from adhering to stromal cells. Mechanistic studies demonstrate that E5 down-regulates CXCL12-induced phosphorylation of Akt, Erk, and p38, which affects the cytoskeleton F-actin organization and ultimately results in the inhibition of CXCL12- and stroma-mediated leukemia cell responses. E5 can induce concentration-dependent apoptosis in the four AML cell lines tested while did not affect the viability of MS-5 or human umbilical vein cell (ea.hy926) even at 80 ÂµM, both of which have a low level of CXCR4. In vivo experimental results show that immunocompromised mice transplanted with HL-60 cells survived longer when treated with E5 twice a week in comparison to those treated with cyclophosphamide.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiaojin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing 100005, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing 100005, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yanlian</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Nanoscience and Technology, Beijing 100190, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing 100005, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing 100005, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Nanoscience and Technology, Beijing 100190, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Haiyan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp;Peking Union Medical College, Beijing 100005, P. R. China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515255">CXCL12 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000623221">E5 CXCR4-targeting peptide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8N3DW7272P</RegistryNumber>
          <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061307" MajorTopicYN="N">Human Umbilical Vein Endothelial Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015470" MajorTopicYN="N">Leukemia, Myeloid, Acute</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019718" MajorTopicYN="N">Receptors, CXCR4</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>6</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>9</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25312253</ArticleId>
        <ArticleId IdType="pmc">PMC4196105</ArticleId>
        <ArticleId IdType="doi">10.1038/srep06610</ArticleId>
        <ArticleId IdType="pii">srep06610</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Li Z. W. &amp; Dalton W. S. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Reviews 6, 333&#x2013;342 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16920238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopleva M., Konoplev S., Hu W., Zaritskey A. Y., Afanasiev B. V. &amp; Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 16, 1713&#x2013;1724 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12200686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manabe A., Coustan-Smith E., Behm F. G., Raimondi S. C. &amp; Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 79, 2370&#x2013;2377 (1992).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1373973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panayiotidis P., Jones D., Ganeshaguru K., Foroni L. &amp; Hoffbrand A. V. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 92, 97&#x2013;103 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8562418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng Z. et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215&#x2013;24 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699240</ArticleId>
            <ArticleId IdType="pubmed">18955566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger J. A., Tsukada N., Burger M., Zvaifler N. J., Dell'Aquila M. &amp; Kipps T. J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96, 2655&#x2013;2663 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11023495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai K. et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. Br J Haematol. 106, 905&#x2013;911 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10519991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger J. A. &amp; Kipps T. J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107, 1761&#x2013;1767 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16269611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger J. A. &amp; B&#xfc;rkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 137, 288&#x2013;296 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17456052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tavor S. et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 64, 2817&#x2013;2824 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15087398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger J. A., Burger M. &amp; Kipps T. J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94, 3658&#x2013;3667 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10572077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sipkins D. A. et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435, 969&#x2013;973 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2570168</ArticleId>
            <ArticleId IdType="pubmed">15959517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lagneaux L., Delforge A., Bron D., De Bruyn C. &amp; Stryckmans P. Chronic lymphocytic leukemia B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91, 2387&#x2013;2396 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9516138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger J. A. &amp; Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23, 43&#x2013;52 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18987663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami T. et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med. 186, 1389&#x2013;1393 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2199089</ArticleId>
            <ArticleId IdType="pubmed">9334379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juarez J., Bradstock K. F., Gottlieb D. J. &amp; Bendall L. J. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 17, 1294&#x2013;1300 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12835717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juarez J. et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 21, 1249&#x2013;1257 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17410186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger M. et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106, 1824&#x2013;1830 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15905192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawaguchi A. et al. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. Blood 114, 2961&#x2013;2968 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19657116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nervi B. et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113, 6206&#x2013;6214 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699239</ArticleId>
            <ArticleId IdType="pubmed">19050309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parameswaran R., Yu M., Lim M., Groffen J. &amp; Heisterkamp N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 25, 1314&#x2013;1323 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3135709</ArticleId>
            <ArticleId IdType="pubmed">21483439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weisberg E. et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26, 985&#x2013;90 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4124489</ArticleId>
            <ArticleId IdType="pubmed">22182920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng Z. et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther. 5, 3113&#x2013;21 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17172414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhne M. R. et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 19, 357&#x2013;66 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23213054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Domanska U. M. et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 49, 219&#x2013;230 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22683307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juarez J., Bendall L. &amp; Bradstock K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des. 10, 1245&#x2013;1259 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15078139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bleul C. C., Fuhlbrigge R. C., Casasnovas J. M., Aiuti A. &amp; Springer T. A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 184, 1101&#x2013;1109 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2192798</ArticleId>
            <ArticleId IdType="pubmed">9064327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jo D. Y., Hwang J. H., Kim J. M., Yun H. J. &amp; Kim S. Human bone marrow endothelial cells elaborate non-stromal-cell-derived factor-1 (SDF-1)-dependent chemoattraction and SDF-1-dependent transmigration of haematopoietic progenitors. Br J Haematol. 121, 649&#x2013;652 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12752108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen W., Bendall L. J., Gottlieb D. J. &amp; Bradstock K. F. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol. 29, 1439&#x2013;1447 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11750103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peled A. et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34 (+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 95, 3289&#x2013;3296 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10828007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glodek A. M. et al. Focal adhesion kinase is required for CXCL12-induced chemotactic and pro-adhesive responses inhematopoietic precursor cells. Leukemia 21, 1723&#x2013;1732 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17568820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fei F., Stoddart S., M&#xfc;schen M., Kim Y. M., Groffen J. &amp; Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia. 24, 813&#x2013;820 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3038787</ArticleId>
            <ArticleId IdType="pubmed">20111071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voermans C., Anthony E. C., Mul E., van der Schoot E. &amp; Hordijk P. SDF-1-induced actin polymerization and migration in human hematopoietic progenitor cells. Exp Hematol. 29, 1456&#x2013;1464 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11750105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bendall L. J., Baraz R., Juarez J., Shen W. &amp; Bradstock K. F. Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor- alpha in acute lymphoblastic leukemia. Cancer Res. 65, 3290&#x2013;3298 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15833862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tavor S. &amp; Petit I. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia. Semin Cancer Biol. 20, 178&#x2013;185 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20637871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konoplev S. et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 109, 1152&#x2013;1156 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17315232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rombouts E. J., Pavic B., Lowenberg B. &amp; Ploemacher R. E. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104, 550&#x2013;557 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15054042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spoo A. C., L&#xfc;bbert M., Wierda W. G. &amp; Burger J. A. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 109, 786&#x2013;791 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16888090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trent J. O. et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem. 278, 47136&#x2013;47144 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12958314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W. B. et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem. 277, 24515&#x2013;24521 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11923301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao X. B. et al. Binding modes of thioflavin t molecules to prion peptide assemblies identified by using scanning tunneling microscopy. ACS Chemical Neuroscience. 2, 281&#x2013;287 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3369759</ArticleId>
            <ArticleId IdType="pubmed">22778872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao X. B. et al. Beta structure motifs of islet amyloid polypeptides identified through surface-mediated assemblies. PNAS. 108, 19605&#x2013;19610 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3241769</ArticleId>
            <ArticleId IdType="pubmed">22106265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C. X. et al. Determination of relative binding affinities of labeling molecules with amino acids by using scanning tunneling microscopy. Chemical Communications. 47, 10638&#x2013;10640 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21869951</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25253531</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2015</Year>
        <Month>01</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-0851</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>64</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer immunology, immunotherapy : CII</Title>
          <ISOAbbreviation>Cancer Immunol Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment.</ArticleTitle>
        <Pagination>
          <StartPage>15</StartPage>
          <EndPage>27</EndPage>
          <MedlinePgn>15-27</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-014-1608-x</ELocationID>
        <Abstract>
          <AbstractText>The tumor microenvironment represents a burden that hampers the proper activation of immune cells, including the dendritic cells (DCs). It is, therefore, desired that the important characteristics of a given anticancer drug candidate be seen as consisting not solely of its antitumor properties, but that it also lacks potential side effects that could additionally constrain the development and function of immune cells associated with tumor immunity. We have previously identified compounds with a N-amidinopiperidine scaffold that selectively induce apoptosis in Burkitt's lymphoma cells through proteasome inhibition. Here, we demonstrate that SPI-15 affected neither the viability of DCs nor their differentiation. In addition, the compound had no significant effect on their cytokine secretion or allostimulatory capacity. Moreover, DC functionality in the context of tumor microenvironment was also unaffected, as demonstrated by experiments performed on DCs differentiated in Ramos-conditioned media in the presence or absence of SPI-15. The cytokine profile and functional assays revealed that SPI-15 rescues DC differentiation from the immunosuppressive environment produced by Ramos cells; this was seen by their reacquired ability to induce IFN-Î³-secretion from naÃ¯ve CD4(+)CD45RA(+) T cells and the consequently induced Th1-effector differentiation. Herein, we present novel characteristics of an N-amidinopiperidine-based protease inhibitor whose anticancer properties are not associated with the immunosuppression of DCs. We propose future studies toward the design of structurally similar compounds with the aim of developing potent anticancer drugs with minimal negative effects on crucial factors involved in tumor immunity.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Å vajger</LastName>
            <ForeName>Urban</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Blood Transfusion Centre of Slovenia, Å lajmerjeva 6, 1000, Ljubljana, Slovenia, svajgerurban@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gobec</LastName>
            <ForeName>Martina</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Obreza</LastName>
            <ForeName>AleÅ¡</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>MlinariÄ-RaÅ¡Äan</LastName>
            <ForeName>Irena</ForeName>
            <Initials>I</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>09</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Cancer Immunol Immunother</MedlineTA>
        <NlmUniqueID>8605732</NlmUniqueID>
        <ISSNLinking>0340-7004</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000578">Amidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061988">Proteasome Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000596025">SPI-15 compound</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>67I85E138Y</RegistryNumber>
          <NameOfSubstance UI="C032727">piperidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.25.1</RegistryNumber>
          <NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000578" MajorTopicYN="N">Amidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002051" MajorTopicYN="N">Burkitt Lymphoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061988" MajorTopicYN="N">Proteasome Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>9</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25253531</ArticleId>
        <ArticleId IdType="doi">10.1007/s00262-014-1608-x</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25140317</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2314-6141</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2014</Volume>
            <PubDate>
              <Year>2014</Year>
            </PubDate>
          </JournalIssue>
          <Title>BioMed research international</Title>
          <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.</ArticleTitle>
        <Pagination>
          <StartPage>532161</StartPage>
          <MedlinePgn>532161</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">532161</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/532161</ELocationID>
        <Abstract>
          <AbstractText>Triple negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and a worse clinical outcome compared with other breast cancer subtypes. Doxorubicin is considered to be one of the most effective agents in the treatment of TNBC. Unfortunately, resistance to this agent is common. In some drug-resistant cells, drug efflux is mediated by adenosine triphosphate-dependent membrane transporter termed adenosine triphosphate-binding cassette (ABC) transporter, which can drive the substrates across membranes against concentration gradient. In the tumor microenvironment, upon interaction with mesenchymal stem cells (MSCs), tumor cells exhibit altered biological functions of certain gene clusters, hence increasing stemness of tumor cells, migration ability, angiogenesis, and drug resistance. In our present study, we investigated the mechanism of TNBC drug resistance induced by adipose-derived MSCs. Upon exposure of TNBC to MSC-secreted conditioned medium (CM), noticeable drug resistance against doxorubicin with markedly increased BCRP protein expression was observed. Intracellular doxorubicin accumulation of TNBC was also decreased by MSC-secreted CM. Furthermore, we found that doxorubicin resistance of TNBC was mediated by IL-8 presented in the MSC-secreted CM. These findings may enrich the list of potential targets for overcoming drug resistance induced by MSCs in TNBC patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Dar-Ren</ForeName>
            <Initials>DR</Initials>
            <Identifier Source="ORCID">0000-0002-0897-4374</Identifier>
            <AffiliationInfo>
              <Affiliation>Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua 50006, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Dah-Yuu</ForeName>
            <Initials>DY</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate Institute of Neural and Cognitive Sciences, China Medical University, Taichung 40402, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Hui-Yi</ForeName>
            <Initials>HY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, China Medical University, Taichung 40402, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yeh</LastName>
            <ForeName>Wei-Lan</ForeName>
            <Initials>WL</Initials>
            <Identifier Source="ORCID">0000-0003-4398-7610</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cell and Tissue Engineering, Changhua Christian Hospital, Changhua 50006, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>07</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biomed Res Int</MedlineTA>
        <NlmUniqueID>101600173</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2014</Year>
          <Month>6</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>6</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25140317</ArticleId>
        <ArticleId IdType="pmc">PMC4124237</ArticleId>
        <ArticleId IdType="doi">10.1155/2014/532161</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Foundation Symposium. 1988;136:42&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3068016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minteer D, Marra KG, Peter Rubin J. Adipose-derived mesenchymal stem cells: biology and potential applications. Advances in Biochemical Engineering/Biotechnology. 2013;129:59&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22825719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2(4):313&#x2013;319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2613570</ArticleId>
            <ArticleId IdType="pubmed">18397751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tropel P, No&#xeb;l D, Platet N, Legrand P, Benabid A, Berger F. Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. Experimental Cell Research. 2004;295(2):395&#x2013;406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15093739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dominici M, le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315&#x2013;317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16923606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reagan MR, Kaplan DL. Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells. 2011;29(6):920&#x2013;927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4581846</ArticleId>
            <ArticleId IdType="pubmed">21557390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stagg J. Mesenchymal stem cells in cancer. Stem Cell Reviews. 2008;4(2):119&#x2013;124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18493880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-&#x3b2; delivery into tumors. Cancer Research. 2002;62(13):3603&#x2013;3608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12097260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houthuijzen JM, Daenen LGM, Roodhart JML, Voest EE. The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. British Journal of Cancer. 2012;106(12):1901&#x2013;1906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3388567</ArticleId>
            <ArticleId IdType="pubmed">22596239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan J, Chen J. Mesenchymal stem cells in the tumor microenvironment. Biomedical Reports. 2013;1(4):517&#x2013;521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3916973</ArticleId>
            <ArticleId IdType="pubmed">24648978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research. 2007;13(8):2329&#x2013;2334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17438091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andr&#xe9; F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Annals of Oncology. 2012;23(supplement 6):vi46&#x2013;vi51.mds195</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23012302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical Cancer Research. 2008;14(9):2519&#x2013;2526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18451212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clinical Pharmacology and Therapeutics. 2011;89(4):491&#x2013;502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21368752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Current Drug Delivery. 2004;1(1):27&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16305368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaeger W. Classical resistance mechanisms. International Journal of Clinical Pharmacology and Therapeutics. 2009;47(1):46&#x2013;48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19203536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh WL, Lu DY, Liou HC, Fu WM. A forward loop between glioma and microglia: Glioma-derived extracellular matrix-activated microglia secrete IL-18 to enhance the migration of glioma cells. Journal of Cellular Physiology. 2012;227(2):558&#x2013;568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21442623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor &#x3b1; protein in MCF-7 cells require the CSK c-Src tyrosine kinase. PLoS ONE. 2013;8(4)e60889</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3617152</ArticleId>
            <ArticleId IdType="pubmed">23593342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu D-Y, Chen J-H, Tan T-W, Huang C-Y, Yeh W-L, Hsu H-C. Resistin protects against 6-hydroxydopamine-induced cell death in dopaminergic-like MES23.5 cells. Journal of Cellular Physiology. 2013;228(3):563&#x2013;571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22806254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin H, Yeh W, Huang B, Lin C, Lai C, Lu D. Desipramine protects neuronal cell death and induces heme oxygenase-1 expression in Mes23.5 dopaminergic neurons. PLoS ONE. 2012;7(11)e50138</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3507930</ArticleId>
            <ArticleId IdType="pubmed">23209658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh WL, Lu DY, Lee MJ, Fu WM. Leptin induces migration and invasion of glioma cells through MMP-13 production. GLIA. 2009;57(4):454&#x2013;464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18814267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luk CK, Tannock IF. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. Journal of the National Cancer Institute. 1989;81(1):55&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2642304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobuchi H, Moriya K, Ogino T, et al. Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation. PLoS ONE. 2012;7(11)e50082</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3506543</ArticleId>
            <ArticleId IdType="pubmed">23189181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene. 2003;22(47):7340&#x2013;7358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14576842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glavinas H, Kis E, P&#xe1;l &#xc1;, et al. ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions. Drug Metabolism and Disposition. 2007;35(9):1533&#x2013;1542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17537873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SY, Han J, Kim JB, et al. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma. European Journal of Cancer. 2014;50(2):341&#x2013;350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24161763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Research. 2010;70(3):1063&#x2013;1071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3719378</ArticleId>
            <ArticleId IdType="pubmed">20103651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. Journal of Clinical Investigation. 2011;121(10):3804&#x2013;3809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3223613</ArticleId>
            <ArticleId IdType="pubmed">21965337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsawa SF, Novak AJ, Ziesmer SC, et al. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood. 2011;118(20):5540&#x2013;5549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3217355</ArticleId>
            <ArticleId IdType="pubmed">21921047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lorusso G, R&#xfc;egg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochemistry and Cell Biology. 2008;130(6):1091&#x2013;1103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18987874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortez E, Roswall P, Pietras K. Functional subsets of mesenchymal cell types in the tumor microenvironment. Seminars in Cancer Biology. 2014;25:3&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24412106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosaffa F, Lage H, Afshari JT, Behravan J. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflammation Research. 2009;58(10):669&#x2013;676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19333723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poller B, Drewe J, Kr&#xe4;henb&#xfc;hl S, Huwyler J, Gutmann H. Regulation of BCRP (ABCG2) and P-Glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cellular and Molecular Neurobiology. 2010;30(1):63&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19629677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee YS, Choi I, Ning Y, et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. The British Journal of Cancer. 2012;106(11):1833&#x2013;1841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3364111</ArticleId>
            <ArticleId IdType="pubmed">22617157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJJ. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Molecular Cancer Therapeutics. 2008;7(9):2649&#x2013;2661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18790747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brat DJ, Bellail AC, van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology. 2005;7(2):122&#x2013;133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1871893</ArticleId>
            <ArticleId IdType="pubmed">15831231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ning Y, Manegold PC, Hong YK, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. International Journal of Cancer. 2011;128(9):2038&#x2013;2049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3039715</ArticleId>
            <ArticleId IdType="pubmed">20648559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine. 2011;56(2):365&#x2013;375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21742513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo Y, Ellis LZ, Dallaglio K, et al. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. Journal of Investigative Dermatology. 2012;132(10):2440&#x2013;2450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3434242</ArticleId>
            <ArticleId IdType="pubmed">22622430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(26):15665&#x2013;15670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC28101</ArticleId>
            <ArticleId IdType="pubmed">9861027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harati R, Vill&#xe9;gier A, Banks WA, Mabondzo A. Susceptibility of juvenile and adult blood-brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity. Journal of Neuroinflammation. 2012;9, article 273</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3547749</ArticleId>
            <ArticleId IdType="pubmed">23253775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast resistance protein transporter in normal human tissues. Cancer Research. 2001;61(8):3458&#x2013;3464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11309308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Research. 1999;59(18):4559&#x2013;4563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10493507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19(2):257&#x2013;272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3060401</ArticleId>
            <ArticleId IdType="pubmed">21316604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao H, Priebe W, Glod J, Banerjee D. Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells. 2009;27(4):857&#x2013;865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19350687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rattigan Y, Hsu J, Mishra PJ, Glod J, Banerjee D. Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Experimental Cell Research. 2010;316(20):3417&#x2013;3424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20633553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scherzed A, Hackenberg S, Froelich K, et al. BMSC enhance the survival of paclitaxel treated squamous cell carcinoma cells in vitro. Cancer Biology and Therapy. 2011;11(3):349&#x2013;357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21127403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez CG, Penfornis P, Oskowitz AZ, et al. Activation of autophagy in mesenchymal stem cells provides tumor stromal support. Carcinogenesis. 2011;32(7):964&#x2013;972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3128555</ArticleId>
            <ArticleId IdType="pubmed">21317300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Boeck A, Pauwels P, Hensen K, et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut. 2013;62(4):550&#x2013;560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22535374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roodhart JML, Daenen LGM, Stigter ECA, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell. 2011;20(3):370&#x2013;383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21907927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lis R, Touboul C, Mirshahi P, et al. Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. International Journal of Cancer. 2011;128(3):715&#x2013;725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20725999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serletti JM, Fosnot J, Nelson JA, Disa JJ, Bucky LP. Breast reconstruction after breast cancer. Plastic and Reconstructive Surgery. 2011;127(6):124e&#x2013;135e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21617423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimmerlin L, Donnenberg AD, Rubin JP, Basse P, Landreneau RJ, Donnenberg VS. Regenerative therapy and cancer: in vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates. Tissue Engineering A. 2011;17(1-2):93&#x2013;106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3011910</ArticleId>
            <ArticleId IdType="pubmed">20673000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshimura K, Suga H, Eto H. Adipose-derived stem/progenitor cells: roles in adipose tissue remodeling and potential use for soft tissue augmentation. Regenerative Medicine. 2009;4(2):265&#x2013;273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19317645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshimura K, Eto H, Kato H, Doi K, Aoi N. In vivo manipulation of stem cells for adipose tissue repair/reconstruction. Regenerative Medicine. 2011;6(supplement 6):33&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21999260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557&#x2013;563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17914389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin FT, Dwyer RM, Kelly J, et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: Stimulation of epithelial to mesenchymal transition (EMT) Breast Cancer Research and Treatment. 2010;124(2):317&#x2013;326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20087650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao M, Sachs PC, Wang X, et al. Mesenchymal stem cells in mammary adipose tissue stimulate progression of breast cancer resembling the basal-type. Cancer Biology and Therapy. 2012;13(9):782&#x2013;792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3399703</ArticleId>
            <ArticleId IdType="pubmed">22669576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petit JY, Clough K, Sarfati I, Lohsiriwat V, de Lorenzi F, Rietjens M. Lipofilling in breast cancer patients: from surgical technique to oncologic point of view. Plastic &amp; Reconstructive Surgery. 2010;126(5):262e&#x2013;263e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21042082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohsiriwat V, Curigliano G, Rietjens M, Goldhirsch A, Petit JY. Autologous fat transplantation in patients with breast cancer: &#x201c;silencing&#x201d; or &#x201c;fueling&#x201d; cancer recurrence? Breast. 2011;20(4):351&#x2013;357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21295982</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24337970</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1591-9528</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical and experimental medicine</Title>
          <ISOAbbreviation>Clin Exp Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.</ArticleTitle>
        <Pagination>
          <StartPage>73</StartPage>
          <EndPage>83</EndPage>
          <MedlinePgn>73-83</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10238-013-0268-z</ELocationID>
        <Abstract>
          <AbstractText>B-cell chronic lymphocytic leukemia (B-CLL) is one of the most common leukemias among the elderly and, despite many efforts, still stays incurable. Recent studies point to the microenvironment as the critical factor providing leukemic lymphocytes with pro-survival signals. Thus, the neighboring cells appear to be a perfect target for antileukemic therapy. Nurse-like cells (NLCs) largely contribute to CLL microenvironmental support. We developed the CLL lymphocyte/NLC co-culture model for the investigation of microenvironmental interactions. Viability and apoptosis were investigated in CLL lymphocytes treated with dexamethasone (DEX) and chlorambucil (CLB), with and without NLCs' support. For the first time, the capacity of DEX and CLB to affect NLCs viability was also evaluated. Apoptosis-associated gene expression profiles of leukemic lymphocytes ex vivo and cultured with NLCs were assessed by expression arrays. CLL lymphocytes escaped spontaneous apoptosis for several months when cultured with NLCs. The presence of NLCs significantly reduced apoptosis induced with DEX and CLB (p &lt; 0.001; p = 0.012, respectively), and their protective effect was more evident than the effect of recombinant SDF1. Both DEX and CLB also decreased NLCs viability, but to a lesser extent (mean viability in DEX-treated cultures was 37.79% in NLCs compared to 29.24% in lymphocytes). NLCs induced the expression of important anti-apoptotic genes in cultured CLL lymphocytes; median expression of BCL2, SURVIVIN, BCL2A1, and XIAP was significantly higher as compared to ex vivo status. The CLL lymphocyte/NLC co-culture makes up the convenient and close to the natural-state model for studying the relationship between leukemic cells and the microenvironment. Direct cell-to-cell contact with NLCs increases the expression of anti-apoptotic genes in CLL lymphocytes, thus protecting them against induced apoptosis. As the effect of antileukemic drugs is not so apparent in NLCs, the combined therapy targeted at both lymphocytes and the microenvironment should be considered for CLL patients. Simultaneous aiming at the disruption of several different signaling pathways and/or anti-apoptotic proteins may further improve treatment efficiency.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Filip</LastName>
            <ForeName>Agata A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Genetics, Medical University of Lublin, Radziwillowska 11, 20-080, Lublin, Poland, aafilip@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>CiseÅ</LastName>
            <ForeName>BogumiÅa</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>WÄsik-Szczepanek</LastName>
            <ForeName>Ewa</ForeName>
            <Initials>E</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Clin Exp Med</MedlineTA>
        <NlmUniqueID>100973405</NlmUniqueID>
        <ISSNLinking>1591-8890</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000595707">BCL2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C096816">BCL2-related protein A1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515255">CXCL12 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015778">Minor Histocompatibility Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051636">X-Linked Inhibitor of Apoptosis Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C496866">XIAP protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>18D0SL7309</RegistryNumber>
          <NameOfSubstance UI="D002699">Chlorambucil</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7S5I7G3JQL</RegistryNumber>
          <NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024201" MajorTopicYN="N">Bystander Effect</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002699" MajorTopicYN="N">Chlorambucil</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015973" MajorTopicYN="Y">Gene Expression Regulation, Leukemic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015778" MajorTopicYN="N">Minor Histocompatibility Antigens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051636" MajorTopicYN="N">X-Linked Inhibitor of Apoptosis Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24337970</ArticleId>
        <ArticleId IdType="pmc">PMC4308641</ArticleId>
        <ArticleId IdType="doi">10.1007/s10238-013-0268-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>M&#xfc;ller-Hermerink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H, et al. Chronic lymphocytic leukaemia/small lymphocytic leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4. Lyon: IARC Press; 2008. pp. 180&#x2013;182.</Citation>
        </Reference>
        <Reference>
          <Citation>Deaglio S, Malavasi F. Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica. 2009;94:752&#x2013;756. doi: 10.3324/haematol.2009.006676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2009.006676</ArticleId>
            <ArticleId IdType="pmc">PMC2688562</ArticleId>
            <ArticleId IdType="pubmed">19483151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponzoni M, Doglioni C, Caligaris-Cappio F. Chronic lymphocytic leukemia: the pathologist&#x2019;s view of lymph node microenvironment. Semin Diagn Pathol. 2011;28:161&#x2013;166. doi: 10.1053/j.semdp.2011.02.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.semdp.2011.02.014</ArticleId>
            <ArticleId IdType="pubmed">21842701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hendrix TM, Chilukuri RV, Martinez M, Olushoga Z, Blake A, Brohi M, Walker C, Samms M, Guyden JC. Thymic nurse cells exhibit epithelial progenitor phenotype and create unique extra-cytoplasmic membrane space for thymocyte selection. Cell Immunol. 2010;261:281&#x2013;292. doi: 10.1016/j.cellimm.2009.11.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellimm.2009.11.004</ArticleId>
            <ArticleId IdType="pmc">PMC2830717</ArticleId>
            <ArticleId IdType="pubmed">20035931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell&#x2019;Aquilla M, Kipps TJ. Blood derived nurse cells protect leukemia B cells from spontaneous apoptosis through stromal-cell derived factor-1. Blood. 2000;96:2655&#x2013;2663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11023495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsukada N, Burger AJ, Zvaifler NJ, Kipps TJ. Distinctive features of &#x201c;nurselike&#x201d; cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002;99:1030&#x2013;1037. doi: 10.1182/blood.V99.3.1030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V99.3.1030</ArticleId>
            <ArticleId IdType="pubmed">11807009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Quiroga MP, Hartmann E, B&#xfc;rkle A, Wierda WG, Keating MJ, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell co-cultures and after BCR stimulation. Blood. 2009;113:3050&#x2013;3058. doi: 10.1182/blood-2008-07-170415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2008-07-170415</ArticleId>
            <ArticleId IdType="pmc">PMC4916945</ArticleId>
            <ArticleId IdType="pubmed">19074730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cols M, Barra CM, He B, Puga I, Xu W, Chiu A, Tam W, Knowles DM, Dillon SR, Leonard JP, Furman RR, Chen K, Cerutti A. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol. 2012;188:6071&#x2013;6083. doi: 10.4049/jimmunol.1102066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1102066</ArticleId>
            <ArticleId IdType="pmc">PMC3370079</ArticleId>
            <ArticleId IdType="pubmed">22593611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filip AA, Cise&#x142; B, Koczkodaj D, W&#x105;sik-Szczepanek E, Piersiak T, Dmoszy&#x144;ska A. Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages? Blood Cells Mol Dis. 2013;50:263&#x2013;270. doi: 10.1016/j.bcmd.2012.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcmd.2012.12.003</ArticleId>
            <ArticleId IdType="pubmed">23313631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Natoni A, O&#x2019;Dwyer M, Santocanale C. A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization. Methods Mol Biol. 2013;986:217&#x2013;226. doi: 10.1007/978-1-62703-311-4_14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-62703-311-4_14</ArticleId>
            <ArticleId IdType="pubmed">23436415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D&#xf6;hner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute&#x2014;working Group 1996 guidelines. Blood 111:5446&#x2013;5456. doi:10.1182/blood-2007-06-093906</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972576</ArticleId>
            <ArticleId IdType="pubmed">18216293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219&#x2013;234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1139039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>B&#xf6;yum A. Separation of leukocytes from blood and bone marrow, introduction. Scand J Lab Clin Invest Suppl. 1968;97:7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5707208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duff MD, Mestre J, Maddali S, Yan ZP, Stapleton P, Daly JM. Analysis of gene expression in the tumor-associated macrophage. J Surg Res. 2007;142:119&#x2013;128. doi: 10.1016/j.jss.2006.12.542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jss.2006.12.542</ArticleId>
            <ArticleId IdType="pubmed">17597158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on bias and variance. Bioinformatics. 2003;19:185&#x2013;193. doi: 10.1093/bioinformatics/19.2.185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/19.2.185</ArticleId>
            <ArticleId IdType="pubmed">12538238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herishanu Y, P&#xe9;rez-Gal&#xe1;n P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563&#x2013;574. doi: 10.1182/blood-2010-05-284984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2010-05-284984</ArticleId>
            <ArticleId IdType="pmc">PMC3031480</ArticleId>
            <ArticleId IdType="pubmed">20940416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gin&#xe9; E, Martinez A, Villamor N, L&#xf3;pez-Guillermo A, Camos M, Martinez D, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (&#x201c;accelerated&#x201d; chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95:1526&#x2013;1533. doi: 10.3324/haematol.2010.022277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2010.022277</ArticleId>
            <ArticleId IdType="pmc">PMC2930954</ArticleId>
            <ArticleId IdType="pubmed">20421272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fecteau JF, Kipps TJ. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed) 2012;4:61&#x2013;73. doi: 10.2741/S251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2741/S251</ArticleId>
            <ArticleId IdType="pmc">PMC4114230</ArticleId>
            <ArticleId IdType="pubmed">22202043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchner M, Brantner P, Stickel N, Prinz G, Burger M, B&#xe4;r C, Dierks C, Pfeifer D, Ott A, Mertelsmann R, Gribben JG, Veelken H, Zirlik K. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia&#x2014;CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol. 2010;151:167&#x2013;178. doi: 10.1111/j.1365-2141.2010.08316.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.2010.08316.x</ArticleId>
            <ArticleId IdType="pubmed">20738306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCaig AM, Cosimo E, Leach MT, Michie AM. Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12. PLoS ONE. 2012;7:e48929. doi: 10.1371/journal.pone.0048929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0048929</ArticleId>
            <ArticleId IdType="pmc">PMC3487834</ArticleId>
            <ArticleId IdType="pubmed">23133664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>di Celle PF, Carbone A, Marchis D, Zhou D, Sozzani S, Zupo S, Pini M, Mantovani A, Foa R. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood. 1994;84:220&#x2013;228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7517209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poggi A, Prevosto C, Catellani S, Rocco I, Garuti A, Zocchi MR. Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells. Br J Haematol. 2010;151:252&#x2013;264. doi: 10.1111/j.1365-2141.2010.08343.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.2010.08343.x</ArticleId>
            <ArticleId IdType="pubmed">20813004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deaglio S, Aydin S, Grand MM, Vaisitti T, Bergui L, D&#x2019;Arena G, et al. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med. 2010;16:87&#x2013;91. doi: 10.2119/molmed.2009.00146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2119/molmed.2009.00146</ArticleId>
            <ArticleId IdType="pmc">PMC2785473</ArticleId>
            <ArticleId IdType="pubmed">19956559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolej L. The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opin Invest Drugs. 2013;21:1009&#x2013;1017. doi: 10.1517/13543784.2012.690393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543784.2012.690393</ArticleId>
            <ArticleId IdType="pubmed">22616646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Montserrat E. Coming full circle: 70&#xa0;years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013;121:1501&#x2013;1509. doi: 10.1182/blood-2012-08-452607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2012-08-452607</ArticleId>
            <ArticleId IdType="pmc">PMC4968370</ArticleId>
            <ArticleId IdType="pubmed">23264597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baptista MJ, Munta&#xf1;ola A, Calpe E, Abrisqueta P, Salamero O, Fern&#xe1;ndez E, Codony C, Gin&#xe9; E, Kalko SG, Crespo M, Bosch F. Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status. Clin Cancer Res. 2012;18:5924&#x2013;5933. doi: 10.1158/1078-0432.CCR-11-2771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-2771</ArticleId>
            <ArticleId IdType="pubmed">22966019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw RK, Boggs DR, Silberman HR, Frei E. A study of prednisone therapy in chronic lymphocytic leukemia. Blood. 1961;17:182&#x2013;195.</Citation>
        </Reference>
        <Reference>
          <Citation>Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 2013;88:803&#x2013;816. doi: 10.1002/ajh.23491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.23491</ArticleId>
            <ArticleId IdType="pubmed">23720127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA. 1986;83:5214&#x2013;5218. doi: 10.1073/pnas.83.14.5214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.83.14.5214</ArticleId>
            <ArticleId IdType="pmc">PMC323921</ArticleId>
            <ArticleId IdType="pubmed">3523487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2012;17:215&#x2013;220. doi: 10.1038/cdd.2009.69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2009.69</ArticleId>
            <ArticleId IdType="pubmed">19498445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488&#x2013;496. doi: 10.1200/JCO.2011.34.7898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2011.34.7898</ArticleId>
            <ArticleId IdType="pmc">PMC4979082</ArticleId>
            <ArticleId IdType="pubmed">22184378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013;54:1823&#x2013;1825. doi: 10.3109/10428194.2013.796051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10428194.2013.796051</ArticleId>
            <ArticleId IdType="pmc">PMC4557771</ArticleId>
            <ArticleId IdType="pubmed">23614795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5:1087&#x2013;1098. doi: 10.1158/1535-7163.MCT-05-0375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-05-0375</ArticleId>
            <ArticleId IdType="pubmed">16731740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasanen AK, Kuitunen H, Haapasaari KM, Karihtala P, Kyll&#xf6;nen H, Soini Y, Turpeenniemi-Hujanen T, Kuittinen O. Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas. Leuk Lymphoma. 2012;53:624&#x2013;631. doi: 10.3109/10428194.2011.624226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10428194.2011.624226</ArticleId>
            <ArticleId IdType="pubmed">21929285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem. 1999;274:27891&#x2013;27897. doi: 10.1074/jbc.274.39.27891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.274.39.27891</ArticleId>
            <ArticleId IdType="pubmed">10488136</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24280212</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1083-351X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>289</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of biological chemistry</Title>
          <ISOAbbreviation>J Biol Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>1071</StartPage>
          <EndPage>1078</EndPage>
          <MedlinePgn>1071-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M113.491589</ELocationID>
        <Abstract>
          <AbstractText>The bone marrow microenvironment provides important signals for the survival and proliferation of hematopoietic and malignant cells. In multiple myeloma, plasma cells are surrounded by stromal cells including osteoblasts. These stromal cells protect multiple myeloma cells from apoptosis induced by chemotherapeutic agents. Osteoprotegerin (OPG), a soluble receptor of the cytokine TNF-related apoptosis-inducing ligand (TRAIL), is secreted by osteoblasts and has been implicated in the prevention of cell death induced by TRAIL in malignant cells. Previously, we have designed death receptor-specific TRAIL variants that induce apoptosis exclusively via one of its death receptors. Here, we have studied in detail the interaction between recombinant human (rhTRAIL) variants and OPG. We show that a DR5-specific variant (rhTRAIL D269H/E195R) displays a significantly decreased affinity to OPG. Furthermore, this rhTRAIL variant shows a much higher activity when compared with rhTRAIL WT and retains its effectiveness in inducing cell death in multiple myeloma cell lines, in the presence of OPG secreted by stromal cells. We also demonstrate that stromal cells are largely insensitive to high concentrations of this rhTRAIL variant. In conclusion, rhTRAIL D269H/E195R is a potential therapy for multiple myeloma due to its high effectiveness and diminished binding to OPG.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bosman</LastName>
            <ForeName>Matthieu C J</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV Groningen and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reis</LastName>
            <ForeName>Carlos R</ForeName>
            <Initials>CR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schuringa</LastName>
            <ForeName>Jan J</ForeName>
            <Initials>JJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vellenga</LastName>
            <ForeName>Edo</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quax</LastName>
            <ForeName>Wim J</ForeName>
            <Initials>WJ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Biol Chem</MedlineTA>
        <NlmUniqueID>2985121R</NlmUniqueID>
        <ISSNLinking>0021-9258</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053244">Osteoprotegerin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053244" MajorTopicYN="N">Osteoprotegerin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020349" MajorTopicYN="N">Surface Plasmon Resonance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053221" MajorTopicYN="N">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Drug Design</Keyword>
        <Keyword MajorTopicYN="N">Multiple Myeloma</Keyword>
        <Keyword MajorTopicYN="N">Surface Plasmon Resonance (SPR)</Keyword>
        <Keyword MajorTopicYN="N">Trail</Keyword>
        <Keyword MajorTopicYN="N">Tumor Microenvironment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24280212</ArticleId>
        <ArticleId IdType="pmc">PMC3887175</ArticleId>
        <ArticleId IdType="doi">10.1074/jbc.M113.491589</ArticleId>
        <ArticleId IdType="pii">S0021-9258(20)41574-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kyle R. A., Rajkumar S. V. (2004) Multiple myeloma. N. Engl. J. Med. 351, 1860&#x2013;1873</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15509819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palumbo A., Anderson K. (2011) Multiple myeloma. N. Engl. J. Med. 364, 1046&#x2013;1060</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21410373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones R. J., Armstrong S. A. (2008) Cancer stem cells in hematopoietic malignancies. Biol. Blood Marrow Transplant. 14, Suppl. 1, 12&#x2013;16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18162216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valent P., Bonnet D., De Maria R., Lapidot T., Copland M., Melo J. V., Chomienne C., Ishikawa F., Schuringa J. J., Stassi G., Huntly B., Herrmann H., Soulier J., Roesch A., Schuurhuis G. J., W&#xf6;hrer S., Arock M., Zuber J., Cerny-Reiterer S., Johnsen H. E., Andreeff M., Eaves C. (2012) Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer 12, 767&#x2013;775</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23051844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huff C. A., Matsui W. (2008) Multiple myeloma cancer stem cells. J. Clin. Oncol. 26, 2895&#x2013;2900</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2610256</ArticleId>
            <ArticleId IdType="pubmed">18539970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsui W. (2011) Perspective: A model disease. Nature 480, S58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4339071</ArticleId>
            <ArticleId IdType="pubmed">22169808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donnenberg V. S., Donnenberg A. D. (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J. Clin. Pharmacol. 45, 872&#x2013;877</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16027397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silvestris F., Cafforio P., Tucci M., Grinello D., Dammacco F. (2003) Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br. J. Haematol. 122, 39&#x2013;52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12823344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalvez F., Ashkenazi A. (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29, 4752&#x2013;4765</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20531300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang A., Wilson N. S., Ashkenazi A. (2010) Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr. Opin. Cell Biol. 22, 837&#x2013;844</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20813513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gazitt Y. (1999) TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13, 1817&#x2013;1824</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10557057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lincz L. F., Yeh T. X., Spencer A. (2001) TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 15, 1650&#x2013;1657</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11587225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsiades C. S., Treon S. P., Mitsiades N., Shima Y., Richardson P., Schlossman R., Hideshima T., Anderson K. C. (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795&#x2013;804</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11468181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitovski S., Chantry A. D., Lawson M. A., Croucher P. I. (2012) Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. PLoS One 7, e35830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3353958</ArticleId>
            <ArticleId IdType="pubmed">22615740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Locklin R. M., Croucher P. I., Russell R. G., Edwards C. M. (2007) Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. Leukemia 21, 805&#x2013;812</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17315027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shipman C. M., Croucher P. I. (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63, 912&#x2013;916</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12615702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holen I., Shipman C. M. (2006) Role of osteoprotegerin (OPG) in cancer. Clin. Sci. 110, 279&#x2013;291</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16464170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Sloot A. M., Tur V., Szegezdi E., Mullally M. M., Cool R. H., Samali A., Serrano L., Quax W. J. (2006) Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl. Acad. Sci. U.S.A. 103, 8634&#x2013;8639</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1482632</ArticleId>
            <ArticleId IdType="pubmed">16731632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis C. R., van der Sloot A. M., Natoni A., Szegezdi E., Setroikromo R., Meijer M., Sjollema K., Stricher F., Cool R. H., Samali A., Serrano L., Quax W. J. (2010) Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis. 1, e83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3035906</ArticleId>
            <ArticleId IdType="pubmed">21368856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis C. R., van Assen A. H., Quax W. J., Cool R. H. (2011) Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors. Mol. Cell. Proteomics 10, M110.002808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3013454</ArticleId>
            <ArticleId IdType="pubmed">20852190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis C. R., van der Sloot A. M., Szegezdi E., Natoni A., Tur V., Cool R. H., Samali A., Serrano L., Quax W. J. (2009) Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry 48, 2180&#x2013;2191</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19236007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tur V., van der Sloot A. M., Reis C. R., Szegezdi E., Cool R. H., Samali A., Serrano L., Quax W. J. (2008) DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J. Biol. Chem. 283, 20560&#x2013;20568</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18474604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitovski S., Phillips J. S., Sayers J., Croucher P. I. (2007) Investigating the interaction between osteoprotegerin and receptor activator of NF-&#x3ba;B or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J. Biol. Chem. 282, 31601&#x2013;31609</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17702740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M. P., Deen K. C., McLaughlin M. M., Srinivasula S. M., Livi G. P., Marshall L. A., Alnemri E. S., Williams W. V., Doyle M. L. (2000) Temperature-sensitive differential affinity of TRAIL for its receptors: DR5 is the highest affinity receptor. J. Biol. Chem. 275, 23319&#x2013;23325</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10770955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasparian M. E., Chernyak B. V., Dolgikh D. A., Yagolovich A. V., Popova E. N., Sycheva A. M., Moshkovskii S. A., Kirpichnikov M. P. (2009) Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis 14, 778&#x2013;787</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19412666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emery J. G., McDonnell P., Burke M. B., Deen K. C., Lyn S., Silverman C., Dul E., Appelbaum E. R., Eichman C., DiPrinzio R., Dodds R. A., James I. E., Rosenberg M., Lee J. C., Young P. R. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363&#x2013;14367</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9603945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luan X., Lu Q., Jiang Y., Zhang S., Wang Q., Yuan H., Zhao W., Wang J., Wang X. (2012) Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J. Immunol. 189, 245&#x2013;252</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22664871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson C. A., Warren J. T., Wang M. W., Teitelbaum S. L., Fremont D. H. (2012) RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure. 20, 1971&#x2013;1982</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3607351</ArticleId>
            <ArticleId IdType="pubmed">23039992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zinonos I., Labrinidis A., Lee M., Liapis V., Hay S., Ponomarev V., Diamond P., Findlay D. M., Zannettino A. C., Evdokiou A. (2011) Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J. Bone Miner. Res. 26, 630&#x2013;643</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5568243</ArticleId>
            <ArticleId IdType="pubmed">20818644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picarda G., Trichet V., T&#xe9;letch&#xe9;a S., Heymann D., R&#xe9;dini F. (2012) TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am. J. Cancer Res. 2, 45&#x2013;64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3236571</ArticleId>
            <ArticleId IdType="pubmed">22206045</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23972545</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-0023</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>64</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cytokine</Title>
          <ISOAbbreviation>Cytokine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells.</ArticleTitle>
        <Pagination>
          <StartPage>196</StartPage>
          <EndPage>207</EndPage>
          <MedlinePgn>196-207</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cyto.2013.07.029</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1043-4666(13)00647-9</ELocationID>
        <Abstract>
          <AbstractText>Cytokines in tumor microenvironment play an important role in the success or failure of molecular targeted therapies. We have chosen tumor necrosis factor Î± (TNF-Î±), TNF related apoptosis inducing ligand (TRAIL), insulin-like growth factor 1 (IGF-1) and transforming growth factor Î² (TGF-Î²) as representative pro-inflammatory, pro-apoptotic, anti-apoptotic and anti-inflammatory tumor derived cytokines. Analysis of Oncomine database revealed the differential expression of these cytokines in a subset of cancer patients. The effects of these cytokines on cytotoxicity of FDA approved drugs - cisplatin and taxol and inhibitors of epidermal growth factor receptor - AG658, Janus kinase - AG490 and SIRT1 - sirtinol were assessed in A549 lung cancer cells. TRAIL augmented cytotoxicity of sirtinol and IGF-1 had a sparing effect. Since TRAIL and IGF-1 differentially modulated sirtinol cytotoxicity, further studies were carried out to identify the mechanisms. Sirtinol or knockdown of SIRT1 increased the expression of death receptors DR4 and DR5 and sensitized A549 cells to TRAIL. Increased cell death in presence of TRAIL and sirtinol was caspase independent and demonstrated classical features of necroptosis. Inhibition of iNOS increased caspase activity and switched the mode of cell death to caspase mediated apoptosis. Interestingly, sirtinol or SIRT1 knockdown did not increase IGF-1R expression. Instead, it abrogated ligand induced downregulation of IGF-1R and increased cell survival through PI3K-AKT pathway. In conclusion, these findings reveal that the tumor microenvironment contributes to modulation of cytotoxicity of drugs and that combination therapy, with agents that increase TRAIL signaling and suppress IGF-1 pathway may potentiate anticancer effect.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pal</LastName>
            <ForeName>Shyama</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Radiation Biology &amp; Health Sciences Division, Bio-Medical Group, Bhabha Atomic Research Centre, Modular Laboratories, Mumbai 400085, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shankar</LastName>
            <ForeName>Bhavani S</ForeName>
            <Initials>BS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sainis</LastName>
            <ForeName>Krishna B</ForeName>
            <Initials>KB</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cytokine</MedlineTA>
        <NlmUniqueID>9005353</NlmUniqueID>
        <ISSNLinking>1043-4666</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009284">Naphthols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053220">Receptors, TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C105190">TNFRSF10A protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C114109">TNFRSF21 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C505653">TNFSF10 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020032">Tyrphostins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C095512">alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C439060">sirtinol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>67763-96-6</RegistryNumber>
          <NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D017526">Receptor, IGF Type 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.-</RegistryNumber>
          <NameOfSubstance UI="C447939">SIRT1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.-</RegistryNumber>
          <NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007334" MajorTopicYN="N">Insulin-Like Growth Factor I</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009284" MajorTopicYN="N">Naphthols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017526" MajorTopicYN="N">Receptor, IGF Type 1</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053220" MajorTopicYN="N">Receptors, TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056564" MajorTopicYN="N">Sirtuin 1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053221" MajorTopicYN="N">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020032" MajorTopicYN="N">Tyrphostins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">IGF-1</Keyword>
        <Keyword MajorTopicYN="N">Necroptosis</Keyword>
        <Keyword MajorTopicYN="N">SIRT1</Keyword>
        <Keyword MajorTopicYN="N">TGF-&#x3b2;</Keyword>
        <Keyword MajorTopicYN="N">TNF related apoptosis inducing ligand</Keyword>
        <Keyword MajorTopicYN="N">TNF-&#x3b1;</Keyword>
        <Keyword MajorTopicYN="N">TRAIL</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
        <Keyword MajorTopicYN="N">iNOS</Keyword>
        <Keyword MajorTopicYN="N">inducible nitric oxide synthase</Keyword>
        <Keyword MajorTopicYN="N">insulin-like growth factor-1</Keyword>
        <Keyword MajorTopicYN="N">sirtuin1</Keyword>
        <Keyword MajorTopicYN="N">transforming growth factor &#x3b2;</Keyword>
        <Keyword MajorTopicYN="N">tumor necrosis factor &#x3b1;</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23972545</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cyto.2013.07.029</ArticleId>
        <ArticleId IdType="pii">S1043-4666(13)00647-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23953881</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>02</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2017</Year>
        <Month>11</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-5835</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>38</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Leukemia research</Title>
          <ISOAbbreviation>Leuk Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells.</ArticleTitle>
        <Pagination>
          <StartPage>103</StartPage>
          <EndPage>108</EndPage>
          <MedlinePgn>103-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.leukres.2013.07.026</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0145-2126(13)00269-5</ELocationID>
        <Abstract>
          <AbstractText>Galectin-3 is induced in chronic myelogenous leukemia (CML) cells by co-culture with bone marrow stromal cells, making paracrine growth promotion of CML cells in conditioned medium (CM) from galectin-3 overexpressing CML cells more potent. We used gel filtration chromatography to demonstrate that the bovine SERPINA1-fetal bovine serum albumin (BSA) complex was specifically suppressed in CM from galectin-3 overexpressing cells. The SERPINA1-BSA complex as well as human plasma SERPINA1 inhibited the growth of CML cells, while exogenous galectin-3 partly offset this effect. These findings suggest that galectin-3 overexpression promotes paracrine growth of CML cells by interfering with the action of the growth inhibitory SERPINA1-albumin complex.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nakayama</LastName>
            <ForeName>Ryuko</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuroda</LastName>
            <ForeName>Junya</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. Electronic address: junkuro@koto.kpu-m.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taniyama</LastName>
            <ForeName>Nobuko</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamamoto-Sugitani</LastName>
            <ForeName>Mio</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wada</LastName>
            <ForeName>Sayori</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kiyota</LastName>
            <ForeName>Miki</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mizutani</LastName>
            <ForeName>Shinsuke</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chinen</LastName>
            <ForeName>Yoshiaki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsumoto</LastName>
            <ForeName>Yosuke</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagoshi</LastName>
            <ForeName>Hisao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimura</LastName>
            <ForeName>Yuji</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kobayashi</LastName>
            <ForeName>Tsutomu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Horiike</LastName>
            <ForeName>Shigeo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sato</LastName>
            <ForeName>Kenji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Applied Life Sciences, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taniwaki</LastName>
            <ForeName>Masafumi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Leuk Res</MedlineTA>
        <NlmUniqueID>7706787</NlmUniqueID>
        <ISSNLinking>0145-2126</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037502">Galectin 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C043392">SERPINA1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000515">alpha 1-Antitrypsin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>27432CM55Q</RegistryNumber>
          <NameOfSubstance UI="D012710">Serum Albumin, Bovine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="Y">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037502" MajorTopicYN="N">Galectin 3</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020014" MajorTopicYN="N">K562 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015464" MajorTopicYN="N">Leukemia, Myelogenous, Chronic, BCR-ABL Positive</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012710" MajorTopicYN="N">Serum Albumin, Bovine</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000515" MajorTopicYN="N">alpha 1-Antitrypsin</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bone marrow stromal cell</Keyword>
        <Keyword MajorTopicYN="N">Chronic myelogenous leukemia</Keyword>
        <Keyword MajorTopicYN="N">Galectin-3</Keyword>
        <Keyword MajorTopicYN="N">SERPINA1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23953881</ArticleId>
        <ArticleId IdType="doi">10.1016/j.leukres.2013.07.026</ArticleId>
        <ArticleId IdType="pii">S0145-2126(13)00269-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23826077</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>10</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TGF-Î²-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>e62785</StartPage>
          <MedlinePgn>e62785</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e62785</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0062785</ELocationID>
        <Abstract>
          <AbstractText>Hypoxia and interactions with bone marrow (BM) stromal cells have emerged as essential components of the leukemic BM microenvironment in promoting leukemia cell survival and chemoresistance. High levels of transforming growth factor beta 1 (TGFÎ²1) produced by BM stromal cells in the BM niche regulate cell proliferation, survival, and apoptosis, depending on the cellular context. Exogenous TGFÎ²1 induced accumulation of acute myeloid leukemia (AML) cells in a quiescent G0 state, which was further facilitated by the co-culture with BM-derived mesenchymal stem cells (MSCs). In turn, TGFÎ²-neutralizing antibody 1D11 abrogated rhTGFÎ²1 induced cell cycle arrest. Blocking TGFÎ² with 1D11 further enhanced cytarabine (Ara-C)-induced apoptosis of AML cells in hypoxic and in normoxic conditions. Additional constituents of BM niche, the stroma-secreted chemokine CXCL12 and its receptor CXCR4 play crucial roles in cell migration and stroma/leukemia cell interactions. Treatment with 1D11 combined with CXCR4 antagonist plerixafor and Ara-C decreased leukemia burden and prolonged survival in an in vivo leukemia model. These results indicate that blockade of TGFÎ² by 1D11 and abrogation of CXCL12/CXCR4 signaling may enhance the efficacy of chemotherapy against AML cells in the hypoxic BM microenvironment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tabe</LastName>
            <ForeName>Yoko</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America ; Department of Clinical Laboratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Yue Xi</ForeName>
            <Initials>YX</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zeng</LastName>
            <ForeName>Zhihong</ForeName>
            <Initials>Z</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Linhua</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shikami</LastName>
            <ForeName>Masato</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hatanaka</LastName>
            <ForeName>Yasuhito</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miida</LastName>
            <ForeName>Takashi</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsu</LastName>
            <ForeName>Frank J</ForeName>
            <Initials>FJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andreeff</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Konopleva</LastName>
            <ForeName>Marina</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 CA055164</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA016672</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>06</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001596">Benzylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515255">CXCL12 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C514936">CXCR4 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000080027">Cyclams</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006571">Heterocyclic Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>04079A1RDZ</RegistryNumber>
          <NameOfSubstance UI="D003561">Cytarabine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S915P5499N</RegistryNumber>
          <NameOfSubstance UI="C088327">plerixafor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001596" MajorTopicYN="N">Benzylamines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080027" MajorTopicYN="N">Cyclams</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003561" MajorTopicYN="N">Cytarabine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006571" MajorTopicYN="N">Heterocyclic Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015470" MajorTopicYN="N">Leukemia, Myeloid, Acute</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019718" MajorTopicYN="N">Receptors, CXCR4</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Competing Interests: Marina Konopleva currently serves on the PLOS ONE Editorial Board. Frank J. Hsu is employed by Genzyme Corporation. This does not alter the authors' adherence to all of the PLOS ONE policies on sharing data and materials.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23826077</ArticleId>
        <ArticleId IdType="pmc">PMC3695026</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0062785</ArticleId>
        <ArticleId IdType="pii">PONE-D-12-32582</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Garrido SM, Appelbaum FR, Willman CL, Banker DE (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Experimental Hematology 29: 448&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11301185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taichman RS (2005) Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 105: 2631&#x2013;2639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15585658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, et al. (2005) TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A 102: 18813&#x2013;18818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1323171</ArticleId>
            <ArticleId IdType="pubmed">16354837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL (2001) Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 12: 3328&#x2013;3339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC60258</ArticleId>
            <ArticleId IdType="pubmed">11694570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang CW, Chen CH, Chen CC, Chen JY, Su YH (2002) TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nature Cell Biol 4: 51&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11740493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169&#x2013;178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11252892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narayan S, Thangasamy T, Balusu R (2005) Transforming growth factor -beta receptor signaling in cancer. Front Biosci 10: 1135&#x2013;1145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15769612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J, Gomis RR (2006) The logic of TGFbeta signaling. FEBS Lett 580: 2811&#x2013;2820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16678165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fortunel NO, Hatzfeld A, Hatzfeld JA (2000) Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96: 2022&#x2013;2036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10979943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruscetti FW, Akel S, Bartelmez SH (2005) Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context. Oncogene 24: 5751&#x2013;5763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16123808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Tabe Y, Jin L, Watt J, McQueen T, et al. (2008) TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol 142: 192&#x2013;201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18492113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin BY, Petrache I, Choi AM, Choi ME (1999) Transforming growth factor beta1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J Biol Chem 274: 11362&#x2013;11368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10196228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, et al. (2004) Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10: 7540&#x2013;7546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15569984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18: 816&#x2013;827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15117886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350&#x2013;1358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10793168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim CH, Broxmeyer HE (1998) In vitro behaviour of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow microenvironment. Blood 91: 100&#x2013;110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9414273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, et al. (2000) Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 165: 3423&#x2013;3429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10975862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katoh M, Katoh M (2010) Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int J Oncol 36: 415&#x2013;420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20043076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 104: 5431&#x2013;5436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1838452</ArticleId>
            <ArticleId IdType="pubmed">17374716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortensen BT, Jensen PO, Helledie N, Iversen PO, Ralfkiaer E, et al. (1998) Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 102: 458&#x2013;464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9695960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benito J, Shi Y, Szymanska B, Carol H, Boehm I, et al. (2011) Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. Plos One 6: e23108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3154919</ArticleId>
            <ArticleId IdType="pubmed">21853076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saed GM, Collins KL, Diamond MP (2002) Transforming growth factors beta1, beta2 and beta3 and their receptors are differentially expressed in human peritoneal fibroblasts in response to hypoxia. Am J Reprod Immunol 48: 387&#x2013;393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12607775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Akman HO, Smith EL, Zhao J, Murphy-Ullrich JE, et al. (2003) Cellular response to hypoxia involves signaling via Smad proteins. Blood 101: 2253&#x2013;2260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12411310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piret JP, Mottet D, Raes M, Michiels C (2002) Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 64: 889&#x2013;892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12213583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, et al. (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391&#x2013;1402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2194248</ArticleId>
            <ArticleId IdType="pubmed">14597738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, et al. (2009) CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 113: 1504&#x2013;1512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2644078</ArticleId>
            <ArticleId IdType="pubmed">18957686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L (1989) Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 142: 1536&#x2013;1541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2537357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Small D, Levenstein M, Kim E, Carow C, Amin S, et al. (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A 91: 459&#x2013;463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC42968</ArticleId>
            <ArticleId IdType="pubmed">7507245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100: 1532&#x2013;1542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12176867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, et al. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911&#x2013;1918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8946930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levis M, Allebach J, Tse KF, Zheng R, Badwin BR, et al. (2002) A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99: 3885&#x2013;3891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12010785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palacios R, Steinmetz M (1985) Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41: 727&#x2013;734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3924409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, et al. (2004) PML-RAR&#x3b1; is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 103: 1815&#x2013;1822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14630813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143&#x2013;147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10102814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, et al. (2007) Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67: 684&#x2013;694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17234779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, et al. (2002) Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16: 1713&#x2013;1724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12200686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dallas SL, Park-Snyder S, Miyazono K, Twardzik D, Mundy GR, et al. (1994) Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. J Biol Chem 269: 6815&#x2013;6821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8120044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fortunel NO, Hatzfeld A, Hatzfeld JA (2000) Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96: 2022&#x2013;2036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10979943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Peled A (2009) CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23: 43&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18987663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, et al. (2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113: 6215&#x2013;6224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699240</ArticleId>
            <ArticleId IdType="pubmed">18955566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soma T, Yu JM, Dunbar CE (1996) Maintenance of murine long-term repopulating stem cells in ex vivo culture is affected by modulation of transforming growth factor-beta but not macrophage inflammatory protein-1 alpha activities. Blood 87: 4561&#x2013;4567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8639824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blank U, Karlsson S (2011) The role of Smad signaling in hematopoiesis and translational hematology. Leukemia 25: 1379&#x2013;1388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21566654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, et al. (2012) Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood 119: 540&#x2013;550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3384480</ArticleId>
            <ArticleId IdType="pubmed">21957195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, et al. (2005) TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A 102: 18813&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1323171</ArticleId>
            <ArticleId IdType="pubmed">16354837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ao M, Williams K, Bhowmick NA, Hayward SW (2006) Transforming growth factor-&#x3b2; promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 66: 8007&#x2013;8016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4067141</ArticleId>
            <ArticleId IdType="pubmed">16912176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ao M, Franco OE, Park D, Raman D, Williams K, et al. (2007) Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 67: 4244&#x2013;4253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17483336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, et al. (2010) Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 107: 20009&#x2013;200014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2993333</ArticleId>
            <ArticleId IdType="pubmed">21041659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruzek MC, Hawes M, Pratt B, McPherson J, Ledbetter S, et al. (2003) Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 25: 235&#x2013;237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12784916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris JC, Shapiro GI, Tan AR, Lawrence DP, Olencki TE, et al. (2008) Phase I/II Study of GC1008: A human anti-transforming growth factor-beta (TGFb) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 26: abstr 9028.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23785504</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Normalization of tumor microenvironment by neem leaf glycoprotein potentiates effector T cell functions and therapeutically intervenes in the growth of mouse sarcoma.</ArticleTitle>
        <Pagination>
          <StartPage>e66501</StartPage>
          <MedlinePgn>e66501</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e66501</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0066501</ELocationID>
        <Abstract>
          <AbstractText>We have observed restriction of the murine sarcoma growth by therapeutic intervention of neem leaf glycoprotein (NLGP). In order to evaluate the mechanism of tumor growth restriction, here, we have analyzed tumor microenvironment (TME) from sarcoma bearing mice with NLGP therapy (NLGP-TME, in comparison to PBS-TME). Analysis of cytokine milieu within TME revealed IL-10, TGFÎ², IL-6 rich type 2 characters was switched to type 1 microenvironment with dominance of IFNÎ³ secretion within NLGP-TME. Proportion of CD8(+) T cells was increased within NLGP-TME and these T cells were protected from TME-induced anergy by NLGP, as indicated by higher expression of pNFAT and inhibit related downstream signaling. Moreover, low expression of FasR(+) cells within CD8(+) T cell population denotes prevention from activation induced cell death. Using CFSE as a probe, better migration of T cells was noted within TME from NLGP treated mice than PBS cohort. CD8(+) T cells isolated from NLGP-TME exhibited greater cytotoxicity to sarcoma cells in vitro and these cells show higher expression of cytotoxicity related molecules, perforin and granzyme B. Adoptive transfer of NLGP-TME exposed T cells, but not PBS-TME exposed cells in mice, is able to significantly inhibit the growth of sarcoma in vivo. Such tumor growth inhibition by NLGP-TME exposed T cells was not observed when mice were depleted for CD8(+) T cells. Accumulated evidences strongly suggest NLGP mediated normalization of TME allows T cells to perform optimally to inhibit the tumor growth.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Barik</LastName>
            <ForeName>Subhasis</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute (CNCI); Kolkata, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Banerjee</LastName>
            <ForeName>Saptak</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mallick</LastName>
            <ForeName>Atanu</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goswami</LastName>
            <ForeName>Kuntal Kanti</ForeName>
            <Initials>KK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roy</LastName>
            <ForeName>Soumyabrata</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bose</LastName>
            <ForeName>Anamika</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baral</LastName>
            <ForeName>Rathindranath</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>06</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053222">Fas Ligand Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019014">fas Receptor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D031601" MajorTopicYN="N">Azadirachta</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053222" MajorTopicYN="N">Fas Ligand Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008212" MajorTopicYN="N">Lymphocyte Depletion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018515" MajorTopicYN="N">Plant Leaves</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012509" MajorTopicYN="N">Sarcoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019014" MajorTopicYN="N">fas Receptor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Competing Interests: The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23785504</ArticleId>
        <ArticleId IdType="pmc">PMC3681973</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0066501</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-07379</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lorusso G, R&#xfc;egg C (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130: 1091&#x2013;1103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18987874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prager GW, Poettler M, Unseld M, Zielinski CC (2012) Angiogenesis in cancer: Anti-VEGF escapes mechanisms. Transl Lung Cancer Res 1: 14&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4367591</ArticleId>
            <ArticleId IdType="pubmed">25806151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witz IP (2009) The tumor&#x2013;microenvironment interactions: The making of a paradigm. Cancer Microenviron 2: 9&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2756342</ArticleId>
            <ArticleId IdType="pubmed">19701697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18: 884&#x2013;901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2905377</ArticleId>
            <ArticleId IdType="pubmed">20627072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rehman J, Li J, Orscell C, March K (2003) Peripheral blood endothelial cells are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107: 1164&#x2013;1169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12615796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432: 332&#x2013;337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3050735</ArticleId>
            <ArticleId IdType="pubmed">15549095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whiteside TL (2006) Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16153857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mbeunkui F, Johann DJ Jr (2009) Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63: 571&#x2013;582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2858592</ArticleId>
            <ArticleId IdType="pubmed">19083000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biswas K, Chattopadhyay I, Banerjee RK, Bandopadhyay U (2002) Biological activities and medicinal properties of neem (Azadirachta indica). Curr Sci 82: 1336&#x2013;1345.</Citation>
        </Reference>
        <Reference>
          <Citation>Paul R, Prasad M, Sah NK (2011) Anticancer biology of Azadirachta indica L (neem) A mini review. Cancer Biol Ther 12: 467&#x2013;476</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21743298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujiwara T, Takeda T, Ogihara Y, Shimizu M, Nomura T, et al. (1982) Studies on the structure of polysaccharides from the bark of Melia azadirachta. Chem Pharm Bull 30: 4025&#x2013;4030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7165877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baral R, Chattopadhyay U (2004) Neem (Azadirachta indica) leaf mediated immune activation causes prophylactic growth inhibition of murine Ehrlich carcinoma and B16 melanoma. Int Immunopharmacol 4: 355&#x2013;366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15037213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baral R, Mandal I, Chattopadhyay U (2005) Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine. Int Immunopharmacol 5: 1343&#x2013;1352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15914339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakraborty K, Bose A, Pal S, Sarkar K, Goswami S, et al. (2008) Neem leaf glycoprotein restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by maintaining CXCR3/CXCL10 balance. Int Immunopharmacol 8: 330&#x2013;340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18182249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallick A, Ghosh S, Banerjee S, Majumder S, Das A, et al. (2013) Neem leaf glycoprotein is nontoxic to physiological functions of Swiss mice and Sprague Dawley rats: histological, biochemical and immunological perspectives. Int Immunopharmacol 15: 73&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23178577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bose A, Chakraborty K, Sarkar K, Goswami S, Chakraborty T, et al. (2009) Neem leaf glycoprotein induces perforin mediated tumor cell killing by T and NK cells through differential regulation of IFN&#x3b3; signaling. J Immunother 32: 42&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19307993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goswami S, Bose A, Sarkar K, Roy S, Chakraborty T, et al. (2010) Neem leaf glycoprotein matures myeloid derived dendritic cells and optimizes anti-tumor T cell functions. Vaccine 28: 1241&#x2013;1252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19969119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haque E, Baral R (2006) Neem (Azadirachta indica) leaf preparation induces prophylactic growth inhibition of murine Ehrlich carcinoma in Swiss and C57BL/6 by activation of NK cells and NK-T cells. Immunobiology 211: 721&#x2013;731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17015147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakraborty T, Bose A, Barik S, Goswami KK, Banerjee S, et al. (2011) Neem leaf glycoprotein inhibits CD4+CD25+Foxp3+ Tregs to restrict murine tumor growth. Immunotherapy 3: 949&#x2013;969.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21843083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bose A, Chakraborty K, Sarkar K, Goswami S, Haque E, et al. (2009) Neem leaf glycoprotein directs T-bet associated type 1 immune commitment. Human Immunol 70: 6&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18983881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarkar K, Bose A, Haque E, Chakraborty K, Chakraborty T, et al. (2009) Induction of type 1 cytokines during neem leaf glycoprotein assisted carcinoembryonic antigen vaccination is associated with nitric oxide production. Int Immunopharmacol 9: 753&#x2013;760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19285575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakraborty K, Bose A, Chakraborty T, Sarkar K, Goswami S, et al. (2010) Restoration of dysregulated CC chemokine signaling for monocyte/macrophage chemotaxis in head and neck squamous cell carcinoma patients by neem leaf glycoprotein maximizes tumor cell cytotoxicity. Cell Mol Immunol 7: 396&#x2013;408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4002678</ArticleId>
            <ArticleId IdType="pubmed">20622890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarkar K, Bose A, Chakraborty K, Haque E, Ghosh D, et al. (2008) Neem leaf glycoprotein helps to generate carcinoembryonic antigen specific anti-tumor immune responses utilizing macrophage-mediated antigen presentation. Vaccine 26: 4352&#x2013;4362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18590789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarkar K, Goswami S, Roy S, Mallick A, Chakraborty K, et al. (2010) Neem leaf glycoprotein enhances carcinoembryonic antigen presentation of dendritic cells to T and B cells for induction of antitumor immunity by allowing generation of immune effector/memory response. Int Immunopharmacol 10: 865&#x2013;887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20472099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallick A, Barik S, Goswami KK, Banerjee S, Ghosh S, et al. (2013) Neem leaf glycoprotein activates CD8+ T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma. PLoS ONE 8: e47434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3543399</ArticleId>
            <ArticleId IdType="pubmed">23326300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zamarron BF, Chen W (2011) Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression. Int J Biol Sci 7: 651&#x2013;658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3107473</ArticleId>
            <ArticleId IdType="pubmed">21647333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinrichs C, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, et al. (2008) IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111: 5326&#x2013;5333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2396726</ArticleId>
            <ArticleId IdType="pubmed">18276844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebert LM, Schaerli P, Moser B (2005) Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 42: 799&#x2013;809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15829268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu B, Finn OJ (2008) T-cell death and cancer immune tolerance. Cell Death Differ 15: 70&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18007660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y, Zha Y, Gajewski TF (2008) Molecular regulation of T-cell anergy. EMBO ep 9: 50&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2246614</ArticleId>
            <ArticleId IdType="pubmed">18174897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wood KJ, Sakaguchi S (2003) Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3: 199&#x2013;210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12658268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618&#x2013;663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18633355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13: 31&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1722975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu L, Xu W, Qiu S, Xiong S (2010) Enrichment of CCR6(+)Foxp3(+) regulatory T cells in the tumour mass correlates with impaired CD8(+) T cell function and poor prognosis of breast cancer. Clin Immunol 135: 466&#x2013;475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20181533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stadler WM, Kuzel T, Dumas M, Vogelzang NJ (1998) Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 16: 1820&#x2013;1825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9586896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318&#x2013;1321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3489291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, et al. (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89: 1172&#x2013;1179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2394324</ArticleId>
            <ArticleId IdType="pubmed">14520441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Tian R, Xiu B, Yan J, Jia R, et al. (2009) Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells. Int J Biol Sci 5: 135&#x2013;146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2631223</ArticleId>
            <ArticleId IdType="pubmed">19173035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bailey JL (1967) Miscellaneous analytical methods. In: Bailey JL, editor. Techniques in Protein Chemistry. New York: Elsevier Science Publishing 340&#x2013;346.</Citation>
        </Reference>
        <Reference>
          <Citation>Hayashi RJ, Loh DY, Kanagawa O, Wang F (1998) Differences between responses of naive and activated T cells to anergy induction. J Immunol 160: 33&#x2013;38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9551953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komita H, Zhao X, Taylor JL, Sparvero LJ, Amoscato AA, et al. (2008) CD8+ T-cell responses against hemoglobin-b prevent solid tumor growth. Cancer Res 68: 8076&#x2013;8084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2597529</ArticleId>
            <ArticleId IdType="pubmed">18829566</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23536722</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1538-8514</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer therapeutics</Title>
          <ISOAbbreviation>Mol Cancer Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Endothelial cells enhance prostate cancer metastasis via IL-6âandrogen receptorâTGF-Î²âMMP-9 signals.</ArticleTitle>
        <Pagination>
          <StartPage>1026</StartPage>
          <EndPage>1037</EndPage>
          <MedlinePgn>1026-37</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/1535-7163.MCT-12-0895</ELocationID>
        <Abstract>
          <AbstractText>Although the potential roles of endothelial cells in the microvascules of prostate cancer during angiogenesis have been documented, their direct impacts on the prostate cancer metastasis remain unclear. We found that the CD31-positive and CD34-positive endothelial cells are increased in prostate cancer compared with the normal tissues and that these endothelial cells were decreased upon castration, gradually recovered with time, and increased after prostate cancer progressed into the castration-resistant stage, suggesting a potential linkage of these endothelial cells with androgen deprivation therapy. The in vitro invasion assays showed that the coculture of endothelial cells with prostate cancer cells significantly enhanced the invasion ability of the prostate cancer cells. Mechanism dissection found that coculture of prostate cancer cells with endothelial cells led to increased interleukin (IL)-6 secretion from endothelial cells, which may result in downregulation of androgen receptor (AR) signaling in prostate cancer cells and then the activation of TGF-Î²/matrix metalloproteinase-9 (MMP-9) signaling. The consequences of the IL-6âARâTGFÎ²âMMP-9 signaling pathway might then trigger the increased invasion of prostate cancer cells. Blocking the IL-6âARâTGFÎ²âMMP-9 signaling pathway either by IL-6 antibody, AR-siRNA, or TGF-Î²1 inhibitor all interrupted the ability of endothelial cells to influence prostate cancer invasion. These results, for the first time, revealed the important roles of endothelial cells within the prostate cancer microenvironment to promote the prostate cancer metastasis and provide new potential targets of IL-6âARâTGFÎ²âMMP-9 signals to battle the prostate cancer metastasis.</AbstractText>
          <CopyrightInformation>&#xa9;2013 AACR</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiaohai</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>George Whipple Lab for Cancer Research, Department of Pathology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Soo Ok</ForeName>
            <Initials>SO</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Shujie</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yeh</LastName>
            <ForeName>Shuyuan</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Chawnshang</ForeName>
            <Initials>C</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA122840</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA127300</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA122840</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA127300</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>03</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Cancer Ther</MedlineTA>
        <NlmUniqueID>101132535</NlmUniqueID>
        <ISSNLinking>1535-7163</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.35</RegistryNumber>
          <NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061307" MajorTopicYN="N">Human Umbilical Vein Endothelial Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23536722</ArticleId>
        <ArticleId IdType="mid">NIHMS461198</ArticleId>
        <ArticleId IdType="pmc">PMC3782851</ArticleId>
        <ArticleId IdType="doi">10.1158/1535-7163.MCT-12-0895</ArticleId>
        <ArticleId IdType="pii">1535-7163.MCT-12-0895</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Akaza H. Current status and prospects of androgen depletion therapy for prostate cancer. Best Pract Res Clin Endocrinol Metab. 2008;22:293&#x2013;302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18471787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valdespino V, Tsagozis P, Pisa P. Current perspectives in the treatment of advanced prostate cancer. Med Oncol. 2007;24:273&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17873302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev. 2009;28:177&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4476244</ArticleId>
            <ArticleId IdType="pubmed">19259624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, Vethanayagam RR, et al. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab. 2011;300:E263&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3280699</ArticleId>
            <ArticleId IdType="pubmed">20699437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, et al. Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology. 2008;149:2959&#x2013;69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2408806</ArticleId>
            <ArticleId IdType="pubmed">18292195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, et al. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. The Prostate. 1998;36:201&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9687993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shabsigh A, Lee B, Buttyan R. Unique morphological aspects of the rat ventral prostate gland revealed by vascular corrosion casting. The Prostate. 1999;39:240&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10344213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gustavsson H, Welen K, Damber JE. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. The Prostate. 2005;62:364&#x2013;73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15389782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomic TT, Gustavsson H, Wang W, Jennbacken K, Welen K, Damber JE. Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. The Prostate. 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21809353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eum SY, Lee YW, Hennig B, Toborek M. VEGF regulates PCB 104-mediated stimulation of permeability and transmigration of breast cancer cells in human microvascular endothelial cells. Exp Cell Res. 2004;296:231&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15149853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, Zhang C, et al. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:12679&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1937526</ArticleId>
            <ArticleId IdType="pubmed">17652515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen SU, Chou CH, Lin CW, Lee H, Wu JC, Lu HF, et al. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. Hum Reprod. 2010;25:757&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20008399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penet MF, Pathak AP, Raman V, Ballesteros P, Artemov D, Bhujwalla ZM. Noninvasive multiparametric imaging of metastasis-permissive microenvironments in a human prostate cancer xenograft. Cancer research. 2009;69:8822&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2783669</ArticleId>
            <ArticleId IdType="pubmed">19861534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He H, Yang X, Davidson AJ, Wu D, Marshall FF, Chung LW, et al. Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis. The Prostate. 2010;70:518&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3180894</ArticleId>
            <ArticleId IdType="pubmed">19918799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, et al. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer. 2010;17:481&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6260789</ArticleId>
            <ArticleId IdType="pubmed">20233708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao CH, Guh JH, Chueh SC, Yu HJ. Anti-angiogenic effects and mechanism of prazosin. The Prostate. 2011;71:976&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21541974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Uren A. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PloS one. 2011;6:e19343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3084826</ArticleId>
            <ArticleId IdType="pubmed">21559405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005;11:4653&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16000557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer research. 2004;64:765&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14744796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altuwaijri S, Wu CC, Niu YJ, Mizokami A, Chang HC, Chang C. Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells. Asian J Androl. 2007;9:181&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17334587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stachon A, Schluter T, Koller M, Weisser H, Krieg M. Primary culture of microvascular endothelial cells from human benign prostatic hyperplasia. The Prostate. 2001;48:156&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11494331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng SS, Lukacs NW, Kunkel SL. Eotaxin/CCL11 suppresses IL-8/CXCL8 secretion from human dermal microvascular endothelial cells. J Immunol. 2002;168:2887&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11884459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, Alitalo K, et al. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer research. 2010;70:10411&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21056990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001;7:2941&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11555613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001;58:1008&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11744478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000;6:2104&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10815938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer research. 2007;67:6854&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17638896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kesarwani P, Ahirwar DK, Mandhani A, Mittal RD. Association between &#x2212;174 G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population. DNA and cell biology. 2008;27:505&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18694328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nature reviews Urology. 2011;8:428&#x2013;39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6858788</ArticleId>
            <ArticleId IdType="pubmed">21691304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol. 1994;127:2021&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2120317</ArticleId>
            <ArticleId IdType="pubmed">7806579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1703045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodyear SM, Kheyfets SB, Garcia FU, Stearns ME. Role of the VEGFR3/VEGFD receptor axis in TGFbeta1 activation of primary prostate cell lines. The Prostate. 2009;69:982&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19301310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nature clinical practice Oncology. 2007;4:536&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17728712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer. 1991;67:3057&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1710537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. The Prostate. 1996;28:129&#x2013;35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8604394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, Wilson EM, et al. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996;2:889&#x2013;95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9816246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. The Journal of urology. 1992;147:798&#x2013;803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1371552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. International journal of cancer Journal international du cancer. 1991;48:189&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1708363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kung HJ, Evans CP. Oncogenic activation of androgen receptor. Urol Oncol. 2009;27:48&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2629789</ArticleId>
            <ArticleId IdType="pubmed">19111798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, et al. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol. 2006;169:682&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1698802</ArticleId>
            <ArticleId IdType="pubmed">16877366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer. 2008;15:841&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2740735</ArticleId>
            <ArticleId IdType="pubmed">18667687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kageyama Y, Hyochi N, Kihara K, Sugiyama H. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer. Recent Pat Anticancer Drug Discov. 2007;2:203&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18221063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2645653</ArticleId>
            <ArticleId IdType="pubmed">18612114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17:4854&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3657705</ArticleId>
            <ArticleId IdType="pubmed">21632851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, Welen K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer. 2010;17:469&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20233707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, et al. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res. 2008;6:1259&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2643879</ArticleId>
            <ArticleId IdType="pubmed">18708358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee YC, Cheng CJ, Huang M, Bilen MA, Ye X, Navone NM, et al. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol. 2010;221:68&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2936767</ArticleId>
            <ArticleId IdType="pubmed">20191612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI, et al. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer research. 2007;67:9199&#x2013;206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3072059</ArticleId>
            <ArticleId IdType="pubmed">17909025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer research. 2012;72:527&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22108827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiota M, Zardan A, Takeuchi A, Kumano M, Beraldi E, Naito S, et al. Clusterin Mediates TGF-beta-Induced Epithelial-Mesenchymal Transition and Metastasis via Twist1 in Prostate Cancer Cells. Cancer research. 2012;72:5261&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22896337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene. 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3495247</ArticleId>
            <ArticleId IdType="pubmed">22797064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 1997;57:4687&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9354422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y, Wang L, Goloubeva O, Khan MA, Zhang B, Hussain A. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy. Clin Cancer Res. 2008;14:2936&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18483360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:12182&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2527886</ArticleId>
            <ArticleId IdType="pubmed">18723679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iacopino F, Pinto F, Bertaccini A, Calarco A, Proietti G, Totaro A, et al. Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy. Oncol Rep. 2012;28:370&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22552350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnke RM, Edwards JM, Evans MJ, Nangami GN, Bakken NT, Kilburn JM, et al. Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression. In Vivo. 2009;23:827&#x2013;33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19779119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol. 2012;360:52&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3409376</ArticleId>
            <ArticleId IdType="pubmed">21664423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee GT, Kwon SJ, Lee JH, Jeon SS, Jang KT, Choi HY, et al. Induction of interleukin-6 expression by bone morphogenetic protein-6 in macrophages requires both SMAD and p38 signaling pathways. The Journal of biological chemistry. 2010;285:39401&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2998138</ArticleId>
            <ArticleId IdType="pubmed">20889504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol. 2009;182:1621&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19683746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L, et al. Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PloS one. 2012;7:e52279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3534088</ArticleId>
            <ArticleId IdType="pubmed">23300633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen JP, Frost CD, Lane ML, Skelton WP, Iv, Skelton M, Vesely DL. Novel dual inhibitors of vascular endothelial growth factor and VEGFR2 receptor. Eur J Clin Invest. 2012;42:1061&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22703300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh HL, Wang HH, Wu WB, Chu PJ, Yang CM. Transforming growth factor-beta1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-kappaB pathways. Journal of neuroinflammation. 2010;7:88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3002339</ArticleId>
            <ArticleId IdType="pubmed">21134288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinkas J, Teicher BA. TGF-beta in cancer and as a therapeutic target. Biochem Pharmacol. 2006;72:523&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16620790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Lee J, Lu S, Pettaway CA, Dong Z. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res. 2005;11:4512&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15958637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Festuccia C, Angelucci A, Gravina GL, Villanova I, Teti A, Albini A, et al. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. International journal of cancer Journal international du cancer. 2000;85:407&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10652434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han YP, Tuan TL, Hughes M, Wu H, Garner WL. Transforming growth factor-beta - and tumor necrosis factor-alpha -mediated induction and proteolytic activation of MMP-9 in human skin. The Journal of biological chemistry. 2001;276:22341&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2651823</ArticleId>
            <ArticleId IdType="pubmed">11297541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon GM, Ledee DR, Feuer WJ, Fini ME. Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. Journal of cellular physiology. 2009;221:402&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2990951</ArticleId>
            <ArticleId IdType="pubmed">19626678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clin Cancer Res. 2004;10:8728&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15623658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin JJ, Zhang L, Munasinghe J, Linnoila RI, Kelly K. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer research. 2010;70:8662&#x2013;73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2989818</ArticleId>
            <ArticleId IdType="pubmed">20959486</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23481325</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1525-0024</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular therapy : the journal of the American Society of Gene Therapy</Title>
          <ISOAbbreviation>Mol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mechanisms of the antitumor activity of human VÎ³9VÎ´2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.</ArticleTitle>
        <Pagination>
          <StartPage>1034</StartPage>
          <EndPage>1043</EndPage>
          <MedlinePgn>1034-43</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/mt.2013.38</ELocationID>
        <Abstract>
          <AbstractText>Low expression of surface major histocompatibility complex (MHC) class I molecules and defects in antigen processing machinery make human neuroblastoma (NB) cells appropriate targets for MHC unrestricted immunotherapeutic approaches. Human T-cell receptor (TCR) VÎ³9VÎ´2 lymphocytes exert MHC-unrestricted antitumor activity and are activated by phosphoantigens, whose expression in cancer cells is increased by aminobisphosphonates. With this background, we have investigated the in vivo anti-NB activity of human VÎ³9VÎ´2 lymphocytes and zoledronic acid (ZOL). SH-SY-5Y human NB cells were injected in the adrenal gland of immunodeficient mice. After 3 days, mice received ZOL or human VÎ³9VÎ´2 T cells or both agents by intravenous administration once a week for 4 weeks. A significantly improved overall survival was observed in mice receiving VÎ³9VÎ´2 T cells in combination with ZOL. Inhibition of tumor cell proliferation, angiogenesis and lymphangiogenesis, and increased tumor cell apoptosis were detected. VÎ³9VÎ´2 T lymphocytes were attracted to NB-tumor masses of mice receiving ZOL where they actively modified tumor microenvironment by producing interferon-Î³ (IFN-Î³), that in turn induced CXCL10 expression in NB cells. This study shows that human VÎ³9VÎ´2 T cells and ZOL in combination inhibit NB growth in vivo and may provide the rationale for a phase I clinical trial in patients with high-risk NB.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Di Carlo</LastName>
            <ForeName>Emma</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Anatomic Pathology and Molecular Medicine, Department of Medicine and Sciences of Aging, G. d'Annunzio University, Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bocca</LastName>
            <ForeName>Paola</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Emionite</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cilli</LastName>
            <ForeName>Michele</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cipollone</LastName>
            <ForeName>Giuseppe</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morandi</LastName>
            <ForeName>Fabio</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raffaghello</LastName>
            <ForeName>Lizzia</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pistoia</LastName>
            <ForeName>Vito</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prigione</LastName>
            <ForeName>Ignazia</ForeName>
            <Initials>I</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>03</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Ther</MedlineTA>
        <NlmUniqueID>100890581</NlmUniqueID>
        <ISSNLinking>1525-0016</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004164">Diphosphonates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016692">Receptors, Antigen, T-Cell, gamma-delta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6XC1PAD3KF</RegistryNumber>
          <NameOfSubstance UI="D000077211">Zoledronic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019264" MajorTopicYN="Y">Adoptive Transfer</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054357" MajorTopicYN="N">Chemokine CXCL10</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004164" MajorTopicYN="N">Diphosphonates</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016130" MajorTopicYN="N">Immunophenotyping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016692" MajorTopicYN="Y">Receptors, Antigen, T-Cell, gamma-delta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077211" MajorTopicYN="N">Zoledronic Acid</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23481325</ArticleId>
        <ArticleId IdType="pmc">PMC3666635</ArticleId>
        <ArticleId IdType="doi">10.1038/mt.2013.38</ArticleId>
        <ArticleId IdType="pii">S1525-0016(16)30683-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106&#x2013;2120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17586306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21:181&#x2013;189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10363850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27:1007&#x2013;1013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2738615</ArticleId>
            <ArticleId IdType="pubmed">19171716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol. 2011;21:229&#x2013;237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3658311</ArticleId>
            <ArticleId IdType="pubmed">21971567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, et al. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci. 2004;1028:69&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15650233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007;67:6433&#x2013;6441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17616704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA. 2004;101:12640&#x2013;12645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC515110</ArticleId>
            <ArticleId IdType="pubmed">15314238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raffaghello L, Prigione I, Airoldi I, Camoriano M, Morandi F, Bocca P, et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett. 2005;228:155&#x2013;161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15923080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soldati R, Berger E, Zenclussen AC, Jorch G, Lode HN, Salatino M, et al. Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer. 2012;131:1131&#x2013;1141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22020795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene. 2005;24:4634&#x2013;4644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15897905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foreman NK, Rill DR, Coustan-Smith E, Douglass EC, Brenner MK. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer. 1993;67:933&#x2013;938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1968443</ArticleId>
            <ArticleId IdType="pubmed">8494726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schilbach KE, Geiselhart A, Wessels JT, Niethammer D, Handgretinger R. Human gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells. J Immunother. 2000;23:536&#x2013;548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11001547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schilbach K, Frommer K, Meier S, Handgretinger R, Eyrich M. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy. J Immunother. 2008;31:896&#x2013;905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18832998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pistoia V, Bianchi G, Borgonovo G, Raffaghello L. Cytokines in neuroblastoma: from pathogenesis to treatment. Immunotherapy. 2011;3:895&#x2013;907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21751957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Rosa SC, Andrus JP, Perfetto SP, Mantovani JJ, Herzenberg LA, Herzenberg LA, et al. Ontogeny of gamma delta T cells in humans. J Immunol. 2004;172:1637&#x2013;1645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14734745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev. 2007;215:59&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17291279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gober HJ, Kistowska M, Angman L, Jen&#xf6; P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163&#x2013;168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2193814</ArticleId>
            <ArticleId IdType="pubmed">12538656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother. 2007;56:1285&#x2013;1297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17265022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benza&#xef;d I, M&#xf6;nkk&#xf6;nen H, Stresing V, Bonnelye E, Green J, M&#xf6;nkk&#xf6;nen J, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011;71:4562&#x2013;4572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21646473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581&#x2013;589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9556058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, et al. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res. 2007;67:9346&#x2013;9355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17909043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>B&#xe4;ckman U, Svensson A, Christofferson RH, Azarbayjani F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res. 2008;28 3A:1551&#x2013;1557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18630510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010;14:2803&#x2013;2815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3822730</ArticleId>
            <ArticleId IdType="pubmed">19818098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green JR, Guenther A. The backbone of progress&#x2013;preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol. 2011;77 Suppl 1:S3&#x2013;S12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21353178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gnant M, Cl&#xe9;zardin P. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev. 2012;38:407&#x2013;415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21983264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cl&#xe9;zardin P, Massaia M. Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des. 2010;16:3007&#x2013;2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20722623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy. 2008;10:842&#x2013;856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19016372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer. 2005;116:94&#x2013;99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15756684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol. 2006;18:539&#x2013;546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16870417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol. 2006;18:539&#x2013;546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16870417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nussbaumer O, Gruenbacher G, Gander H, Thurnher M. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by ?d T lymphocytes. Blood. 2011;118:2743&#x2013;2751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21673342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pinti&#xe8;re C, Daniel P, et al. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother. 2008;57:531&#x2013;539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17764010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castella B, Vitale C, Coscia M, Massaia M. V?9Vd2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci. 2011;68:2419&#x2013;2432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21584812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer. 2011;105:778&#x2013;786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3171009</ArticleId>
            <ArticleId IdType="pubmed">21847128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan G, Lipton A. Antitumor effects and anticancer applications of bisphosphonates. Semin Oncol. 2010;37 Suppl 2:S30&#x2013;S40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21111246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cl&#xe9;zardin P. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone. 2011;48:71&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20655399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio N, Fujita M, Tanaka Y, Maki H, Zhang R, Hirosawa T, et al. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human ?d T cells. J Immunother. 2012;35:598&#x2013;606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22996365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engler S, Thiel C, F&#xf6;rster K, David K, Bredehorst R, Juhl H. A novel metastatic animal model reflecting the clinical appearance of human neuroblastoma: growth arrest of orthotopic tumors by natural, cytotoxic human immunoglobulin M antibodies. Cancer Res. 2001;61:2968&#x2013;2973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11306475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ. Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo. 2002;16:77&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12073775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otto M, Barfield RC, Martin WJ, Iyengar R, Leung W, Leimig T, et al. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin Cancer Res. 2005;11:8486&#x2013;8491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16322312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pezzolo A, Parodi F, Corrias MV, Cinti R, Gambini C, Pistoia V. Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol. 2007;25:376&#x2013;383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17264333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003;3:411&#x2013;421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12778131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298&#x2013;307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4049445</ArticleId>
            <ArticleId IdType="pubmed">21593862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell. 2010;140:460&#x2013;476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20178740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamashita J, Koi K, Yang DY, McCauley LK. Effect of zoledronate on oral wound healing in rats. Clin Cancer Res. 2011;17:1405&#x2013;1414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3060285</ArticleId>
            <ArticleId IdType="pubmed">21149614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89:207&#x2013;215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3863330</ArticleId>
            <ArticleId IdType="pubmed">21221121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, et al. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011;57:275&#x2013;282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3117015</ArticleId>
            <ArticleId IdType="pubmed">21671363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42:1228&#x2013;1236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12412821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Paolo D, Loi M, Pastorino F, Brignole C, Marimpietri D, Becherini P, et al. Liposome-mediated therapy of neuroblastoma. Meth Enzymol. 2009;465:225&#x2013;249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19913170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morandi F, Chiesa S, Bocca P, Millo E, Salis A, Solari M, et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia. 2006;8:833&#x2013;842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1715922</ArticleId>
            <ArticleId IdType="pubmed">17032500</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22952424</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>02</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1476-5586</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neoplasia (New York, N.Y.)</Title>
          <ISOAbbreviation>Neoplasia</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>709</StartPage>
          <EndPage>718</EndPage>
          <MedlinePgn>709-18</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Several in vitro and in vivo models have revealed the key role of CXCR4/CXCL12 axis in tumor-stroma interactions. Stromal cells present in the tumor microenvironment express high levels of CXCL12 protein, directly stimulating proliferation and migration of CXCR4-expressing cancer cells. This specific prosurvival influence of stromal cells on tumor cells is thought to protect them from cytotoxic chemotherapy and is postulated as a possible explanation for the minimal residual disease in hematological and solid cancers. Therefore, CXCR4/CXCL12 signaling is an attractive therapeutic target in cancer, as proven in preclinical leukemia mouse models, where CXCR4 inhibition sensitized cancer cells to conventional chemotherapy. This study investigates whether inhibition of CXCR4 with the specific inhibitor AMD3100 sensitizes human prostate cancer cells to docetaxel. We showed that both mouse and human stromal cell lines have a protective effect on PC3-luc cells by promoting their survival after chemotherapy. Furthermore, we demonstrated that AMD3100 sensitizes PC3-luc cells to docetaxel. In a subcutaneous xenograft mouse model of human prostate carcinoma, we showed that a combination of docetaxel and AMD3100 exerts increased antitumor effect compared with docetaxel alone. We concluded that CXCR4 inhibition chemosensitizes prostate cancer cells, both in vitro and in vivo. To explore the relevance of these findings, we analyzed CXCR4 expression levels in human prostate cancer samples. We found that cancer cells present in bone metastatic lesions express higher CXCR4 levels relative to the cells present in primary tumors and lymph node metastatic lesions. These findings underscore the potential of CXCR4 inhibitors as chemosensitizing agents.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Domanska</LastName>
            <ForeName>Urszula M</ForeName>
            <Initials>UM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Timmer-Bosscha</LastName>
            <ForeName>Hetty</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagengast</LastName>
            <ForeName>Wouter B</ForeName>
            <Initials>WB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oude Munnink</LastName>
            <ForeName>Thijs H</ForeName>
            <Initials>TH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kruizinga</LastName>
            <ForeName>Roeliene C</ForeName>
            <Initials>RC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ananias</LastName>
            <ForeName>Hildo J K</ForeName>
            <Initials>HJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kliphuis</LastName>
            <ForeName>Nathalie M</ForeName>
            <Initials>NM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huls</LastName>
            <ForeName>Gerwin</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Vries</LastName>
            <ForeName>Elisabeth G E</ForeName>
            <Initials>EG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Jong</LastName>
            <ForeName>Igle J</ForeName>
            <Initials>IJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Walenkamp</LastName>
            <ForeName>Annemiek M E</ForeName>
            <Initials>AM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neoplasia</MedlineTA>
        <NlmUniqueID>100886622</NlmUniqueID>
        <ISSNLinking>1476-5586</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001596">Benzylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515255">CXCL12 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000080027">Cyclams</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006571">Heterocyclic Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>15H5577CQD</RegistryNumber>
          <NameOfSubstance UI="D000077143">Docetaxel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S915P5499N</RegistryNumber>
          <NameOfSubstance UI="C088327">plerixafor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001596" MajorTopicYN="N">Benzylamines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080027" MajorTopicYN="N">Cyclams</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077143" MajorTopicYN="N">Docetaxel</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006571" MajorTopicYN="N">Heterocyclic Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019718" MajorTopicYN="N">Receptors, CXCR4</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>2</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2012</Year>
          <Month>6</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>6</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22952424</ArticleId>
        <ArticleId IdType="pmc">PMC3431178</ArticleId>
        <ArticleId IdType="doi">10.1593/neo.12324</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119:2026&#x2013;2029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16671092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci. 2008;99:539&#x2013;542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18201276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11:1835&#x2013;1841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15756007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yopp AC, Shia J, Butte JM, Allen PJ, Fong Y, Jarnagin WR, Dematteo RP, D'Angelica MI. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. Ann Surg Oncol. in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21584832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat. 2006;97:275&#x2013;283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16344916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18987663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:879&#x2013;894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15888687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315&#x2013;1321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17952057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller J, Fruehauf S. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to imatinib and nilotinib. Leuk Lymphoma. 2009;50:1676&#x2013;1686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19657955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206&#x2013;6214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699239</ArticleId>
            <ArticleId IdType="pubmed">19050309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005;106:1824&#x2013;1830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15905192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, Alitalo K, Kim I, Koh GY. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res. 2010;70:10411&#x2013;10421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21056990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, Alsawafi Y, Mourskaia AA, Siegel PM, Salvucci O, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011;129:225&#x2013;232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20830712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121:1298&#x2013;1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3069764</ArticleId>
            <ArticleId IdType="pubmed">21436587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335&#x2013;348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15882617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59:5002&#x2013;5011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3300837</ArticleId>
            <ArticleId IdType="pubmed">10519415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765&#x2013;781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20116997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21056534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572&#x2013;583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21315502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502&#x2013;1512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15470213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147&#x2013;1154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20888992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832&#x2013;1837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11912162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14:2519&#x2013;2526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18451212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Vries EGE, Meijer C, Timmer-Bosscha H, Berendsen HH, de Leij L, Scheper RJ, Mulder NH. Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res. 1989;49:4175&#x2013;4178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2545337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008;68:918&#x2013;926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2519173</ArticleId>
            <ArticleId IdType="pubmed">18245495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS, II, Revelo MP, Bhowmick NA, Hayward SW. Altered TGF-beta signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res. 2011;71:1272&#x2013;1281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3076790</ArticleId>
            <ArticleId IdType="pubmed">21303979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143:355&#x2013;366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972353</ArticleId>
            <ArticleId IdType="pubmed">21029859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopleva MY, Jordan CT. Leukemia stemcells andmicroenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591&#x2013;599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4874213</ArticleId>
            <ArticleId IdType="pubmed">21220598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832&#x2013;1837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11912162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil) Biochem Pharmacol. 2009;77:1655&#x2013;1664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19161986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, Rosser CJ. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate. 2009;69:1460&#x2013;1469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19588526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64:8604&#x2013;8612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15574767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009;155:231&#x2013;236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19482312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA. 2003;100:13513&#x2013;13518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC263845</ArticleId>
            <ArticleId IdType="pubmed">14595012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redjal N, Chan JA, Segal RA, Kung AL. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res. 2006;12:6765&#x2013;6771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17121897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120:694&#x2013;705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2827954</ArticleId>
            <ArticleId IdType="pubmed">20179352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uy GL, Rettig MP, McFarland KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein K, Vij R, Westervelt P, et al. Mobilization and chemosensitization of AML with the CXCR4 antagonist plerixafor (AMD3100): a phase I/II study of AMD3100 + MEC in patients with relapsed or refractory disease. Blood. 2008;112:678.</Citation>
        </Reference>
        <Reference>
          <Citation>Uy GL, Rettig MP, McFarland K, Hladnik L, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein K, Vij R, Westervelt P, et al. A phase I/II study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory AML. Blood. 2009;114:787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3350358</ArticleId>
            <ArticleId IdType="pubmed">22308295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andritsos L, Byrd JC, Jones JA, Hewes B, Kipps TJ, Hsu FJ, Burger JA. Preliminary results from a phase I dose escalation study to determine the maximum tolerated dose of plerixafor in combination with rituximab in patients with relapsed chronic lymphocytic leukemia. Haematologica. 2010;116:321.</Citation>
        </Reference>
        <Reference>
          <Citation>Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220&#x2013;231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2874829</ArticleId>
            <ArticleId IdType="pubmed">19249680</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22926264</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7217</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>135</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Breast cancer research and treatment</Title>
          <ISOAbbreviation>Breast Cancer Res Treat</ISOAbbreviation>
        </Journal>
        <ArticleTitle>RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.</ArticleTitle>
        <Pagination>
          <StartPage>771</StartPage>
          <EndPage>780</EndPage>
          <MedlinePgn>771-80</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-012-2222-2</ELocationID>
        <Abstract>
          <AbstractText>Tumor cells in bone can induce the activation of osteoclasts, which mediate bone resorption and release of growth factors and calcium from the bone matrix, resulting in a cycle of tumor growth and bone breakdown. Targeting the bone microenvironment by the inhibition of RANKL, an essential mediator of osteoclast function, not only prevents tumor-induced osteolysis but also decreases skeletal tumor burden in preclinical models. The inhibition of skeletal tumor progression after the inhibition of osteoclasts is via interruption of the "vicious cycle" of tumor/bone interactions. The majority of breast cancer patients at risk for bone metastases harbor estrogen receptor-positive (ER+) tumors. We developed a mouse model for ER+ breast cancer bone metastasis and evaluated the effect of RANKL inhibition on tumor-induced osteolysis and skeletal tumor growth both alone and in combination with tamoxifen. Luciferase-labeled MCF-7 cells (MCF-7Luc) formed metastatic foci in the hind limbs following intracardiac injection and caused mixed osteolytic/osteoblastic lesions. RANKL inhibition by OPG-Fc treatment blocked osteoclast activity and prevented tumor-induced osteolysis, as well as caused a marked decrease in skeletal tumor burden. Tamoxifen as a single agent reduced MCF-7Luc tumor growth in the hind limbs. In a combination experiment, OPG-Fc plus tamoxifen resulted in significantly greater tumor growth inhibition than either single agent alone. Histologic analysis revealed a decrease in the proliferation of tumor cells by both single agents, which was enhanced in the combination treatment. Upon treatment with OPG-Fc alone or in combination with tamoxifen, there was a complete absence of osteolytic lesions, demonstrating the ability of RANKL inhibition to prevent skeletal related morbidity in an ER+ model. The combination approach of targeting osteoclasts and the bone microenvironment by RANKL inhibition and the tumor directly via hormonal therapy may provide additional benefit to reducing skeletal tumor progression in ER+ breast cancer patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Canon</LastName>
            <ForeName>Jude</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology Research, Amgen Inc, 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA. jcanon@amgen.com</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bryant</LastName>
            <ForeName>Rebecca</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roudier</LastName>
            <ForeName>Martine</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Branstetter</LastName>
            <ForeName>Daniel G</ForeName>
            <Initials>DG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dougall</LastName>
            <ForeName>William C</ForeName>
            <Initials>WC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>08</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Breast Cancer Res Treat</MedlineTA>
        <NlmUniqueID>8111104</NlmUniqueID>
        <ISSNLinking>0167-6806</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053244">Osteoprotegerin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053245">RANK Ligand</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020845">Selective Estrogen Receptor Modulators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C505689">Tnfsf11 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>094ZI81Y45</RegistryNumber>
          <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010010" MajorTopicYN="N">Osteoclasts</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053244" MajorTopicYN="N">Osteoprotegerin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053245" MajorTopicYN="N">RANK Ligand</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020845" MajorTopicYN="N">Selective Estrogen Receptor Modulators</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>8</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>8</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22926264</ArticleId>
        <ArticleId IdType="doi">10.1007/s10549-012-2222-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22804248</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-5666</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current molecular medicine</Title>
          <ISOAbbreviation>Curr Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>952</StartPage>
          <EndPage>966</EndPage>
          <MedlinePgn>952-66</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Breast cancer is one of the most common cancers among women in India and around the world. Despite recent advancement in the treatment of breast cancer, the results of chemotherapy to date remain unsatisfactory, prompting a need to identify natural agents that could target cancer efficiently with least side effects. Andrographolide (Andro) is one such molecule which has been shown to possess inhibitory effect on cancer cell growth. In this study, Andro, a natural diterpenoid lactone isolated from Andrographis paniculata has been shown to inhibit breast cancer cell proliferation, migration and arrest cell cycle at G2/M phase and induces apoptosis through caspase independent pathway. Our experimental evidences suggest that Andro attenuates endothelial cell motility and tumor-endothelial cell interaction. Moreover, Andro suppresses breast tumor growth in orthotopic NOD/SCID mice model. The anti-tumor activity of Andro in both in vitro and in vivo model was correlated with down regulation of PI3 kinase/Akt activation and inhibition of pro-angiogenic molecules such as OPN and VEGF expressions. Collectively, these results demonstrate that Andro may act as an effective anti-tumor and anti-angiogenic agent for the treatment of breast cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kumar</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>National Center for Cell Science, NCCS Complex, Pune 411 007, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patil</LastName>
            <ForeName>H S</ForeName>
            <Initials>HS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharma</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kumar</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dasari</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Puranik</LastName>
            <ForeName>V G</ForeName>
            <Initials>VG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thulasiram</LastName>
            <ForeName>H V</ForeName>
            <Initials>HV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kundu</LastName>
            <ForeName>G C</ForeName>
            <Initials>GC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Curr Mol Med</MedlineTA>
        <NlmUniqueID>101093076</NlmUniqueID>
        <ISSNLinking>1566-5240</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004224">Diterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>106441-73-0</RegistryNumber>
          <NameOfSubstance UI="D053495">Osteopontin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>410105JHGR</RegistryNumber>
          <NameOfSubstance UI="C030419">andrographolide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D035685" MajorTopicYN="N">Andrographis</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004224" MajorTopicYN="N">Diterpenes</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059565" MajorTopicYN="N">G2 Phase Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061307" MajorTopicYN="N">Human Umbilical Vein Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053495" MajorTopicYN="N">Osteopontin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2012</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>7</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>7</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22804248</ArticleId>
        <ArticleId IdType="doi">10.2174/156652412802480826</ArticleId>
        <ArticleId IdType="pii">CMM-EPUB-20120718-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22204817</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>07</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-3279</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>217</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Immunobiology</Title>
          <ISOAbbreviation>Immunobiology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Interferon-Î³-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.</ArticleTitle>
        <Pagination>
          <StartPage>385</StartPage>
          <EndPage>393</EndPage>
          <MedlinePgn>385-93</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.imbio.2011.10.016</ELocationID>
        <Abstract>
          <AbstractText>Many cells located in the tumor microenvironment function to protect or promote the ability of tumor cells to escape immune destruction. Previous studies have shown that programmed death ligand-1 (PD-L1), a ligand of the B7 superfamily, is expressed on a series of human tumors and can inhibit anti-tumor immune responses. Interferon-Î³ (IFN-Î³), a cytokine produced and secreted by inflammatory cells in the tumor microenvironment, is a main stimulator of PD-L1 expression in tumor cells. Making clear the mechanism of IFN-Î³ induced the expression of PD-L1 on tumor cells that is benefit to find a way to inhibit the function of PD-L1 and improve cancer cell-reactive immune responses. Herein, we have identified protein kinase D isoform 2 (PKD2) as an important regulator of PD-L1 expression on human oral squamous carcinoma cells induced by IFN-Î³. IFN-Î³ induced the expression of PD-L1 and PKD2 in human oral squamous carcinoma Tca8113 in both time and dose dependent manner. The expression of PD-L1 was decreased significantly after PKD2 knockdown with shRNA/siRNA interference or PKD chemical inhibitor following induction with IFN-Î³. The apoptosis of CD8(+) T cell which is induced by tumor cells via PD-1/PD-L1 pathway was significantly decreased, as a result, the anti-tumor effects of tumor antigen specific T cell were increased in vivo. Together, these data combined with our previous results, indicate PKD2 as an important target candidate for tumor biotherapy. Inhibition of PKD2 activation not only inhibits PD-L1 expression and promotes an anti-tumor effect, but also decreases drug resistance in chemotherapy.</AbstractText>
          <CopyrightInformation>Copyright &#xc2;&#xa9; 2011 Elsevier GmbH. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Jiao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University, PR China. cj0123@163.com</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Libing</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Lina</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ping</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2011</Year>
          <Month>11</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Immunobiology</MedlineTA>
        <NlmUniqueID>8002742</NlmUniqueID>
        <ISSNLinking>0171-2985</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C465664">2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002227">Carbazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008301">Maleimides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091283">Protein Kinase D2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.-</RegistryNumber>
          <NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002227" MajorTopicYN="N">Carbazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008301" MajorTopicYN="N">Maleimides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009062" MajorTopicYN="N">Mouth Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091283" MajorTopicYN="N">Protein Kinase D2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2011</Year>
          <Month>4</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2011</Year>
          <Month>8</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2011</Year>
          <Month>10</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2011</Year>
          <Month>12</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2011</Year>
          <Month>12</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>7</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22204817</ArticleId>
        <ArticleId IdType="doi">10.1016/j.imbio.2011.10.016</ArticleId>
        <ArticleId IdType="pii">S0171-2985(11)00226-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22194466</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2012</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1538-7445</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>72</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer research</Title>
          <ISOAbbreviation>Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metastatic cells can escape the proapoptotic effects of TNF-Î± through increased autocrine IL-6/STAT3 signaling.</ArticleTitle>
        <Pagination>
          <StartPage>865</StartPage>
          <EndPage>875</EndPage>
          <MedlinePgn>865-75</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-11-1357</ELocationID>
        <Abstract>
          <AbstractText>The liver is a common site for cancer metastases in which the entrance of tumor cells has been shown to trigger a rapid inflammatory response. In considering how an inflammatory response may affect metastatic colonization in this setting, we hypothesized that tumor cells may acquire resistance to the proapoptotic and tumoricidal effects of TNF-Î±, a cytokine that is elevated in a proinflammatory tissue microenvironment. In this study, we investigated molecular mechanisms by which such resistance may emerge using tumor cells in which the overexpression of the type I insulin-like growth factor receptor (IGF-IR) enhanced the inflammatory and metastatic capacities of poorly metastatic cells in the liver. Mechanistic investigations in vitro revealed that IGF-IR overexpression increased cell survival in the presence of high levels of TNF-Î±, in a manner associated with increased autocrine production of interleukin-6 (IL)-6. In turn, tumor cell-derived IL-6 induced gp130 and IL-6R-dependent activation of STAT3, leading to reduced caspase-3 activation and apoptosis. We found that IL-6 production and cell death resistance were dose dependent with increasing TNF-Î± levels. In addition, RNA interference-mediated knockdown of either IL-6 or gp130 that established a blockade to autocrine STAT3 induction was sufficient to abolish the prosurvival effect of TNF-Î± and to inhibit liver metastasis. Taken together, our findings define an IGF-IR-mediated mechanism of cancer cell survival that is critical for metastatic colonization of the liver.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Shun</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, McGill University and the McGill University Health Center-Royal Victoria Hospital, Montreal, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ni</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brodt</LastName>
            <ForeName>Pnina</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>MOP-81201</GrantID>
            <Agency>Canadian Institutes of Health Research</Agency>
            <Country>Canada</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2011</Year>
          <Month>12</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Res</MedlineTA>
        <NlmUniqueID>2984705R</NlmUniqueID>
        <ISSNLinking>0008-5472</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D017526">Receptor, IGF Type 1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017526" MajorTopicYN="N">Receptor, IGF Type 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2011</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2011</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22194466</ArticleId>
        <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-1357</ArticleId>
        <ArticleId IdType="pii">0008-5472.CAN-11-1357</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">21692746</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>02</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1573-4935</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bioscience reports</Title>
          <ISOAbbreviation>Biosci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-neoplastic action of aspirin against a T-cell lymphoma involves an alteration in the tumour microenvironment and regulation of tumour cell survival.</ArticleTitle>
        <Pagination>
          <StartPage>91</StartPage>
          <EndPage>104</EndPage>
          <MedlinePgn>91-104</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1042/BSR20110027</ELocationID>
        <Abstract>
          <AbstractText>The present study explores the potential of the anti-neoplastic action of aspirin in a transplantable murine tumour model of a spontaneously originated T-cell lymphoma designated as Dalton's lymphoma. The antitumour action of aspirin administered to tumour-bearing mice through oral and/or intraperitoneal (intratumoral) routes was measured via estimation of survival of tumour-bearing mice, tumour cell viability, tumour progression and changes in the tumour microenvironment. Intratumour administration of aspirin examined to assess its therapeutic potential resulted in retardation of tumour progression in tumour-bearing mice. Oral administration of aspirin to mice as a prophylactic measure prior to tumour transplantation further primed the anti-neoplastic action of aspirin administered at the tumour site. The anti-neoplastic action of aspirin was associated with a decline in tumour cell survival, augmented induction of apoptosis and nuclear shrinkage. Tumour cells of aspirin-treated mice were found arrested in G0/G1 phase of the cell cycle and showed nuclear localization of cyclin B1. Intratumoral administration of aspirin was accompanied by alterations in the biophysical, biochemical and immunological composition of the tumour microenvironment with respect to pH, level of dissolved O2, glucose, lactate, nitric oxide, IFNÎ³ (interferon Î³), IL-4 (interleukin-4), IL-6 and IL-10, whereas the TGF-Î² (tumour growth factor-Î²) level was unaltered. Tumour cells obtained from aspirin-treated tumour-bearing mice demonstrated an altered expression of pH regulators monocarboxylate transporter-1 and V-ATPase along with alteration in the level of cell survival regulatory molecules such as survivin, vascular endothelial growth factor, heat-shock protein 70, glucose transporter-1, SOCS-5 (suppressor of cytokine signalling-5), HIF-1Î± (hypoxia-inducible factor-1Î±) and PUMA (p53 up-regulated modulator of apoptosis). The study demonstrates a possible indirect involvement of the tumour microenvironment in addition to a direct but limited anti-neoplastic action of aspirin in the retardation of tumour growth.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kumar</LastName>
            <ForeName>Anjani</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biotechnology, Banaras Hindu University, Varanasi-221 005, UP, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vishvakarma</LastName>
            <ForeName>Naveen Kumar</ForeName>
            <Initials>NK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tyagi</LastName>
            <ForeName>Abhishek</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bharti</LastName>
            <ForeName>Alok Chandra</ForeName>
            <Initials>AC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Sukh Mahendra</ForeName>
            <Initials>SM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biosci Rep</MedlineTA>
        <NlmUniqueID>8102797</NlmUniqueID>
        <ISSNLinking>0144-8463</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C534700">Ccnb1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056744">Cyclin B1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>130068-27-8</RegistryNumber>
          <NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>207137-56-2</RegistryNumber>
          <NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31C4KY9ESH</RegistryNumber>
          <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>33X04XA5AT</RegistryNumber>
          <NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>R16CO5Y76E</RegistryNumber>
          <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056744" MajorTopicYN="N">Cyclin B1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015552" MajorTopicYN="N">Injections, Intralesional</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016399" MajorTopicYN="N">Lymphoma, T-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2011</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2011</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">21692746</ArticleId>
        <ArticleId IdType="doi">10.1042/BSR20110027</ArticleId>
        <ArticleId IdType="pii">BSR20110027</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">21261597</PMID>
      <DateCompleted>
        <Year>2011</Year>
        <Month>10</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2012</Year>
        <Month>08</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1095-8355</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2011</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell biology international</Title>
          <ISOAbbreviation>Cell Biol Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Malignant potential of H22 hepatocarcinoma cells increases after recovery from IFN-Î³-mediated inhibition.</ArticleTitle>
        <Pagination>
          <StartPage>747</StartPage>
          <EndPage>754</EndPage>
          <MedlinePgn>747-54</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1042/CBI20100268</ELocationID>
        <Abstract>
          <AbstractText>IFN-Î³ (interferon Î³) can effectively suppress tumours, but it has also been found to promote tumour progression. However, the underlying mechanisms by which it enhances malignancy have not been fully elucidated. By using a mouse model that expresses IFN-Î³ locally in muscle, we found that the growth potential of tumours was increased after a quick decrease of IFN-Î³. Furthermore, the up-regulation of IRF-2 (IFN regulatory factor 2) and down-regulation of IRF-1 were also found in the tumour cells. Along these lines, IFN-Î³ led to down-regulated expression of cyclin-D1, Bcl-2 and Bcl-xL and up-regulated expression of p21WAF1 and Bax in tumour cells. Yet, the expression of these genes, as well as activation of ERK (extracellular signal-regulated kinase) and NF-ÎºB (nuclear factor-ÎºB), was also reversed shortly after a decrease in IFN-Î³, all of which resulted in increase tumour cell proliferation and apoptosis resistance. These findings indicate that the malignant potential of tumour cells may be suppressed by interfering with IRF-2 signalling pathways during and after decreased IFN-Î³ in tumour microenvironments.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Xiangfan Hospital Xiangfan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Xiangfan, Peoples Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Ke-Zhong</ForeName>
            <Initials>KZ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Xinjun</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>YanYan</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>JiuLiang</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>HuaiYun</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Wen-Wei</ForeName>
            <Initials>WW</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Biol Int</MedlineTA>
        <NlmUniqueID>9307129</NlmUniqueID>
        <ISSNLinking>1065-6995</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050856">Interferon Regulatory Factor-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050836">Interferon Regulatory Factor-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050856" MajorTopicYN="Y">Interferon Regulatory Factor-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050836" MajorTopicYN="Y">Interferon Regulatory Factor-2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2011</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2011</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2011</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">21261597</ArticleId>
        <ArticleId IdType="doi">10.1042/CBI20100268</ArticleId>
        <ArticleId IdType="pii">CBI20100268</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">18727400</PMID>
      <DateCompleted>
        <Year>2008</Year>
        <Month>10</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0041-3771</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>50</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2008</Year>
            </PubDate>
          </JournalIssue>
          <Title>Tsitologiia</Title>
          <ISOAbbreviation>Tsitologiia</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Autocrine factor participation in defence of cytotoxic CTLL-2 cells from oxidative stress].</ArticleTitle>
        <Pagination>
          <StartPage>492</StartPage>
          <EndPage>499</EndPage>
          <MedlinePgn>492-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The role of autocrine factors (AF) secreted by cytotoxic IL-2-dependent CTLL-2 cells along with pyruvate in cell defense from oxidative stress was investigated. The addition of conditioned medium (CM) containing pyruvate and AF into CTLL-2 cell cultures increased significantly cell survival under oxidative stress condition. The kinetics of hydrogen peroxide removal from cell cultures under oxidative stress in the case of CM addition has been obtained. The removal of H2O2 mostly by means of its reaction with pyruvate that is contained in CM has been shown at the beginning of oxidative stress (up to 15 min). Pyruvate content in CM was determined as 138 +/- 7 microM. Cell filtration on column with Bio-Gel P-10 was used for removal pyruvate from CM. Three fractions of CM (A, B and C) were obtained as a result of gel filtration. Pyruvate was not detected in any fraction. The fraction A was eluted from column as the first one and contained the largest molecules. Cell survival test showed the fraction B to have the highest ability to protect CTLL-2 cells under oxidative stress. The fraction A supported cell survival to a less degree and fraction C was shown to have no protective ability. The addition of the fraction B to the cell cultures resulted in preservation of significantly higher intracellular ATP level in the cells under oxidative stress than in the control ones. Moreover, AF of the fraction B was shown to react directly with hydrogen peroxide and inactivate it in the absence of cells. AF of the fraction A did not have such properties.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lutsenko</LastName>
            <ForeName>G V</ForeName>
            <Initials>GV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grechikhina</LastName>
            <ForeName>M V</ForeName>
            <Initials>MV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'iachkova</LastName>
            <ForeName>L G</ForeName>
            <Initials>LG</Initials>
          </Author>
        </AuthorList>
        <Language>rus</Language>
        <PublicationTypeList>
          <PublicationType UI="D004740">English Abstract</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Russia (Federation)</Country>
        <MedlineTA>Tsitologiia</MedlineTA>
        <NlmUniqueID>0417363</NlmUniqueID>
        <ISSNLinking>0041-3771</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001685">Biological Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8558G7RUTR</RegistryNumber>
          <NameOfSubstance UI="D019289">Pyruvic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019898" MajorTopicYN="N">Autocrine Communication</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001685" MajorTopicYN="N">Biological Factors</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002850" MajorTopicYN="N">Chromatography, Gel</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019289" MajorTopicYN="N">Pyruvic Acid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2008</Year>
          <Month>8</Month>
          <Day>30</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2008</Year>
          <Month>10</Month>
          <Day>25</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2008</Year>
          <Month>8</Month>
          <Day>30</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">18727400</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
